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SUMMARY 
Prenyltransferases (PTs) catalyze the transfer of one or more prenyl units with chain lengths of n x 
C5 (n = 1, 2 etc.) to diverse acceptors. Prenylations are essential in both the primary and secondary 
metabolism of all organisms. PTs are often involved in the biosynthetic pathways of secondary 
metabolites (SMs). Many indole alkaloids (IAs) from Ascomycota are such SMs generated by 
diverse enzymes and PTs of the dimethylallyl tryptophan synthase (DMATS) superfamily with L-
tryptophan as a precursor. These PTs mostly use the prenyl donor dimethylallyl diphosphate 
(DMAPP) to catalyze metal ion-independently and regiospecific Friedel-Crafts alkylation at the 
indole ring. The increased lipophilicity of prenylated substances is often associated with improved 
bioactivity. Prenylated tryptophan-containing cyclic dipeptides (CDPs) with a 2,5 diketopiperazine 
ring and their derivatives are such representative structures with significant biological and 
pharmacological activities. Echinulin and derivatives thereof possess antiviral, antitumor and 
neuroprotective activities. Fumitremorgin C is a potential inhibitor of the breast cancer resistance 
protein. Tryprostatin A and B are known as microtubule inhibitors. The demand for new bioactive 
substances such as antibiotics or cancer therapeutics prompted in this thesis the targeted 
manipulation of PTs on the basis of protein structure data. The obtained mutants were then used 
for the production of new prenylated IAs. Furthermore, pharmacologically relevant substances were 
produced by the combination of chemical and enzymatic synthesis. 
In this thesis, five tryptophan PTs, FgaPT2, 5-DMATS, 5-DMATSSc, 6-DMATSSa and 7-DMATS, 
were investigated for their potential to prenylate the tripeptide derivative ardeemin fumiquinazoline 
(FQ) and its stereoisomers. Ardeemin FQ is the precursor of the reverse C3-prenylated ardeemin 
and 5-N-acetylardeemin. These substances block the MultiDrug Resistance (MDR) export pump in 
cancer cells, thereby increasing the potency of cancer therapeutics such as Vinca alkaloids in the 
cell. This thesis demonstrates that PTs from other biosynthetic gene clusters are also able to 
prenylate ardeemin FQ. The chemically synthesized stereoisomers could also be converted by 
these PTs, which has not been reported prior to this study. Here, the two stereo centers of these 
substrates impact the activity and regioselectivity of these enzymes. 18 new prenylated tripeptide 
derivatives were obtained. Since the tryptophan PTs catalyze only prenylations on the indole’s 
benzene ring of the tripeptide derivatives, five further PTs were investigated in a cooperation project 
with Lindsay Coby. BrePT, FtmPT1, CdpNPT, CdpC3PT and AnaPT are cyclic dipeptide PTs that 
prenylate their natural or best-accepted substrates at the pyrrole ring of the indole. A high 
conversion rate with ardeemin FQ has been determined for BrePT, FtmPT1 and CdpNPT, whereas 
CdpC3PT and AnaPT show less acceptance. The enantiomer was poorly converted by all 
enzymes. These results also show that the stereochemistry of the substrates affects their 
acceptance by the cyclic dipeptide PTs. 8 new pyrrole-ring prenylated tripeptide derivatives were 
produced. From both projects, 26 new obtained substances are available for further studies on their 
bioactivity. 
Another focus of this thesis is the structure-based protein manipulation through targeted mutation 
to generate PTs with novel catalytic properties and their application for the production of new 
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prenylated IAs. For this purpose, FgaPT2, which catalyzes regular C4-prenylation of L-tryptophan, 
was used as a model for mutational experiments. The targeted combinational mutation of two 
amino acids (K174 and R244) has produced several FgaPT2 double mutants that catalyze reverse 
C3-prenylation of CDPs with high product yields. This work is a cooperation with Liujuan Zheng. 
In another study, targeted mutations were performed also on FgaPT2, which is a DMAPP-specific 
PT, in order to expand the prenyl donor specificity. Molecular modeling identified methionine 328 
as potential key amino acid residue for the acceptance of the prenyl donor. The FgaPT2_M328G 
mutant shows a high turnover with GPP and low acceptance with FPP. An enzymatic geranylation 
or farnesylation of tryptophan as free amino acid was not described prior to this study. The decrease 
in DMAPP-acceptance by different FgaPT2_M328X mutants indicate that, in addition to size, the 
polarity of the amino acid also contributes to prenyl donor selectivity. The mutants with an amino 
acid smaller than methionine (FgaPT2_M328X; X = C, A, T, S, G, V, N) show high rates of GPP-
utilization. The mutants FgaPT2_M328X (X = C, S, G, A) also possess FPP-activity. Due to their 
polar properties, high GPP- and high DMAPP-acceptance was observed by FgaPT2_M328X (X = 
C, T, V, N) mutants. To increase FPP-utilization, L263 and Y398 were identified as potential amino 
acids. The generation of the mutants FgaPT2_L263A_M328A and FgaPT2_L263A_M328A_Y398F 
led to a further increase in the FPP-utilization. In this study, 21 mutants were produced and 7 
mutants can be used as geranyltransferases for chemoenzymatic syntheses of new IAs. 
In a cooperation study with Ge Liao, five additional DMATSs were selected for mutation 
experiments to achieve GPP-activity. The C2-PT FtmPT1 catalyzes a regular, BrePT and CdpC2PT 
a reverse transfer of the prenyl residue from DMAPP to the C-2 position of CDPs. The C3-PTs 
CdpNPT and CdpC3PT attach the prenyl residue to the C-3 position of CDPs in a reverse manner. 
Based on sequence alignments and molecular modeling, M364 in FtmPT1, I337 in BrePT, T351 in 
CdpC2PT, M349 in CdpNPT and F335 in CdpC3PT were identified to be responsible for prenyl 
donor selectivity and thus were replaced by glycine via site-directed mutagenesis. The generated 
mutants FtmPT1_M364G, BrePT_I337G, CdpNPT_M349G and CdpC3PT_F335G show clear 
acceptance of GPP compared to their wildtype. The CdpC2PT wildtype has already accepted GPP. 
The mutant CdpC2PT_T351G, however, displays a different geranylation pattern. 42 geranylated 
derivatives could be obtained from 15 CDPs. For cyclo-L-Trp-L-Trp the geranyl moiety of GPP could 
be transferred to almost all possible positions. 
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ZUSAMMENFASSUNG 
Prenyltransferasen (PTs) katalysieren die Übertragung einer oder mehrerer Prenyleinheiten mit 
Kettenlängen von n x C5 (n = 1, 2 etc.) auf verschiedene Akzeptoren. Prenylierungen sind sowohl 
im Primär- als auch im Sekundärmetabolismus aller Organismen unerlässlich. PTs sind oft in 
biosynthetische Wege von Sekundärmetaboliten (SMs) involviert. Viele Indolalkaloide (IAs) aus 
Schlauchpilzen (Ascomycota) sind solche SMs und von verschiedenen Enzymen inklusive PTs der 
Dimethylallyl Tryptophan Synthase (DMATS) Superfamilie ausgehend von L-Tryptophan erzeugt. 
Diese PTs katalysieren meistens unter Verwendung des Prenyldonors Dimethylallyldiphosphat 
(DMAPP) ionenunabhängig und regiospezifisch eine Friedel-Crafts Alkylierung des Indolrings. Die 
erhöhte Lipophilizität prenylierter Substanzen steht oftmals in Zusammenhang mit einer 
gesteigerten Bioaktivität. Prenylierte tryptophanhaltige cyclische Dipeptide (CDPs) mit einem 2,5-
Diketopiperazinring und Derivate sind solche repräsentative Strukturen mit signifikanten 
biologischen und pharmakologischen Aktivitäten. Echinulin und Derivate davon besitzen antivirale, 
antitumorale und neuroprotektive Aktivitäten. Fumitremorgin C ist ein potenzieller Inhibitor des 
Brustkrebs-Resistenzproteins. Tryprostatin A und B sind als Mikrotubulininhibitoren bekannt. Der 
Bedarf an neuen bioaktiven Substanzen wie Antibiotika oder Zytostatika veranlasste in dieser 
Doktorarbeit die gezielte Manipulation von PTs auf Basis von Proteinstrukturdaten und der 
Verwendung von Mutanten zur Herstellung neuer prenylierter IAs. Darüber hinaus wurden 
pharmakologisch relevante Substanzen durch Kombination von chemischer und enzymatischer 
Synthese hergestellt. 
In dieser Doktorarbeit wurden fünf Tryptophan PTs, FgaPT2, 5-DMATS, 5-DMATSSc, 6-DMATSSa 
und 7-DMATS, auf ihr Potenzial untersucht, das Tripeptid-Derivat Ardeemin FQ und seine 
Stereoisomere zu prenylieren. Ardeemin FQ ist die Vorstufe des C3-prenylierten Ardeemin und 5-
N-Acetylardeemin. Diese Substanzen blockieren die MultiDrugResistance (MDR) Exportpumpe in 
Krebszellen und erhöhen so die Wirksamkeit von Zytostatika wie Vincaalkaloide in der Zelle. Diese 
Doktorarbeit zeigt, dass PTs aus anderen biosynthetischen Genclustern auch in der Lage sind, 
Ardeemin FQ zu prenylieren. In dieser Arbeit konnten zum ersten Mal die chemisch synthetisierten 
Stereoisomere durch diese PTs umgesetzt werden. Hierbei beeinflussen die beiden Stereozentren 
die Aktivität und die Regioselektivität dieser Enzyme. 18 neue prenylierte Tripeptid-Derivate 
wurden hergestellt. Da die Tryptophan PTs nur Prenylierungen an dem Indol-Benzenring der 
Tripeptid-Derivate katalysieren, wurden in einem Kooperationsprojekt mit Lindsay Coby fünf 
weitere PTs untersucht. BrePT, FtmPT1, CdpNPT, CdpC3PT und AnaPT sind cyclische Dipeptid 
PTs, die ihre natürlichen oder am besten akzeptierten Substrate am Pyrrolring des Indols 
prenylieren. Hohe Umsatzraten mit Ardeemin FQ konnten für BrePT, FtmPT1 und CdpNPT gezeigt 
werden, während CdpC3PT und AnaPT geringe Akzeptanz aufweisen. Das Enantiomer wurde von 
diesen fünf Enzymen wenig umgesetzt. Diese Ergebnisse zeigen auch, dass die Stereochemie der 
Substrate ihre Akzeptanz durch die cyclischen Dipeptid PTs beeinflusst. Acht neue am Pyrrolring 
prenylierte Tripeptid-Derivate wurden hergestellt. Aus beiden Projekten stehen 26 neue produzierte 
Substanzen für weitere Studien über ihre Bioaktivität zur Verfügung. 
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Ein weiterer Schwerpunkt dieser Doktorarbeit ist die strukturbasierte Proteinmanipulation durch 
zielgerichtete Mutation zur Erzeugung von PTs mit neuen katalytischen Eigenschaften und deren 
Anwendung für die Herstellung neuer prenylierter IAs. Zu diesem Zweck wurde FgaPT2, die eine 
reguläre C4-Prenylierung am L-Tryptophan katalysiert, als Modell für Mutationsexperimente 
verwendet. Die zielgerichtete kombinatorische Mutation zweier Aminosäuren (K174 und R244) hat 
mehrere FgaPT2 Doppelmutanten generiert, die eine reverse C3-Prenylierung von CDPs mit 
hohen Produktausbeuten katalysieren. Diese Arbeit ist eine Kooperation mit Liujuan Zheng. 
In einer weiteren Studie wurden zielgerichtete Mutationen auch an FgaPT2, die eine DMAPP-
spezifische PT ist, durchgeführt, um die Substratspezifität gegenüber dem Prenyldonor zu 
erweitern. Die computergestützte molekulare Modellierung identifizierte Methionin 328 als 
potenziellen Schlüsselaminosäurerest für die Akzeptanz des Prenyldonors. Die FgaPT2_M328G 
Mutante zeigt einen hohen Umsatz mit GPP und eine niedrige Akzeptanz von FPP. Eine 
enzymatische Geranylierung oder Farnesylierung von L-Tryptophan als freie Aminosäure wurde 
vor dieser Studie nicht beschrieben. Die Herabsetzung der DMAPP-Akzeptanz durch 
FgaPT2_M328X Mutanten deutet darauf hin, dass neben der Größe auch die Polarität der 
Aminosäure zur Selektivität des Prenyldonors beiträgt. Mutanten mit einer Aminosäure, die kleiner 
als Methionin ist (FgaPT2_M328X; X= C, A, T, S, G, V, N) zeigen hohe Umsatzraten mit GPP. Die 
Mutanten FgaPT2_M328X (X = C, S, G, A) weisen zudem eine Akzeptanz von FPP als Prenyldonor 
auf. Aufgrund ihrer polaren Eigenschaften wurde sowohl eine hohe GPP- als auch eine hohe 
DMAPP-Akzeptanz von FgaPT2_M328X (X = C, T, V, N) Mutanten beobachtet. Um die FPP-
Akzeptanz zu erhöhen, wurden L263 und Y398 als potentielle Aminosäuren identifiziert. Die 
Erzeugung der Mutanten FgaPT2_L263A_M328A und FgaPT2_L263A_M328A_Y398F führte zur 
weiteren Erhöhung der Umsetzung von FPP. In dieser Studie wurden insgesamt 21 Mutanten 
hergestellt und sieben davon können als Geranyltransferasen für chemoenzymatische Synthesen 
neuer IAs verwendet werden.  
In einer Kooperationsstudie mit Ge Liao wurden fünf weitere DMATSs für Mutationsexperimente 
ausgewählt, um eine GPP-Akzeptanz zu erzielen. Die C2-PT FtmPT1 katalysiert eine reguläre, 
BrePT und CdpC2PT eine reverse Übertragung des Prenylrestes von DMAPP auf die C2-Position 
von CDPs. Die C3-PTs CdpNPT und CdpC3PT heften den Prenylrest revers an die C3-Position 
von CDPs an. Basierend auf Sequenzvergleichen und molekularer Modellierung wurde der 
Aminosäurerest M364 in FtmPT1, I337 in BrePT, T351 in CdpC2PT, M349 in CdpNPT und F335 
in CdpC3PT identifiziert, der für die Prenyldonorselektivität verantwortlich ist und deshalb durch 
Glycin mittels zielgerichteter Mutation ausgetauscht. Die generierten Mutanten FtmPT1_M364G, 
BrePT_I337G, CdpNPT_M349G und CdpC3PT_F335G zeigen eine deutliche GPP-Akzeptanz im 
Vergleich zu ihrem Wildtypen. Im Falle von CdpC2PT hat bereits der Wildtyp GPP akzeptiert. Die 
Mutante CdpC2PT_T351G weist hingegen eine andere Geranylierungsaktivität auf. 42 geranylierte 
Derivate aus 15 verwendeten CDPs konnten hergestellt werden. An das Substrat cyclo-L-Trp-L-Trp 
konnte sogar GPP an fast alle möglichen Positionen übertragen werden. 
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1. INTRODUCTION
1.1 Ascomycota: pathogen and source of bioactive compounds 
Taxonomically, Ascomycota is one of seven phyla in the kingdom of fungi with about 64,000 known 
species in approximately 6,300 genera (Kirk et al. 2008). The Ascomycota´s life cycle undergoes 
either the asexual (anamorph) or sexual (teleomorph) stages. The main asexual reproduction 
emerges from the formation of conidia or occurs through budding as observed in yeast. The conidia 
are vegetative reproductive haploid spores, mitotically produced by specialized cells of mycelia´s 
hyphae (conidiophores) and therefore termed as mitospores or conidiospores. The members of 
Ascomycota possess the so called “ascus” from which the name of Ascomycota derived from. The 
ascus is a sac-like unit in which the meiosis takes place resulting in the haploid ascospores. The 
fusion of different mating types of hyphae initiates the sexual stage resulting in the fruiting body 
“ascocarp” which is composed of the dikaryotic hyphae. The ascus is located at the tip of the 
hyphae and harbors the ascospores being the sexual spores. Two haploid nuclei exist in parallel 
in one ascus subsequently undergoing reproduction and fusion to diploid zygotes. In the next stage 
the ascus passes the meiosis leading to recombined haploid nuclei. Mitosis and cell division 
generate the haploid ascospores which serve for propagation (Webster and Weber 2007). 
Claviceps purpurea (C. purpurea) belonging to the family Clavicipitaceae parasitizes on wheat or 
rye. In 1853, Tulasne made the connection between the consumption of bread contaminated with 
the sclerotium (resting structure) and the poisoning effects (Tulasne 1853). These symptoms were 
initially described as “Saint Anthony´s Fire” in the middle age and are known dependent on the 
symptoms as ergotismus convulsivus (paranoia with hallucinations) or ergotismus gangraenosus 
(De Costa 2002; Lee 2009; Strickland et al. 2011). Another fungus producing clavine-type ergot 
alkaloids is Aspergillus fumigatus (A. fumigatus) from the family Aspergillaceae. This fungus is 
known to cause Aspergillosis, an infection of the lungs in immune compromised patients (Latgé 
1999). Oral thrush and candidiasis are infectious diseases caused by the yeast Candida albicans 
which infects oral or vaginal mucosa (Shepherd et al. 1985). 
Ascomycota contains also an impressive repertoire of enzymes being valuable for food- and 
pharmaceutical industry as well as research. For example, Penicillium camemberti and Penicillium 
roqueforti are used for the refining of cheese, e.g. to Camembert or Roquefort, respectively (Ropars 
et al. 2012). Saccharomyces cerevisiae (S. cerevisiae) is indispensable in the production of bread, 
beer and wine. During the fermentation process S. cerevisiae utilizes glucose or sucrose to yield 
ethanol and carbon dioxide. The directed genetic manipulation of yeast enables this organism for 
the production of recombinant proteins, e.g. insulin (Kjeldsen 2000). 
The steadily growing phylum of the Ascomycota is a valuable genetic source encoding enzymes 
that produce biologically active SMs (Keller et al. 2005; Li 2010). Several SMs are strongly toxic 
and some are of pharmacological relevance (Evidente et al. 2014; Kornienko et al. 2015). 
Aspergillus species produce a variety of mycotoxins. Among the best known representatives are 
aflatoxins (potent carcinogens), cyclopiazonic acid (focal necrosis in most vertebrates), 
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cytochalasin E (toxic metabolite), gliotoxin (strongly immunosuppressive), ochratoxin A 
(nephrotoxic), sterigmatocystin (possible carcinogen), verruculogen and fumitremorgins (extremely 
toxic tremorgenic mycotoxins) (Frisvad et al. 2006) (Figure 1.1). 
 
Figure 1.1 Mycotoxins from Aspergillus species 
C. purpurea produces ergot alkaloids possessing a structural relationship to the neurotransmitters 
noradrenaline, dopamine, and serotonin and therefore interacting with the corresponding receptors 
of the central nervous system and adrenergic receptors of blood vessels (Gerhards et al. 2015; Mai 
and Li 2013). Ergot alkaloids such as ergotamine, ergometrine and ergocryptine serve as drugs in 
the modern medicine for the treatment of migraine, postpartum haemorrhage and endocrine-
related tumor, e.g. prolactin dependent mammary carcinoma, respectively (Figure 1.2) (Bills and 
Gloer 2016). The discovery of the β-lactam antibiotic penicillin produced by Penicillium 
chrysogenum led to a breakthrough in the therapy of bacterial infections (Figure 1.2) (Keller et al. 
2005). Another milestone is the application of cyclosporin (Figure 1.2) from Tolypocladium niveum 
as immunosuppressive drug after the transplantation of organs in order to prevent the rejection of 
the foreign tissue (Dittmann et al. 1994; Weber et al. 1994). Lovastatin (Figure 1.2) is derived from 
Aspergillus terreus and used to prevent cardiovascular diseases. The inhibition of the HMG-CoA 
reductase by statins lowers the cholesterol level and thus reduces the production of low-density 
lipoprotein (LDL) being amongst others responsible for coronary heart disease (Alberti et al. 2017; 
Keller et al. 2005; Manzoni and Rollini 2002; Tobert 2003). The Aspergillus ustus derived (-)-
phenylahistin exhibits antitumor activity against eight tumor cell lines in vitro and against P-388 
leukemia and Lewis lung carcinoma cells in vivo. Combined with docetaxel, the semisynthetic 
phenylahistin derivative, plinabulin (Figure 1.2) was evaluated in phase II of clinical trials against 
non-small cell lung cancer (Kanoh et al. 1997; Kanoh et al. 1999; Kornienko et al. 2015). 
The ascomycetous fungus Aspergillus fischeri produces the hexacyclic peptidyl alkaloid ardeemin 
which consists of a tripeptidyl backbone and a dimethylallyl moiety. Ardeemin undergoes enzymatic 
acetylation to yield 5-N-acetylardeemin (Table 1.1 and Table 1.2) (Haynes et al. 2013). These 
SMs, tailored by the PT ArdB, exhibit significant interaction with a membrane P-glycoprotein (Pgp) 
that acts as MDR export pump (Juliano and Ling 1976; Kartner et al. 1983). The binding of ardeemin 
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or 5-N-acetylardeemin to the Pgp reduces the resistance against antitumor drugs, e.g. vinca 
alkaloids (Chou et al. 1998). Due to their pharmacological relevance, various ardeemin derivatives 
have been isolated and modifications have also been chemically performed (Ge et al. 2010; 
Hayashi et al. 2015; Hochlowski et al. 1993; Karwowski et al. 1993; Zhang et al. 2010; Zhang et al. 
2014; Zheng et al. 2014). 
Figure 1.2 Pharmacologically active substances from fungal origin 
Several prenylated IAs have been isolated from fungal origin with promising biological and 
pharmacological activities (Table 1.1). Ergotamine is a representative which is used as drug in the 
modern medicine (Table 1.1). Out of these structures, prenylated tryptophan-containing CDPs are 
an impressive group of SMs with diverse biological activities. For example, tryprostatins A and B 
as well as fumitremorgin C have been shown to act as anticancer agents (Table 1.1). In a previous 
study, fourteen tryptophan-containing CDPs have been regularly prenylated at the C-2 position by 
a PT. Using human leukemia K562, ovarian cancer A2780 sens and A2780 CisR cell lines, these 
prenylated CDPs showed significant cytotoxic effects in comparison to the non-prenylated 
substrates (Wollinsky et al. 2012a). These results clearly demonstrate that PTs are valuable 
catalytic tools for the production of bioactive prenylated compounds. Thus this thesis covers the 
application and manipulation by site-directed mutagenesis of such enzymes for the production of 
new prenylated IAs including CDPs and tripeptide derivatives. 
1.2 The diversity of prenyltransferases 
PTs catalyze a prenyl transfer reaction from dimethylallyl diphosphate (DMAPP; C5), geranyl 
diphosphate (GPP; C10), farnesyl diphosphate (FPP; C15) and geranylgeranyl diphosphate (GGPP; 
C20) onto diverse acceptors, e.g. aliphatic and aromatic low-molecular-weight compounds, 
polynucleotides and proteins (Heide 2009) and are involved in various metabolic pathways of the 
primary and secondary metabolism in all kingdoms of life. They play crucial roles in physiological 
processes and contribute to the structural diversity of SMs.  
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Table 1.1 Prenylated IAs and their corresponding biological and pharmacological activities 
 
  
    ergotamine fumitremorgin B R = OCH3 tryprostatin A 
R = H tryprostatin B 
fumitremorgin C 
C. purpurea Aspergillus sp. Aspergillus sp. Aspergillus sp. 
antimigraine mycotoxin microtubule inhibitors BCRP inhibitor 
(Robertson et al. 2010) 
(Sabater-Vilar et al. 
2003) 
(Pindiprolu et al. 2018) 
(Rabindran et al. 1998; 
Rabindran et al. 2000) 
    
terezine D acetylaszonalenin roquefortine amauromine 
Sporormiella teretispora 
N. fischeri 
Aspergillus sp. 
Penicillium sp. 
Aspergillus sp. 
Amauroascus sp. 
antibacterial nematicide neurotoxic antibacterial Ca
2+-antagonist 
(Wang et al. 1995) (Hayashi et al. 2007) 
(Keblys et al. 2004; 
Kopp-Holtwiesche and 
Rehm 1990) 
(Takase et al. 1984a; 
Takase et al. 1984b; 
Takase et al. 1985) 
 
  
 
fellutanine D okaramine A 5-N-acetylardeemin terpeptin 
Penicillium sp. 
 
Penicillium 
simplicissimum 
A. fischeri A. terreus 
cytotoxic insecticide MDR export pump inhibitor cell cycle inhibitor 
(Kozlovsky et al. 2000; Li 
2010) 
(Kato et al. 2018; 
Matsuda 2018) 
(Juliano and Ling 1976; 
Kartner et al. 1983) 
(Kagamizono et al. 1997) 
 
 
 
 
α -cyclopiazonic acid variecoloritide C echinulin and derivatives  
Aspergillus sp. 
Penicillium sp. 
Aspergillus variecolor Aspergillus ruber  
Ca2+-ATPase inhibitor cytotoxic antiviral/ antitumor/ neuroprotective  
(Chang et al. 2009; 
Holzapfel 1971) 
(Wang et al. 2007) 
(Chen et al. 2015; 
Dewapriya et al. 2013; 
Wijesekara et al. 2013) 
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The enormous diversity of PTs, which differ in their substrate specificity, regioselectivity, ion-
dependency, reaction site, reaction velocity, function etc., makes this class of enzymes an 
interesting area of research. The search in PubMed with over 6000 hits for “prenylation” and over 
1000 hits for “prenyltransferase” underlines their importance. The posttranslational modification of 
proteins or RNA by PTs shows that they are part of physiological processes and therefore also 
represent target structures for drug development. The prenylation reactions result in the formation 
of C-C, C-O, C-N or C-S bond between the C-1 or C-3 atom of the prenyl donor and the activated 
carbon or hetero atom of the prenyl acceptor. The targeted structures often obtain their functionality 
after being prenylated as exemplified by prenylated proteins, special peptide pheromones and t-
RNA (Dumelin et al. 2012; Okada et al. 2005; Tsuji et al. 2012; Wang and Casey 2016). 
 
1.2.1 Isoprenyl diphosphate synthases 
In the biosynthesis of over 60,000 known natural isoprenoids (terpenes), isoprenyl diphosphate 
synthases catalyze the linkage of an allylic diphosphate (C5-DMAPP, C10-GPP, C15-FPP or C20-
GGPP) with a varying number of isopentenyl diphosphate (IPP) units. The chain elongation occurs 
in a head-to-tail (1’-4) condensation resulting in products with either trans- or cis-double bond 
configuration that is catalyzed by trans-PTs or cis-PTs, respectively (Kobayashi and Kuzuyama 
2019). Further classification of isoprenyl diphosphate synthases can be done depending on the 
catalyzed product chain length, i.e. short- (C10 - C25), medium- (C30 - C45), or long-chain (≥ C40) 
prenyl diphosphates (Nagel et al. 2019). Isoprenoids with a chain length up to C-20 such as 
monoterpenes, sesquiterpenes and diterpenes, are mainly synthesized by trans-PTs and therefore 
are also termed as short chain trans-PTs (Dhar et al. 2013; Poulter 2006). Cis-PTs have been 
shown to synthesize longer isoprenoids as exemplified by the undecaprenyl diphosphate (C55, 
UPP) which is an essential molecule for the peptidoglycan biosynthesis of bacterial cell walls. 
Another example is the natural rubber with more than 4,000 isoprene units (Takahashi and Koyama 
2006; Yamashita et al. 2016).  
 
1.2.2 Prenylation of proteins 
The prenylation of proteins is a post-translational modification which is ubiquitous in the eukaryotic 
cells and has initially been identified in fungi (Kamiya et al. 1978). Prenylated proteins possess 
increased lipophilicity facilitating the interaction with other proteins or membranes. Three types of 
protein PTs have been discovered to catalyze farnesylation or geranylation of their target protein 
structures (e.g. Ras enzymes and G-Proteins). Farnesyltransferase and geranylgeranyl transferase 
type I attach FPP or GGPP to a cysteine at the C-terminus which is part of the so-called CaaX 
motif. Generally, two aliphatic amino acids follow the cysteine and the subsequent amino acid “X” 
is the determining factor to distinguish between FPP and GGPP as prenyl donor. The 
geranylgeranyl transferase type II is responsible for the attachment of two GGPPs on two cysteines 
of Rab proteins containing “CXC” or “CCXX” as characteristic motifs. The protein prenylation 
attracted high attention based on the findings that prenylation of Ras proteins increased their 
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oncogenic activity. Great efforts have been made to provide inhibitors for protein prenylation. 
However, promising candidates have been tested in clinical trials with no or low effects 
(Palsuledesai and Distefano 2015; Wang and Casey 2016). 
 
1.2.3 Prenylation of aromatic small molecules 
In the secondary metabolism of bacteria, fungi and plants, a set of PTs have been identified that 
attach diverse prenyl moieties to aromatic acceptors, e.g. indole derivatives, tyrosine, naphthalenes 
and xanthones (El-Seedi et al. 2009; Li 2010; Winkelblech et al. 2015). PTs utilizing aromatic 
acceptors for prenylation may be grouped considering the type of aromatic substrates, the 
dependency on divalent cations, the organism source and the cell localization (soluble or 
membrane-bound). In addition, characteristic amino acid sequences or structural features may 
serve as a criterion to distinguish between different families. 
 
1.2.3.1 UbiA superfamily 
The PTs of the UbiA superfamily are transmembrane enzymes and ubiquitously found in various 
organisms. They catalyze the formation of bioactive molecules, e.g. ubiquinones, menaquinones, 
plastoquinones, hemes, chlorophylls, vitamin E and lipids which contribute to cellular mechanisms 
(Li 2016). The eponym for this family is the gene ubiA from E. coli (Young et al. 1972). The encoding 
enzyme UbiA uses all-trans-octaprenyl diphosphate preferably in the presence of Mg2+ ions for 
prenylation of 4-hydroxybenzoate at the C-3 position (meta-position) to yield 4-hydroxy-3-all-trans-
octaprenylbenzoate which is an essential intermediate in the ubiquinone biosynthesis (Melzer and 
Heide 1994). The homologous enzyme COQ2 has also been identified in eukaryotes (Ashby et al. 
1992; Forsgren et al. 2004; Melzer and Heide 1994; Suzuki et al. 1994). The LePGT1 from 
Lithospermum erythrorhizon also uses 4-hydroxybenzoate as aromatic acceptor. However, this 
enzyme geranylates 4-hydroxybenzoate to yield the SM shikonin precursor (Ohara et al. 2013). 
The bacterial MenA and the eukaryotic UBIAD1 enzymes are involved in the biosynthesis of 
menaquinones (Nakagawa et al. 2010; Suvarna et al. 1998). The COX10, a farnesyltransferase 
involved in the heme biosynthesis, generates heme O (protoheme IX) by farnesylation of heme b 
utilizing in addition one water molecule (Kim et al. 2012). Chlorophyll is a further porphyrin ring 
containing system which serves as substrate for prenylation with phytyl diphosphate by the enzyme 
ChlG (Rudiger et al. 2005). Other members of the UbiA superfamily also participate in the 
production of SMs in plants, e.g. bitter acids and aurachins (Li et al. 2015; Stec et al. 2011). 
 
1.2.3.2 CloQ/NphB group 
PTs of the CloQ/NphB group are, distinct to the members of the UbiA superfamily, soluble enzymes 
that prenylate aromatic substrates such as naphthalenes, phenazines, quinones and phenolic 
compounds. While PTs of the UbiA family act dependent on metal ions and thus contain the 
characteristic NDxxD motif for the coordination of divalent cations, PTs belonging to CloQ/NphB 
group catalyze the prenylation reactions, with the exception of NphB, ion-independently. Their 
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amino acid sequences lack the aspartate rich motif NDxxD. The crystal structure of NphB revealed 
that four H2O molecules and two oxygen atoms of Asp 62 and α-phosphate are arranged in a planar 
manner that enables the coordination of a Mg2+ ion (Kuzuyama et al. 2005). The structure of 
clorobiocin, an antibiotic agent, derived from Streptomyces roseochromogenes is assembled with 
4-hydroxyphenylpyruvic acid carrying a dimethylallyl moiety at the meta-position. The cloQ gene 
showed no sequence similarity to known PTs and the recombinant expressed enzyme catalyzes 
the transfer of a dimethylallyl moiety from DMAPP to the C-3 position of 4-hydroxyphenylpyruvic 
acid ion-independently (Pojer et al. 2003). Based on the sequence data of cloQ, nphB in the 
naphterpin gene cluster encoding the PT NphB has been identified. This PT geranylates 1,6-
dihydroxynaphthalene and is also promiscuous toward a wide range of phenolic substrates for 
geranylation (Kuzuyama et al. 2005). SCO7190 identified in Streptomyces coelicolor A3(2) also 
applies 1,6-dihydroxynaphthalene as an aromatic substrate, but can only use DMAPP as a prenyl 
donor (Kumano et al. 2008). The PT Fnq26 from the furanonaphthoquinone I biosynthetic pathway 
utilizes GPP for the alkylation of flaviolin and additionally shows a wide acceptance toward phenolic 
substrates for regular and reverse prenylation at C- or O-atoms (Haagen et al. 2007). The marine 
Streptomyces sp. strain CNH-189 comprises a gene cluster for the biosynthesis of merochlorine A 
and B which are halogenated meroterpenoids. Four enzymes have been confirmed to catalyze the 
formation of these compounds. A prenyl diphosphate synthase forms a branched C15 prenyl donor 
termed isosesquilavandulyl-PP for the prenylation of 1,3,6,8-tetrahydroxynapthalene by Mcl23 
(Teufel et al. 2014). EpzP and PzpP from Streptomyces cinnamonensis and Streptomyces 
anulatus, respectively, are C9-prenylating enzymes of 5,10-dihydrophenazine-1-carboylic acid 
(Saleh et al. 2009; Seeger et al. 2011). A further member is DzmP from Micromonospora sp. 
RV115. Its unique feature, is the application of FPP as prenyl donor for the attachment at the N-
atom of dibenzodiazepinone, since it belongs to the CloQ/NphB enzymes (Bonitz et al. 2013).  
 
1.2.3.3 DMATS superfamily 
A large group of soluble PTs utilizing aromatic acceptors is the DMATS superfamily. Table 1.2 
gives an overview of the selected members of the DMATS superfamily and the corresponding 
prenylation reactions in the presence of their natural or best accepted substrate. These PTs can 
be found either at the beginning of biosynthetic pathways or in later steps for tailoring assembled 
scaffolds by prenylation, thus providing particular benefits to the structural diversity of SMs (Li 2010; 
Winkelblech et al. 2015). In ascomycetes, genes encoding PTs are often found in IA biosynthetic 
gene clusters (Xu et al. 2014). The majority of the members is limited to DMAPP as prenyl donor 
(Table 1.2). The catalyzed Friedel-Crafts alkylation by these PTs does not require metal ions for 
the formation of the carbocation. The generated dimethylallyl carbocation undergoes nucleophilic 
attack at C-1 or C-3 resulting in a regularly or reversely attached prenyl moiety, respectively 
(Winkelblech et al. 2015). Numerous biochemical studies clearly demonstrate the promiscuity 
toward a wide range of aromatic acceptors often possessing a distinct structure compared to their 
natural substrates (Fan et al. 2015a). Only a few DMATSs are accessible for longer prenyl donors 
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such as GPP or FPP. VrtC strictly requires GPP for geranylation of the intermediate 
naphthacenedione carboxamide in the biosynthesis of the tetracyclic viridicatumtoxin (Table 1.2) 
(Chooi et al. 2012). However, only some DMATSs, e.g. AtaPT, MpnD, TleC, BAE61387 and AstPT, 
are accessible for various prenyl donors (Table 1.2) (Chen et al. 2017; Mori et al. 2016; Pockrandt 
et al. 2014; Tarcz et al. 2014b). The first member of the DMATS superfamily was identified in the 
ergot alkaloid gene cluster of Claviceps sp. The gene dmaW encoding the 4-dimethylallyltryptophan 
synthase (4-DMATS) was initially identified from C. fusiformis (Table 1.2) (Tsai et al. 1995). Based 
on the obtained sequence, genes also encoding 4-DMATSs, catalyzing the first pathway-specific 
step in ergot alkaloid biosynthesis, could be found in different Claviceps species and families of 
Ascomycota, e.g. C. purpurea, A. fumigatus and Penicillium species (Gerhards et al. 2015; 
Tudzynski et al. 1999; Unsöld 2006; Unsöld and Li 2005). The enzyme FgaPT2, a 4-DMATS from 
A. fumigatus, is a large part of the focus of this thesis. It is used as a biocatalyst and model for the 
structure-based protein engineering by site-directed and site-saturation mutagenesis. Therefore, 
the preceding studies are briefly summarized here. 
FgaPT2 catalyzes a strict regiospecific and regular transfer of the dimethylallyl moiety from DMAPP 
to the C-4 of L-tryptophan as the first pathway-specific step in the biosynthesis of the ergot alkaloid 
fumigaclavine C in A. fumigatus (Table 1.2) (Unsöld and Li 2005). When tryptophan-containing 
CDPs have been applied as aromatic substrates, only relative low activities for regular C4-
prenylation has been demonstrated by FgaPT2 (Steffan and Li 2009). In a later study, various 
mutants of the amino acid residue R244 have been generated in order to improve the catalytic 
activities. FgaPT2_R244X (X = G, A, S, T, V, L, I, M, Y, N, Q, H, and K) clearly showed increased 
activities toward different tryptophan-containing CDPs while retaining C4-prenylation at the indole 
ring (Fan and Li 2016). FgaPT2 can also use non-natural alkyl donors such as monoallyl 
diphosphate (MAPP), 2-pentenyl diphosphate (2-pen-PP) and benzyl diphosphate for the alkylation 
of L-tryptophan. In the case of 2-pen-PP and benzyl-PP, C5-alkylated or C5-benzylated L-
tryptophan has been identified, whereas FgaPT2 attaches MAPP both at the C-4 and C-5 position 
of the indole moiety (Liebhold et al. 2012; Liebhold and Li 2013). Based on the obtained crystal 
structure of the FgaPT2 wildtype, the carboxyl group of E89 forms a hydrogen bond to the indole 
amine group and thus facilitates the electrophilic attack by the dimethylallyl carbocation. The basic 
amino acid residue K174 is responsible for re-aromatization by abstracting the proton at C-4 from 
the indole σ-complex (Metzger et al. 2009). These amino acid residues have been mutated to 
generate E89Q, E89A, K174Q and K174A by site-directed mutagenesis and used for the 
determination of their kcat. The turnover numbers were drastically reduced in the presence of 
DMAPP and L-tryptophan. Incubation of FgaPT2_K174A with L-tryptophan in the presence of 
DMAPP resulted, additionally to the minor 4-dimethylallyl tryptophan product, in the formation of 
the reverse C3-prenylated L-tryptophan generating a hexahydropyrroloindole alkaloid (Luk et al. 
2011). This is a sole example for a prenylation shift by the mutated FgaPT2. In another study, the 
substrate preference of FgaPT2 was changed from L-tryptophan to L-tyrosine by mutating the 
amino acid residue K174 to K174F. FgaPT2_K174F possesses an almost 5-fold higher catalytic 
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efficiency for prenylation of L-tyrosine at the C3-position than the wildtype enzyme. In contrast, the 
acceptance of L-tryptophan was nearly abolished by this mutant (Fan et al. 2015c). In addition to 
FgaPT2, the L-tryptophan prenylating enzymes 5-DMATS, 5-DMATSSc, 6-DMATSSa and 7-DMATS 
were biochemically investigated in the presence of ardeemin FQ and its stereoisomers in the 
course of this thesis. The 5-DMATS originates from Aspergillus clavatus and catalyzes the C5-
prenylation in an unresolved biosynthetic pathway (Table 1.2) (Yu et al. 2012). In the biosynthesis 
of 5-dimethylallylindole-3-acetonitrile in Streptomyces coelicolor, 5-DMATSSc attaches DMAPP to 
the C-5 position of L-tryptophan (Table 1.2) (Ozaki et al. 2013; Subramanian et al. 2012). The C6-
PT 6-DMATSSa from Streptomyces ambofaciens is most likely involved in the biosynthesis of 6-
prenyltryptophanol (Table 1.2) (Winkelblech and Li 2014). 7-DMATS (C7-PT) from A. fumigatus is 
part of the astechrome biosynthetic pathway (Table 1.2) (Kremer et al. 2007; Yin et al. 2013c). As 
aforementioned CDPs serve as substrates for PTs possessing promising pharmacological and 
biological activities after being prenylated. These compounds are naturally occurring 2,5-
diketopiperazines. A wide range of structurally diverse CDPs have been isolated from various 
microorganisms (Borthwick 2012). The assembly of two α-amino acids is catalyzed by 
nonribosomal peptide synthetases (NRPSs) in fungi (Hoffmeister and Keller 2007; Schwarzer et al. 
2003), whereby cyclodipeptide synthases (CDPSs) utilize amino acid-loaded t-RNAs as substrates 
for the formation of CDPs in bacteria (Giessen and Marahiel 2014). Numerous fungal CDPs are 
constructed from L-tryptophan and a second variable amino acid. These structures are frequently 
modified by prenylation, hydroxylation, methylation, dimerization and cyclisation (Borthwick 2012; 
Giessen et al. 2013; Li 2010; Xu et al. 2014). A group of PTs belonging to the DMATS superfamily 
uses such aromatic acceptors for the prenylation at the indole ring and therefore are termed as 
cyclic dipeptide PTs. Many of these PTs are characterized to transfer the dimethylallyl moiety from 
DMAPP to the indole ring of tryptophan-containing CDPs. In contrast, only few examples have 
been reported for geranylation of CDPs (Chen et al. 2017; Pockrandt and Li 2013). In this thesis, 
the following cyclic dipeptide PTs have been applied for protein engineering by site-directed 
mutagenesis and as biocatalysts for chemoenzymatic synthesis of new prenylated compounds. 
CdpC2PT from N. fischeri catalyzes the reverse C2-prenylation of various tryptophan-containing 
CDPs in the presence of DMAPP with (S)-benzodiazepinedione and cyclo-L-tryptophanyl-L-
tryptophanyl as the best accepted aromatic substrates (Table 1.2) (Mundt and Li 2013). FtmPT1 
and BrePT use cyclo-L-tryptophanyl-L-prolinyl known as brevianamide F for C2- prenylation. BrePT 
catalyzes the formation of deoxybrevianamide E by reverse C2-prenylation in the notoamide 
biosynthesis in Aspergillus versicolor (Yin et al. 2013a), whereas FtmPT1 attaches dimethylallyl 
moiety to C-2 in a regular manner to yield tryprostatin B in the biosynthesis of fumitremorgine-type 
alkaloids in A. fumigatus (Table 1.2) (Grundmann and Li 2005). The C3-PT CdpNPT from N. 
fischeri prenylates (S)-benzodiazepinedione in a reverse manner to give the enzymatic product 
(2S,3R,11S)-aszonalenin (Table 1.2). CdpC3PT is also a C3-PT that accepts various CDPs for 
reverse prenylation resulting in syn-cis or anti-cis configuration dependent on substrate’s 
stereochemistry (Yin et al. 2010). AnaPT from N. fischeri is a reverse C3-PT contributing to the 
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biosynthesis of acetylaszonalenin by prenylation of (R)-benzodiazepinedione (Table 1.2) (Yin et al. 
2009). 
 
Table 1.2 Prenylation reactions catalyzed by the members of the DMATS superfamily.  
This table was adopted from (Winkelblech et al. 2015) 
enzyme 
organism product 
biosynthetic 
pathway reference 
tryptophan prenyltransferases 
CymD 
Salinispora arenicola 
 
cyclomarin/ 
cyclomarazine (Schultz et al. 2010) 
DmaW 
C. fusiformis 
 
ergot alkaloids (Tsai et al. 1995) 
FgaPT2 
A. fumigatus 
fumigaclavine C (Unsöld and Li 2005) 
DmaW-Cs 
Periglandula sp. 
ergot alkaloids (Markert et al. 2008; Steiner et al. 2011) 
MaPT 
Malbranchea aurantiaca 
unknown (Ding et al. 2008) 
5-DMATS 
A. clavatus 
 
unknown (Yu et al. 2012) 
5-DMATSSc 
Streptomyces coelicolor 
5-DMAI-3-acetonitrile (Subramanian et al. 2012) 
IptA 
Streptomyces sp. 
 
6-DMAI-3-carbaldehyde (Takahashi et al. 2010) 
6-DMATSSa 
Streptomyces 
ambofaciens 
 
unknown (Winkelblech and Li 2014) 
6-DMATSSv 
Streptomyces 
violaceusniger 
unknown (Winkelblech and Li 2014) 
6-DMATSMo 
Malbranchea 
olivasterospora 
unknown (Winkelblech et al. 2016) 
7-DMATS 
A. fumigatus 
 
astechrome (Kremer et al. 2007) 
7-DMATSNeo 
Neosartorya sp. unknown (Miyamoto et al. 2014) 
tryptophan-containing cyclic dipeptide prenyltransferases 
CTrpPT 
Aspergillus oryzae 
 
unknown (Zou et al. 2010) 
FtmPT1 
A. fumigatus 
 
fumitremorgin/ 
verruculogen (Grundmann and Li 2005) 
NotF 
Aspergillus sp. 
 
notoamide (Ding et al. 2010) 
BrePT 
Aspergillus versicolor 
brevianamide (Yin et al. 2013a) 
N
COOH
NH2
N
H
COOH
NH2
N
H
COOH
NH2
N
H
H
O
N
H
COOH
NH2
N
H
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O
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O
O
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EchPT1 
Aspergillus ruber 
 echinulin (Wohlgemuth et al. 2017) 
EchPT2 
Aspergillus ruber 
 CdpC2PT 
N. fischeri 
 
fellutanine (Mundt and Li 2013) 
CpaD-Af 
Aspergillus flavus 
 
cyclopiazonic acid (Liu and Walsh 2009) 
CpaD-Ao 
Aspergillus oryzae cyclopiazonic acid (Liu and Walsh 2009) 
CdpC7PT 
A. terreus 
 
unknown (Wunsch et al. 2015) 
AnaPT 
N. fischeri 
 
acetylaszonalenin (Yin et al. 2009) 
CdpNPT 
A. fumigatus 
 
unknown (Schuller et al. 2012) 
CdpC3PT 
N. fischeri 
 
roquefortine D (Kosalkova et al. 2015) 
ArdB 
Aspergillus fischeri 
 
ardeemin (Haynes et al. 2013) 
LtxC 
Lyngbya majuscula 
 
lyngbyatoxins (Edwards and Gerwick 2004) 
TleC 
Streptomyces 
blastmyceticus 
teleocidin B (Awakawa et al. 2014) 
DMATSs of diverse substrates 
FtmPT2 
A. fumigatus 
 
fumitremorgin/ 
verruculogen (Grundmann et al. 2008) 
NotC 
Aspergillus sp. 
 
stephacidin/ 
notoamide (Ding et al. 2010) 
FgaPT1 
A. fumigatus 
 
fumigaclavine C (Unsöld and Li 2006) 
TdiB 
Aspergillus nidulans 
 
terrequinone A (Schneider et al. 2008) 
N
H
HN
NH
H
N
O
O
N
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OH
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AstPT 
Aspergillus terreus 
 
unknown (Tarcz et al. 2014a) 
AtmD 
Aspergillus flavus 
 
(β-)aflatrem (Liu et al. 2013) 
PaxD 
Penicillium paxilli 
 
diprenylated paxillin, 
paspalitrem (Liu et al. 2014) 
FtmPT3 
N. fischeri 
 
fumitremorgin (Mundt et al. 2012) 
PenI 
Penicillium thymicola 
 
penigequinolones (Zou et al. 2015) 
PenG 
Penicillium thymicola 
 
penigequinolones (Zou et al. 2015) 
XptB 
Aspergillus nidulans 
 
shamixanthone/ 
epishamixanthone (Pockrandt et al. 2012) 
PAPT 
Phomopsis amygdali 
 
fusicoccin J (Noike et al. 2012) 
BAE61387 
Aspergillus oryzae 
 
unknown (Pockrandt et al. 2014) 
NscD 
N. fischeri 
 
neosartoricins 
(Chooi et al. 2013) 
Mc03599 
Microsporum canis (Chooi et al. 2012) 
Tt06703 
Trichophyton tonsurans (Yin et al. 2013b) 
VrtC 
Penicillium aethiopicum 
 
viridicatumtoxin (Chooi et al. 2012) 
tyrosine prenyltransferases 
SirD 
Leptosphaeria 
maculans 
 
Sirodesmin PL (Kremer and Li 2010) 
TyrPT 
Aspergillus niger unknown (Fan and Li 2014) 
N
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1.3 Reaction mechanism and X-ray crystal structure data of aromatic 
prenyltransferases 
All PTs belonging to the DMATS superfamily share a common, conserved architecture termed PT 
barrel fold. This fold is also known as ABBA fold as it is characterized by five ααββ repeating units 
forming a central, ten-stranded, antiparallel β-barrel surrounded by ten (or more) α-helices (Figure 
1.3). The architecture of this enzyme class was first established for the bacterial PT NphB 
(Kuzuyama et al. 2005). Later it was shown that fungal PTs like the C4-dimethylallyltryptophan 
synthase FgaPT2 is evolutionarily linked to the bacterial aromatic PTs (Metzger et al. 2009) sharing 
the same protein fold despite a fairly low sequence similarity. The mechanism of prenylation is best 
described as an electrophilic aromatic substitution. In the first step of the reaction, the enzymatic 
environment of the PT facilitates the formation of a carbocation from an activated prenyl donor like 
dimethylallyl pyrophosphate. The carbocation attacks the aromatic nucleus to form a so-called σ-
complex (also termed Wheland complex) which is characterized by the loss of the aromaticity and 
the sp3-hybridization of the attacked carbon atom of the prenyl acceptor. The enzymatic cycle is 
completed by the deprotonation. For re-aromatization and to yield the prenylated product a 
deprotonation at the certain reactive position occurs. 
PTs of the DMATS superfamily are known to occupy a broad substrate specificity towards aromatic 
substrates. From nearly 50 biochemically characterized enzymes, most PTs use DMAPP as prenyl 
donor for a regiospecific alkylation reaction of their aromatic substrates. A minority of these PTs 
can also transfer prenyl donors such as GPP and FPP. The reaction mechanisms of AtaPT, MpnD, 
TleC and PriB have been elucidated by crystal structures. So far, mutation experiments have only 
been able to change the substrate specificity of the prenyl donor in AtaPT, MpnD and TleC. It 
should be noted that these PTs already possessed a high flexibility with respect to the prenyl donor 
and that a higher yield could be achieved by mutations. The question was whether the flexibility 
towards the prenyl donor could also be extended for PTs, which are almost limited to the use of 
DMAPP. A total of six DMAPP-specific PTs (FgaPT2, FtmPT1, BrePT, CdpC2PT, CdpNPT and 
CdpC3PT) were selected for these investigations in course of this thesis. The biochemical 
investigation of the corresponding mutants showed that DMAPP-specific PTs can be changed into 
GPP-specific PTs and thus can also be used for chemoenzymatic syntheses of new geranylated 
IAs. 
 
1.3.1 NphB 
The first structurally characterized aromatic PT was the bacterial enzyme NphB from a 
Streptomyces strain (Kuzuyama et al. 2005). The enzyme is part of the gene cluster for the 
biosynthesis of the anti-oxidative naphterpin catalyzing the attachment of the geranyl moiety from 
GPP to the 1,3,6,8-tetra-hydroxynaphthalene-derived intermediate flaviolin. Biochemical 
investigation with the purified recombinant enzyme and tetra-hydroxynaphthalene analogues as 
well as a wide range of aromatic acceptors carrying hydroxyl moieties showed the promiscuous 
INTRODUCTION 
18 
geranylation catalyzed by NphB. The two geranylated products trans-2-geranyl 1,6-
dihydroxynaphthalene and trans-5-geranyl 1,6-dihydroxynaphthalene could also be obtained by 
incubation of 1,6 hydroxynaphthalene (1,6-DHN), Mg2+ and GPP in the presence of the enzyme 
NphB (Kuzuyama et al. 2005). NphB is a magnesium-dependent enzyme but does not contain a 
(N/D)DXXD motif. This motif is found in other PTs and was assigned to the magnesium dependency 
of the enzymes. The binding of the Mg2+ ion is structurally determined in NphB and showed its 
coordination. The ternary complex containing geranyl S-thiolodiphosphate (GSPP), a non-
hydrolysable GPP analogue, Mg2+ and 1,6-DHN (pdb-code: 1ZDW) revealed that the octahedral 
coordinated cation is bound by the pyrophosphate group of GSPP, the carboxy group of D62 and 
four water molecules which form a hydrogen network to the residues K119, D110, additional water 
molecules and the α-phosphate moiety (non-bridging oxygen) (Figure 1.3 A). Y121 links the 
diphosphate moiety of the geranyl chain (Kuzuyama et al. 2005). The amino acid side chains V49, 
F123, M162, Y175 and Y216 protrude into the active site to hold the geranyl moiety in place (Figure 
1.3 A and Table 1.3). The inspection of the aromatic binding pocket revealed that both aromatic 
rings of 1,6-DHN are anchored by the hydrophobic residues M162 and F213 (Figure 1.3 A). 
Furthermore, contacts to the aromatic substrate have been determined for Q161, Y175, Q295, 
L298, F213, S214, V271 and Y288 (Figure 1.3 A and Table 1.3) (Kuzuyama et al. 2005). 
 
Table 1.3 Amino acid residues in the active center responsible for interaction with the prenyl 
pyrophosphate, prenyl residue and the aromatic substrate 
 
1.3.2 FgaPT2 
The first fungal PT of which a structure was determined was FgaPT2 from A. fumigatus. The X-ray 
structure of this dimethylallyl tryptophan synthase (pdb-code 3I4X) was solved as ternary complex 
with its aromatic substrate L-tryptophan and its non-hydrolysable substrate analogue dimethylallyl 
S-thiolodiphosphate (DMSPP) (Metzger et al. 2009). Although FgaPT2 shares no gene sequence 
similarity to NphB (sequence identity 15.6%), their crystal structures are closely related possessing  
 amino acids interacting with: 
enzyme pyrophosphate prenyl/ allylic cation aromatic substrate 
NphB K119, Y121, N173, Y216, R228, K284 V49, F123, M162, Y175, Y216 M162, F213, S214, Y288, Q295, L298 
FgaPT2 K87, R100, Y189, R257, K259, Y261, Q343, Y345, R404, Y409 Y189, Y261, Y345, Y398, Y413 E89, I80, L81, K174, Y191, R244, 
FtmPT1 R113, Y203, K294, Q380, Y446, Y450 
Y203, F280, Y296, 
Y382, Y450 
S92, M94, L96, E102, G115, W182, 
L187, Y203, Y205, H279, F280, M364, 
Y435 
CdpNPT R129, Y221, R284, K286, Y288, Y366, Y431, Y435 
Y221, F272, Y288, Y366, Y221, 
Y435 
T108, E116, A131, Y195, F199, V201, 
V206, Y221, F223, F272, Y288, M349, 
W419 
AnaPT Q355, A421, T424 Y282, Y357, Y426, W410 F103, G126, F212, I266, V340, W410 
TleC R119, K187, R248, R378 W97, E123, F170, A173, F189, Y252, Y317, Y382 I26, E28, W97, E106, K297, P298, N367 
MpnD R103, K173, Y175, K235, Y237, Y367 Y80, W157, M159, Y175 D4, Y80, E89, Q239, K279, P280, N349 
AtaPT K95, R104, K188, R264, K266, N328, Q342, N411 Y190, Y268, Y344, Y413 
H88, E91, L194, L204, L249, L252, 
A270, F272, L323, R396, W397 
PriB R108, K179, Y181, R232, K234, Y236, R376, Y380 Y181, F220, Y236, Y380 
F85, L86, E94, L110, W165, F220, 
L293, H312, R316, Y364, Y380 
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a Cα-rms deviation of 3.3 Å (240 aligned residues). FgaPT2 is 152 amino acids larger than NphB. 
These amino acids are located in additional α-helices and extended loop regions. FgaPT2 contains 
13 α-helices and three of these are located at the N-terminus. In comparison, NphB contains 
altogether 11 α-helices two of which are located at the N-terminus. The central barrel of both 
enzymes is assembled by 10 antiparallel β-strands. The amino acids that interact with the 
substrates have been found to be located mainly in the β-strands or directly adjacent loop regions. 
The positively charged arginine amino acid residues at position R100, R257 and R404 and lysine 
at position K187 and K259 compensate for the negatively charged diphosphate group (Figure 1.3 
B and Table 1.3). Additionally, the hydroxyl groups of Y189, Y261, Y345, Y409, Y413 and the 
amide of Q343 are in contact via hydrogen bonds to the prenyl donor (Figure 1.3 B and Table 1.3) 
(Metzger et al. 2009). The initial binding of the aromatic substrate L-tryptophan is necessary as the 
reactive carbocation is stabilized by the π-interaction of the indole ring and the benzene ring of 
Y345. The interaction of the carboxylate group of E89 and the N-H of the indole ring facilitates the 
electrophilic attack of the carbocation at the C-4 position. Since the carbocation would be attacked 
by nucleophiles such as H2O, a tyrosine shield consisting of Y189, Y261, Y345, Y398 and Y413 
protect the reactive prenyl intermediate from quenching (Figure 1.3 B and Table 1.3). The 
regiospecific C4-prenylation is explained by the interactions via hydrogen bonds of the amino acids 
Y191, R244, I80 and L81 which provide the convenient orientation of L-tryptophan for the 
electrophilic attack at the carbocation (Figure 1.3 B and Table 1.3) (Metzger et al. 2009). 
The measurement of the distances between the C-1 atom of the dimethylallyl cation to the benzene 
ring of the prenyl acceptor revealed similar distances in the range of 3.5-3.7 Å for C4-, C5- and C6-
positions. The regioselectivity of the reaction seems to be achieved by a combination of steric 
restraints in the first step of the catalysis and the position of the catalytic base K174 (Figure 1.3 B 
and Table 1.3). The formation of the σ-complex is unlikely at position C5 to C7 as the rigid amino 
acid side chains of the tyrosine shield (Y189, Y398, Y413) disfavor the formation of a sp3-
hybridized intermediate whereas C-4 position is less restricted due to the shorter and less rigid side 
chain of L245 (Figure 1.3 B). The lysine at 174 position contributes to the re-aromatization by 
abstraction of a proton at the C-4 position and its location contributes to the regiospecificity of the 
reaction (Metzger et al. 2009). 
 
1.3.3 FtmPT1 
The gene ftmPT1 belongs to the gene cluster of fumitremorgin-type alkaloids in A. fumigatus. The 
ternary complex structure (pdb-code 3O2K) of FtmPT1 with its substrates brevianamide F and 
DMSPP provides insight into the catalytic mechanism of the regioselective C-2 prenylation of 
brevianamide F (Jost et al. 2010). Moreover, the prenylation reaction is chemoselective as the 
product observed in catalysis is exclusively linked to the C-1 atom of DMAPP (regular prenylation) 
yielding to the product tryprostatin B (Table 1.2). A reverse prenylation where the prenyl donor 
attaches via its C-3 atom to the prenyl acceptor is not observed. The aromatic substrate is bound 
in the hydrophobic reaction chamber by the amino acid residues Y435, Y203, L96, L187, M94, 
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Figure 1.3 Active centers of PTs belonging to the DMATS superfamily prepared with the help of 
Georg Zocher 
M364 and F280 (Figure 1.3 C and Table 1.3) (Jost et al. 2010). Additionally, hydrogen bonds 
contribute to the fixation of the substrate, e.g. the carboxylate group of E102 interacts with the N-1 
of the indolyl residue as well as the hydroxyl group of Y205 contacts the O-18 of the prenyl acceptor 
(Figure 1.3 C and Table 1.3). Both interactions stabilize the prenyl acceptor binding. Two 
backbone amino acid interactions (S92 and W182) stabilize a water molecule which stabilizes the 
prenyl acceptor at the oxygen atom O-19 (Jost et al. 2010). The binding location is similar to the 
binding of the substrates in FgaPT2 and is located near the center of the barrel. The terminal 
phosphate group of the prenyl donor is hold in place by two positively charged residues (R113 and 
K294) and further interactions to the amino acids Q380 and Y446 (Figure 1.3 C and Table 1.3). 
The phosphate group linking the terminal phosphate with the dimethylallyl moiety binds to R113 
via a salt bridge and additionally hydrogen contacts are formed to Y203 and Y450. The hydroxyl 
groups of the four tyrosine residues Y203, Y296, Y382 and Y450 create the so-called tyrosine 
shield which is responsible for the protection of the brevianamide F and DMAPP from the solvent 
by providing a hydrophobic binding pocket (Figure 1.3 C and Table 1.3) (Jost et al. 2010). This is 
necessary to prevent the reaction of the dimethylallyl cation with nucleophilic agents. G115 and 
H279 contribute the binding of larger aromatic substrates. The corresponding amino acids in 
FgaPT2 are T102 and R244, respectively, allowing preferably the accommodation of smaller 
substrates like L-tryptophan and influence the orientation of these substrates in the binding pocket. 
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The differences in the regioselective prenylations between FgaPT2 and FtmPT1 can be explained 
mainly by the amino acid side chain G115 in FtmPT1. In FgaPT2, the corresponding amino acid 
(T102) pushes the indole ring system in a nearly coplanar orientation towards the π-system of the 
dimethylallyl cation resulting in substrate distances (C1-atom of DMAPP) of approx. 3.6 Å to the 
benzene ring system. As G115 in FtmPT1 lacks the side chain atoms, the indole ring system of 
brevianamide F is tilted away from DMAPP increasing the prenyl donor to prenyl acceptor distances 
at the benzene ring system (position C-4 to C-7) to more than 4.7 Å. This disfavors the prenylation 
at these positions and facilitates the prenylation at either N-1 or C-2 position (Jost et al. 2010). 
Nevertheless, a reverse prenylation which would be a consequence of the structural data was not 
observed, most likely because a rearrangement of the cationic intermediate takes place during 
catalysis resulting in the product formation. 
 
1.3.4 CdpNPT 
CdpNPT from A. fumigatus acts as a C-3β reverse PT (Table 1.2). The (S)- and (R)-
benzodiazepinediones have been identified to be well accepted by CdpNPT for prenylation and 
therefore (S)-benzodiazepinedione ((S)-BDZD) has been applied together with thiolodiphosphate 
(SPP) as ligands for the determination of the ternary crystal structure (pdb-code: 4E0U) (Schuller 
et al. 2012). The electron density for dimethylallyl moiety of dimethylallyl S-thiolodiphosphate 
(DMSPP) could not be observed. Presumably, the DMAPP analogue was hydrolyzed displaying 
only the electron density for SPP in the crystal. A closer look at the binding of the diphosphate 
group reveals that the residues R129, R284 and K286 with a positive charge stabilize the negatively 
charged terminal phosphate and Y431 contributes with a hydrogen bond (Figure 1.3 D and Table 
1.3) (Schuller et al. 2012). In comparison, four tyrosine residues of Y221, Y288, Y366 and Y435 
are responsible for the coordination with the second phosphate group (Figure 1.3 D and Table 
1.3). The dimethylallyl moiety is modelled into the binding pocket based on the basis of the structure 
of FtmPT1 in order to gain insight into the catalytic mechanism. The amino acid residues that 
contribute to the binding of (S)-BDZD are mostly located at the β-strands. These are F223, F272, 
M349, Y288, Y221, A131, V201, V206 and W419 (Figure 1.3 D and Table 1.3). Two hydrogen 
bonds between E116 and N-1 of the indole nucleus of (S)-BDZD and T108 to O-13’ of the liganded 
molecule contribute to the orientation. Contacts from V201, F199 and Y195 have also been 
observed (Figure 1.3 D and Table 1.3) (Schuller et al. 2012). The aromatic ring system of the 
prenyl acceptor takes place in an orientation that is similar to that observed in the FtmPT1, mainly 
caused by the amino acid A131 which tilted the indole ring away from the DMAPP, thereby 
facilitating the prenylation at C-2 or C-3. It is likely that the prenylation takes place exclusively at C-
3 position as position N-1 and C-2 are sterically blocked by the rigid side chains of W419 and Y435 
(Schuller et al. 2012). 
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1.3.5 AnaPT 
Although the ternary complex of AnaPT with CDPs and DMSPP could not be obtained, a complex 
with the hydrolysis product of DMSPP could be generated (pdb-code: 4LD7) (Yu et al. 2013). This 
crystal structure revealed that the diphosphate binding site is also conserved in AnaPT as shown 
for FgaPT2, FtmPT1 and CdpNPT. A structure-based sequence alignment identified CdpNPT to 
be closely related to AnaPT. The active site for diphosphate recognition of AnaPT differs in the 
amino acid residues Q355K, A421S and T424S. In AnaPT, the amino acids F103, G126, F212, 
I266, V340 and W410 contribute to the binding of the indole moiety of the substrate (Figure 1.3 E 
and Table 1.3) (Yu et al. 2013). It has been shown that small changes in the indole binding site 
impact the regio- and stereoselectivity (Yu et al. 2013). The corresponding amino acids are larger 
in CdpNPT, thus resulting in a smaller pocket for substrate accommodation. 
 
1.3.6 TleC and MpnD 
TleC from Streptomyces blastmyceticus and MpnD from Marinaactinospora thermotolerans utilize 
DMAPP or GPP as prenyl donor for the attachment at the C-7 position in a reverse manner to (-)-
indolactam V (Figure 1.3 F and G). TleC uses GPP as donor resulting in the enzyme product 
lyngbyatoxin (Table 1.2). MpnD preferably applies DMAPP to yield the product pendolmycin (Table 
1.2) (Mori et al. 2016). Both enzymes are also capable to accept prenyl donors with a chain length 
of up to 25 carbon atoms. The ternary crystal structure of TleC with (-)-indolactam V and DMSPP 
(pdb-code: 4YZL) revealed that E106 interacts as base with the N-1 of the indolyl residue of the 
aromatic substrate (Mori et al. 2016). E28, E106, K297 and N367 contribute with hydrogen bonds 
to hold the acceptor in place (Figure 1.3 G and Table 1.3). E106 and N367 form hydrogen bonds 
to N-1, whereas K297 and E28 linked via hydrogen bonds to the O-14 (Figure 1.3 G). Furthermore, 
I26, W97 and P298 are linked via two molecules with carbonyl oxygen of C-11 and the N-10. The 
terminal and the bridging phosphate group are anchored by the positively charged R119, K187, 
R248 and R378 (Figure 1.3 G and Table 1.3). The tyrosine of Y252, Y317 and Y382 stabilize the 
carbocation by shielding the prenyl moiety from solvent molecule and thus is called as tyrosine 
shield (Figure 1.3 G and Table 1.3) (Mori et al. 2016). Additionally, the carbocation is placed 
between indole ring of the aromatic substrate and the benzene ring of F189. These aromatic 
molecules contribute via π-π interaction to the stabilization of the carbocation. In the active site of 
MpnD (pdb-code: 4YLA), hydrogen bonds are formed from E89, K279, P280, N349 and the two 
water molecules, D4, Y80 and Q239 to the substrate in MpnD (Figure 1.3 F and Table 1.3). N-10 
and the carbonyl of C-11 and O-14 are linked via the two water molecules with D4, Y80 and Q239 
of the indole lactam. In MpnD, the benzene ring of Y175 and the indole nucleus of the aromatic 
substrate bind the prenyl donor via π-π interaction. In MpnD, the amino acid residues Y80, W157 
and M159 construct the binding pocket for the prenyl donor (Figure 1.3 F and Table 1.3) (Mori et 
al. 2016). In contrast, the homologous amino acid residues in TleC are W97, F170 and A173. 
Distinct to MpnD, the binding of the acceptor in TleC yields to the 70° rotation of the W97 which is 
determined to be mandatory for substrate binding. This rotation creates an enlarged binding pocket 
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and thus provides convenient space for GPP accommodation. In MpnD, the change of protein 
conformation does not occur after substrate binding. In TleC, the active site pocket for prenyl donor 
coordination is provided by the hydrophobic residues W97, E123, F170, A173 and F189 (Figure 
1.3 G and Table 1.3) (Mori et al. 2016). Due to the steric hindrance between Y80 (corresponding 
residue to W97 in TleC) and M159, the rotation of Y80 cannot take place in MpnD. Mutagenesis 
experiments have been performed considering the amino acids W97, F170, and A173 in TleC and 
the corresponding positions Y80, W157 and M159 in MpnD in order to alter the acceptance of 
prenyl donors. The mutants W97Y and A173M of TleC were incubated with (-)-indolactam V in the 
presence of the prenyl donors DMAPP, GPP and FPP. An increased activity toward DMAPP could 
be observed. In contrast, the acceptance of GPP was abolished with the A173M mutant. Through 
the small to large mutation, a GPP prenyltransferase was converted to a DMAPP prenyltransferase. 
The mutant W97Y highly increased the activity with DMAPP and still remains the activity towards 
GPP. Both single mutants Y80W and M159A in MpnD decreased the activity for dimethylallyl 
transfer. In contrast, a higher activity towards GPP was achieved. Additionally, the FPP-acceptance 
could be switched on by the M159A mutant (Mori et al. 2016). To investigate the catalytic action of 
double and triple mutants, the W97Y/A173M and W97Y/F170W/A173M of TleC and the 
Y80W/M159A and Y80W/W157F/M159A of MpnD have been created. Both mutants of TleC 
significantly decreased the activity toward DMAPP, but still maintain the preference for DMAPP as 
donor. The incubation of the double and triple mutant of TleC with GPP revealed the formation of 
a new product. This shows that the mutations in order to alter the prenyl donor acceptance also 
impact the regio- and stereoselective prenylation (Mori et al. 2016). From a structural point of view, 
it is remarkable that both enzymes (MpnD and TleC) catalyze reverse C7-prenylations and for both 
of them, the binding mode is substantially different to that observed for FgaPT2, FtmPT1, and 
CdpNPT. The binding situation clearly show a drastic reorientation of the aromatic systems (prenyl-
acceptor and –donor are both orientated almost perpendicular to each other). It remains so far 
unclear, if this is a situation observed for bacterial PTs or if C7-prenylating enzymes use this binding 
mode in general. 
 
1.3.7 AtaPT 
AtaPT from Aspergillus terreus has been characterized to accept various aromatic acceptors for 
the alkylation with different prenyl donors, e.g. DMAPP, GPP and FPP. Out of 106 tested 
substrates, 72 can be prenylated in the presence of DMAPP, GPP and/or FPP. Further, AtaPT is 
capable to catalyze mono-, di- and tri-prenylation at one aromatic substrate. The electrophilic 
alkylation occurs at the O- or C-atom of the substrate. With (+)-butyrolactone II, AtaPT has the 
ability to alkylate this substrate using GGPP or phytyl diphosphate (PPP) as prenyl donor (Chen et 
al. 2017). The top of the active site contains amino acid residues which are responsible for the 
prenyl donor binding. These positively charged basic amino acids K95, R104, K188, R264 and 
K266 and the polar amino acids N328, Q342 and N411 coordinate to the terminal phosphate group 
in order to stabilize the negative charge of the prenyl donor. The four tyrosines Y190, Y268, Y344 
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and Y413 form the tyrosine shield. These residues interact with the bridging phosphate group and 
protect the carbocation from nucleophilic attacks by solvent molecules. The hydrophobic core for 
substrate binding is composed of L252, L249, L323, F272, W397, A270, L204 and L194 (Chen et 
al. 2017). The comparison of the aromatic substrate binding pocket of other PTs identified the 
binding pocket of AtaPT to be unique and thus is not or little conserved. Herein, the binding pocket 
is constructed of hydrophobic amino acids with small side chains. Based on the crystallographic 
data of the binary complex of AtaPT and GPP, the G326 has been identified as the key residue for 
prenyl donor selectivity. This residue enlarges the active site and thus provides more space for 
prenyl donors with longer chain length. While the wildtype AtaPT clearly shows preference in the 
acceptance of GPP and FPP, the mutant G326M abolished the acceptance of these prenyl donors. 
In contrast, the activity towards DMAPP was significantly enhanced (Chen et al. 2017). 
 
1.3.8 PriB 
The PT PriB from Streptomyces sp. RM-5-8 catalyzes the transfer of the dimethylallyl moiety from 
DMAPP to the C-6 position of L-tryptophan. Furthermore, this PT accepts a wide range of aromatic 
substrates and utilizes prenyl donors with longer chain, e.g. GPP, FPP and GGPP. The 
antimicrobial agent daptomycin can also be applied as substrate for C6-prenylation with DMAPP 
by PriB (Elshahawi et al. 2017).  
The structure of the ternary complex of PriB with L-Trp-dimethylallyl and S-thiolodiphosphate was 
the first structure of a C6-prenylating ABBA PT (pdb-code: 5INJ). The ligand-bound structure shows 
that PriB undergoes a conformational change when the aromatic substrate and the prenyl donor 
are present in the enzyme binding pocket. This was shown by the rotation of R108 and Y181 of 
123° and 34°, respectively (Figure 1.3 H and Table 1.3) (Elshahawi et al. 2017). PriB also 
catalyzes the prenylation ion-independently which is consistent with presence of R108 and K179, 
which take on the role of divalent cations. The substrate orientation in PriB is comparable to that in 
MpnD and TleC and shows that the C6- and C7-prenylation reactions are closely related regarding 
substrate stabilization. The tyrosine residues Y181, Y236 and Y380 are responsible for the 
stabilization of the prenyl carbocation providing π-interaction (Figure 1.3 H). The residue E94 acts 
as base for abstraction of the N-1 proton of the indole nucleus and therefore initiates the σ-complex 
for C-prenylation. H312 was shown also to stabilize the complex for the prenyl transfer to C-6 
position (Figure 1.3 H) (Elshahawi et al. 2017). 
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2. AIMS OF THIS THESIS AND EXPERIMENTS 
In this thesis, the studies addressed are the following: 
 
Biochemical investigations of different dimethylallyl transferases toward their catalytic 
potential for generation of prenylated tripeptide fumiquinazolines 
Naturally occurring prenylated IAs with a tripeptidyl backbone are found in filamentous fungi. 
Specific PTs are responsible for the prenylation of such tripeptides.  
In this study, the objective was to investigate the conversion of these compounds by PTs from the 
DMATS superfamily. One tryptophan PT has been selected for site-directed mutagenesis 
experiments. Based on molecular modeling, two mutants have been created in order to achieve 
new catalytic abilities. 
The following experiments have been performed: 
• chemical preparation of ardeemin FQ and its three stereoisomers ent-ardeemin FQ, dia-
ardeemin FQ and dia,ent-ardeemin FQ and structure confirmation by HR-MS, 1H NMR, 13C 
NMR and 2D NMR (1H-1H COSY; 1H-13C HSQC; 1H-13C HMBC) which was carried out by 
Lena Ludwig-Radtke 
• site-directed mutagenesis of FgaPT2 to obtain the mutants FgaPT2_M328L and 
FgaPT2_Y398F 
• overproduction and purification of the His-tagged recombinant tryptophan 
prenyltransferases His8-FgaPT2, 5-DMATS-His6, His8-5-DMATSSc, 6-DMATSSa-His6, His6-
7-DMATS and the mutants His8-FgaPT2_M328L and His8-FgaPT2_Y398F 
• overproduction and purification of the His-tagged recombinant cyclic dipeptide 
prenyltransferases His5-BrePT, FtmPT1-His6, CdpNPT-His6, CdpC3PT-His6 and AnaPT-
His6 
• performance of enzyme assays and analysis of the product formation by LC-MS 
• application of NMR and mass analyses for structure elucidation of the enzyme products  
• determination of the kinetic parameters including Michaelis-Menten constants (Km) and 
turnover numbers (kcat) 
• molecular docking experiments of FgaPT2 with ardeemin FQ and its stereoisomers in order 
to explain the dependency of the regioselective prenylations on the substrate configuration 
and to identify potential amino acid residues for guidance of the prenylation position  
 
Creation of new biocatalysts for prenylation shift by combinational site-directed 
mutagenesis of two amino acid residues in FgaPT2 
High yields of C3-prenylated L-tyrosine, high acceptance of diverse cyclic dipeptides for C4-
prenylation as well as the reverse C3-prenylation and regular C4-geranylation of L-tryptophan could 
already be obtained by FgaPT2 mutants (Fan et al. 2015c; Fan and Li 2016; Luk et al. 2011; Mai 
et al. 2018).  
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However, altering the prenylation position of tryptophan-containing CDPs have not been reported 
prior to this work. Although PTs are already available with reverse C3-prenylation activity of CDPs, 
the objective of this study was to demonstrate that combinational site-directed mutagenesis 
enables to switch FgaPT2 from a regular tryptophan C4-prenyltransferase to a reverse cyclic 
dipeptide C3-prenyltransferase. 
The following experiments have been performed to generate the biocatalysts for chemoenzymatic 
synthesis: 
• creation of the mutants FgaPT2_K174A, FgaPT2_K174F_R244Q,
FgaPT2_K174F_R244N, FgaPT2_K174F_R244Y and FgaPT2_K174F_R244L by site-
directed mutagenesis
• overproduction and purification of the His-tagged His8-FgaPT2 wildtype and the mutants
His8-FgaPT2_K174A, His8-FgaPT2_K174F, His8-FgaPT2_K174F_R244Q, His8-
FgaPT2_K174F_R244N, His8-FgaPT2_K174F_R244Y and His8-FgaPT2_K174F_R244L
• performance of enzyme assays and analysis of the product formation by LC-MS
• isolation of the enzyme products by HPLC and structure elucidation by NMR and mass
analyses
• determination of kinetic parameters including Michaelis-Menten constants (Km) and
turnover numbers (kcat)
• molecular docking experiments with FgaPT2_K174A, FgaPT2_K174F and
FgaPT2_K174F_R244L
Identification and mutagenesis of the gate-keeping residue controlling the prenyl donor 
selectivity in FgaPT2 for creation of GPP- and FPP-accepting enzymes 
To date, more than fifty PTs belonging to the DMATS superfamily have been biochemically 
characterized concerning their actions toward versatile aromatic acceptors as well as prenyl donors 
with various chain lengths. Despite their clear promiscuity toward aromatic acceptors, the majority 
of DMATS-type PTs are DMAPP-specific and very few members can use GPP or FPP as a prenyl 
donor. The availability of crystal structures for several DMATS-type PTs provides a molecular basis 
for understanding the reaction mechanisms and enables structure-based protein design and 
engineering.  
The aim of this work is to engineer, based on structure-guided molecular modeling, the available 
dimethylallyl tryptophan synthase FgaPT2 for new and finely tuned enzymatic prenylation activities 
such as geranylation and farnesylation and thus providing biocatalysts for chemoenzymatic 
synthesis of new and potentially bioactive compounds. 
The following experiments have been performed in the course of this project: 
• molecular modeling of GPP and FPP into the crystal structure of FgaPT2 with DMSPP after
mutating methionine 328 to glycine
• in silico modeling of selected FgaPT2 variants at position M328
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• structure-based sequence alignments with other DMATSs in order to identify corresponding
residues to M328 of FgaPT2
• performance of site-directed and site-saturation mutagenesis to generate the nineteen
FgaPT2_M328X (X = C, A, T, S, G, V, N, P, I, D, F, Q, H, L, Y, W, E, K and R) mutants, the
double mutant FgaPT2_L263A_M328A and the triple mutant
FgaPT2_L263A_M328A_Y398F
• heterologous overexpression in E. coli and purification of the engineered recombinant
histidine-tagged proteins
• performance of enzyme activity assays and subsequent analysis by LC-MS
• upscaling enzyme reactions and product isolation by semi-preparative HPLC
• structure elucidation via NMR and mass analysis
• determination of KM, kcat and kcat/Km of FgaPT2 and the FgaPT2_M328X (X = C, A, T, S, G,
V, and N) mutants toward DMAPP and GPP in the presence of L-tryptophan
Engineering of dimethylallyl transferases for the geranylation of tryptophan-containing 
cyclic dipeptides 
DMATS-type PTs have been demonstrated to be promiscuous towards aromatic acceptors. In 
contrast, the majority of these PTs are DMAPP-specific and only show low or no activity towards 
longer donors like geranyl diphosphate (GPP, C10). The high specificity for prenyl donor limits their 
application for structural diversification. The particular importance and necessity of GPP-accepting 
enzymes as biocatalytic tools led us to perform a directed evolution study. 
In this study, we identified gate-keeping residues for prenyl donor specificity and genetically 
engineered six PTs for the production of geranylated tryptophan-containing CDPs. 
The following experiments have been performed in the course of this project: 
• identification of the gate-keeping residues for controlling the prenyl donor selectivity by
structure based sequence alignments with FgaPT2 and AtaPT, i.e. M364 in FtmPT1, I337
in BrePT, T351 in CdpC2PT, M349 in CdpNPT and F335 in CdpC3PT
• molecular modeling and docking of GPP into the crystal structure of FtmPT1 and CdpNPT
• performance of site-directed mutagenesis to generate the following mutants:
FtmPT1_M364G, BrePT_I337G, CdpC2PT_T351G, CdpNPT_M349G, CdpC3PT_F335G
and the double mutant FgaPT2_M328G_R244Q
• heterologous overproduction in E. coli and purification of the recombinant histidine-tagged
wild-type prenyltransferases and the corresponding engineered proteins His5-
BrePT_I337G, FtmPT1_M364G-His6, CdpNPT_M349G-His6, CdpC3PT_F335G-His6,
CdpC2PT_T351G-His6 and His8-FgaPT2_M328G_R244Q
• performance of enzyme activity assays with 15 tryptophan-containing CDPs and
subsequent analysis by LC-MS
• upscaling enzyme reactions and product isolation by semi-preparative HPLC
• structure elucidation via NMR and mass analyses
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3. RESULTS AND DISCUSSION 
3.1 Biochemical investigations of different dimethylallyl transferases 
toward their catalytic potential for generation of prenylated tripeptide 
fumiquinazolines 
In nature, the PT ArdB converts ardeemin FQ to ardeemin by reverse prenylation at the C-3 position 
of the indole moiety (Table 1.2) (Haynes et al. 2013). Ardeemin interacts with a membrane Pgp 
that acts as a MDR export pump (section 1.1) and thus is a focus for drug discovery. Based on 
this finding, the acceptance of ardeemin FQ and its stereoisomers by other PTs would provide new 
prenylated structures as candidates for promising bioactivities.  
The five tryptophan PTs FgaPT2 (C4-PT), 5-DMATS (C5-PT), 5-DMATSSc (C5-PT), 6-DMATSSa 
(C6-PT), 7-DMATS (C7-PT) and two FgaPT2 mutants (Kremer et al. 2007; Mai et al. 2016; 
Subramanian et al. 2012; Unsöld and Li 2005; Winkelblech and Li 2014; Yu et al. 2012) were 
incubated with ardeemin FQ, ent-ardeemin FQ, dia-ardeemin FQ and dia,ent-ardeemin FQ 
(Scheme 3.1) in the presence of DMAPP. 18 new prenylated structures were obtained and 
identified by HR-MS and NMR analyses. 
FgaPT2 catalyzes the C4- and C5-prenylation of ardeemin FQ with 4-dimethylallylardeemin FQ as 
the main product. Incubation of FgaPT2 with the enantiomer ent-ardeemin FQ results in the 
predominant formation of 5-dimethylallyl-ent-ardeemin FQ. C4- and C6-prenylated products have 
been determined as minor products. In the case of dia-ardeemin FQ, FgaPT2 transfers the 
dimethylallyl moiety to the C-4 and mainly to the C-5 position of the indole ring. A very low product 
formation was detected with dia,ent-ardeemin FQ. The retention times of the two product peaks 
correspond to those of C4- and C5-prenylated products. As FgaPT2 catalyzes a strict regiospecific 
and regular transfer of the dimethylallyl moiety from DMAPP to the C-4 position of L-tryptophan and 
tryptophan-containing CDPs, these results were unexpected and clearly demonstrate that the 
stereochemistry of ardeemin FQ and its stereoisomers strongly influences the acceptance and the 
regioselective prenylation by FgaPT2 (Steffan and Li 2009; Unsöld and Li 2005).  
Molecular modeling experiments have been performed by Georg Zocher (Interfakultäres Institut für 
Biochemie, Eberhard Karls Universität Tübingen) in order to explain how the four stereoisomers 
are accommodated in the active center of FgaPT2 and thus breaking the regioselectivity. The 
docking experiments of FgaPT2 with ardeemin FQ and its stereoisomers show that the distances 
are similar between the indole NH-1 of all four substrates to the carboxyl group of E89 which is 
determined to facilitate the proton abstraction at the C-4 position of the indole ring (Figure 5 in 
publication under section 4.5). However, the indole moiety of ent-ardeemin FQ and dia,ent-
ardeemin FQ is tilted in a manner that hydrogen bonds are insufficient to stabilize the substrate 
binding in this orientation. Furthermore, the binding pocket for substrates with 11S configuration 
shows less steric hindrance and the residue R244 facilitates their binding. The 14R configuration 
of the methyl group in dia,ent-ardeemin FQ results in high steric pressure to the residue Y398 and 
thus is almost not converted. The amino acid residue K174 has been shown to be responsible for 
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the proton abstraction at the C-4 position from the σ-complex of L-tryptophan. In the case of ent-
ardeemin and dia-ardeemin FQ the position of the indole entity is shifted in the binding pocket 
related to the K174 residue. This could be the reason for the mainly C5-prenylation with these 
substrates. 
In order to shift the prenylation position from C-4 to C-5 with ardeemin FQ, the mutants 
FgaPT2_M328L and FgaPT2_Y398F have been constructed. Both amino acid residues have been 
shown to interact with the anthranyl moiety. Thus, the replacement of these amino acids is a 
promising strategy to reduce the steric pressure and thereby contributing to a prenylation shift. 
Incubation assays showed that the prenylation activity at C-4 position was reduced by both 
mutants. In contrast the yield for C5-prenylation could slightly be increased by FgaPT2_M328L. 
However, a crystal structure with ardeemin FQ and DMSPP is necessary to identify further 
important amino acid residues or/and to predict the convenient amino acid variants for a prenylation 
shift. 
Incubation of 7-DMATS with ardeemin FQ and its enantiomer ent-ardeemin FQ resulted in the 
formation of 7-dimethylallylardeemin FQ and 7-dimethylallyl-ent-ardeemin FQ, respectively. In the 
NMR spectrum of 7-dimethylallylardeemin FQ, signals with low intensities for 6-
dimethylallylardeemin FQ could also be detected. The enantiomer pair dia-ardeemin FQ and 
dia,ent-ardeemin FQ have been also tested with 7-DMATS. Herein, one product peak each could 
be observed in the HPLC chromatograms. The NMR spectra of the isolated products revealed the 
presence of two prenylated products each. In addition to 7-dimethylallyl-dia-ardeemin FQ, the 
structure of 6-dimethylallyl-dia-ardeemin FQ could be elucidated as minor product. Interestingly, 
C6-prenylation occurs as the main reaction when 7-DMATS is incubated with dia,ent-ardeemin FQ. 
Based on these results, the 11R,14R configuration of dia,ent-ardeemin FQ disfavors the prenylation 
at C-7 position. It is very likely, that the distance between the C-6 of the indolyl moiety is closer 
than that of C-7 to the amino acid residue being responsible for proton abstraction and re-
aromatization.  
The bacterial tryptophan PT 5-DMATSSc catalyzes the C5-, C6-, C7-monoprenylation and 5,6-di-
prenylation of ardeemin FQ and ent-ardeemin FQ, thus displaying a reduced regioselectivity toward 
these substrates. Dia-ardeemin FQ and dia,ent-ardeemin FQ are less accepted by 5-DMATSSc. 
The relaxed regioselective prenylation of ardeemin FQ and ent-ardeemin FQ points out the high 
flexibility of these substrates in the reactive center. Interestingly, a di-prenylated product carrying a 
dimethylallyl moiety at C-7 position could not be detected. Presumably, the C5-prenylation firstly 
occurred undergoing the second prenylation at the C-6 position. It can only be speculated that an 
initial prenylation at C-6 position would also result in a second prenylation at C-7 position to give a 
6,7-di-prenylated product. However, the 11S,14S configuration of dia-ardeemin FQ and the 
11R,14R configuration of dia,ent-ardeemin FQ trigger a tilt of the indole moiety in the binding 
pocket. This likely leads to a disfavored orientation of the indolyl moiety for proton abstraction. The 
investigated fungal 5-DMATS converts the four tripeptides to their corresponding C5- and C6-
prenylated derivatives with low product yields. This was unexpected as the both fungal PTs FgaPT2 
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and 7-DMATS demonstrated at least with three stereoisomers relatively high conversion rates. It is 
possible that the binding pocket for aromatic substrate is smaller in 5-DMATS than those of FgaPT2 
and 7-DMATS. However, structural data for 5-DMATS are not available to confirm this assumption. 
The incubation of the bacterial tryptophan C6-PT 6-DMATSSa with the four fumiquinazolines and 
DMAPP resulted in the formation of the major C6- and the minor C5-prenylated products. 
Additionally, a di-prenylated product was detected with ent-ardeemin FQ as substrate. These 
results show that 6-DMATSSa remains its activity toward C6-prenylation. The relatively high yields 
of the C6-prenylated stereoisomers indicate a less flexibility of these substrates in the reaction 
chamber of 6-DMATSSa. 
In summary, our study shows that tryptophan PTs can transfer the dimethylallyl moiety to ardeemin 
FQ and its stereoisomers (Scheme 3.1). However, the conversion rate and the regioselective 
prenylation is dependent on the stereochemistry at C-11 and C-14 of these substrates (Mai et al. 
2016). 
To create fumiquinazolines prenylated at the pyrrole ring, in a further cooperation study with 
Lindsay Coby, the catalytic ability of two cyclic dipeptide C2-PTs BrePT and FtmPT1 and three C3-
PTs CdpNPT, CdpC3PT and AnaPT (Grundmann and Li 2005; Mai et al. 2019; Schuller et al. 2012; 
Yin et al. 2013a; Yin et al. 2009; Yin et al. 2010) has been investigated toward ardeemin FQ and 
its enantiomer ent-ardeemin FQ in the presence of DMAPP. 
BrePT, FtmPT1 and CdpNPT showed high conversion rates with ardeemin FQ, while the product 
yield is relatively low with CdpC3PT and AnaPT. The enantiomer ent-ardeemin FQ was less 
accepted by all enzymes, whereas CdpNPT showed the best activity. These results highlight the 
importance of the substrate’s stereochemistry concerning the acceptance by cyclic dipeptide PTs. 
Unexpectedly, all tested cyclic dipeptide PTs converted ent-ardeemin less than the tryptophan PTs 
described above. CdpNPT catalyzes the reverse C3-prenylation of ardeemin FQ as likewise with 
its natural aromatic substrate (Schuller et al. 2012). The reverse C2-prenylation was determined 
for BrePT with diverse CDPs in a previous study (Yin et al. 2013a). The incubation with ardeemin 
FQ also revealed that BrePT catalyzes mainly reverse C2-prenylation. However, regularly N1- and 
reversely C3-prenylated derivatives could also be obtained as minor products. FtmPT1, as a 
regular C2-PT of brevianamide, has been shown to transfer the dimethylallyl moiety regularly at C-
3 or N-1 position onto diverse CDPs in a previous study (Wollinsky et al. 2012b). Interestingly, 
FtmPT1 shows a distinct catalytic behavior in the presence of ardeemin FQ, which has not been 
reported prior to this study. FtmPT1 catalyzes mainly reverse C3-prenylation of ardeemin FQ, 
whereas regularly N1-, C2-, and C3- and even reversely C2-prenylated derivatives have been 
isolated as minor products. C6-prenylated derivatives have been obtained as main products from 
the incubations with enzyme possessing low activity with ardeemin FQ and/or ent-ardeemin FQ 
(CdpC3PT and AnaPT with ardeemin FQ and FtmPT1, CdpNPT, CdpC3PT and AnaPT with ent-
ardeemin FQ). In addition, C7-prenylation is catalyzed by CdpC3PT with ardeemin FQ and by 
FtmPT1, CdpNPT and CdpC3PT with ent-ardeemin FQ. CdpNPT and AnaPT also catalyze C5- 
prenylation with ent-ardeemin FQ. These results show that enzymes, which possess low catalytic 
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Scheme 3.1 Prenylation of ardeemin FQ and its stereoisomers by DMATSs [modified from (Mai et 
al. 2016; Mai et al. 2019)] 
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activity with the fumiquinazoline derivatives, mainly catalyze C6- and C7-prenylation.  
These studies clearly demonstrate that alternative aromatic substrates, as in the cases of ardeemin 
FQ and its stereoisomers, can redirect or break the regioselective prenylation compared to the 
natural substrates where these PTs mostly catalyze the formation of one prenylated product. It is 
plausible that substrates, only sharing the indole moiety with the natural substrate, are diversely or 
not tightly accommodated into the reaction chamber so that prenylation can also occur at other 
reactive positions. 
For a more detailed overview on this work, please see the publications under sections 4.1 and 4.5 
Peter Mai*, Lindsay Coby* and Shu-Ming Li 
Different behaviors of cyclic dipeptide prenyltransferases toward the tripeptide derivative ardeemin 
fumiquinazoline and its enantiomer 
Applied Microbiology and Biotechnology. 2019, 103(9), 3773-3781 
Peter Mai, Georg Zocher, Lena Ludwig, Thilo Stehle and Shu-Ming Li 
Actions of tryptophan prenyltransferases toward fumiquinazolines and their potential application for 
the generation of prenylated derivatives by combining chemical and chemoenzymatic syntheses 
Advanced Synthesis and Catalysis. 2016, 358, 1639-165 
3.2 Creation of new biocatalysts for prenylation shift by 
combinational site-directed mutagenesis of two amino acid residues 
in FgaPT2 
Mutational experiments with FgaPT2 presented in previous studies revealed that site-directed 
mutagenesis is a valuable tool to achieve special catalytic features (refer to section 1.2.3.3). 
However, altering the prenylation position of tryptophan-containing CDPs has not been reported 
prior to this work. 
As aforementioned, Luk et. al demonstrated that the FgaPT2_K174A mutant catalyzes the reverse 
C3-prenylation of L-tryptophan (Luk et al. 2011). We (Peter Mai and Liujuan Zheng) created this 
mutant by site-directed mutagenesis and tested its activity toward various tryptophan-containing 
CDPs. Almost no product formation could be observed.  
Further, we speculated that the FgaPT2_K174F mutant could have the potential to switch the 
prenylation position of CDPs. This mutant has been demonstrated to catalyze the C3-prenylation 
of L-tyrosine (Fan et al. 2015c). Interestingly, low product formation was detected in the incubation 
mixture of FgaPT2_K174F with cyclo-L-Trp-L-Ala, cyclo-L-Trp-L-Trp, cyclo-L-Trp-Gly, cyclo-L-Trp-L-
Phe, cyclo-L-Trp-L-Pro and cyclo-L-Trp-L-Tyr. The retention times differ from that of C4-prenylated 
products, thus indicating a prenylation shift. Based on the knowledge that various FgaPT2_R244 
mutants strongly increased their activity toward C4-prenylation of various CDPs (Fan and Li 2016), 
in the course of this thesis combinational site-directed mutagenesis at the residues K174 and R244 
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has been performed. The created four double mutants FgaPT2_K174F_R244X (X = L, N, Q, Y) by 
Peter Mai were incubated by Liujuan Zheng with the aforementioned CDPs in the presence of 
DMAPP and analyzed by LC-MS (Scheme 3.2). The double mutants clearly increased the product 
yield with retention times being comparable to that observed with FgaPT2_K174F. Thus, a 
prenylation shift must have occurred. FgaPT2_K174F_R244N showed the best acceptance of 
cyclo-L-Trp-L-Ala, cyclo-L-Trp-Gly and cyclo-L-Trp-L-Phe, whereas FgaPT2_K174F_R244Q 
displays a slightly higher conversion of cyclo-L-Trp-L-Trp. The mutant FgaPT2_K174F_R244L 
showed the best conversion rate for cyclo-L-Trp-L-Pro and cyclo-L-Trp-L-Tyr.  
Scheme 3.2 Prenylation of cyclic dipeptides by FgaPT2 and its mutants [modified from (Zheng et 
al. 2018)] 
Structure elucidation of the enzyme products with the FgaPT2_K174F_R244X mutants by HR-MS 
and NMR analyses revealed a hexahydropyrroloindole structure of each isolated compound which 
is generated by a reverse C3-prenylation at the indole moiety with a syn-cis configuration. These 
results demonstrate the ability to switch a regular C4-prenyltransferase to a reverse tryptophan-
containing cyclic dipeptide C3-prenyltransferase by two step-mutations on K174 and R244 (Zheng 
et al. 2018). 
For a more detailed overview on this work, please see the publication under section 4.4 
Liujuan Zheng*, Peter Mai*, Aili Fan and Shu-Ming Li 
Switching a regular tryptophan C4-prenyltransferase to a reverse tryptophan-containing cyclic 
dipeptide C3-prenyltransferase by sequential site-directed mutagenesis 
Organic & Biomolecular Chemistry. 2018, 16, 6688-6694  
3.3 Identification and mutagenesis of the gate-keeping residue 
controlling the prenyl donor selectivity in FgaPT2 for creation of 
GPP- and FPP-accepting enzymes 
FgaPT2, a regioselective C4-prenylating dimethylallyl tryptophan synthase, was in the focus of 
many researchers. Previous works demonstrated the acceptance of L-tryptophan and indole 
derivatives, various tryptophan-containing CDPs and even phenyl compounds for prenylation in the 
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presence of DMAPP (Fan et al. 2015b; Fan et al. 2015c; Steffan et al. 2007; Steffan and Li 2009). 
Further studies showed the catalytic ability of FgaPT2 to use non-natural prenyl donors such as 
MAPP, 2-pen-PP and benzyl-PP (Liebhold et al. 2012; Liebhold and Li 2013). Mutants of FgaPT2 
can change the transfer of the dimethylallyl moiety from DMAPP reversely to the C-3 position of L-
tryptophan or various CDPs and even enhance the conversion of CDPs or L-tyrosine for regularly 
C4- or C3-prenylation, respectively (Fan et al. 2015c; Fan and Li 2016; Luk et al. 2011; Zheng et 
al. 2018). However, neither GPP- nor FPP-acceptance has been reported for FgaPT2 prior to this 
study. Incubation of FgaPT2 with GPP or FPP in the presence of the natural aromatic substrate L-
tryptophan resulted in a very low conversion or no conversion. These results highlight that FgaPT2 
is a DMAPP-specific PT when excluding the aforementioned non-natural alkyl donors.  
Protein sequence alignments of various PTs display highly conserved motifs, i.e. donor binding 
pocket and the tyrosine shield. When comparing the DMAPP-specific FgaPT2 with those PTs being 
promiscuous toward GPP and FPP, the aromatic acceptor binding pockets show substantial 
differences. Docking of GPP and FPP on the basis of the DMAPP conformation into the catalytic 
chamber of FgaPT2 led to the identification of amino acid residues that hampers the binding of 
bulky prenyl donors and thus contribute to the DMAPP-specificity. The amino acid residues R244, 
L263, M328 and Y398 show potential collisions with GPP/FPP whereby M328 possesses the 
strongest hindrance effect. M328 acts as a gate-keeping residue to enable DMAPP to enter the 
reaction chamber and simultaneously preventing the accommodation of larger prenyl donors. 
Based on these findings, M328 is a promising amino acid residue for mutagenesis in order to 
achieve GPP- and FPP-accepting enzymes. 
M328 was then replaced with glycine by site-directed mutagenesis and the FgaPT2_M328G mutant 
was assayed with L-tryptophan in the presence of DMAPP, GPP and FPP under the same 
conditions as for the wildtype (Figure 3.3). 
This mutant drastically reduced the activity toward DMAPP determining an almost fourteen fold 
conversion decrease compared to the wildtype. In contrast, FgaPT2_M328G shows an almost 
tenfold increase of GPP-acceptance (Figure 3.3). The isolated enzyme product from the incubation 
mixture of FgaPT2_M328G with GPP and L-tryptophan was elucidated by NMR- and HR-MS 
analyses to be C4-geranyl-L-tryptophan (Figure 3.3). Also the formation of farnesylated L-
tryptophan catalyzed by FgaPT2_M328G could clearly be detected by LC-MS. These data 
confirmed our molecular modeling calculations that G328 reduces the steric hindrance for 
accommodation of prenyl donors with larger chain length. 
The decreased activity toward DMAPP by FgaPT2_M328G was unexpected as the smaller G328 
provides more space for DMAPP accommodation than the wildtype. This result indicates that 
additionally to the size of the amino acid residue also its hydrophobicity may contribute to 
distinguishing between the prenyl donors. To get an insight into the molecular interactions between 
various prenyl donors and the gate-keeping residue, all variants at position M328 of FgaPT2 have 
been obtained by site-saturation mutagenesis. Biochemical investigations and molecular modeling 
of the nineteen FgaPT2_M328X mutants provided understanding on the molecular effects for the 
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prenyl donor selectivity. Out of these mutants, M328C, M328A, M328S, M328G, M328P, M328D, 
M328K and M328R strongly reduced their activities in the presence of DMAPP (Figure 3.3). In 
contrast, amino acids with smaller side chains than methionine, i.e. M328A, M328V, M328T, 
M328G, M328S, M328C, and M328N, strongly enhanced the conversion rates with GPP (Figure 
3.3). The formation of farnesylated L-tryptophan could be clearly detected with M328C, M328S, 
M328G and M328A, whereby M328A bears the best FPP-acceptance. Remarkably, M328T, 
M328V and M328N maintained their catalytic ability toward DMAPP and additionally possess high 
GPP-acceptance compared to the wildtype (Figure 3.3). Isolation and structure elucidation by HR-
MS and 1H NMR of the products of the GPP-accepting mutants (M328A, M328V, M328T, M328G, 
M328S, M328C, and M328N) verified the C4-geranylation of L-tryptophan as already reported for 
M328G above. In conclusion, the steric effect of the amino acid residues at the position M328 is 
the key factor for prenyl donor selectivity. As exemplified by M328T and M328V polarity effect can 
also have a major impact on the prenyl donor specificity. Although, the mutants M328G, M328A 
and M328V strongly reduce the steric hindrance for the interaction with GPP/FFP, they insufficiently 
anchor the small DMAPP in the reaction chamber and thereby reduce the DMAPP utilization. 
However, none of these nineteen M328X mutants is sufficient to catalyze high yields of farnesylated 
product. M328A showed the best FPP-acceptance, but the turnover remained low. The entrance 
of FPP into the reaction chamber is more than likely prevented due to the steric pressure resulted 
from R244, L263 or Y398. Another explanation could be that FPP enters the active site at first and 
the long hydrophobic FPP molecule seals the reaction chamber for binding of the prenyl acceptor. 
As aforementioned, the amino acid residues L263 and Y398 are additional promising candidates 
for mutagenesis in order to reduce steric hindrance. For this purpose, the double mutant 
FgaPT2_L263A_M328A and the triple mutant FgaPT2_L263A_M328_Y398F were created. These 
mutants displayed enhanced activities toward FFP compared to the wildtype, but their conversion 
rate still remains too low to be used for chemoenzymatic synthesis of farnesylated products (Mai 
et al. 2018). 
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Figure 3.3 Prenylation of L-tryptophan by FgaPT2 and its mutants in the presence of DMAPP (blue) 
and GPP (red). (a) Enzyme products and activities presented by the extracted ions chromatograms 
(EICs) of their incubation mixtures with L-tryptophan and DMAPP (blue) or GPP (red) and (b) 
absolute conversion yields [modified from (Mai et al. 2018)] 
For a more detailed overview on this work, please see the publication under section 4.3 
Peter Mai, Georg Zocher, Thilo Stehle and Shu-Ming Li 
Structure-based protein engineering enables prenyl donor switching of a fungal aromatic 
prenyltransferase 
Organic & Biomolecular Chemistry. 2018, 16, 7461-7469 
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3.4 Engineering of dimethylallyl transferases for the geranylation of 
tryptophan-containing cyclic dipeptides 
In the course of this cooperation work with Ge Liao, five DMAPP-specific cyclic dipeptide PTs, i.e. 
CdpC2PT, FtmPT1, BrePT, CdpC3PT and CdpNPT, have been selected for creation of GPP-
accepting enzymes by protein engineering. Initially, these wild-type PTs were tested toward their 
ability to accept GPP as a prenyl donor. With the exception of CdpC2PT all other four enzymes 
show very low (CdpC3PT) or no activity (FtmPT1, BrePT, CdpNPT) toward GPP. As described in 
section 3.3, FgaPT2 was switched from a dimethylallyl tryptophan synthase to a geranyl 
tryptophan synthase by a single point mutation (Mai et al. 2018). Comparison of the ternary crystal 
structure of FgaPT2 with those of FtmPT1 and CdpNPT led to the identification of the 
corresponding gate-keeping residues, i.e. M364 in FtmPT1 and M349 in CdpNPT (Jost et al. 2010; 
Schuller et al. 2012). As the structures of CdpC2PT, BrePT and CdpC3PT are not available, their 
protein sequences were aligned with those of AtaPT, FgaPT2, FtmPT1 and CdpNPT. The 
corresponding gate-keeping residues were identified as T351 in CdpC2PT, I337 in BrePT and F335 
in CdpC3PT. Replacement by site-directed mutagenesis of these residues with glycine resulted in 
the mutants FtmPT1_M364G, BrePT_I337G, CdpNPT_M349G, CdpC2PT_T351G and 
CdpC3PT_F335G possessing a significantly increased GPP-acceptance or changed geranylation 
pattern (Scheme 3.4 A). The acceptance of DMAPP was reduced in all of these mutants. 15 CDPs 
were selected for incubation with the generated mutants (Figure 3.4). CdpNPT_M349G accepted 
all the tested aromatic acceptors for geranylation with relative high product yields. Except (S)- and 
(R)-benzodiazepinedione, the other 13 aromatic substrates have been geranylated by 
FtmPT1_M364G. Especially in the presence of the natural aromatic substrate cyclo-L-Trp-L-Pro, 
BrePT_I337G exhibits a high conversion rate with GPP. An increase of product yields was 
determined for CdpC3PT_F335G with all 15 tested aromatic compounds and GPP. With this mutant 
the most significant increase in conversion rate to the geranylated product was determined for 
cyclo-L-Trp-L-Leu. Compared to the wildtype (2.9%) a product yield of 51.8% was detected. 
Interestingly, CdpC2PT and its mutant CdpC2PT_T351G both accept GPP when using cyclo-L-
Trp-L-Trp as a substrate. In this case, the replacement of threonine at the position 351 to glycine 
resulted in a changed geranylation pattern. The chromatogram of the incubation mixture of 
CdpC2PT, cyclo-L-Trp-L-Trp and GPP showed one predominant product peak consisting of two 
products. This peak is nearly vanished in the HPLC chromatogram of CdpC2PT_T351G, whereas 
a new product peak appeared with retention time typical for a di-geranylated product. Comparison 
of the HPLC chromatograms of the incubation mixtures of the wildtype enzymes with DMAPP and 
the mutants with GPP in the presence of the 15 tested CDPs (Figure 3.4) clearly demonstrates a 
relaxed regioselective geranylation by the mutants. For example, CdpNPT catalyzes the formation 
of one product with DMAPP and (S)-benzodiazepinedione. In contrast, four product peaks were 
detected in the incubation mixture of CdpNPT_M349G with GPP and (S)-benzodiazepinedione. In 
this study, 41 geranylated products have been obtained by chemoenzymatic synthesis with these 
engineered enzymes. 
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Figure 3.4 tryptophan-containing cyclic dipeptides used as substrates in this study 
BrePT_I337G catalyzes the reverse C2-geranylation of cyclo-L-Trp-L-Pro and its stereoisomers 
cyclo-L-Trp-D-Pro and cyclo-D-Trp-L-Pro. Six regular C2- and eight C3-geranylated products were 
generated by FtmPT1_M364G with GPP and the respective substrates. Eight substrates (cyclo-L-
Trp-L-Trp, cyclo-L-Trp-D-Pro, cyclo-L-Trp-L-Ala, cyclo-D-Trp-L-Ala, cyclo-L-Trp-L-Leu, cyclo-L-Trp-L-
Tyr, cyclo-L-Trp-L-Phe, cyclo-L-Trp-Gly) have been regularly geranylated by FtmPT1_M364G at  
N-1. CdpC2PT as well as its mutant CdpC2PT_T351G possess the ability for geranylation, but 
catalyze distinct regioselective GPP-attachment. Reverse C2-, regular C5- and C7-geranylation 
were determined when cyclo-L-Trp-L-Trp was subjected to the incubation with CdpC2PT. The 
engineered enzyme CdpC2PT_T351G catalyzes in addition to the reverse C2-monogeranylation 
also the reverse C2-digeranylation of cyclo-L-Trp-L-Trp. CdpNPT_M349G attaches the geranyl 
moiety at C-3 position in reverse and at C-6 position in regular manner. Interestingly, out of the 15 
tested substrates, cyclo-L-Trp-L-Leu was the best accepted substrate by CdpC3PT_F335G, 
whereas the activities were much lower toward other substrates. The structures of all four 
geranylated products were elucidated as regular N1-, C7-, reverse N1- and C3-geranylated 
products. Taking cyclo-L-Trp-L-Trp as a model, all non-bridgehead carbons and the N-1 have been 
geranylated via one-step chemoenzymatic synthesis by the engineered enzymes (Scheme 3.4 B). 
The C4-geranylation could be obtained by creating the double mutant FgaPT2_M328G_R244Q. 
Our results provide evidence that a switch of the prenyl donor acceptance is not only possible for 
enzymes with high flexibility for these substrates such as AtaPT, MpnD and TleC (Chen et al. 2017; 
Mori et al. 2016), but can also be applied for enzymes which are practically limited to the use of 
DMAPP as a donor (Liao et al. 2018).  
cyclo-L-Trp-L-Trp cyclo-L-Trp-L-Pro cyclo-L-Trp-D-Pro cyclo-D-Trp-L-Pro 
cyclo-D-Trp-D-Pro cyclo-L-Trp-L-Ala cyclo-L-Trp-D-Ala cyclo-D-Trp-L-Ala 
cyclo-D-Trp-D-Ala cyclo-L-Trp-L-Leu cyclo-L-Trp-L-Tyr cyclo-L-Trp-L-Phe 
cyclo-L-Trp-GLY (S)-benzodiazepinedione (R)-benzodiazepinedione 
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Scheme 3.4 (A) Geranylation of cyclic dipeptides and (B) complete decoration of the indolyl 
residue of cyclo-L-Trp-L-Trp with the geranyl moiety by engineered dimethylallyl transferases 
[modified from (Liao et al. 2018)] 
For a more detailed overview on this work, please see the publication under section 4.2 
Ge Liao*, Peter Mai*, Jie Fan, Georg Zocher, Thilo Stehle, and Shu-Ming Li 
Complete decoration of the indolyl residue in cyclo-L-Trp-L-Trp with geranyl moieties by using 
engineered dimethylallyl transferases 
Organic Letters. 2018, 20, 7201-7205 
3.5 Alkaloids derived from tryptophan: A focus on ergot alkaloids 
In addition to my research work, we (Peter Mai and Prof. Dr. Shu-Ming Li) contributed to the 
Handbook of Natural Products with a chapter on ergot alkaloids, which gives an overview about 
the importance of ergot alkaloids as SMs mainly produced by ascomycetous fungi, e.g. C. 
purpurea, A. fumigatus and Penicillium commune. This substance group with a characteristic 
tetracyclic ergoline ring system attracted attention by many researcher due to their pharmacological 
and toxicological properties. Different enzyme classes are involved in the biosynthesis of ergot 
alkaloids, e.g. prenyltransferase, methyltransferase, oxidoreductase, cytochrome P450 etc. Among 
them, a prenyltransferase is responsible for the first reaction step in the ergot alkaloid biosynthesis 
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by transferring the dimethylallyl moiety from DMAPP to the C-4 of L-tryptophan. Further issues like 
the production in industrial level, biological activities including the use in the modern medicine as 
well as methods for cultivation, purification and analyses of ergot alkaloids have also been 
presented in this overview article. 
 
For a more detailed overview on this work, please see the publication under section 4.6  
Peter Mai and Shu-Ming Li 
Alkaloids derived from tryptophan: A focus on ergot alkaloids 
Handbook of Natural Products. 2013, Chapter 23, 683-714 
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4.1 Different behaviors of cyclic dipeptide prenyltransferases 
toward the tripeptide derivative ardeemin fumiquinazoline and 
its enantiomer  
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Abstract
In nature, cyclic dipeptide prenyltransferases catalyze regioselective Friedel-Crafts alkylations of tryptophan-containing cyclic
dipeptides. This enzyme class, belonging to the dimethylallyl tryptophan synthase superfamily, is known to be flexible toward
aromatic prenyl acceptors, while mostly retaining its typical regioselectivity. Ardeemin fumiquinazoline (FQ) (1), a tryptophan-
containing cyclic tripeptide derivative, is assembled in Aspergillus fischeri by the non-ribosomal peptide synthetase ArdA and
modified by the prenyltransferase ArdB, leading to the pharmaceutically active hexacyclic ardeemin. Therefore, 1 and its
enantiomer ent-ardeemin FQ (2) constitute potential substrates for aromatic prenyltransferases. In this study, we investigated
the acceptance of both enantiomers by two cyclic dipeptide C2-prenyltransferases BrePT and FtmPT1 and three C3-
prenyltransferases CdpNPT, CdpC3PT, and AnaPT. LC-MS analysis of the incubationmixtures and NMR analysis of the isolated
products revealed that the stereochemistry at C11 and C14 in 1 and 2 has a strong influence on their acceptance by these enzymes
and the regioselectivity of the prenylation reactions. 1was very well accepted by BrePT, FtmPT1, and CdpNPT, with C2- or C3-
prenylated derivatives as predominant products, which fills the prenylation gaps by tryptophan prenyltransferases reported in a
previous study. 2 was a poor substrate for all the enzymes and converted with low regioselectivity and mainly prenylated at C6
and C7 of the indole moiety.
Keywords Cyclic dipeptide prenyltransferases . Friedel-Crafts alkylation . Ardeemin FQ . Enantiomeric effect
Introduction
Natural products from plants, bacteria, and fungi, espe-
cially those known as secondary metabolites (SMs), often
exhibit interesting properties (Keller et al. 2005; Li 2010;
Oya et al. 2015; Ruiz-Sanchis et al. 2011). The probably
most famous SMs with major pharmaceutical relevance
are antibiotics belonging to the group of penicillin
(Keller et al. 2005). Cholesterol-lowering agents such as
statins, including lovastatin, are also fungal SMs, e.g.,
from Aspergillus terreus (Alberti et al. 2017). A further
interesting class of SMs is indole alkaloids often contain-
ing one or more prenyl moieties before undergoing addi-
tional modifications like cyclization, oxidation, or acety-
lation (Haynes et al. 2013; Kato et al. 2009; Li 2010;
Williams et al. 2000). Fumitremorgin C is such an exam-
ple and is known as a potent inhibitor of the breast cancer
resistance protein (Kato et al. 2009; Li 2010; Williams
et al. 2000). The introduction of a prenyl moiety can in-
crease the biological activity in comparison with its non-
prenylated precursor due to the more lipophilic character
(Botta et al. 2005; Wollinsky et al. 2012a). Such a prenyl
transfer is catalyzed by prenyltransferases and occurs gen-
erally from the activated isoprene unit, dimethylallyl di-
phosphate (DMAPP). Prenyltransferases of a subgroup
belonging to the dimethylallyl tryptophan synthase
(DMATS) superfamily are frequently found in fungi of
the Ascomycota (Winkelblech et al. 2015; Yu and Li
2012). Enzymes of this group, including cyclic dipeptide
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prenyltransferases, are of special interest since they cata-
lyze regioselective and stereospecific transfer reactions of
dimethylallyl moieties from DMAPP onto structurally and
chemically demanding molecules. Investigations in the
last years have shown that these prenyltransferases also
accept aromatic substrates, which differ distinctly from
their natural substrates. This feature makes them a useful
tool for chemoenzymatic reactions (Fan et al. 2015). In
nature, cyclic dipeptide prenyltransferases catalyze a re-
gioselective prenylation at the indole moiety of
tryptophan-containing cyclic dipeptides in a regular
(normal) or reverse manner (Winkelblech et al. 2015).
For example, FtmPT1 from Aspergillus fumigatus cata-
lyzes a regular C2-prenylation of brevianamide F (cyclo-
L-Trp-L-Pro) to give tryprostatin B (Grundmann and Li
2005). BrePT from Aspergillus versicolor is a reverse
C2-prenylating enzyme of brevianamide F (Yin et al.
2013) (Fig. 1a). AnaPT and CdpC3PT, both from
Neosartorya f ischeri , as wel l as CdpNPT from
Aspergillus fumigatus are examples of reverse C3-
prenyltransferases (Fig. 1b) (Yin et al. 2007, 2009,
2010). Depending on the stereochemistry of the substrate,
these prenyltransferases can catalyze prenylation in syn-
cis or syn-anti configuration (Yu et al. 2013). AnaPT is
involved in the biosynthesis of acetylaszonalenin and cat-
alyzes the C3-prenylation of (R)-benzodiazepinedione
(BDZD) subsequently leading to a ring formation between
the diazepinedione and the indole ring (Fig. 1b) (Yin et al.
2009). This kind of reaction has also been observed in the
ardeemin biosynthesis in Aspergillus fischeri (Haynes
et al. 2013), i.e., the reverse C3-prenylation of ardeemin
FQ (1) by ArdB and subsequent ring closure (Fig. 1c).
The resulting pharmaceutically active hexacyclic
ardeemin can block multidrug resistance (MDR) export
pumps and therefore reduces the resistance against antitu-
mor drugs (Chou et al. 1998; Juliano and Ling 1976;
Kartner et al. 1983). Due to their promising activities as
chemotherapeutics (Prata-Sena et al. 2016), this kind of
fumiquinazolines and structurally related alkaloids are
still part of current interest and were reviewed recently
(Resende et al. 2018). In a previous study, we investigated
the behaviors of five tryptophan prenyltransferases
FgaPT2, 5-DMATS, 6-DMATSSc, 6-DMATSSa, and 7-
DMATS, toward 1 and its enantiomer ent-ardeemin FQ
(2) as well as their diastereomers. In that study, only reg-
ular prenylations at the benzene ring of the indole moiety,
i.e., C4, C5, C6 or C7, were observed (Mai et al. 2016).
These results made us curious to find enzymes to cover
the positions at C2 and C3 of the indole ring. Therefore,
we selected the cyclic dipeptide C2-prenyltransferases
BrePT and FtmPT1 as well as the C3-prenyltransferases
CdpNPT, CdpC3PT, and AnaPT as biocatalysts for the
prenylation of 1 and 2.
Materials and methods
Chemicals
DMAPP was synthesized according to the method described
for geranyl diphosphate (Woodside et al. 1988). The substrates
1 and 2 were synthesized as described previously (Haynes
et al. 2013). The crude reaction mixture was then fractionated
over a silica gel column and purified with HPLC as published
previously (Mai et al. 2016). Cyclo-L-Trp-L-Pro, (R)-, and (S)-
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benzodiazepinedione were synthesized as described in the lit-
erature (Barrow and Sun 1994; Yu et al. 2012). Cyclo-L-Trp-
Gly was obtained from Bachem (Bubendorf, Switzerland).
Overproduction and purification of the cyclic
dipeptide prenyltransferases
The recombinant cyclic dipeptide prenyltransferases AnaPT-
His6, CdpC3PT-His6, CdpNPT-His6, His5-BrePT, and
FtmPT1-His6 were overproduced and purified according to
published procedures (Grundmann and Li 2005; Yin et al.
2007, 2009, 2010, 2013).
Enzyme assays
To determine the enzyme activities, reaction mixtures in total
volumes of 50 μL contained 0.5 mM cyclic dipeptides, 1 or 2,
1 mM DMAPP, 10 mM CaCl2, 0.5–1,5% (v/v) glycerol, 5%
(v/v) DMSO, 50 mM Tris-HCl (pH 7.5), and 10 μg purified
recombinant enzymes. After incubation at 37 °C for 4 h, the
reaction mixtures were extracted three times with 50 μL ethyl
acetate and evaporated to dryness. The residues were dis-
solved in 100 μL MeOH and centrifuged. Five microliters of
these solutions was analyzed on the LC-MS system described
below. Enzyme assays for product isolation were scaled up to
a volume of 2.4 to 12.0 mL. The reaction mixtures contained
0.5 mM of 1 or 2, 2 mMDMAPP, 10 mMCaCl2, 0.5–10% (v/
v) glycerol, 2.0 to 2.5% (v/v) DMSO, 50 mM Tris-HCl
(pH 7.5), and 1.0 to 4.8 mg of the purified proteins. The
enzyme assays were incubated at 37 °C for 16 h and extracted
twice with the double volume of ethyl acetate. The extracts
were combined and evaporated to dryness for isolation on
HPLC.
The enzyme assays to determine the kinetic parameters of
BrePT, FtmPT1, and CdpNPT toward 1 were performed in
duplicate. The reaction mixtures containing 1 in concentra-
tions of up to 1.0 mM, 2 mM DMAPP, 10 mM CaCl2, 0.3–
0.6% (v/v) glycerol, 5.0% (v/v) DMSO, 50 mM Tris-HCl
(pH 7.5), and different protein amounts (3.0 μg of BrePT,
5.0 μg of FtmPT1, and 0.5 μg of CdpNPT) were incubated
at 37 °C for 5 min. The reactions were then quenched by
addition of 50 μL MeOH. After centrifugation at 17.000×g
for 15 min, 50 μL was analyzed on HPLC.
LC-MS analysis of incubation mixtures and isolation
of the enzyme products
The enzyme products were analyzed on an Agilent HPLC
1260 series system equipped with a photodiode array detector
and a Bruker micrOTOF-Q III mass spectrometer by using an
Agilent Eclipse XDB-C18, 5 μm, 4.6 × 150 mm column. H2O
(solvent A) and CH3CN (B), both containing 0.1% (v/v)
formic acid, were adjusted to a flow rate of 0.5 mL·min−1.
The separation began with a linear gradient from 45 to 80%
CH3CN over 30 min, followed by a linear gradient from 80 to
100% CH3CN in 5 min. The column was then washed with
100% B for 10 min and subsequently equilibrated with 45%
CH3CN for 5 min. LC-MS data were processed using Bruker
Compass DataAnalysis version 4.2 (Build 383.1) software.
LC-MS data of substrates and products are provided in
Table 1.
For structure elucidation, the enzyme products were isolat-
ed from the up-scaled assays with an Agilent HPLC 1200
series system by using a semi-preparative Multospher 120
RP 18-HP column (250 × 10 mm, 5 μm) at a flow rate of
2.5 mL·min−1. A linear gradient from 60 to 100% CH3CN
over 40 min was used for isolation of most of the products.
The reaction mixture containing BrePT and 2 was purified
with a semi-preparative Agilent ZORBAX Eclipse XDB-
C18 column (250 × 9.4 mm, 5 μm) at a flow rate of 2.5 mL·
min−1 and a linear gradient from 45 to 60% CH3CN over
30 min. The isolated products were dissolved in CDCl3 and
subjected to NMR analysis.
NMR analysis
NMR spectra were recorded at 500 MHz on a JEOL ECA
spectrometer (JEOL Germany GmbH, Munich, Germany)
and processed by using MestReNova version 6.0.2-5475.
The CHCl3 signal at 7.26 ppm serves as an internal standard.
The NMR data are provided in Tables S1 − S4 and spectra in
Figs. S1 − S14.
Results
Acceptance of ardeemin FQ (1) and its enantiomer (2)
by cyclic dipeptide prenyltransferases with different
activities
To prove the acceptance of the tryptophan-containing cyclic
tripeptide derivative ardeemin FQ (1) and its enantiomer ent-
ardeemin FQ (2) by the cyclic dipeptide prenyltransferases
BrePT, FtmPT1, CdpNPT, CdpC3PT, and AnaPT, we
overproduced the recombinant proteins according to the pub-
lished protocols (Grundmann and Li 2005; Yin et al. 2007,
2009, 2010, 2013). The obtained proteins were first incubated
with their natural or best accepted cyclic dipeptide (Fig. 1).
These positive controls were used to evaluate assay conditions
and enzyme activity. The expected products of these assays
were confirmed by LC-MS analysis and correspond well to
those reported previously (Grundmann and Li 2005; Yin et al.
2007, 2009, 2010, 2013). As shown in Fig. 2, cyclo-L-Trp-L-
P ro (cWP) was we l l a ccep t ed by the two C2 -
prenyltransferases BrePT and FtmPT1 and product yields of
85.6 and 98.0% were calculated after incubation with 10 μg
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enzyme at 37 °C for 4 h, respectively. Almost complete con-
version of (S)- and (R)-benzodiazepindione was observedwith
CdpNPT and AnaPT under the same conditions, respectively.
In the case of CdpC3PT, 70.3% of cyclo-L-Trp-Gly (cWG)
was converted.
After proving the availability of active enzymes, 1 and 2
were also incubated with 10 μg of each of the five
prenyltransferases at 37 °C for 4 h. Product formation in the
reaction mixtures was monitored via LC-MS. In Fig. 2, the
UV absorptions at 274 nm and the extracted ion chromato-
grams (EICs) for the monoprenylated products of 1 and 2 at
m/z = 427.2129 ± 0.005 are illustrated. Inspection of the
HPLC chromatograms revealed a very good acceptance of 1
by BrePT, FtmPT1, and CdpNPTwith product yields of 77.2,
66.8, and 76.8% (Fig. 2), respectively. As observed for several
cycl ic dipept ides (Yu et al . 2013), the two C3 -
prenyltransferases CdpC3PT and AnaPT, with product yields
of only 17 and 2%, respectively, also showed significantly
lower activities toward 1 than CdpNPT. In comparison with
1, its enantiomer 2 was a poor substrate for all the five tested
enzymes, with a maximal product yield of 21.8% for
CdpNPT. This demonstrated the strong influence of the ste-
reochemistry at C11 and C14 on the acceptance by the cyclic
dipeptide prenyltransferases.
Detailed inspection of the chromatograms revealed that
only one sole or one predominant peak was detected in the
incubation mixtures of 1 with BrePT, FtmPT1, CdpNPT, and
CdpC3PT (Fig. 2) as well as 2 with FtmPT1 and CdpC3PT.
Previous studies indicated that the high regiospecificity of the
prenyltransferase reactions will be broken with unnatural sub-
strates, especially those with low acceptance (Fan and Li
2013; Liebhold et al. 2013; Wollinsky et al. 2012b). This
phenomenon was clearly observed for the reactions of 2 with
BrePT and CdpNPT, in which at least three and five product
peaks were detected (peaks with product yields less than 1.5%
were not taken into consideration).
Product identification and structure elucidation
To verify their structures, a total of 12 compounds were iso-
lated from incubation mixtures of 1 or 2with the five enzymes
on HPLC, 1b2, 1b3ß, 1b6, 1b7, 2a1, 2b1, 2b2, 2b3α, 2b3ß,
2a5, 2b6, and 2b7 in high purity and 1a1 and 1a2 as mixtures
with 1b3ß and 1b2, respectively. To achieve a better reading
flow, we named the products by a combination of substrate
number (1 or 2), prenylation pattern (a for regular and b for
reverse prenylation), and position (1 – 7), e.g., 1a5 for C5-
regularly prenylated ardeemin FQ. Prenylation at C3 subse-
quently leads to a ring formation between the indole and the
piperazine rings. We added α and β after the combination to
distinguish between the two configurations, 1b3β for reverse-
ly C3ß-prenylated ardeemin FQ.
These isolated products were identified with the help of
HR-MS and 1H NMR analysis. High-resolution mass spectro-
metric data (Table 1) show a monoprenylation of all the iso-
lated products, by detection of the [M +H]+ ions, which are
Table 1 MS data of the substrates
and their prenylated products Compound Product from assay
with
Chemical
formula
HR-ESI-MS ([M+H]+) Deviation
[ppm]
Calculated
[Da]
Measured
[Da]
1 (ardeemin FQ) – C21H18N4O2 359.1503 359.1527 6.68
1a1 1 and BrePT C26H26N4O2 427.2129 427.2147 4.21
1a2 1 and FtmPT1 C26H26N4O2 427.2129 427.2152 5.38
1b2 1 and BrePT C26H26N4O2 427.2129 427.2153 5.62
1a3β 1 and FtmPT1 C26H26N4O2 427.2129 427.2162 7.72
1b3β (ardeemin) 1 and CdpNPT C26H26N4O2 427.2129 427.2147 4.21
1a6 1 and AnaPT C26H26N4O2 427.2129 427.2131 0.47
1a7 1 and CdpC3PT C26H26N4O2 427.2129 427.2150 4.92
2 (ent-ardeemin FQ) – C21H18N4O2 359.1503 359.1519 4.45
2a1 2 and CdpNPT C26H26N4O2 427.2129 427.2145 3.75
2b1 2 and BrePT C26H26N4O2 427.2129 427.2128 − 0.23
2b2 2 and BrePT C26H26N4O2 427.2129 427.2127 − 0.47
2b3α 2 and BrePT C26H26N4O2 427.2129 427.2136 1.64
2b3β 2 and CdpNPT C26H26N4O2 427.2129 427.2151 5.15
2a5 2 and AnaPT C26H26N4O2 427.2129 427.2137 1.87
2a6 2 and AnaPT C26H26N4O2 427.2129 427.2145 3.75
2a7 2 and CdpC3PT C26H26N4O2 427.2129 427.2143 3.28
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68 daltons larger than those of 1 and 2. The prenylation posi-
tion and pattern as well as the configuration (in the case of
prenylation at C3) of the introduced prenyl moieties were
determined by the interpretation of the 1H NMR data
Fig. 2 LC-MS analysis of the reaction mixtures of selected cyclic
dipeptides, ardeemin FQ (1), and its enantiomer ent-ardeemin FQ (2)
with BrePT, FtmPT1, AnaPT, CdpC3PT, and CdpNPT. UV
chromatograms and EICs with a tolerance of ± 0.005 Da for
monoprenylated derivatives are illustrated. cWP stands for cyclo-L-Trp-
L-Pro, cWG for cyclo-L-Trp-Gly, and BDZD for benzodiazepinedione
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(Table S1−S4). Regular and reverse prenylation can be easily
distinguished by the characteristic chemical shifts and cou-
pling pattern of the protons at H-1′ and H-2′ as well as of the
two methyl groups of the prenyl moieties. For a regular
prenylation, a multiplet at approximately 5.4 ppm is expected
for H-2′. The signals of the two protons for H-1′ at about
4.7 ppm indicate the attachment to N-1 and 3.5 ppm to an
aromatic carbon atom (Liao et al. 2018; Yin et al. 2007).
The signals for the two methyl groups are found around
1.8 ppm as singlets or doublets with small coupling constants.
In the case of a reverse prenylation, a doublet of doublets with
a chemical shift between 6.16 and 6.03 ppm is observed for
H-2′. This signal has characteristic coupling constants of
17 Hz and 10 Hz with the two protons at H-1′, which also
appear as a doublet of doublets with a chemical shift around
5.10 to 5.20 ppm. The coupling constants of the two protons at
H-1′ are found between 0.5 and 1.5 Hz. The signals of the two
methyl groups at approximately 1.60 ppm indicate the attach-
ment of the prenyl moiety to C2 of the indole ring or 1.10 ppm
for C3-attachment of the pyrroloindole ring (Yin et al. 2013;
Yu et al. 2013).
A prenylation at N-1 can be determined by the disappear-
ance of the broad signal at around 8.10 ppm and by the ap-
pearance of H-1′ of the prenyl moiety at about 4.70 ppm (Yin
et al. 2007). Verification of the prenyl moiety at C2 is the
disappearance of the characteristic signal for the H-2 at
7.10–7.20 ppm observed as a singlet or a doublet with a small
coupling constant of about 2.2 Hz. C3-prenylation results in
an up-field shifting of H-2 as a singlet to 5.50 to 5.60 ppm, due
to dearomatization. The configuration of the prenyl moiety
attached to C3 after ring formation (syn or anti) can be iden-
tified by the coupling of H-11 with the two protons at H-10.
The presence of doublet of doublets with coupling constants
of 10 Hz and 6 Hz proves a syn-cis configuration. In the case
of an anti-cis configuration, the signal of H-11 will be split
into a triplet with a coupling constant of 8.7 Hz (Yu et al.
2013). Comparison of the NMR data of 1b3β from the incu-
bation of CdpNPT and 1 with literature data confirmed its
structure as ardeemin (Haynes et al. 2013). Regular
prenylation at the positions C5–C7 of the benzene ring for
both enantiomers 1 and 2 changes the four proton-coupling
to three proton-coupling systems. The prenylation position
can be determined by comparison with NMR data from the
literature (Liao et al. 2018; Mai et al. 2016).
C2 and C3 as the main prenylation positions
of enzyme reactions with high product yields
Structure elucidation of the isolated products revealed compa-
rable prenylation positions and patterns of 1 by BrePT and
CdpNPTwith those of the cyclic dipeptides published in pre-
vious studies. The reversely C3-prenylated derivative 1b3β
was found as the sole product of 1 with CdpNPT, which
corresponds well to the prenylation position and pattern of
its enzyme products with cyclic dipeptides (Schuller et al.
2012; Yu et al. 2013). A previous study with BrePT and 14
cyclic dipeptides showed that reversely C2-prenylated deriv-
atives are the predominant products (Yin et al. 2013). As
shown in Figs. 2 and 3, also the reversely C2-prenylated de-
rivative 1b2 was detected as the major product of 1 with
BrePT, with a product yield of 57.0%, i.e., 75% of the total
product yield. In addition, the regularlyN1- (1a1) and reverse-
ly C3-prenylated derivative (1b3ß) were also identified.
Structure elucidation of the isolated products revealed dis-
tinct prenylations of 1 by FtmPT1 from those of the cyclic
dipeptides. Previous studies proved that FtmPT1 catalyzes
the regular C2-prenylation of its natural substrate cWP
(Grundmann and Li 2005; Wollinsky et al. 2012b). Using
other 13 tryptophan-containing cyclic dipeptides as substrates,
FtmPT1 also catalyzes the regular C3-prenylation and in two
cases, even regular N1-prenylation. Nevertheless, regular C2-
prenylation remains the main reaction of FtmPT1 with cyclic
dipeptides (Wollinsky et al. 2012b). With 1 as a substrate,
FtmPT1 mainly transferred the prenyl moiety to C3 in a re-
verse orientation resulting in the formation of 1b3β with a
product yield of 44.5%, being 66% of the total product yield.
Analogous products to those of cyclic dipeptides, i.e., regular-
ly N1-, C2-, and C3-prenylated derivatives, were detected as
minor products (Fig. 3). In addition, a reverselyC2-prenylated
derivative was also obtained. It seems that C3 of 1 is a favor-
able prenylation position for C2-prenyltransferases, since
even in the incubation mixture of 1 with BrePT, 1b3β was
identified with a product yield of 12.7% (Fig. 3).
C6 and C7 are the favored prenylation positions
of enzymes with low activity
Structure elucidation of the products of reactions with low
conversions, i.e., 1 with CdpC3PT and AnaPT as well as 2
with FtmPT1, CdpNPT, CdpC3PT, and AnaPT, revealed
prenylation at C6 (1a6 and 2a6) in all the reactions. C7-
prenylated derivatives 1a7 and 2a7 were identified in the re-
action mixtures of 1 with CdpC3PT as well as those of 2 with
FtmPT1, CdpNPT, and CdpC3PT. 2a5 was found in the reac-
tion mixtures of CdpNPT and AnaPT. Determination and
comparison of the product yields (Fig. 3) showed that C6-
and C7-prenylated derivatives are major products or at least
higher than other products. This indicates that the positions at
the benzene ring, especially C6 and C7, are the preferred po-
sitions for reactions with low conversion rates. The poor ac-
ceptance of 1 by CdpC3PT and AnaPT as well as 2 by all the
five enzymes could indicate their bad accommodation into the
active sites of these enzymes and therefore their distinct ori-
entation from those of cyclic dipeptides for prenylation.C6- or
C7-prenylation of cyclic dipeptides was observed with the
wi ld type AnaPT and the mutan t s o f CdpC2PT
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(CdpC2PT_T351G), CdpNPT (CdpNPT_M349G), and
CdpC3PT (CdpC3PT_F335G) in the presence of geranyl di-
phosphate as a prenyl donor (Liao et al. 2018; Pockrandt and
Li 2013).
Kinetic parameters of BrePT, FtmPT1, and CdpNPT
toward 1
To compare the catalytic efficiency of the cyclic dipeptide
prenyltransferases for the tripeptide derivative ardeemin FQ
(1) with those for their natural substrates and with each other,
kinetic parameters including Michaelis-Menten constants
(KM) and turnover numbers (kcat) were determined for the
three enzymes BrePT, FtmPT1, and CdpNPTwith high activ-
ity toward 1. All the reactions followed the Michaelis-Menten
kinetics (Fig. S15 – S17). KM values between 0.009 and
0.19 mM and turnover numbers from 0.02 to 0.23 s−1
(Table 2) were determined, which are in the range of those
these enzymes with most cyclic dipeptides (Wollinsky et al.
2012b; Yin et al. 2013).
Discussion
Our main object in this study was the identification of en-
zymes, in order to close the prenylation gap of ardeemin FQ
1 and its enantiomer 2 at the positions C2 and C3 of the indole
moiety. Generally, the cyclic dipeptide prenyltransferases
BrePT and FtmPT1 attach a prenyl moiety to C2 of the
tryptophan-containing cyclic dipeptides in a reverse and reg-
ular manner, respectively. In comparison, AnaPT, CdpC3PT,
and CdpNPT catalyze the reverse C3-prenylation.
Identification of the isolated products proved the C2- and
C3-prenylation of 1 by BrePT, FtmPT1, and CdpNPT with
high product yields (Figs. 2 and 3). Unfortunately, the conver-
sion of 2 by these enzymes was very low and accompanied by
various products, which prohibits their potential biotechno-
logical applications and should be overcome in the future by
using other enzymes. Nevertheless, with these enzymes, we
successfully obtained 15 different products with prenylations
at six positions of the indole ring.
The much higher activities observed for BrePT, FtmPT1,
and CdpNPT toward 1 compared with 2 differ significantly
from their actions toward cyclic dipeptides. With the enantio-
mer cyclo-D-Trp-D-Pro, BrePT showed a relative activity of
16% of its natural substrate cyclo-L-Trp-L-Pro and accepted
cyclo-L-Trp-L-Ala and cyclo-D-Trp-D-Alawith an activity ratio
of 4:1 (Yin et al. 2013). FtmPT1 and CdpNPTaccepted cyclo-
L-Trp-L-Pro, cyclo-D-Trp-D-Pro, L-Trp-L-Ala, and cyclo-D-
Trp-D-Ala with ratios of 5.9:3.9:4.7:1 and 1.2:1.4:1:1.2, re-
spectively (Wollinsky et al. 2012b; Yu et al. 2013). The main
prenylation positions of 1 and 2 observed in our experiments
catalyzed by the five enzymes are similar to those of cyclo-L-
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Fig. 3 Identified prenylated products after incubation of ardeemin FQ (1) and ent-ardeemin FQ (2) with BrePT, FtmPT1, AnaPT, CdpC3PT, or CdpNPT.
Product yields are calculated based on UV chromatograms at 274 nm and are given as the mean of two independent measurements in %
Table 2 Kinetic parameters of BrePT, FtmPT1, and CdpNPT toward 1
in the presence of DMAPP
Ardeemin FQ (1)
KM [mM] kcat [s
−1] kcat/KM [s
−1 M−1]
BrePT 0.009 0.021 2333
FtmPT1 0.19 0.13 684
CdpNPT 0.013 0.23 17,692
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homotryptophan-D-valine (Fan and Li 2013). In that study,
reversely C2- and C3-prenylated derivatives were proven to
be products of BrePT and FtmPT1 reactions, while regularly
C6- and C7-prenylated derivatives as main products in those
of CdpC3PT and AnaPT. The reversely C3-prenylated prod-
uct was also identified as a product of the CdpNPT reaction.
Differing from the results with 1 and 2 observed in this study,
the activities of the tested enzymes showed comparable high
activities toward L-homotryptophan-D-valine (Fan and Li
2013).
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Table S1. 1H NMR data of prenylated ardeemin FQ derivatives 1a1, 1a2, 1b2 
compound 
20
19
18
23
22
21
N
17
16
N
15
24
11
NH12
13
14
25
10
3
9 8
N
1
2
4
5
6
7
O
O
(R)
(S)
1'
2' 3'
4'
5'
1a1 
20
19
18
23
22
21
N
17
16
N
15
24
11
NH 12
13
14
25
10
3
9
8
NH 1
2
4
5
6
7
O
O
(R)
(S)
1'
2'
3'
5'
4'
1a2 
20
19
18
23
22
21
N
17
16
N
15
24
11
NH12
13
14
25
10
3
9 8
NH 1
2
4
5
6
7
O
O
(R)
(S)
3'
4'
2'
5'
1'
1b2
position δH (ppm) multi. J (Hz) δH (ppm) multi. J (Hz) δH (ppm) multi. J (Hz) 
1 - 8.02 br s 8.12 br s 
2 7.09 s - - 
4 7.64 d (7.7) 7.543 d (8.0) 7.543 dd (8.1, 1.0) 
5 7.16 t (7.7)a 7.13 dd (8.0, 7.0) 7.14 ddd (8.1, 7.0, 1.0) 
6 7.26c 7.20 dd (8.0, 7.0)b 7.21 ddd (8.1, 7.0, 1.0) 
7 7.38 d (8.3) 7.37d (8.0) 7.38 dt (8.1, 1.0) 
10 4.26 dd (15.0, 3.6) 4.19 dd (15.1, 3.5) 4.22 dd (15.2, 4.0) 
3.12 dd (15.0, 10.7) 3.15 dd (15.1, 10.8) 3.40 dd (15.2, 11.1) 
11 4.89 dd (10.7, 3.6) 4.89 dd (10.8, 3.5) 4.99 dd (11.1, 4.0) 
12 5.99 br s 5.86 br s 5.90 br s 
14 5.45 q (7.2) 5.45 q (7.0)b 5.45 q (7.3) 
18 7.78 dd (8.2, 1.3) 7.79 db 7.79 ddd (8.2, 1.7, 0.6) 
19 7.82 ddd (8.2, 7.0, 1.5) 7.82 dddb 7.82 ddd (8.2, 6.7, 1.5) 
20 7.54 ddd (8.0, 7.0, 1.3) 7.544 dd (8.2, 6.6)b 7.542 ddd (8.2, 6.7, 1.7) 
21 8.32 dd (8.0, 1.5) 8.32 d (8.2)b 8.32 ddd (8.2, 1.5, 0.6) 
25 1.59 d (7.2)d 1.575 d (7.4)  1.57 d (7.3)d 
1’ 4.70 d (7.0) 3.54 d (7.8) 5.20 dd (10.4, 0.8) 
3.52 d (7.1) 5.19 dd (17.6, 0.8) 
2’ 5.41 m 5.34 m 6.18 dd (17.6, 10.4) 
4’ 1.85 d (0.9) 1.80 d (0.7) 1.611 s 
5’ 1.79 d (1.2) 1.76 d (0.6) 1.606 s 
solvent 7.26 (CDCl3) 7.26 (CDCl3) 7.26 (CDCl3) 
a signal overlaps with those of 1b3β; b signal overlaps with those of 1b2; c signals overlap with those of solvent; d signals overlap with H2O 
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Table S2. 1H NMR data of prenylated ardeemin FQ derivatives 1b3β, 1a6, 1a7 
compound 
20
19
18
23
22
21
N
17
16
N
15
24
11
N 12
13
14
25O
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1a6 
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1a7 
position δH (ppm) multi. J (Hz) δH (ppm) multi. J (Hz) δH (ppm) multi. J (Hz) 
1 - 8.10 br s 8.19 br s 
2 5.60 s 7.14 d (2.2) 7.19 d (2.3) 
4 7.26a 7.56 d (8.1) 7.52 d (7.5) 
5 6.81 td (7.6, 1.0) 7.02 dd (8.1, 1.4) 7.12 t (7.5) 
6 7.15 td (7.6, 1.2) - 7.09 d (7.5) 
7 6.66 dd (7.6, 1.0) 7.24 s - 
10 2.94 dd (12.9, 6.2) 4.24 ddd (15.0, 3.6, 0.9) 4.26 dd (15.0, 3.8) 
 2.75 dd (12.9, 10.5) 3.13 dd (15.0, 10.7) 3.16 dd (15.0, 10.7) 
11 4.52 dd (10.5, 6.2) 4.89 dd (10.7, 3.6) 4.90dd (10.7, 3.8) 
12 - 5.98 br s 5.94 br s 
14 5.46 q (7.2) 5.45 q (7.3) 5.46 q (7.4) 
18 7.68 dd (8.1, 1.1) 7.78 dt (8.2, 1.3) 7.78 dd (8.0, 1.1) 
19 7.78 ddd (8.1, 7.2, 1.5) 7.82 ddd (8.2, 7.0, 1.3) 7.82 ddd (8.0, 7.0, 1.4) 
20 7.50 ddd (8.1, 7.2, 1.1) 7.54 ddd (8.2, 7.0, 1.3) 7.54 ddd (8.0, 7.0, 1.1) 
21 8.28 dd (8.1, 1.2) 8.32 dd (8.2, 1.3) 8.32 dd (8.0, 1.1) 
25 1.49 d (7.2) 1.58 d (7.2) 1.58 d (7.2) 
1’ 5.13 dd (10.9, 0.9) 3.47 d (7.4) 3.60 m 
 5.12 dd (17.3, 0.9)   
2’ 6.03 dd (17.3, 10.9) 5.39 tsept (7.4, 1.3) 5.43 tsept (7.1, 1.4) 
4’ 1.19 s 1.77 d (1.1) 1.85 s 
5’ 1.05 s 1.76 s 1.81 d (1.0) 
solvent 7.26 (CDCl3) 7.26 (CDCl3) 7.26 (CDCl3) 
a signals overlap with those of solvent 
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Table S3. 1H NMR data of prenylated ent-ardeemin FQ derivatives 2a1, 2b1, 2b2, 2b3α, 2b3β 
compound 
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2b3β 
position δH (ppm) multi. J (Hz) δH (ppm) multi. J (Hz) δH (ppm) multi. J (Hz) δH (ppm) multi. J (Hz) δH (ppm) multi. J (Hz) 
1 -  8.12 br s - - 
2 7.09 s 7.26a - 5.59 s 5.55 s 
4 7.64 d (7.9) 7.62 d (8.0) 7.538 d (7.9) 7.26a 7.23 d (7.5) 
5 7.16 dd (7.9, 7.0) 7.13 dd (8.0, 7.0) 7.14 ddd (7.9, 7.1, 1.0) 6.80 td (7.5, 1.1) 6.70 td (7.5, 1.1) 
6 7.28a 7.19 dd (8.3, 7.0) 7.21 ddd (8.1, 7.1, 1.0) 7.14 ddd (7.8, 7.5, 1.1) 7.03 td (7.7, 1.1) 
7 7.38 d (8.1) 7.58 d (8.3) 7.38 dt (8.1, 1.0) 6.65 d (7.8) 6.54 d (7.7) 
10 4.26 dd (15.0, 3.6) 4.27 dd (15.0, 3.5) 4.22 dd (15.3, 4.0) 2.93 dd (13.0, 6.1) 3.16 dd (14.0, 8.6) 
 3.12 dd (15.0, 10.7) 3.11 dd (15.0, 10.6) 3.40 dd (15.2, 11.2) 2.75 dd (13.0, 10.7) 2.90 dd (14.0, 8.6) 
11 4.89 dd (10.7, 3.6) 4.90 dd (10.6, 3.5) 4.99 dd (11.1, 4.2) 4.51 dd (10.7, 6.1) 4.72 t (8.6) 
12 5.99 br s 5.97 br s 5.91 br s - - 
14 5.45 q (7.3) 5.45 q (7.2) 5.45 q (7.2) 5.45 q (7.5) 5.45 q (7.3) 
18 7.78 dd (8.1, 1.3) 7.78 dd (8.2, 1.3) 7.79 ddd (7.9, 1.6, 0.5) 7.68 d (8.2) 7.61 d (8.2) 
19 7.82 ddd (8.1, 6.9, 1.5) 7.82 ddd (8.2, 6.8, 1.5) 7.82 ddd (8.2, 6.7, 1.4) 7.77 ddd (8.2, 6.9, 1.5) 7.72 ddd (8.2, 7.1, 1.5) 
20 7.54 ddd (8.1, 6.9, 1.3) 7.54 ddd (8.0, 6.8, 1.3) 7.539 ddd (7.9, 6.5, 1.6) 7.49 ddd (8.1, 6.9, 1.0) 7.46 ddd (8.0, 7.1, 1.0) 
21 8.32 dd (8.1, 1.5) 8.32 dd (8.0, 1.5) 8.32 ddd (8.0, 1.4, 0.5) 8.27 dd (8.1, 1.5) 8.22 dd (8.0, 1.5) 
25 1.59 d (7.0)b 1.59 d (7.4)b 1.58 db 1.49 d (7.2) 1.61 d (7.3) 
1’ 4.70 d (6.9) 5.27 dd (10.7, 0.5) 5.20 dd (10.3, 0.6) 5.12 dd (10.8, 1.1) 5.22 dd (10.8, 1.1) 
  5.22 dd (17.4, 0.5) 5.19 dd (17.6, 0.6) 5.11 dd (17.2, 1.1) 5.20 dd (17.3, 1.1) 
2’ 5.40 m 6.16 dd (17.4, 10.7) 6.19 dd (17.6, 10.3) 6.03 dd (17.2, 10.8) 6.03 dd (17.3, 10.8) 
4’ 1.85 d (0.5) 1.79 s 1.61 s 1.18 s 1.23 s 
5’ 1.79 d (1.0) 1.78 s 1.60 s 1.04 s 1.06 s 
solvent 7.26 (CDCl3) 7.26 (CDCl3) 7.26 (CDCl3) 7.26 (CDCl3) 7.26 (CDCl3) 
 a signals overlap with those of solvent; b signals overlap with H2O 
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Table S4. 1H NMR data of prenylated ent-ardeemin FQ derivatives 2a5, 2a6, 2a7 
compound 
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2a7 
position δH (ppm) multi. J (Hz) δH (ppm) multi. J (Hz) δH (ppm) multi. J (Hz) 
1 8.12 br s 8.10 br s 8.19 br s 
2 7.17 d (2.3) 7.14 d (2.0) 7.18 d (2.3) 
4 7.41 s 7.56 d (8.2) 7.52 dd (7.5, 1.1) 
5 - 7.02 dd (8.2, 1.3) 7.11 dd (7.5, 7.2) 
6 7.11 d (8.4) - 7.09 dd (7.1, 1.1) 
7 7.36 d (8.4) 7.24 s - 
10 4.23 dd (14.9, 3.7) 4.24 ddd (14.9, 3.6, 0.7) 4.26 ddd (15.0, 3.7, 0.9) 
 3.16 dd (14.9, 10.7) 3.13 dd (14.9, 10.7) 3.16 dd (14.9, 10.7) 
11 4.91 dd (10.7, 3.7) 4.89 dd (10.7, 3.6) 4.90 dd (10.6, 3.6) 
12 5.94 br s 5.94 br s 5.93 br s 
14 5.45 q (7.3) 5.45 q (7.1) 5.46 q (7.0) 
18 7.79 dd (8.2, 1.4) 7.78 dd (8.2, 1.3) 7.78 dd (8.2, 1.3) 
19 7.82 ddd (8.2, 6.8, 1.4) 7.82 ddd (8.2, 6.9, 1.4) 7.82 ddd (8.2, 7.0, 1.4) 
20 7.54 ddd (8.1, 6.8, 1.5) 7.54 ddd (8.1, 6.9, 1.3) 7.54 ddd (8.0, 7.0, 1.3) 
21 8.32 d (8.1) 8.32 dd (8.1, 1.4) 8.32 dd (8.0, 1.4) 
25 1.60 d (7.3) 1.58 d (7.2) 1.58 d (7.2) 
1’ 3.44 d (7.3) 3.47 d (7.4) 3.60 m 
    
2’ 5.37 m 5.39 m 5.43 m 
4’ 1.74 d (0.7) 1.77 d (1.0) 1.85 d (0.7) 
5’ 1.73 d (1.0) 1.76 d (0.6) 1.81 d (1.2) 
solvent 7.26 (CDCl3) 7.26 (CDCl3) 7.26 (CDCl3) 
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Figure S1. 1H NMR spectrum of 1a1 and 1b3β as a mixture in CDCl3 (500 MHz) 
S7 
 
 
Figure S2. 1H NMR spectrum of 1a2 and 1b2 as a mixture in CDCl3 (500 MHz) 
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Figure S3. 1H NMR spectrum of 1b2 in CDCl3 (500 MHz) 
S9 
 
 
Figure S4. 1H NMR spectrum of 1b3β in CDCl3 (500 MHz) 
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Figure S5. 1H NMR spectrum of 1a6 in CDCl3 (500 MHz) 
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Figure S6. 1H NMR spectrum of 1a7 in CDCl3 (500 MHz) 
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Figure S7. 1H NMR spectrum of 2a1 in CDCl3 (500 MHz) 
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Figure S8. 1H NMR spectrum of 2b1 in CDCl3 (500 MHz) 
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Figure S9. 1H NMR spectrum of 2b2 in CDCl3 (500 MHz) 
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Figure S10. 1H NMR spectrum of 2b3α in CDCl3 (500 MHz) 
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Figure S11. 1H NMR spectrum of 2b3β in CDCl3 (500 MHz) 
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Figure S12. 1H NMR spectrum of 2a5 in CDCl3 (500 MHz) 
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Figure S13. 1H NMR spectrum of 2a6 in CDCl3 (500 MHz) 
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Figure S14. 1H NMR spectrum of 2a7 in CDCl3 (500 MHz)
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Figure S 15. Determination of kinetic parameters of BrePT for ardeemin FQ (1) 
 
FtmPT1
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Figure S 16. Determination of kinetic parameters of FtmPT1 for ardeemin FQ (1) 
Vmax = 25.36 nmol · mg-1 · min-1 
KM = 0.009 mM 
kcat = 0.021 s-1 
Vmax = 149.2 nmol · mg-1 · min-1 
KM = 0.19 mM 
kcat = 0.13 s-1 
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Figure S 17. Determination of kinetic parameters of CdpNPT for ardeemin FQ (1) 
Vmax = 274.1 nmol · mg-1 · min-1 
KM = 0.013 mM 
kcat = 0.23 s-1 
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ABSTRACT: Mutation of the gatekeeping residues for
prenyl donor selectivity in six dimethylallyl transferases
significantly increased their activities toward geranyl diphos-
phate. Forty-two geranylated derivatives were obtained from
15 cyclic dipeptides by using the engineered enzymes. Taking
cyclo-L-Trp-L-Trp as an example, the geranyl moiety can be
attached to all seven possible positions of the indole nucleus.
This study demonstrates a convenient way to increase the
structural diversity of geranylated products by structure-based
engineering of the available dimethylallyl transferases.
Prenylated natural products are hybrid structures contain-ing prenyl moieties (n × C5) or derivatives thereof and are
widely distributed in plants and microorganisms.1−3 Among
them, prenylated indole alkaloids including prenylated
tryptophan-containing cyclic dipeptides (CDPs) usually exhibit
a wide range of biological and pharmacological activities and,
therefore, are important sources for drug discovery and
development.2,4,5 Representative structures such as notoa-
mides,6,7 roquefortines,8 fumitremorgins,9 and felluta-
nines10−12 are commonly derived from CDPs and often
decorated with one or more dimethylallyl (C5) moieties
(Figure 1).
The key reactions in the biosynthesis of the prenylated
natural products are connections of the prenyl moiety with its
acceptor catalyzed by prenyltransferases (PTs). PTs belonging
to the dimethylallyltryptophan synthase (DMATS) superfamily
catalyze the regiospecific Friedel−Crafts alkylation of aromatic
substrates, mainly of indole derivatives.13,14 The attachment of
the C5 unit to N1 and the six nonbridgehead carbons at the
indole ring can be achieved by the available indole PTs.13−15
However, the transfer of the C10 unit (geranyl) onto the indole
nucleus was rarely reported. Taking CDPs as examples, AnaPT
from Neosartorya fischeri catalyzes in the presence of
dimethylallyl diphosphate (DMAPP) reverse C3-prenylation
and also uses geranyl diphosphate (GPP) for their C6- and C7-
geranylation, as exemplified by cWW (1; for simplicity, one
letter codes are used for proteinogenic amino acids) in Scheme
1.16,17 AtaPT from Aspergillus terreus was reported to catalyze
the C4-geranylation of 1.18 Our recent reinvestigation on this
Received: October 1, 2018
Published: October 31, 2018
Figure 1. Representative examples of prenylated indole alkaloids
derived from cyclic dipeptides.
Scheme 1. Reverse Dimethylallyl C3-PT AnaPT from N.
fischeri Can Also Use GPP for C6- and C7-Geranylationa
aAtaPT from A. terreus attaches a geranyl moiety to C7 of 1. To
facilitate the reading flow, geranylated products are named by using
substrate number, prenylation pattern (a for regular or normal and b
for reverse prenylation), and prenylation position at the indole ring (1
to 7 for N1- to C7-alkylated products), e.g., 1a6 for C6-regularly
geranylated cWW.
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reaction revealed a C7- instead of a C4-geranylation (data not
shown). Other CDPs with geranyl residues have not yet been
reported. Furthermore, only a few members of PTs are able to
accept GPP as a prenyl donor and act as geranyl transferases,
e.g. TleC,19 VrtC,20 and AmbP1.21 Therefore, it is necessary to
find new geranyl transferases or to manipulate available
dimethylallyl transferases for GPP acceptance to enrich the
biocatalysis toolboxes.
Inspired by the activities of AtaPT and AnaPT toward GPP
for prenylation of CDPs, we first evaluated the GPP acceptance
of five dimethylallyl transferases, FtmPT1,22 CdpNPT,23
BrePT,24 CdpC2PT,25 and CdpC3PT,26 in the presence of
CDPs as acceptors. These enzymes catalyze regular (normal)
or reverse prenylations at C-2 or C-3 of the indole ring. The
tested CDPs include 1, cWP (2) and its stereoisomers (3−5),
cWA (6) and its stereoisomers (7−9), cWL (10), cWY (11),
cWF (12), cWG (13), (S)-(14), and (R)-benzodiazepinedin-
one (15). HPLC analysis of the incubation mixtures showed
that the five PTs well accepted their natural or best aromatic
substrates in the presence of DMAPP (Figure S1 in the
Supporting Information (SI)), confirming the presence of
active proteins. In the presence of GPP, CdpC2PT showed
clear activity toward 1, 2, 14, and 15 (Figure S2). The other
four enzymes exhibited very low (CdpC3PT toward 1, 2, 5,
and 14, Figure 2, Figure S3) or no activity (CdpNPT,
FtmPT1, and BrePT) (Figure 2, Figures S4−S6), when GPP
was used as a prenyl donor.
AtaPT was previously reported to have broad tolerance for
prenyl donors. The residue Gly326 was proven to contribute to
the enlarged pocket for donor binding.18 Mutation of Gly326
to methionine dramatically reduced the activity of G326M
toward GPP and FPP, but substantially enhanced the catalytic
activity with DMAPP. This proved that the size of the residue
at 326 controls the prenyl donor selectivity in AtaPT. Mutation
of Met328 in the tryptophan prenyltransferase FgaPT2 to
small amino acids such as cysteine, threonine, serine, glycine,
or alanine significantly increased the acceptance of GPP.27
Encouraged by these findings, structure-based protein
sequence alignments of AtaPT and FgaPT2 with the five
PTs mentioned above led to the identification of the
corresponding residues Met364 in FtmPT1, IIe337 in BrePT,
Thr351 in CdpC2PT, Met349 in CdpNPT, and Phe335 in
CdpC3PT (Figure 3, Figure S7).
Molecular modeling with the ternary crystal structures of
FtmPT1 and CdpNPT23,28 also uncovered Met364 in FtmPT1
and Met349 in CdpNPT as key residues for DMAPP
selectivity (Figure S8). The side chain of this residue seals
the active site to form a pocket for DMAPP. In the active site
of both enzymes, GPP would clash with the side chain of the
gatekeeping residue methionine. Therefore, reducing the steric
pressure in the DMAPP binding site by replacement of this
bulky residue with a small amino acid like glycine would
increase the enzymatic activity toward GPP.
To switch the prenyl donor specificity from DMAPP to GPP
for FtmPT1, BrePT, CdpNPT, and CdpC3PT and to expand
the GPP acceptance of CdpC2PT, we replaced the mentioned
amino acids of the five dimethylallyl transferases by glycine,
resulting in the mutants FtmPT1_M364G, BrePT_I337G,
C d p N P T _M 3 4 9 G , C d p C 2 P T _ T 3 5 1 G , a n d
CdpC3PT_F335G, respectively (see Table S1 for constructs
and SI for description). As expected, replacing bulky amino
acids by glycine significantly improved in most cases the CDP
consumption in the presence of GPP (Figure 2, Figures S2−
S6, S9). In comparison, the acceptance of DMAPP by the
mutants was reduced to different levels (Figure S1). In sharp
contrast to no activity in the presence of GPP by wild type
CdpNPT, FtmPT1, and BrePT, all the tested CDPs (1−15)
were accepted by CdpNPT_M349G with total product yields
from 13.7% to 95.8% (Figure 2, Figures S4 and S9). 1−13 with
a diketopiperazine ring were consumed by FtmPT1_M349G
with total product yields from 9.6% to 75.4%. The two
benzodiazepinediones 14 and 15 were not accepted (Figure 2,
Figures S5 and S9).
Figure 2. HPLC chromatograms of the incubation mixtures of six
dimethylallyl transferases and their corresponding mutants with their
natural or best accepted substrates in the presence of GPP. Regular
geranylated products are labeled in red, and reverse, in blue. The
product yields are given in parentheses after the product number. See
please Figure S1 for their behavior toward DMAPP.
Organic Letters Letter
DOI: 10.1021/acs.orglett.8b03124
Org. Lett. 2018, 20, 7201−7205
7202
The activity of BrePT toward GPP can be strongly increased
by mutation at the gatekeeping residue Ile337, at least for its
natural substrate 2 (79.8%) and the two stereoisomers 3
(71.4%) and 4 (28.4%) (Figure 2, Figure S6). In the case of
CdpC3PT_F335G, conversion of almost all substrates was
significantly increased, especially for 10. Its conversion was
improved from 2.9% by the wild type enzyme to 51.8% by this
mutant (Figure 2, Figure S3). CdpC2PT_T351G exhibited
different behaviors toward 1−15 from CdpC2PT, with distinct
products or different ratios of the same products (Figure 2,
Figures S2 and S9). Detailed inspection of the HPLC
chromatograms of 1−15 with FtmPT1_M364G, BreP-
T_I337G, CdpNPT_M349G, CdpC2PT_T351G, and
CdpC3PT_F335G (Figures S2−S6, S9) revealed the presence
of one to four product peaks with different ratios. Most
reactions have two or three products. This shows the relaxed
regiospecific geranylation by the mutants in comparison to the
wild type enzymes in the presence of DMAPP.
For structure elucidation, 41 representative products of
selected substrates were isolated by preparative HPLC from
different incubation mixtures (Table S2) and subjected to HR-
ESI-MS and 1H NMR analyses (Tables S2−S18, Figures S10−
S54). Structure elucidation (see the SI) confirmed reverse or
regular geranylation at different positions of the indole ring
(Scheme 2).
Three of the tested PTs catalyze regular (FtmPT1) or
reverse (BrePT and CdpC2PT) C2-prenylations of CDPs in
the presence of DMAPP.22,24,25 Structure elucidation proved
that BrePT_I337G catalyzes solely or predominantly still
reverse C2-geranylation of 2− 4. In the reaction mixtures of
FtmPT1_M364G with six substrates, regularly C2-prenylated
derivatives were obtained as major products, i.e. 1a2, 2a2, 3a2,
10a2, 11a2, and 12a2. Regularly C3-prenylated derivatives
such as 1a3, 3a3, 6a3, 8a3, 10a3, 11a3, 12a3, and 13a3 were
identified in at least eight incubation mixtures. This is not
surprising, because regularly C3-prenylated CDPs were also
reported for FtmPT1 in the presence of DMAPP.29 In that
study, however, regularly C2-prenylated derivatives have been
identified as the major products. Interestingly, in the assays of
FtmPT1_M364G with GPP and 6, 8, and 13, no C2-, but
regularly N1- and C3-geranylated derivatives were obtained
(Scheme 2, Figure S5). The behavior of CdpC2PT_T351G
toward GPP also differs significantly from that of the wild type
enzyme. For example, 1 was converted by CdpC2PT to 1b2,
1a5, and 1a7, while CdpC2PT_T351G mainly catalyzes C2-
geranylation, resulting in the formation of mono- (1b2) and
digeranylated (1b2-2) derivatives (Figure 2, Figure S9).
CdpC3PT and CdpNPT both catalyze reverse C3-prenylation
of CDPs in the presence of DMAPP.23,26 Reverse C3-
geranylation was also detected for CdpNPT_M349G with
the selected substrates 1, 5, and 14. In addition, regularly C6-
geranylated products 1a6, 5a6, and 14a6 were also identified.
In the incubation mixture of CdpNPT_M349G with 15, the
product 15a6 was even the predominant peak (Figure S4).
CdpC3PT_F335G converted 10 to a mixture of at least four
products 10a1, 10b1, 10b3, and 10a7 with 10b3 as the major
one (Figure S3). These results indicate the trends of C6- and
C7-geranylation of CDPs by dimethylallyl transferases, which
catalyze C3-prenylation in the presence of DMAPP, as
observed for AnaPT (Scheme 1).16,17
In summary, our results presented in this study showed that
replacing the gatekeeping residue not only changes the
tolerance of PTs toward prenyl donor with longer chain but
Figure 3. Selected region of structure-based alignments of PTs used
in this study with AtaPT and FgaPT2. See Figure S7 for complete
alignments.
Scheme 2. Structures of Enzyme Products with Different
Prenylation Patterns and Positions (Products of 1 Are
Presented in Scheme 3)
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also breaks their regiospecificity, leading to several prenylated
products in one incubation. To some extent, this change
broadens their application in creation of structure diversity of
geranylated indole derivatives. The possible reason for the
relaxed regioselective prenylation by the mutants could be that
the enlarged pocket allows the binding of aromatic substrates
in different orientations. However, the reduced regioselectivity
requires more efforts for product isolation. Therefore, further
mutagenesis experiments are necessary in the future to increase
the desired regio- and stereoselectivity. This would require
more structural information, e.g. of the available single mutants
of the gatekeeping residues. Nevertheless, the single mutants
constructed in this study clearly showed different preferences
toward the 15 tested CDPs and converted them to geranylated
derivatives at various positions. As shown in Scheme 2,
products obtained in this study also carry the geranyl moiety at
the N1-, C2-, and C3-position of the pyrrole ring in a regular or
reverse manner.
To the best of our knowledge, known geranylations of
diverse substrates usually occur at the benzene ring of the
indole nucleus, e.g. C7-geranylation of indolactam V by TleC,
C6-geranylation of tryptophan derivatives by 6-DMATSSa, and
C6- and C7-geranylation of CDPs by AnaPT.16,19,30 As
mentioned above, the reported C4-geranylation of 1 by
AtaPT18 should be at C-7. Attachment of the geranyl moiety
has been reported at neither C-4 or C-5 nor at N-1, C-2, or C-
3 prior to this study.
The achieved relaxed regioselective geranylation by the
mutants encouraged us to decorate all nucleophilic reactive
positions (N-1 and the six nonbridgehead carbons) at the
indole ring of one CDP with the geranyl moiety. For this
purpose, 1 has been selected as the favorable CDP. HPLC
analysis of the incubation mixture of 1 and GPP with
FtmPT1_M364G, CdpNPT_M349G, CdpC2PT, and
CdpC2PT_T351G revealed the presence of two to four
product peaks each with product yields between 37.4 and
68.0% (Figure S9). Isolation and structure elucidation
confirmed geranylations at N-1 (1a1), C-2 (1a2 and 1b2),
C-3 (1a3 and 1b3), C-5 (1a5), C-6 (1a6), and C-7 (1a7) of
the indole ring (Scheme 3). To get the remaining C4-position
filled by geranylation, we applied the mutant FgaPT2_M328G,
which uses GPP for C4-geranylation of tryptophan.27 HPLC
analysis of the incubation mixture of 1 and GPP with
FgaPT2_M328G indicated product formation with a low
yield (7.2%, Figure 2). In another previous study, we
demonstrated that mutation on Arg244 of FgaPT2 significantly
increased the catalytic activity toward CDPs in the presence of
DMAPP.31 To enhance the geranylation of 1, we combined
mutations at Met328 and Arg244 and created the double
mutant FgaPT2_M328G_R244Q. As shown in Figure 2, one
peak with a product yield of 29.7% was detected. Structure
elucidation confirmed the desired geranylated product 1a4
(Scheme 3). In this way, nine products with a geranyl moiety
at all nucleophilic reactive positions of the indole ring can be
obtained from 1 by one-step chemoenzymatic reactions
(Scheme 3, Figure S9).
With the tremendously increasing availability of protein
structures, structure-based enzyme engineering becomes more
important for modification of drug-like molecules. Indolactam
geranyl transferase (TleC) can be changed to dimethylallyl
transferase by small-to-large mutation.19 MpnD and PagF were
changed from selective dimethylallyl to geranyl transferases by
large-to-small substitution.19,32 In analogy, our study provides
an excellent example for rational engineering of desirable
enzymes. Mutation of the gatekeeping residues in six PTs
turned on or improved the acceptance of GPP for geranylation
of diverse CDPs. Forty-two geranylated products were
obtained from in vitro enzymatic reactions of CDPs and
GPP. Using 1 as an acceptor and GPP as a donor, N-1 and the
six nonbridgehead carbons of the indole ring were decorated
with geranyl moieties. Derivatives of other CDPs could also be
obtained by the mutants described in this study or by mutation
of additional available dimethylallyl transferase at the
corresponding positions.
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Experimental Procedures 
Chemicals. Dimethylallyl diphosphate (DMAPP) and geranyl diphosphate (GPP) were chemically prepared according to the literature.1 
Cyclo-Trp-Pro isomers (2 − 5) and cyclo-Trp-Ala isomers (6 − 9) were synthesized according to the method published previously.2,3 
Cyclo-L-Trp-L-Pro and cyclo-L-Trp-D-Pro were synthesized from H-L-Trp-OMeꞏHCl and N-Boc-L-Pro-OH, cyclo-D-Trp-L-Pro and cyclo-
D-Trp-D-Pro from H-D-Trp-OMeꞏHCl and N-Boc-D-Pro-OH. In analogy, the two pairs H-L-Trp-OMeꞏHCl and N-Boc-L-Ala-OH as well as 
H-D-Trp-OMeꞏHCl and N-Boc-D-Ala-OH were used for the preparation of the four stereoisomers of cyclo-Trp-Ala (6 − 9). (R)-
benzodiazepinedione (14) and (S)-benzodiazepinedione (15) were synthesized by condensation of D- or L-tryptophan with isatoic 
anhydride in the presence of triethylamine according to the method described by Barrow and Sun.4 Other cyclic dipeptides (1, 10 − 13) 
were obtained from Bachem (Bubendorf, Switzerland).  
 
Strains. E. coli strains M15 [pREP4] (Qiagen, Hilden, Germany), BL21(DE3) pLysS (Invitrogen, Karlsruhe, Germany), and XL1-Blue 
MRF´ (Stratagene, Amsterdam, the Netherlands) were used for the overproduction of recombinant proteins. Luria-Bertani (LB) medium 
supplemented with 50 µg/mL carbenicillin or 50 µg/mL kanamycin was used for cultivation of recombinant E. coli strains.  
 
Site-directed mutagenesis. Plasmids harboring genes encoding recombinant PTs were used as DNA template for mutagenesis by 
PCR. To obtain specific mutations at desired gene position, (degenerated) primers were designed as described in the optimized site-
directed mutagenesis protocols and synthesized by Eurofins Genomics GmbH (Ebersberg, Germany) or Seqlab GmbH (Göttingen, 
Germany) (Table S1).5,6 Expand Long Template PCR System (Roche Diagnostics GmbH, Mannheim) was applied for PCR amplification. 
PCR reaction mixtures and thermal profiles were set as recommended by the manufacturer instructions. An annealing temperature of 
62°C and elongation time of 8 min for brePTand fgaPT2, and 4 min for ftmPT1, cdpNPT, cdpC2PT and cdpC3PT were adjusted to the 
thermal profile. The obtained plasmids were subjected to sequencing to confirm the desired mutations in the respective constructs. 
 
Protein overproduction and purification as well as enzyme assays. The recombinant histidine-tagged PTs, His8-FgaPT2, His5-
BrePT, FtmPT1-His6, CdpNPT-His6, CdpC2PT-His6, and His6-CdpC3PT as well as the corresponding engineered mutants were 
overproduced in E.coli and purified by Ni-NTA affinity chromatography (Qiagen, Hilden) according to the published procedures.7-11 The 
enzymatic reaction mixtures (50 μL) of FgaPT2, FtmPT1, and BrePT contained 50 mM Tris-HCl (pH 7.5), 10 mM CaCl2, 1 mM cyclic 
dipeptide, 2 mM DMAPP or GPP, 0.7%–6% (v/v) glycerol, up to 5% (v/v) DMSO, and 10 μg of purified protein. For determination of the 
relative activities of CdpC2PT, CdpC3PT, and CdpNPT with different cyclic dipeptides, each reaction mixture (50 µL) contained 50 mM 
Tris-HCl (pH 7.5), 2 mM DTT, 1 mM aromatic substrate, 2 mM DMAPP or GPP, 0.7%–6% (v/v) glycerol, up to 5% (v/v) DMSO, and 50 
μg purified protein for CdpC2PT and CdpC3PT and 30 μg for CdpNPT. The reaction mixtures were incubated at 37 °C for 2 h (FgaPT2, 
FtmPT1, and BrePT) or 16 h (CdpC2PT, CdpC3PT, and CdpNPT). The reaction mixtures were terminated by addition of one volume 
methanol. Before injecting to HPLC, the proteins were removed by centrifugation at 13,000 rpm for 20 min. The enzyme reactions of 
the mutated proteins were performed as for the wildtype enzymes. Product yields of the enzyme reactions were calculated from peak 
areas of prenylated products and substrates as analyzed on HPLC. Repeated enzyme assays were performed independently.  
 
HPLC conditions for analysis and isolation of enzyme products. Analysis of reaction mixtures were performed on an Agilent series 
1200 HPLC (Agilent Technologies, Böblingen, Germany) with an Agilent Eclipse XDB-C18 column (150 × 4.6 mm, 5 μm). Water (A) 
and acetonitrile (B) were used as solvents at flow rate of 0.5 mL/min. The substances were eluted with a linear gradient from 20–45 % 
B in 10 min, followed by 45–75% B in 5 min and 75–100% B in another 10 min. The column was then washed with 100 % (v/v) solvent 
B for 5 min and equilibrated with 5 % (v/v) solvent B for 5 min. Detection was carried out on a photodiode array detector and illustrated 
for aborptions at 296 nm. For isolation, the same HPLC equipment with a semipreparative Agilent ZORBAX Eclipse XDB C18 HPLC 
column (250 ×9.4 mm, 5 μm) at a fow rate of 2.5 mL/min was used. Water and acetonitrile were also used as solvents. Isocratic elution 
was performed with 75%, 80% or 85% acetonitrile/water for product isolation. 
 
LC-MS analysis of enzyme reactions. LC-MS analysis was performed on a microTOF-Q III spectrometer (Bruker, Bremen, Germany) 
with an Agilent 1260 HPLC system (Agilent Technologies, Böblingen, Germany) by using the same column and elution condition. 
Electrospray positive ionization mode was selected for determination the accuracy masses. Sodium formate was used in each run for 
mass calibration. The masses were scanned in the range of m/z 100 − 1500. The capillary voltage was set to 4.5 kV and a collision 
energy of 8.0 eV. Data were evaluated with the Compass DataAnalysis 4.2 software (Bruker Daltonik, Bremen, Germany). 
 
Preparation and identification of the reaction products. To prepare the enzyme products for structural elucidation, assays were 
carried out in large scales (10 − 20 mL) containing 2 mM GPP, 1 mM cyclic dipeptide, 10 mM CaCl2 or 2 mM DTT, 50 mM Tris-HCl (pH 
7.5), up to 5% (v/v) DMSO, and 2 − 10 mg purified recombinant protein per 10 mL mixtures. After incubation for 16 h at 37 °C, the 
reaction mixtures were extracted subsequently with double volume of ethyl acetate for three times. The organic phases were combined 
and concentrated under vacuum. The resulted residues were dissolved in MeOH and centrifuged at 13,000 rpm for 20 min. The enzyme 
products were then purified on a semi-preparative HPLC. 1H NMR spectra were recorded on a JOEL ECA-500 MHz spectrometer 
(JEOL, Tokyo, Japan). All spectra were processed with MestReNova 6.1.0 (Metrelab). Chemical shifts are referenced to those of the 
solvent signals.  
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Structure-based protein sequence alignments. Protein sequence alignments were carried out by using the sequence alignment 
function of MEGA 5.2 and visualized with ESPript 3.0 (http://espript.ibcp.fr/ESPript/ESPript/). For the secondary structure prediction, 
AtaPT (accession number 5KCG, www.rcsb.org) was taken as a reference. 
 
Molecular modeling and docking. The conformations of the mutants were calculated in silico using foldx.12,13 Substrate docking was 
done  manually  for  GPP  using  COOT14  and  DMAPP  of  FtmPT1  (pdb‐code:  3I4X)  and  CdpNPT    (pdb‐code:  3O2K)  as  templates.  The 
conformation of the prenyl donors were energetically optimized. Figure S8 was generated with pymol (The PyMOL Molecular Graphics 
System, Version 1.8 Schrödinger, LLC.). 
 SUPPORTING INFORMATION          
6 
 
Structural elucidation 
In total, 42 enzyme products were obtained in this study. LC-HR-ESI-MS data (Table S2) showed that [M+H]+ ions of 41 compounds 
are 136 Da larger than those of the respective substrates, proving the presence of a geranyl moiety each in their structures. In the case 
of 1b2-2, the [M+H]+ ion at m/z 645.4209 indicates a digeranylation. Inspection of the 1H NMR spectra revealed that 31 products 
exhibited signals of regular geranyl moieties and 11 products are reversely geranylated products.  
The different chemical shifts of the methylene group and of olefinic protons can be conveniently used to differentiate reversely or 
regularly prenylated derivatives, as exampled in Tables S3 and S4. The reverse geranyl moieties can be easily recognized by the 
presence of typical signals for three olefinic protons as two doublets around 5.0 and 5.2 ppm and one double doublets at 5.7 ppm with 
coupling constants of 17 and 10 Hz (Table S3). The chemical shifts of H-1’ of regular geranyl moieties change dependently upon the 
attached position (Table S4). If the geranyl residue attached to an aromatic carbon like C-2, C-4, C-5, C-6 or C7, H-1’ appears in the 
range of 3.3 − 3.7 ppm (CDCl3). When it connected to C-3 of the indole ring, H-1’ signal shifted upfield to 2.2 − 2.5 ppm (CDCl3, Tables 
S3 and S4). In the case of attachment of a geranyl residue to nitrogen, the signal of H-1’ will be shifted downfield to 4.6 − 4.8 ppm 
(CDCl3).  
According to the prenylation positions, the obtained products can be classified into 4 groups, i.e. N1-, C2-, and C3-geranylated products 
as well as those with geranyl moieties at C- 4 to C-7. These four groups can be easily distinguished by the signals of the protons H-2 
and H-1’ in their 1H NMR as described above (Table S4). In total, 10 products were characterized as N1-geranylated derivatives 
including one reversely geranylated product (10b1). Although structures of N1-geranylated cyclic dipeptides have not been reported, 
signals in the aromatic region of the geranylated derivatives are nearly identical to those carrying a dimethylallyl moiety. Therefore, 1a1, 
2a1, 3a1, and 11a1 were identified by comparison with the reported NMR data of N1-prenylated compounds of the respective cyclic 
dipeptides.10,15 Other five N1-geranylated products (10a1, 6a1, 8a1, 12a1, and 13a1) were characterized in comparison with their non-
substituted substrates and tryptophan part of identified N1-geranylated products. 10b1 was identified as cyclo-N1-tert-geranyl-L-Trp-L-
Leu based on the presence of typical signals for reverse geranyl moiety and N1-substitution pattern, as well as by comparison of the 
NMR data with those of cyclomarazine B.16  
Differing from signals for N1-substitution pattern, regularly C2-geranylated products exhibited chemical shifts for H-1’ at approx. 3.4 
ppm (CDCl3). 1a2, 2a2, and 10a2 were characterized by comparing with the reported NMR data of regularly C2-prenylated compounds. 
The characterization of reversely C2-geranylated products 1b2, 1b2-2, 2b2, 3b2, 4b2, and 14b2 was carried out by comparison of their 
NMR data with those of the reported reversely C2-prenylated compounds of the respective cyclic dipeptides.8,9,11 1H NMR spectra of 
3a2, 11a2, and 12a2 exhibited similar signals for their geranyl moieties and indole skeleton, which also matched with the C2-substitution 
pattern. Therefore, six regularly and six reversely C2-geranylated indole derivatives were identified in this study.  
C3-substitution pattern can be easily recognized in their 1H NMR spectra. Ring closure between H-2 and H-12 resulted in upfield shifting 
of signal for H-2 from 6.4 − 7.2 ppm to 5.3 − 5.5 ppm and disappearance of the signal for H-12. 6a3, 8a3, 11a3, and 13a3 were identified 
as regularly C3-geranylated cyclic dipeptides by comparing their NMR data with those of reported regularly C3-prenylated compounds 
of the respective cyclic dipeptides.17 1b3, 5b3, 10b3, and 14b3 were characterized as reversely C3-geranylated products by comparison 
of their NMR data with those reported for reversely C3-prenylated derivatives.15,17-19 Typical signals for regular C3-geranyaltion are 
easily observed not only for the aforementioned H-2 and H-12 protons, but also for H-1’ of the C10 unit. Differing from the N1- or C2-
susbstitution, signals of H-1’ of C3-susbtitution shifted to approx. 2.4 ppm. Thus, 1a3, 3a3, 10a3, and 12a3 were accordingly identified 
as regular C3-geranylated products. The relative configuration of geranyl and H-2 were determined according to 1H-1H vicinal coupling 
patterns of H-11 and chemical shifts of H-10syn of known anti-cis and syn-cis configured prenylated pyrroloindoline diketopiperazines 
that summarized in a previous paper.15 With the exception for 5b3, all C3-geranylated products obtained in this study have a syn-cis 
configuration. 
In addition to the products with geranyl moieties at position 1 to 3 of the pyrrole ring, seven products with geranyl substitution at the 
benzene ring were also identified. A set of characteristic signals for three protons at the benzene ring was observed in their 1H NMR 
spectra, which differs clearly from the coupling pattern consisting of four protons in the case of pyrrole ring substitution. The signals of 
the three coupling protons on the C4- and C7-geranylated benzene ring are found as doublet, triplet and doublet with coupling constants 
of approximate 7 − 8 Hz. In comparison, the signals of the three protons on the C5- and C6-geranylated benzene ring appear as two 
doublets with a coupling constant of approximate 8 Hz and one (broad) singlet. The difference between C5- and C6- as well as between 
C4- and C7-substitution in 1H NMR spectra can be distinguished by the order of the signals of the three protons, as listed in Table S5. 
One C4-geranylated product 1a4, four C6-geranylated derivatives 1a6, 5a6, 14a6, and 15a6, and two C7-geranylated compounds 1a7 
and 10a7 were identified by comparing with the reported data of known geranylated compounds of the respective cyclic dipeptides.20-
22 1a5 was identified as a C5-geranylated compound by the presence of nearly identical signals on the indole ring as those of C5-
prenylated tryptophan derivatives.23,24 
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Table S1. List of primers and constructed plasmids used in this study.  
Mutant Plasmid Template Primer Sequence (5`→3`) Protein yield  
(mg/L culture) 
BrePT_I337G pPM81 pSY19 I337G_f 
I337G_r 
CCATCGGGTGGAACTACGAGATCAGTCCTGGG 
GTTCCACCCGATGGGCGATGGGATCTGGTC 
1.5 
FtmPT1_M364G pPM83 pAG0128 M364G_f 
M364G_r 
TATGGGGTTCCACTTCCACCTGGACGGGAGTC 
GAAGTGGAACCCCATAGGCGCCTCGAACCC 
4.3 
CdpNPT_M349G pPM85 pHL510 M349G_f 
M349G_r 
CATTGGGCTGAACTATGAGATGAAGGCCGGCCAGC 
TCATAGTTCAGCCCAATGGGCAAGAGCCCTTTCTCC 
1.6 
CdpC2PT_T351G pPM82 pKM1611 T351G_f 
T351G_r 
TTTAGGGTGGAATTACGAGCTGCAACCTGGCATTTCCCATCC 
GCTCGTAATTCCACCCTAAAGGGGGTTGAAATTTCTGCTGTGC 
1.5 
CdpC3PT_F335G pPM86 pWY257 F335G_f 
F335G_r 
GTTCGGGATGAACTACGAGATAACCCCGGGGCAGC 
CGTAGTTCATCCCGAACGGCACAATGCTCAGAGGG 
2.3 
FgaPT2_M328G_R244Q pPM46 pPM2825 R244Q_f 
R244Q_r 
CAGTCCCCAACTAGTGTCCTGTGATCTGACCAGTCCTGC 
GACACTAGTTGGGGACTGGCAGTGCTCTTGGAACCGC 
2.5 
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Table S2. LC-HR-ESI-MS data of enzyme products.  
   LC-HR-ESI-MS data [M+H]+  
Phisical 
description 
approx. 
amount 
(mg) Compund Chemical formula Isolated from Calculated Measured 
Deviation 
[ppm] 
1a1 C32H36N4O2  1 with FtmPT1_M364G 509.2911 509.2912 -0.3 colorless oil 1.1 
2a1 C26H33N3O2  2 with BrePT_I337G 420.2646  420.2660 -3.5 colorless oil 0.4 
3a1 C26H33N3O2  3 with FtmPT1_M364G 420.2646  420.2641 1.1 white powder 0.8 
6a1 C24H31N3O2 6 with FtmPT1_M364G 394.2489 394.2505 -4.0 colorless oil 0.8 
8a1 C24H31N3O2  8 with FtmPT1_M364G 394.2489 394.2488 0.4 colorless oil 1.0 
10a1 C27H37N3O2  10 with FtmPT1_M364G or CdpC3PT_F335G 436.2959 436.2963 -1.0 white powder 0.5 
11a1 C30H35N3O3  11 with FtmPT1_M364G 486.2751 486.2760 -1.8 white powder 0.6 
12a1 C30H35N3O2  12 with FtmPT1_M364G 470.2802 470.2823 -4.4 white powder 0.4 
13a1 C23H29N3O2  13 with FtmPT1_M364G 380.2333 380.2320 3.2 colorless oil 1.1 
10b1 C27H37N3O2  10 with CdpC3PT_F335G 436.2959 436.2963 -1.1 white powder 1.0 
1a2 C32H36N4O2  1 with FtmPT1_M364G 509.2911 509.2912 -0.2 colorless oil 1.0 
2a2 C26H33N3O2  2 with FtmPT1_M364G 420.2646 420.2655 -2.3 colorless oil 1.5 
3a2 C26H33N3O2  3 with FtmPT1_M364G 420.2646 420.2647 -0.3 white powder 1.1 
10a2 C27H37N3O2 10 with FtmPT1_M364G 436.2959 436.2961 -0.6 white powder 1.0 
11a2 C30H35N3O3  11 with FtmPT1_M364G 486.2751 486.2763 -2.5 colorless oil 1.0 
12a2 C30H35N3O2  12 with FtmPT1_M364G 470.2802 470.2797 1.1 white powder 0.1 
1b2 C32H36N4O2  1 with CdpC2PT or CdpC2PT_T351G  509.2911 509.2923 -2.4 white powder 1.3 
1b2-2 C42H52N4O2  1 with CdpC2PT_T351G  645.4163 645.4209 -7.1 colorless oil 0.8 
2b2 C26H33N3O2  2 with BrePT_I337G or CdpC2PT_T351G  420.2646 420.2655 -2.2 white powder 2.0 
3b2 C26H33N3O2  3 with BrePT_I337G 420.2646 420.2651 -1.4 colorless oil 1.3 
4b2 C26H33N3O2  4 with BrePT_I337G 420.2646 420.2649 -0.8 colorless oil 1.1 
14b2 C28H31N3O2  14 with CdpC2PT_T351G 442.2489 442.2487 0.5 colorless oil 1.1 
1a3 C32H36N4O2  1 with FtmPT1_M364G 509.2911 509.2901 2.1 colorless oil 0.9 
3a3 C26H33N3O2 3 with FtmPT1_M364G 420.2646 420.2654 -2.0 white powder 0.6 
6a3 C24H31N3O2 6 with FtmPT1_M364G 394.2489 394.2495 -1.5 colorless oil 0.7 
8a3 C24H31N3O2  8 with FtmPT1_M364G 394.2489 394.2508 -4.9 colorless oil 0.7 
10a3 C27H37N3O2  10 with FtmPT1_M364G 436.2959 436.2946 2.8 colorless oil 1.1 
11a3 C30H35N3O3  11 with FtmPT1_M364G 486.2751 486.2780 -6.0 white powder 0.5 
12a3 C30H35N3O2  12 with FtmPT1_M364G 470.2802 470.2820 -3.7 white powder 0.2 
13a3 C23H29N3O2  13 with FtmPT1_M364G 380.2333 380.2342 -2.5 colorless oil 0.4 
1b3 C32H36N4O2  1 with CdpNPT_M349G 509.2911 509.2931 -4.0 colorless oil 0.9 
5b3 C26H33N3O2 5 with CdpNPT_M349G 420.2646 420.2647 -0.3 colorless oil 0.8 
10b3 C27H37N3O2  10 with CdpC3PT_F335G 436.2959 436.2968 -2.2 white powder 0.5 
14b3 C28H31N3O2  14 with CdpNPT_M349G 442.2489 442.2487 0.5 colorless oil 1.1 
1a6 C32H36N4O2  1 with CdpNPT_M349G 509.2911 509.2925 -2.8 colorless oil 1.4 
5a6 C26H33N3O2  5 with CdpNPT_M349G 420.2646 420.2650 -1.0 colorless oil 1.6 
14a6 C28H31N3O2  14 with CdpNPT_M349G or CdpC2PT_T351G 442.2489 442.2482 1.5 colorless oil 0.5 
15a6 C28H31N3O2  15 with CdpNPT_M349G or CdpC2PT_T351G 442.2489 442.2493 -0.9 colorless oil 1.1 
1a4 C32H36N4O2 1 with FgaPT2_M328G_R244Q 509.2911 509.2917 -1.1 colorless oil 1.7 
1a5 C32H36N4O2  1 with CdpC2PT 509.2911 509.2891 4.0 white powder 1.2 
1a7 C32H36N4O2  1 with CdpC2PT 509.2911 509.2894 3.3 white powder 1.2 
10a7 C27H37N3O2  10 with CdpC3PT_F335G 436.2959 436.2968 -2.1 colorless oil 0.3 
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Table S3. Chemical shifts (ppm) of protons on regularly and reversely C3-substituted geranyl moiety of cyclo-L-Trp-L-Leu (CDCl3).  
 
 
C3-regular  C3-reverse 
H-1’ 2.40, dd, 14.3, 7.4, 1H 5.26, d, 10.8, 1H 
 2.44, dd, 14.3, 7.9, 1H 5.07, d, 17.4, 1H 
H-2’ 5.17, br t, 7.6, 1H 5.77, dd, 17.4, 10.8, 1H 
H-4’ 2.04, m, 2H 1.76, dd, 16.0, 7.7, 2H 
H-5’ 1.99, m, 2H  1.58, m, 1H* 
 - 1.22, ddd, 17.5, 11.5, 5.6, 1H 
H-6’ 5.06, br t, 6.6, 1H 4.98, br t, 7.3, 1H 
H-8’ 1.68, s, 3H 1.63, s, 3H  
H-9’ 1.60, s, 3H 1.10, s, 3H  
H-10’ 1.52, s, 3H 1.51, s, 3H  
[*] signal is overlapping with water. 
 
Table S4. Typical proton signals of N1-, C2-, C3-, or benzene ring-geranylated derivatives.  
 
 
 
 
 
 N1-substitution[b] C2-substitution[b] C3-substitution[c] benzene ring-substitution[b] 
H-1’ [a] 4.6 − 4.8 ppm 3.3 − 3.5 ppm 2.2 − 2.5 ppm 3.4 − 3.7 ppm 
H-1 - 7.8 − 8.0 ppm - 7.9 − 8.2 ppm 
H-2 6.4 − 7.2 ppm - 5.3 − 5.5 ppm  6.5 − 7.2 ppm 
H-12 5.6 − 5.8 ppm 5.6 − 5.8 ppm - 5.6 − 6.0 ppm 
benzene ring  AA’BB’ system AA’BB’ system AA’BB’ system ABX system 
[a] Here only referred to H-1’ of regular geranylated products. [b] chemical shifts in CDCl3. [c] chemical shifts in CD3OD. 
 SUPPORTING INFORMATION          
10 
 
Table S5. Signal of protons on the substituted benzene ring of cyclo-L-Trp-L-Trp (CD3COCD3).  
     
 C4-substitution C5-substitution C6-substitution C7-substitution 
H-2 7.10, d, 2.5 6.76, d, 2.4 6.70, d, 2.4 6.63, d, 2.5 
H-4 - 7.34, d, 1.6 7.37, d, 8.1 7.33, d, 7.0 
H-5 6.76, d, 7.3 - 6.88, dd, 8.1, 1.5 6.96, dd, 7.5, 7.0 
H-6 6.94, dd, 8.0, 7.3 6.94, dd, 8.3, 1.6 - 6.93, d, 7.5 
H-7 7.14, d, 8.0 7.24, d, 8.3 7.15, d, 1.5 - 
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Table S6. 1H NMR data of N1-geranylated derivatives (1a1, 2a1, and 3a1).  
Compound 
1a1 (CDCl3)  2a1 (CD3OD)  3a1 (CDCl3) 
Position. δH, multi., J in Hz δH, multi., J in Hz δH, multi., J in Hz 
2 6.42, s, 1H 7.05, s, 1H 6.96, s, 1H 
4 7.58, d, 7.9, 1H 7.58, d, 8.0, 1H 7.60, d, 8.0, 1H 
5 7.15, dd, 8.0, 7.0, 1Ha 7.03, dd, 8.0, 7.1, 1H 7.12, dd, 8.0, 7.0, 1H 
6 7.22, dd, 8.0, 7.0, 1Hb 7.13, dd, 8.0, 7.1, 1H 7.20, dd, 8.0, 7.0, 1H 
7 7.28, d, 8.0, 1H 7.30, d, 8.3, 1H 7.30, d, 8.0, 1H 
10 3.23, dd, 14.4, 3.5, 1Hc 3.44, m, 1H 3.33, dd, 14.6, 6.8, 1H 
 2.50, dd, 14.4, 8.4, 1Hd 3.24, m, 1H 3.21, dd, 14.6, 3.4, 1H† 
11 4.18, m, 1H 3.98, ddd, 11.0, 6.3, 1.7, 1H 4.22, ddd, 6.8, 3.8, 3.4, 1H 
12 5.70, s, 1H - 5.80, d, 3.8, 1H 
14 4.18, m, 1H 4.41, br t, 5.0, 1H 3.57, ddd, 12.0, 8.7, 8.5, 1H 
15 5.72, s, 1H - - 
17 3.24, dd, 14.4, 3.7, 1Hc 3.37, m, 2H§ 3.23, m, 1H† 
 2.40, dd, 14,4, 8.6, 1Hd - 2.97, dd, 11.0, 6.3, 1H 
18 - 1.67, m, 1H 1.87, m, 1He 
 - 0.88, m, 1H 1.49, m, 1He 
19 6,57, s, 1H 1.95, m, 1H 2.12, dtd, 12.0, 7.0, 1.6, 1H 
 - 1.32, m, 1H 1.74, dtd, 12.0, 11.5, 8.1, 1He 
20 8.07, s, 1H - - 
22 7.36, d, 8.0, 1H - - 
23 7.21, dd, 8.0, 7.0, 1Hb - - 
24 7.12, dd, 8.0, 7.0, 1Ha - - 
25 7.52, d, 8.0, 1H - - 
1’ 4.59, dd, 15.6, 6.8, 1H 4.73, d, 6.6, 2H 4.67, d, 6.8, 2H 
 4.64, dd, 15.6, 6.6, 1H - - 
2’ 5.30, br t, 6.8, 1H 5.33, br t, 6.8, 1H  5.31, br t, 6.7, 1H 
4’ 2.08, m, 2H 2.06, m, 2H 2.09, m, 2H 
5’ 2.04, m, 2H 2.12, m, 2H 2.04, m, 2H 
6’ 5.04, br t, 6.6, 1H 5.06, br t, 6.9, 1H 5.05, br t, 6.6, 1H 
8’ 1.82, s, 3H 1.85, s, 3H 1.81, s, 3H 
9’ 1.65, s, 3H 1.62, s, 3H 1.66, s, 3H 
10’ 1.56, s, 3H 1.57, s, 3H 1.58, s, 3H 
Chemical shifts (δ) are given in ppm and coupling constants in Hz. [a~e] assignments of signals with the same letter are interchangeable. [†] signals are 
overlapping with each other. [§] signals are overlapping with those of solvent. 
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Table S7. 1H NMR data of N1-geranylated derivatives (6a1, 8a1, 10a1, and 10b1).  
Compound 
 6a1 (CD3OD) 8a1 (CD3OD)  10a1 (CDCl3)  10b1 (CDCl3) 
Position δH, multi., J in Hz δH, multi., J in Hz δH, multi., J in Hz δH, multi., J in Hz 
2 6.99, s, 1H 6.97, s, 1H 7.00, s, 1H 7.17, s, 1H 
4 7.56, d, 8.0, 1H 7.55, d, 8.0, 1H 7.61, d, 8.2, 1H 7.59, d, 7.2, 1H 
5 6.99, dd, 8.0, 7.0, 1H 6.98, t, 8.0, 1H 7.13, dd, 8.2, 6.9, 1H 7.10, dd, 8.4, 7.2, 1H 
6 7.08, dd, 8.0, 7.0, 1H 7.08, t, 8.0, 1H 7.22, dd, 8.2, 6.9, 1H 7.13, dd, 8.4, 7.2, 1H 
7 7.26, d, 8.0, 1H 7.26, d, 8.0, 1H 7.31, d, 8.2, 1H 7.53, d, 7.2, 1H 
10 3.41, dd, 14.6, 3.7, 1H 3.40, dd, 14.5, 3.9, 1H 3.50, dd, 14.7, 3.6, 1H 3.55, dd, 14.8, 3.8, 1H 
 3.08, dd, 14.6, 4.5, 1H 3.06, dd, 14.5, 4.6, 1H 3.14, dd, 14.7, 8.8, 1H 3.09, dd, 14.8, 9.3, 1H 
11 4.23, ddd, 4.5, 3.7, 1.5, 1H 4.15, ddd, 4.6, 3.9, 1.5, 1H 4.30, br d, 8.8, 1H 4.30, br d, 9.3, 1H 
12 - - 5.80, s, 1H 5.79, s, 1H 
14 3.66, qd, 7.0, 1.2, 1H 3.29, m, 1H§ 3.90, br d, 10.2, 1H 3.93, br d, 10.1, 1H 
15 - - 5.85, s, 1H 5.88, s, 1H 
17 0.29, d, 7.0, 3H 1.04, d, 7.0, 3H 1.62, ddd, 13.8, 10.2, 3.8, 1H 1.68, ddd, 13.7, 10.1, 3.7, 1H 
 - - 1.03, ddd, 13.8, 10.2, 4.6, 1H 1.20, ddd, 13.7, 10.1, 4.5, 1H 
18 - - 1.50, m, 1H 1.59, m, 1H* 
19 - - 0.85, d, 6.6, 3Ha 0.88, d, 6.5, 3Hb 
20 - - 0.83, d, 6.6, 3Ha 0.87, d, 6.5, 3Hb 
1’ 4.69, d, 6.9, 2H 4.66, dd 15.0, 7.2, 1H 4.66, dd, 14.3, 6.5, 1H 5.29, d, 10.8, 1H 
 - 4.71, dd, 15.0, 7.1, 1H 4.70, dd, 14.3, 7.0, 1H 5.18, d, 17.6, 1H 
2’ 5.29, br t, 7.2, 1H 5.25, br t, 7.2, 1H 5.35, br t, 7.0, 1H 6.15, dd, 17.6, 10.8, 1H 
4’ 2.08, m, 2H 2.07, m, 2H 2.11, m, 2H 2.27, ddd, 14.9, 12.9, 5.8, 1H 
 - - - 1.97, ddd, 12.9, 11.4, 3.8, 1H 
5’ 2.02, m, 2H 2.01, m, 2H 2.06, m, 2H 1.91, m, 1H 
 - - - 1.50, m, 1H* 
6’ 5.02, br t, 6.9, 1H 5.01, br t, 7.2, 1H 5.06, br t, 6.7, 1H 4.99, br t, 7.2, 1H 
8’ 1.81, s, 3H 1.80, s, 3H 1.82, s, 3H 1.42, s, 3H 
9’ 1.59, s, 3H 1.57, s, 3H 1.67, s, 3H 1.61, s, 3H 
10’ 1.54, s, 3H 1.53, s, 3H 1.59, s, 3H 1.73, s, 3H 
Chemical shifts (δ) are given in ppm and coupling constants in Hz. [a~b] assignments of signals with the same letter are interchangeable. [*] signals are 
overlapping with those of water. [§] signals are overlapping with those of solvent. 
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Table S8. 1H NMR data of N1-geranylated derivatives (11a1, 12a1, and 13a1).  
Compound 
 11a1 (CD3OD)  12a1 (CD3OD)  13a1 (CDCl3) 
Position δH, multi., J in Hz δH, multi., J in Hz δH, multi., J in Hz 
2 7.02, s, 1H 6.98, s, 1H 7.01, s, 1H 
4 7.61, d, 8.0, 1H 7.58, d, 7.5, 1H 7.62, d, 8.0, 1H 
5 7.10, dd, 8.0, 7.0, 1H 7.06, dd, 8.0, 7.0, 1H 7.13, dd, 8.0, 7.0, 1H 
6 7.19, dd, 8.0, 7.0, 1H 7.15, dd, 8.0, 7.0, 1H 7.23, dd, 8.0, 7.0, 1H 
7 7.32, d, 8.0, 1H 7.28, d, 7.5, 1H 7.32, d, 8.0, 1H 
10 3.02, dd, 14.6, 4.0, 1H 2.97, dd, 14.7, 4.4, 1H 3.48, dd, 14.6, 3.7, 1H 
 2.90, dd, 14.6, 5.4, 1H 2.90, dd, 14.7, 5.1, 1H 3.18, dd, 14.6, 8.6, 1H 
11 4.18, ddd, 5.4, 4.0, 1.0, 1H 4.15, dd, 5.1, 4.4, 1H 4.28, br d, 8.6, 1H 
12 - - 5.67, s, 1H 
14 3.82, ddd, 9.0, 3.7, 1.1, 1H 3.83, ddd, 8.9, 3.6, 1.0, 1H 3.81, ddd, 17.3, 2.3, 1.0, 1H 
 - - 3.49, ddd, 17.3, 2.8, 1.9, 1H 
15 - - 5.87, s, 1H 
17 2.57, dd, 13.6, 3.7, 1H 2.58, dd, 13.5, 3.6, 1H - 
 1.32, dd, 13.6, 9.0, 1H 1.26, dd, 13.5, 8.9, 1H - 
19 6.34, d, 8.6, 1H 6.44, dd, 7.2, 2.0, 1H - 
20 6.58, d, 8.6, 1H 7.10, m, 1H† - 
21 - 7.10, m, 1H† - 
22 6.58, d, 8.6, 1H 7.10, m, 1H† - 
23 6.34, d, 8.6, 1H 6.44, dd, 7.2, 2.0, 1H - 
1’ 4.69, dd, 15.2, 6.8, 1H 4.68, dd, 15.2, 6.8, 1H 4.66, dd, 15.5, 7.0, 1H 
 4.73, dd, 15.2, 6.5, 1H 4.72, dd, 15.2, 6.5, 1H 4.70, dd, 15.5, 6.6, 1H 
2’ 5.31, br t, 6.8, 1H 5.27, br t, 6.8, 1H 5.34, br t, 7.0, 1H 
4’ 2.03, m, 2H 1.98, m, 2H 2.10, m, 2H 
5’ 1.99, m, 2H 1.93, m, 2H 2.05, m, 2H 
6’ 5.01, br t, 6.9, 1H 4.95, br t, 6.9, 1H 5.06, br t, 6.9, 1H 
8’ 1.84, s, 3H 1.79, s, 3H 1.82, s, 3H 
9’ 1.61, s, 3H 1.56, s, 3H 1.66, s, 3H 
10’ 1.53, s, 3H 1.47, s, 3H 1.59, s, 3H 
Chemical shifts (δ) are given in ppm and coupling constants in Hz. [†] signals are overlapping with each other.
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Table S9. 1H NMR data of C2-geranylated derivatives (1a2, 2a2, and 3a2).  
Comound 
1a2 (CDCl3)   2a2 (CDCl3)  3a2 (CDCl3) 
Position δH, multi., J in Hz δH, multi., J in Hz δH, multi., J in Hz 
1 7.99, s, 1Ha 7.93, s, 1H 7.89, s, 1H 
4 7.50, d, 8.0, 1H 7.47, d, 7.8, 1H 7.51, d, 7.2, 1H 
5 7.10, dd, 8.0, 7.0, 1Hb 7.09, dd, 7.8, 7.1, 1H 7.08, dd, 8.5, 7.2, 1H 
6 7.11, dd, 8.0, 7.0, 1Hc 7.15, dd, 8.1, 7.1, 1H 7.11, dd, 8.5, 7.2, 1H 
7 7.28, d, 8.0, 1Hd 7.30, d, 8.1, 1H 7.25, m, 1H§  
10 3.22, dd, 14.7, 3.8, 1H 3.67, dd, 15.1, 3.8, 1H† 3.40, dd, 14.8, 5.7, 1H 
 3.02, dd, 14.7, 7.3, 1H 2.96, dd, 15.1, 11.5, 1H 3.15, dd, 14.8, 4.3, 1H 
11 4.27, m, 1H 4.37, ddd, 11.5, 3.8, 1.3, 1H 4.25, dd, 5.7, 4.3, 1H 
12 5.63, s, 1H 5.61, br s, 1H 5.79, br s, 1H 
14 4.13, br d, 10.0, 1H 4.06, ddd, 8.4, 7.0, 1.3, 1H 3.53, ddd, 11.8, 8.8, 8.2, 1H 
15 5.76, s, 1H - - 
17 3.29, dd, 14.2, 3.2, 1H 3.71, m, 1H† 3.17, m, 1H 
 2.01, dd, 14.2, 10.0, 1H 3.59, ddd, 11.7, 8.8, 3.9, 1H 2.72, dd, 11.0, 6.4, 1H 
18 - 2.02, m, 1H†† 1.82, m, 1H 
 - 1.91, m, 1H 1.38, m, 1H 
19 6.25, s, 1H 2.33, m, 1H 2.05, dtd, 13.0, 6.7, 1.5, 1H 
 - 2.02, m, 1H†† 1.68, m, 1H 
20 7.94, s, 1Ha - - 
22 7.32, d, 8.0, 1Hd - - 
23 7.18, dd, 8.0, 7.0, 1Hc - - 
24 7.15, dd, 8.0, 7.0, 1Hb - - 
25 7.50, d, 8.0, 1H - - 
1’ 3.34, dd, 16.1, 6.3, 1H 3.46, dd, 14.4, 5.4, 1H 3.43, dd, 16.5, 7.0, 1H 
 3.38, dd, 16.1, 6.9, 1H 3.51, dd, 14.4, 5.6, 1H 3.47, dd, 16.5, 7.3, 1H 
2’ 5.31, br t, 6.9, 1H 5.32, br t, 7.3, 1H 5.31, br t, 7.3, 1H 
4’ 2.15, m, 2H‡ 2.12, m, 2H‡‡ 2.15, m, 2H 
5’ 2.15, m, 2H‡ 2.12, m, 2H‡‡ 2.13, m, 2H 
6’ 5.12, br t, 6.8, 1H 5.10, br t, 6.7, 1H 5.10, br t, 6.4, 1H 
8’ 1.75, s, 3H 1.73, s, 3H 1.73, s, 3H 
9’ 1.72, s, 3H 1.72, s, 3H 1.73, s, 3H  
10’ 1.64, s, 3H 1.62, s, 3H 1.63, s, 3H 
Chemical shifts (δ) are given in ppm and coupling constants in Hz. [†,‡] signals are overlapping with each other. [§] signals are overlapping with those of solvent. [a-
d] assignments of signals with the same letter are interchangeable. [*] signals are overlapping with those of water. 
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Table S10. 1H NMR data of C2-geranylated derivatives (10a2, 11a2, and 12a2).  
Comound 
10a2 (CDCl3)  11a2 (DMSO-d6)  12a2 (DMSO-d6) 
Position δH, multi., J in Hz δH, multi., J in Hz δH, multi., J in Hz 
1 7.93, s, 1H 10.61, s , 1H 10.62, s, 1H 
4 7.53, d, 8.0, 1H 7.45, d, 8.0, 1H 7.45,d, 8.0, 1H 
5 7.10, dd, 8.0, 7.0, 1H 6.93, dd, 8.0, 7.0, 1H 6.94, dd, 8.0, 7.0, 1H 
6 7.14, dd, 8.0, 7.0, 1H 7.00, dd, 8.0, 7.0, 1H 7.00, dd, 8.0, 7.0, 1H 
7 7.28, d, 8.0, 1H 7.23, d, 8.0, 1H 7.23, d, 8.0, 1H 
10 3.43, dd, 14.7, 3.9, 1H 3.44, dd, 16.3, 7.0, 1H 3.43, dd, 16.0, 7.6, 1H 
 3.19, dd, 14.7, 8.4, 1H 3.37, dd, 16.3, 7.3, 1H 3.37, dd, 16.4, 7.2, 1H 
11 4.30, br d, 8.4, 1H 3.94, m, 1H 3.96, m, 1H 
12 5.76, s, 1H 7.44, d, 3.0, 1H 7.57, d, 3.0, 1H 
14 3.89, br d, 10.1, 1H 3.64, dt, 8.0, 4.0, 1H 3.73, dt, 8.2, 4.5, 1H 
15 5.95, s, 1H 7.88, d, 2.7, 1H 7.94, d, 2.5, 1H 
17 1.59, ddd, 13.5, 10.0, 3.7, 1H* 2.35, dd, 13.0, 4.0, 1H 2.40, dd, 13.2, 4.5, 1H 
 1.00, ddd, 13.5, 10.0, 4.5, 1H 1.40, dd, 13.0, 8.0, 1H 1.50, dd, 13.6, 8.2, 1H 
18 1.50, m, 1H - - 
19 0.84, d, 6.5, 3Ha 6.33, d, 8.5, 1H 6.54, dd, 7.0, 2.7, 1H 
20 0.82, d, 6.5, 3Ha 6.50, d, 8.5, 1H 7.11, m, 1H‡ 
21 - - 7.11, m, 1H‡ 
22 - 6.50, d, 8.5, 1H 7.11, m, 1H‡ 
23 - 6.33, d, 8.5, 1H 6.54, dd, 7.0, 2.7, 1H 
24 - - - 
25 - - - 
1’ 3.49, d, 7.0, 2H 2.82, dd, 14.5, 6.5, 1H 2.81, dd, 14.8, 6.5, 1H 
 - 2.86, dd, 14.5, 5.5, 1H 2.85, dd, 14.8, 6.0, 1H 
2’ 5.33, br t, 7.0, 1H 5.34, br t, 6.5, 1H 5.33, br t, 6.5, 1H 
4’ 2.14, m, 2H† 2.09, m, 2H 2.09, m, 2H 
5’ 2.14, m, 2H† 2.01, m, 2H 2.01, m, 2H 
6’ 5.11, br t, 6.7, 1H 5.10, br t, 6.0, 1H 5.10, br t, 6.8, 1H 
8’ 1.74, s, 3H†† 1.74, s, 3H 1.74, s, 3H 
9’ 1.74, s, 3H†† 1.62, s, 3H 1.62, s, 3H 
10’ 1.63, s, 3H 1.56, s, 3H 1.56, s, 3H 
-OH - 9.06, s, 1H - 
Chemical shifts (δ) are given in ppm and coupling constants in Hz. [a] assignments of signals with the same letter are interchangeable. [†, ‡] signals are overlapping 
with each other.
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Table S11. 1H NMR data of C2-geranylated derivatives (1b2, 1b2-2, and 2b2).  
Compound 
1b2 (CDCl3) 1b2-2 (CDCl3)  2b2 (CD3OD) 
Position δH, multi., J in Hz δH, multi., J in Hz δH, multi., J in Hz 
1 8.03, s, 1H 8.07, s, 1H - 
4 7.40, d, 8.0, 1H 7.53, d, 8.0, 1H 7.47, d, 8.0, 1H 
5 7.05, dd, 8.0, 7.1, 1H 7.13, dd, 8.0, 7.1, 1H 7.03, dd, 8.0, 7.1, 1H 
6 7.15, dd, 8.0, 7.1, 1H 7.19, dd, 8.0, 7.1, 1H 7.10, dd, 8.0, 7.1, 1H 
7 7.18, d, 8.0, 1H 7.33, d, 8.0, 1H 7.37, d, 8.0, 1H 
10 3.58, dd, 14.6, 3.3, 1H 3.74, dd, 14.6, 3.5, 1H 3.66, dd, 15.1, 4.4, 1H 
 3.05, dd, 14.6, 9.6, 1H 3.26, dd, 14.6, 11.8, 1H 3.14, dd, 15.1, 11.2, 1H 
11 4.29, br d, 9.6, 1H 4.39, br d, 11.8, 1H 4.49, ddd, 11.2, 4.4, 1.4, 1H 
12 5.69, s, 1H 5.72, s, 1H - 
14 4.29, br d, 9.6, 1H - 4.22, ddd, 8.3, 6.4, 1.8, 1H 
15 5.85, s, 1H - - 
16 - - - 
17 3.62, dd, 14.6, 3.3, 1H - 3.61, m, 1H 
 2.88, dd, 14.6, 11.3, 1H - 3.55, ddd, 11.7, 8.6, 3.0, 1H 
18 - - 2.02, m, 1H 
 - - 1.94, m, 1H 
19 7.10, d, 2.3, 1H - 2.27, m, 1H 
 - - 1.94, m, 1H 
20 8.16, s, 1H - - 
21 - - - 
22 7.30, d, 8.0, 1H - - 
23 7.24, dd, 8.0, 7.0, 1H - - 
24 7.20, dd, 8.0, 7.0, 1H - - 
25 7.67, d, 8.0, 1H - - 
1’ 5.24, d, 10.7, 1H 5.31, d, 10.7, 1H 5.18, d, 10.3, 1H 
 5.16, d, 17.5, 1H 5.24, d, 17.5, 1H 5.15, d, 17.5, 1H 
2’ 6.11, dd, 17.5, 10.7, 1H 6.20, dd, 17.5, 10.7, 1H 6.30, dd, 17.5, 10.7, 1H 
4’ 1.81, m, 2H 1.86, m, 2H 1.84, m, 2H 
5’ 1.91, m, 2H 1.95, m, 2H 1.94, m, 2H 
6’ 5.06, m, 1H 5.09, m, 1H 5.11, m, 1H 
8’ 1.64, s, 3H 1.64, s 3H 1.62, m, 3H 
9’ 1.50, s, 3H 1.53, s 3H 1.50, m, 3H  
10’ 1.51, s, 3H 1.57, s 3H 1.55, m, 3H 
Chemical shifts (δ) are given in ppm and coupling constants in Hz.
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Table S12. 1H NMR data of C2-geranylated derivatives (3b2, 4b2, and 14b2).  
Compound 
 3b2 (CD3OD) 
 
4b2 (CD3OD)  14b2 (CDCl3) 
Position δH, multi.,J in Hz δH, multi., J in Hz δH, multi., J in Hz 
1 - - 8.04, s, 1H 
4 7.46, d, 8.0, 1H 7.46, d, 8.0, 1H 7.43, d, 8.0, 1H 
5 6.98, dd, 8.0, 7.0, 1H 6.97, dd, 8.0, 7.0, 1H 7.07, dd, 8.0, 7.4, 1H 
6 7.04, dd, 8.0, 7.0, 1H 7.04, dd, 8.0, 7.0, 1H 7.15, dd, 8.0, 7.4, 1H 
7 7.30, d, 8.0, 1H 7.30, d, 8.0, 1H 7.31, d, 8.0, 1H 
10 3.45, dd, 14.8, 5.3, 1H 3.45, dd, 14.8, 5.3, 1H 3.49, dd, 15.7, 10.0, 1H 
 3.38, dd, 14.8, 6.5, 1H 3.38, dd, 14.8, 6.5, 1H 3.40, dd, 15.7, 4.8, 1H 
11 4.18, dd, 6.5, 5.3, 1H 4.18, dd, 6.5, 5.3, 1H 4.22, td, 10.0, 4.8, 1H 
12 - - 6.04, d, 4.8, 1H 
14 3.46, m, 1H 3.46, m, 1H - 
16 - - 7.60, s, 1H 
17 3.34, m, 2H§ 3.34, m, 2H§ - 
18 1.89, m, 1H 1.90, m, 1H 6.97, d, 8.0, 1H 
 1.56, m, 1H 1.55, m, 1H - 
19 2.10, dtd, 12.3, 5.9, 1.0, 1H 2.10, dtd, 12.5, 6.5, 1.2, 1H 7.50, dd, 8.0, 7.4, 1H 
 1.74, dtd, 12.3, 10.7, 7.0, 1H 1.74, dtd, 12.5, 11.0, 7.0, 1H - 
20 - - 7.25, dd, 8.0, 7.4, 1H 
21 - - 7.84, dd, 8.0, 1H 
1’ 5.22, d, 10.6, 1H 5.22, d, 10.8, 1H 5.18, d, 10.7, 1H 
 5.19, d, 17.5, 1H 5.19, d, 17.5, 1H 5.14, d, 17.6, 1H 
2’ 6.30, dd, 17.5, 10.6, 1H 6.30, dd, 17.5, 10.8, 1H 6.12, dd, 17.6, 10.7, 1H 
4’ 1.83, m, 2H 1.83, m, 2H 1.81, m, 2H 
5’ 1.86, m, 2H 1.87, m, 2H 1.90, m, 2H 
6’ 5.09, m, 1H 5.09, m, 1H 5.03, m, 1H 
8’ 1.53, s, 3H 1.53, s, 3H 1.56, s 3H  
9’ 1.49, s, 3H  1.49, s, 3H  1.51, s 3H 
10’ 1.61, s, 3H 1.61, s, 3H 1.64, s 3H 
Chemical shifts (δ) ate given in ppm and coupling constants in Hz. [§] signals are overlapping with those of solvent.
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Table S13. 1H NMR data of C3-geranylated derivatives (1a3, 3a3, 6a3, and 8a3).  
Compound 
1a3 (CDCl3) 3a3 (CDCl3) 6a3 (CD3OD) 8a3 (CD3OD)
Position δH, multi., J in Hz δH, multi., J in Hz δH, multi., J in Hz δH, multi., J in Hz 
2 5.67, s, 1H 5.54, s, 1H 5.28, s, 1H 5.35, s, 1H 
4 7.08, d, 7.5, 1H 7.10, d, 7.4, 1H 7.11, d, 7.4, 1H 7.10, d, 7.4, 1H 
5 6.77, t, 7.5, 1H 6.76, t, 7.4, 1H 6.69, t, 7.4, 1H 6.69, t, 7.4, 1H 
6 7.10, m, 1H† 7.07, t, 7.4, 1H 7.00, t, 7.4, 1H 7.01, t, 7.4, 1H 
7 6.66, br s, 1H 6.58, d, 7.4, 1H 6.57, d, 7.4, 1H 6.58, d, 7.4, 1H 
10syn 2.61, dd, 12.6, 6.0, 1H 2.64, dd, 12.0, 5.0, 1H 2.57, dd, 12.6, 6.2, 1H 2.58, dd, 12.5, 5.9, 1H 
10anti 2.22, dd, 12.6, 11,3, 1H 2.13, t, 12.0, 1H 2.22, dd, 12.6, 11.3, 1H 2.19, dd, 12.5, 11.5, 1H 
11 3.98, ddd, 11.3, 6.0, 1.2, 1H 4.04, m, 1H†† 4.02, dd, 11.3, 6.2, 1H 4.00, dd, 11.5, 5.9, 1H 
14 4.33, br d, 11.0, 1H 4.04, m, 1H†† 4.10, qd, 6.8, 2.0, 1H 3.87, qd, 7.1, 0.7, 1H 
15 5.35, s, 1H - - - 
17 3.73, dd, 15.0, 3.7, 1H 3.92,ddd, 12.4, 7.3, 3.3, 1H 1.34, d, 6.8, 3H 1.34, d, 7.1, 3H 
 2.97, dd, 15.0, 11.0, 1H 3.28,ddd, 12.4, 10.1, 4.1, 1H - - 
18 - 1.98, m, 1H‡ - - 
 - 1.89, m, 1H - - 
19 7.10, s, 1H† 2.41, m, 1H - - 
 - 1.76, dtd, 12.0, 11.2, 9.1, 1H - - 
20 8.14, s, 1H - - - 
22 7.39, d, 8.0, 1H - - - 
23 7.22, d, 8.0, 7.0, 1H - - - 
24 7.12, d, 8.0, 7.0, 1H - - - 
25 7.55, d, 8.0, 1H - - - 
1’ 2.38, dd, 14.3, 7.3, 1H 2.45, dd, 14.0, 7.1, 1H 2.41, d, 7.8, 2H 2.42, d, 7.8, 2H 
 2.42, dd, 14.3, 7.7, 1H 2.49, dd, 14.0, 7.8, 1H - - 
2’ 5.16, br t, 7.7, 1H 5.11, br t, 7.8, 1H 5.15, br t, 7.8, 1H 5.13, br t, 7.8, 1H 
4’ 1.99, m, 2H 2.02, m, 2H 2.02, m, 2H 2.00, m, 2H 
5’ 2.05, m, 2H 1.98, m, 2H‡ 1.96, m, 2H 1.95, m, 2H 
6’ 5.06, br t, 6.6, 1H 5.04, br t, 6.6, 1H 5.03, br t, 6.8, 1H 5.02, br t, 6.7, 1H 
8’ 1.69, s, 3H 1.68, s, 3H 1.63, s, 3H 1.63, s, 3H 
9’ 1.60, s, 3H  1.59, s, 3H 1.56, s, 3H 1.55, s, 3H 
10’ 1.52, s, 3H 1.55, s, 3H 1.51, s, 3H 1.50, s, 3H 
Chemical shifts (δ) are given in ppm and coupling constants in Hz. [a, b] assignments of signals with the same letter are interchangeable. [†, ‡] signals are overlapping 
with each other. H-10syn has a cis- and H-10anti a trans-configuration to H-11. 
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Table S14. 1H NMR data of C3-geranylated derivatives (10a3, 11a3, 12a3, and 13a3).  
Compound 
10a3 (CDCl3) 11a3 (CD3OD) 12a3 (CD3OD) 13a3 (CD3OD) 
Position δH, multi., J in Hz δH, multi., J in Hz δH, multi., J in Hz δH, multi., J in Hz 
2 5.29, s, 1H 5.15, s, 1H 5.15, s, 1H 5.32, s, 1H 
4 7.10, d, 7.6, 1H 6.98, d, 7.4, 1H 6.97, d, 7.4, 1H† 7.10, d, 7.5, 1H 
5 6.77, t, 7.6, 1H 6.62, t, 7.4, 1H 6.62, t, 7.4, 1H 6.69, t, 7.5, 1H 
6 7.09, t, 7.6, 1H 6.95, t, 7.4, 1H 6.96, t, 7.4, 1H† 7.00, t, 7.5, 1H 
7 6.61, d, 7.6, 1H 6.51, d, 7.4, 1H 6.51, d, 7.4, 1H 6.57, d, 7.5, 1H 
10syn 2.65, dd, 12.8, 6.1, 1H 2.23, dd, 12.0, 5.3, 1H 2.23, dd, 12.0, 5.4, 1H†† 2.57, dd, 12.5, 5.9, 1H 
10anti 2.32, dd, 12.8, 11.2, 1H 1.11, t, 12.0, 1H 1.10, t, 12.0, 1H 2.21, dd, 12.5, 11.4, 1H 
11 4.02, dd, 11.2, 6.1, 1H 3.76, ddd, 12.0, 5.3, 1.9, 1H 3.77, ddd, 12.0, 5.4, 2.0, 1H 4.00, dd, 11.4, 5.9, 1H 
14 3.96, dd, 10.5, 3.2, 1H 4.32, td, 4.4, 2.0, 1H 4.39, td, 4.4, 2.0, 1H 4.05, dd, 16.6, 2.3, 1H 
 - - - 3.70, d, 16.6, 1H 
15 5.64, s, 1H - - - 
17 2.00, m, 1H† 3.15, dd, 13.9, 4.4, 1H 3.28, m, 1H§ - 
 1.55, m, 1H 2.90, dd, 13.9, 4,4, 1H 3.02, dd, 13.8, 4.4, 1H - 
18 1.67, m, 1H - - - 
19 0.99, d, 6.6, 3Ha 7.00, d, 8.7, 1H 7.19, dd, 8.0, 1.4, 1H - 
20 0.92, d, 6.6, 3Ha 6.71, d, 8.7, 1H 7.29, m, 1H‡ - 
21 - - 7.25, m, 1H‡ - 
22 - 6.71, d, 8.7, 1H 7.29, m, 1H‡ - 
23 - 7.00, d, 8.7, 1H 7.19, dd, 8.0, 1.4, 1H - 
1’ 2.40, dd, 14.3, 7.4, 1H 2.18, dd, 14.2, 8.0, 1H 2.14, dd, 14.0, 8.4, 1H 2.42, d, 7.6, 2H 
 2.44, dd, 14.3, 7.9, 1H 2.27, dd, 14.2, 6.6, 1H 2.21, dd, 14.0, 6.0, 1H†† - 
2’ 5.17, br t, 7.6, 1H 4.91, br t, 8.0, 1H 4.99, br t, 8.4, 1H 5.15, br t, 7.6, 1H 
4’ 2.04, m, 2H 1.91, m, 2H 1.97, m, 2H※ 2.01, m, 2H 
5’ 1.99, m, 2H† 1.97, m, 2H 1.90, m, 2H 1.95, m, 2H 
6’ 5.06, br t, 6.6, 1H 5.00, br t, 6.7, 1H 4.90, m, 1H* 5.03, br t, 6.4, 1H 
8’ 1.68, s, 3H 1.63, s, 3H 1.63, s, 3H 1.63, s, 3H 
9’ 1.60, s, 3H 1.54, s, 3H  1.54, s, 3H 1.56, s, 3H 
10’ 1.52, s, 3H 1.49, s, 3H 1.48, s, 3H 1.51, s, 3H 
Chemical shifts (δ) are given in ppm and coupling constants in Hz. [§] signals are overlapping with those of solvent. [*] signals are overlapping with those of water. 
[†, ‡] signals are overlapping with each other. [a] assignments of signals with the same letter are interchangeable. [※] signals are overlapping with impurities. H-
10syn has a cis- and H-10anti a trans-configuration to H-11.
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Table S15. 1H NMR data of C3-geranylated derivatives (1b3, 5b3, 10b3, and 14b3).  
Chemical shifts (δ) are given in ppm and coupling constants in Hz. [†] signals are overlapping with each other. [§] signals are overlapping with those of solvent. [a, b] 
assignments of signals with the same letter are interchangeable. [*] signals are overlapping with those of water. H-10syn has a cis- and H-10anti a trans-
configuration to H-11. 
Compund 
 1b3 (CDCl3)  5b3 (CDCl3) 10b3 (CDCl3)  14b3 (CDCl3) 
Position δH, multi., J in Hz δH, multi., J in Hz δH, multi., J in Hz δH, multi., J in Hz 
2 5.63, s, 1H 5.49, s, 1H 5.57, s, 1H 5.64, s, 1H 
4 7.13, d, 7.5, 1Ha 7.16, d, 7.5, 1H 7.15, d, 7.5, 1H 7.14, d, 7.5, 1H 
5 6.75, t, 7.5, 1H 6.72, t, 7.5, 1H 6.75, t, 7.5, 1H 6.71, t, 7.5, 1H 
6 7.10, t, 7.5, 1Ha 7.06, t, 7.5, 1H 7.10, t, 7.5, 1H 7.07, t, 7.5, 1H 
7 6.61, d, 7.5, 1H 6.53, d, 7.5, 1H 6.58, d, 7.5, 1H 6.61, d, 7.5, 1H 
10syn 2.50, dd, 12.6, 6.4, 1H 2.80, dd, 13.8, 9.0, 1H 2.53, dd, 11.8, 6.0, 1H 3.48, dd, 13.8, 8.0, 1H 
10anti 2.45, dd, 12.6, 11.0, 1H 2.52, dd, 13.8, 8.9, 1H 2.49, dd, 11.8, 10.0, 1H 2.41, dd, 13.8, 8.7, 1H 
11 3.90, ddd, 11.0, 6.4, 1.5, 1H 4.14, t, 8.9, 1H 3.95, m, 1H† 3.96, dd, 8.7, 8.0, 1H 
14 4.31, ddd, 11.0, 3.5, 1.8, 1H 4.09, t, 8.0, 1H 3.95, m, 1H† - 
15 5.65, s, 1H - 5.64, s, 1H - 
16 - - - 7.66, s, 1H 
17 3.75, dd, 15.0, 3.6, 1H 3.45, m, 1H 2.02, ddd, 13.7, 10.0, 3.6, 1H - 
 2.97, dd, 15.0, 11.1, 1H 3.41, m, 1H 1.58, m, 1H* - 
18 - 2.04, m, 1H 1.68, m, 1H 6.88, d, 8.0, 1H 
 - 1.87, m, 1H - - 
19 7.10, d,1.2, 1H 2.32, dtd, 9.0, 6.6, 2.3, 1H 0.99, d, 6.6, 1Hb 7.43, dd, 8.0,7.5, 1H 
 - 1.97, ddd, 10.6, 6.3, 3.1, 1H -  
20 8.13, s, 1H - 0.91, d, 6.6, 1Hb 7.21, dd, 7.9, 7.5, 1H§ 
21 - - - 7.83, d, 7.9, 1H 
22 7.39, d, 8.0, 1H - - - 
23 7.23, dd, 8.0, 7.1, 1H - - - 
24 7.13, dd, 8.0, 7.1, 1Ha - - - 
25 7.55, d, 8.0, 1H - - - 
1’ 5.27, dd, 10.8, 1H 5.28, d, 10.9, 1H 5.26, d, 10.8, 1H 5.29, dd, 10.8, 1.0, 1H 
 5.07, dd, 17.4, 1H 5.12, d, 17.6, 1H 5.07, d, 17.4, 1H 5.10, dd, 17.4, 1,0, 1H 
2’ 5.76, dd, 17.4, 10.8, 1H 5.78, dd, 17.6, 10.9, 1H 5.77, dd, 17.4, 10.8, 1H 5.82, dd, 17.4, 10.8 , 1H 
4’ 1.77, dd, 16.0, 8.0, 2H 1.76, m, 2H 1.76, dd, 16.0, 7.7, 2H 1.72, m, 1H 
5’ 1.59, ddd, 17.6, 12.7, 5.9, 1H* 1.56, m, 1H * 1.58, m, 1H* 1.78, m, 2H 
 1.24, ddd, 17.6, 12.3, 7.6, 1H 1.20, m, 1H 1.22, ddd, 17.5, 11.5, 5.6, 1H 1.25, m, 1H  
6’ 5.00, br t, 7.1, 1H 4.99, br t, 7.0, 1H 4.98, br t, 7.3, 1H 5.01, br t, 6.8, 1H 
8’ 1.64, s, 3H  1.63, s, 3H  1.63, s, 3H  1.64, s, 3H 
9’ 1.09, s, 3H  1.13, s, 3H  1.10, s, 3H  1.12, s, 3H 
10’ 1.53, s, 3H  1.52, s, 3H  1.51, s, 3H  1.53, s, 3H 
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Table S16. 1H NMR data of 1a4 and 1a5.  
Compound 
 1a4   1a5 
Position δH, multi., J in Hz (CDCl3) δH, multi., J in Hz (CD3COCD3) δH, multi., J in Hz (CD3COCD3) 
1 8.18, s, 1H 9.98, s, 1Ha 9.94, s, 1Hc 
2 7.05, d, 2.3, 1H 7.10, d, 2.5, 1H 6.76, d, 2.4, 1Hd 
4 - - 7.34, d, 1.6, 1H† 
5 6.90, d, 7.2, 1H 6.76, d, 7.3, 1H - 
6 7.09, dd, 8.2, 7.2, 1H 6.94, dd, 8.0, 7.3, 1H 6.94, dd, 8.3, 1.6, 1H 
7 7.17, d, 8.2, 1H 7.14, d, 8.0, 1H 7.24, d, 8.3, 1H 
10 3.54, dd, 14.8, 2.9, 1H 3.24, dd, 14.4, 3.0, 1H 3.00, dd, 14.5, 3.8, 1H 
 1.84, dd, 14.8, 11.0, 1H 2.08, m, 1H§ 2.17, dd, 14.5, 7.5, 1H 
11 4.03, br d, 11.0, 1H 3.91, ddd, 4.9, 3.0, 2.7, 1H 4.03, ddd, 7.5, 3.8, 0.9, 1H 
12 5.87, s, 1H 7.08, br s, 1Hb 6.71, s, 1He 
14 4.32, m, 1H 4.23, ddd, 4.7, 2.5, 0.7, 1H 4.08, ddd, 7.0, 4.1, 1.2, 1H 
15 5.63, s, 1H 6.49, s, 1Hb 6.79, s, 1He 
17 3.31, dd, 14.7, 4.3, 1H 3.17, dd, 14.1, 4.8, 1H 3.05, dd, 14.2, 3.8, 1H 
 3.26, dd, 14.7, 6.8, 1H 3.14, dd, 14.1, 4.5, 1H 2.45, dd, 14.2, 7.0, 1H 
19 6.06, d, 2.2, 1H 6.00, d, 2.3, 1H 6.55, d, 2.4, 1Hd 
20 7.99, s, 1H 10.20, s, 1Ha 10.10, s, 1Hc 
22 7.39, d, 8.0, 1H 7.37, d, 8.0, 1H 7.34, d, 8.0, 1H† 
23 7.20, dd, 8.0, 7.0, 1H 7.06, dd, 8.0, 7.0, 1H 7.08, dd, 8.0, 7.0, 1H 
24 7.25, dd, 8.0, 7.0, 1H 7.11, dd, 8.0, 7.0, 1H 7.01, dd, 8.0, 7.0, 1H 
25 7.70, d, 8.0, 1H 7.65, d, 8.0, 1H 7.49, d, 8.0, 1H 
1’ 3.72, dd, 16.0, 6.7, 1H 3.69, d, 6.8, 2H 3.45, dd, 15.7, 6.7, 1H 
 3.66, dd, 16.0, 6.7, 1H - 3.41, dd, 15.7, 7.2, 1H 
2’ 5.29, br t, 6.6, 1H 5.30, br t, 6.8, 1H 5.41, br t, 7.2, 1H 
4’ 2.10, m, 2H 2.10, m, 2H 2.11, m, 2H 
5’ 2.04, m, 2H 2.02, m, 2H§ 2.07, m, 2H§ 
6’ 5.10, br t, 6.8 5.12, br t, 7.0, 1H 5.12, br t, 6.9, 1H 
8’ 1.71, s, 3H 1.72, s, 3H 1.76, s, 3H 
9’ 1.67, s, 3H 1.65, s, 3H 1.63, s, 3H 
10’ 1.58, s, 3H 1.58, s, 3H 1.57, s, 3H 
Chemical shifts (δ) are given in ppm and coupling constants in Hz. [†] signals are overlapping with each other. [§] signals are overlapping with those of solvent. [a~e] 
assignments of signals with the same letter are interchangeable. 
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Table S17. 1H NMR data of 5a6, 14a6, and 15a6, 10a7.  
Chemical shifts (δ) are given in ppm and coupling constants in Hz. [†] signals are overlapping with each other. [§] signals are overlapping with those of solvent. [a, b] 
assignments of signals with the same letter are interchangeable. [*] signals are overlapping with those of water. 
Compound 
5a6 (CDCl3) 14a6 (CDCl3) 15a6 (CDCl3)  10a7 (CDCl3) 
Position δH, multi., J in Hz δH, multi., J in Hz δH, multi., J in Hz δH, multi., J in Hz 
1 8.00, s, 1H, 1H 7.98, s, 1H 7.99, s, 1H 8.15, s, 1H 
2 7.20, s, 1H 7.12, d, 2.3, 1H 7.12, d, 2.3, 1H 7.08, d, 2.6, 1H 
4 7.48, d, 8.1, 1H 7.42, d, 8.1, 1H 7.42, d, 8.1, 1H 7.49, d, 8.0, 1H 
5 7.00, dd, 8.1, 1.5, 1H 6.95, dd, 8.1, 1.0, 1H 6.95, dd, 8.1, 1.1, 1H†† 7.09, dd, 8.0, 7.3, 1H 
6 - - - 7.04, d, 7.3, 1H 
7 7.06, d, 1.5, 1H 7.17, d, 1.0, 1H 7.17, d, 1.1, 1H - 
10 3.75, dd, 15.0, 3.7, 1H 3.50, dd, 15.1, 5.7, 1H 3.50, dd, 15.2, 5.6, 1H 3.51, dd, 15.0, 3.8, 1H 
 2.92, dd, 15.0, 11.1, 1H 3.20, dd, 15.1, 8.4, 1H 3.20, dd, 15.2, 8.1, 1H 3.16, dd, 15.0, 8.9, 1H 
11 4.36, dd, 11.1, 3.7, 1H 4.13, ddd, 8.4, 5.6, 4.9, 1H 4.13, ddd, 8.4, 5.6, 4.9, 1H 4.31, br d, 9.0, 1H 
12 5.71, s, 1H 6.02, d, 4.9, 1H 6.05, d, 4.7, 1H 5.85, s, 1Ha 
14 4.07, t, 8.1, 1H - - 3.90, br d, 10.4, 1H 
15 - - - 5.79, s, 1Ha 
16 - 7.63, s, 1H 7.67, s, 1H - 
17 3.66, ddd, 11.5, 7.4, 7.4, 1H - - 1.58, m, 1H* 
 3.59, ddd, 11.5, 8.7, 3.1, 1H - - 1.04, ddd, 14.6, 10.2, 4.4, 1H 
18 2.01, m, 1H† 6.95, d, 8.0, 1H 6.96, d, 8.0, 1H†† 1.51, m, 1H 
 1.91, m, 1H - - - 
19 2.33, m, 1H 7.50, dd, 8.0, 7.4, 1H 7.50, dd, 8.0,7.4, 1H 0.85, d, 6.5, 3Hb 
 2.01, m, 1H† - - - 
20 - 7.26, dd, 7.9, 7.4, 1H§ 7.26, dd, 7.9, 7.4, 1H§ 0.84, d, 6.5, 3Hb 
21 - 7.91, d, 7.9, 1H 7.91, d, 7.9, 1H - 
1’ 3.41, d, 7.2, 1H 3.44, d, 7.3, 2H 3.44, d, 7.4, 2H 3.57, d, 7.7, 2H 
2’ 5.39, br t, 7.4, 1H 5.37, br t, 7.3, 1H 5.37, br t, 8.0, 1H 5.42, br t, 7.5, 1H 
4’ 2.12, m, 2H 2.11, dd, 15.1, 7.3, 2H 2.12, dd, 14.7, 7.6, 2H 2.15, m, 2H 
5’ 2.06, m, 2H 2.04, m, 2H 2.04, m, 2H 2.11, m, 2H 
6’ 5.12, br t, 6.9, 1H 5.10, br t, 6.9, 1H 5.10, br t, 6.9, 1H 5.10, br t, 6.9, 1H 
8’ 1.74, s, 3H 1.72, s, 3H 1.72, s, 3H 1.81, s, 3H 
9’ 1.69, s, 3H 1.67, s, 3H 1.67, s, 3H 1.69, s, 3H 
10’ 1.60, s, 3H 1.59, s, 3H 1.59, s, 3H 1.61, s, 3H 
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Table S18. 1H NMR data of 1a6, and 1a7.  
Chemical shifts (δ) are given in ppm and coupling constants in Hz. [§] signals are overlapping with those of solvent. [a~j] assignments of signals with the same 
letter are interchangeable. [*] signals are overlapping with those of water.
Compound 
 1a6  1a7 
Position δH, multi., J in Hz (CDCl3) δH, multi., J in Hz (CD3COCD3) δH, multi., J in Hz (CDCl3) 
δH, multi., J in Hz 
(CD3COCD3) 
1 8.05, s, 1H 9.93, s, 1H 8.06, s, 1H  9.93, s, 1H 
2 6.51, d, 2.3, 1Ha 6.70, d, 2.4, 1Hb 6.54, d, 2.3, 1Hd 6.63, d, 2.5, 1Hf 
4 7.56, d, 8.0, 1H 7.37, d, 8.1, 1H 7.41, d, 7.5, 1H 7.33, d, 7.0, 1H 
5 7.00, dd, 8.0, 1.3, 1H 6.88, dd, 8.1, 1.5, 1H 7.08, dd, 7.5, 7.2, 1H 6.96, dd, 7.5, 7.0, 1H 
6 - - 7.03, d, 7.2, 1H 6.93, d, 7.5, 1H 
7 7.15, d, 1.3, 1H 7.15, d, 1.5, 1H - - 
10 3.22, dd, 14.5, 3.5, 1H 2.99, dd, 14.3, 3.9, 1H 3.24, br d, 14.4, 1H 3.02, ddd, 14.0, 4.0, 3.5, 1H 
 2.44, dd, 14.5, 8.5, 1H 2.26, dd, 14.3, 7.5, 1H 2.39, dd, 14.4, 8.8, 1H 2.19, ddd, 14.0, 7.0, 4.0, 1H 
11 4.17, m, 1H 4.04, m, 1H 4.19, br t, 10.4, 1H 4.05, m, 1H 
12 5.69, s, 1H 6.75, s, 1Hc 5.73, s, 1He 6.74, s, 1H 
14 4.18, m, 1H 4.04, m, 1H 4.19, br t, 10.4, 1H 4.05, m, 1H 
15 5.69, s, 1H 6.78, s, 1Hc 5.70, s, 1He 6.74, s, 1H 
17 3.24, dd, 14.5, 3.5, 1H 3.03, dd, 14.4, 4.0, 1H 3.24, br d, 14.4, 1H 3.02, ddd, 14.0, 4.0, 3.5, 1H 
 2.47, dd, 14.5, 8.5, 1H 2.34, dd, 14.3, 7.4, 1H 2.51, dd, 14,4, 8.3, 1H 2.19, ddd, 14.0, 7.0, 4.0, 1H 
19 6.55, d, 2.2, 1Ha 6.59, d, 2.4, 1Hb 6.59, d, 2.3, 1Hd 6.65, d, 2,2, 1Hf 
20 7.94, s, 1H 10.09, s, 1H 8.08, s, 1H  10.07, s, 1H 
22 7.35, d, 8.0, 1H 7.34, d, 8.1, 1H 7.36, d, 8.0, 1H 7.33, d, 8.0, 1H 
23 7.22, dd, 8.0, 7.0, 1H 7.08, dd, 8.1, 7.0, 1H 7.22, d, 8.0, 7.0, 1H 7.08, dd, 8.0, 7.0, 1H 
24 7.14, dd, 8.0, 7.0, 1H 7.00, dd, 8.1, 7.0, 1H 7.15, d, 8.0, 7.0, 1H 7.00, dd, 8.0, 7.0, 1H 
25 7.46, d, 8.0, 1H 7.46, d, 8.1, 1H 7.57, d, 8.0, 1H 7.46, d, 8.0, 1H 
1’ 3.45, d, 7.2, 2H 3.43, d, 7.3, 2H 3.50, d, 7.3, 2H 3.54, d, 7.0, 2H 
2’ 5.38, br t, 7.4, 1H 5.39, br t, 7.8, 1H 5.33, br t, 6.9, 1H 5.38, br t, 7.2, 1H 
4’ 2.13, m, 1H 2.10, m, 2H 2.07, m, 2H 2.07, m, 2H§ 
5’ 2.06, m, 1H 2.03, m, 2H§ 2.02, m, 2H 1.96, m, 2H 
6’ 5.11, br t, 7.0, 1H 5.11, br t, 6.9, 1H 5.05, br t, 6.6, 1H 5.04, br t, 6.9, 1H 
8’ 1.73, s, 3H 1.73, s, 3H 1.76, s, 3H 1.69, s, 3H 
9’ 1.68, s, 3H 1.63, s, 3H 1.68, s, 3H 1.63, s, 3H 
10’ 1.59, s, 3H 1.57, s, 3H 1.58, s, 3H 1.53, s, 3H 
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Figure S1 HPLC chromatograms of the incubation mixtures of cyclic dieptide PTs and their corresponding mutants with their natural or best substrates in the 
presence of DMAPP. The assays (50 μL) contained 50 mM Tris-HCl (pH 7.5), 10 mM CaCl2, 1 mM cyclic dipeptide, 2 mM DMAPP, 0.7–6% (v/v) glycerol, up to 5% 
(v/v) DMSO, and 10 μg purified protein for FtmPT1 and BrePT, or 20 μg for CdpNPT, CdpC2PT, and CdpC3PT. The reaction mixtures were incubated at 37 °C for 
2 h for FtmPT1 and BrePT, and 4h for CdpNPT, CdpC2PT and CdpC3PT. Detection was carried out with a photodiode array detector and illustrated for absorption 
at 296 nm. According to previous results,7-9,11,18 P1 should be tryprostatin B, P2 deoxybrevianamide E, P5 cyclo-3β-prenyl-L-Trp-L-Leu, P6 (2S, 3R, 11S)-aszonalenin, 
and P7 (S)-2-tert-prenyl-benzodiazepinedione. The structures of P1, P2, and P6 have also been confirmed by NMR after isolation friom the incubation mixtures with 
the mutants. 
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Figure S2 HPLC chromatograms of the incubation mixtures of CdpC2PT and CdpC2PT _T351G with 15 cyclic dipeptides in the presence of GPP. The assays (50 
μL) contained 50 mM Tris-HCl (pH 7.5), 2 mM DTT, 1 mM cyclic dipeptide, 2 mM GPP, 5% (v/v) glycerol, up to 5% (v/v) DMSO, and 50 μg purified protein. The 
reaction mixtures were incubated at 37 °C for 16 h. Detection were carried out with a photodiode array detector and illustrated for absorption at 296 nm. The product 
yields (%) are given in average of two replicate. 
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Figure S3 HPLC chromatograms of the incubation mixtures of CdpC3PT and CdpC3PT _F335G with 15 cyclic dipeptides in the presence of GPP. The assays (50 
μL) contained 50 mM Tris-HCl (pH 7.5), 2 mM DTT, 1 mM cyclic dipeptide, 2 mM GPP, 3.3% (v/v) glycerol, up to 5% (v/v) DMSO, and 50 μg purified protein. The 
reaction mixtures were incubated at 37 °C for 16 h. Detection were carried out with a photodiode array detector and illustrated for absorption at 296 nm. The product 
yields (%) are given in average of two replicate. 
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Figure S4 HPLC chromatograms of the incubation mixtures of CdpNPT and CdpNPT _M349G with 15 cyclic dipeptides in the presence of GPP. The assays (50 
μL) contained 50 mM Tris-HCl (pH 7.5), 2 mM DTT, 1 mM cyclic dipeptide, 2 mM GPP, 5% (v/v) glycerol, up to 5% (v/v) DMSO, and 30 μg purified protein. The 
reaction mixtures were incubated at 37 °C for 16 h. Detection were carried out with a photodiode array detector and illustrated for absorption at 296 nm. The product 
yields (%) are given in average of two replicate. 
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Figure S5 HPLC chromatograms of the incubation mixtures of FtmPT1 and FtmPT1_M364G with 15 cyclic dipeptides in the presence of GPP. The assays (50 μL) 
contained 50 mM Tris-HCl (pH 7.5), 10 mM CaCl2, 1 mM cyclic dipeptide, 2 mM GPP, 0.7 % (v/v) glycerol, up to 5% (v/v) DMSO, and 10 μg purified protein. The 
reaction mixtures were incubated at 37 °C for 2 h. Detection were carried out with a photodiode array detector and illustrated for absorption at 296 nm. The product 
yields (%) are given in average of two replicate. 
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Figure S6 HPLC chromatograms of the incubation mixtures of BrePT and BrePT_I337G with 15 cyclic dipeptides in the presence of GPP. The assays (50 μL) 
contained 50 mM Tris-HCl (pH 7.5), 10 mM CaCl2, 1 mM cyclic dipeptide, 2 mM GPP, 2% (v/v) glycerol, up to 5% (v/v) DMSO, and 10 μg purified protein. The 
reaction mixtures were incubated at 37 °C for 2 h. Detection were carried out with a photodiode array detector and illustrated for absorption at 296 nm. The product 
yields (%) are given in average of two replicate. 
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Figure S7 Protein alignments of AtaPT with PTs used in this study. AtaPT (PDB code: 5KCG), FgaPT2 (PDB code: 3I4Z), FtmPT1 (PDB code: 3O24), BrePT 
(GenBank: I4AY86.1), CdpC2PT (GenBank: AGR03830.1), CdpC3PT (GenBank: EAW17508.1), and CdpNPT (PDB code: 4E0T). 
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Figure S8: Models of catalysis for PTs. DMAPP (orange) and GPP (green) were modelled into the crystal structures of FtmPT1 (A) (pdb-code: 3I4X) with 2 (blue) 
and of CdpNPT (B) (pdb-code: 3O2K) with 14 (blue) as acceptor. The GPP molecule was modelled into the active site on the basis of the DMAPP binding of both 
enzymes. The pyrophosphate of the prenyl donor was kept as fixed anchor and the geranyl entity was placed into the DMAPP binding pocket by avoiding clashes 
with the active site residues of the enzyme variant where the gatekeeper residue was in silico mutated to glycine. In the native state, the gatekeeper residue (pink) 
would clash with the GPP molecule. This clash is emphasized by transparent spheres (pink).  
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Figure S9 HPLC analysis of enzyme assays of FtmPT1_M364G, CdpNPT_M349G, CdpC2PT, and CdpC2PT_T351G with GPP and cyclo-L-Trp-L-Trp (1). The 
assay (50 μL) for FtmPT1_M364G contained 50 mM Tris-HCl (pH 7.5), 10 mM CaCl2, 1 mM cyclo-L-Trp-L-Trp, 2 mM GPP, 0.7% (v/v) glycerol, 5% (v/v) DMSO, and 
10 μg purified protein. The assay (50 μL) for CdpNPT_M349G contained 50 mM Tris-HCl (pH 7.5), 2 mM DTT, 1 mM cyclo-L-Trp-L-Trp, 2 mM GPP, 5% (v/v) glycerol, 
5% (v/v) DMSO, and 30 μg purified protein. The assays for CdpC2PT and CdpC2PT_T351G contained 50 mM Tris-HCl (pH 7.5), 2 mM DTT, 1 mM cyclo-L-Trp-L-
Trp, 2 mM GPP, 0.7-6% (v/v) glycerol, 5% (v/v) DMSO, and 50 μg purified protein. The reaction mixtures were incubated at 37 °C for 2 h for FtmPT1, and 16 h for 
CdpNPT_M349G, CdpC2PT and CdpC2PT_T351G. Detection were carried out with a photodiode array detector and illustrated for absorption at 296 nm. Product 
yields are given in parenthesis after compound numbers.  
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Figure S10 1H NMR spectrum of 1a1 in CDCl3 (500MHz). 
 
Figure S11 1H NMR spectrum of 2a1 in CD3OD (500MHz). 
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Figure S12 1H NMR spectrum of 3a1 in CDCl3 (500MHz). 
 
Figure S13 1H NMR spectrum of 6a1 in CD3OD (500MHz). 
 SUPPORTING INFORMATION          
35 
 
 
Figure S14 1H NMR spectrum of 8a1 in CD3OD (500MHz). 
 
Figure S15 1H NMR spectrum of 10a1 in CDCl3 (500MHz). 
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Figure S16 1H NMR spectrum of 11a1 in CD3OD (500MHz). 
 
Figure S17 1H NMR spectrum of 12a1 in CD3OD (500MHz). 
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Figure S18 1H NMR spectrum of 13a1 in CDCl3 (500MHz). 
 
Figure S19 1H NMR spectrum of 10b1 in CDCl3 (500MHz). 
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Figure S20 1H NMR spectrum of 1a2 in CDCl3 (500MHz). 
 
Figure S21 1H NMR spectrum of 2a2 in CDCl3 (500MHz). 
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Figure S22 1H NMR spectrum of 3a2 in CDCl3 (500MHz). 
 
Figure S23 1H NMR spectrum of 10a2 in CDCl3 (500MHz). 
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Figure S24 1H NMR spectrum of 11a2 in DMSO-d6 (500MHz). 
 
Figure S25 1H NMR spectrum of 12a2 in DMSO-d6 (500MHz). 
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Figure S26 1H NMR spectrum of 1b2 in CDCl3 (500MHz). 
 
Figure S27 1H NMR spectrum of 1b2-2 in CDCl3 (500MHz). 
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Figure S28 1H NMR spectrum of 2b2 in CD3OD (500MHz). 
 
Figure S29 1H NMR spectrum of 3b2 in CD3OD (500MHz). 
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Figure S30 1H NMR spectrum of 4b2 in CD3OD (500MHz). 
 
Figure S31 1H NMR spectrum of 14b2 in CDCl3 (500MHz). 
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Figure S32 1H NMR spectrum of 1a3 in CDCl3 (500MHz). 
 
Figure S33 1H NMR spectrum of 3a3 in CDCl3 (500MHz). 
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Figure S34 1H NMR spectrum of 6a3 in CD3OD (500MHz). 
 
Figure S35 1H NMR spectrum of 8a3 in CD3OD (500MHz). 
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Figure S36 1H NMR spectrum of 10a3 in CDCl3 (500MHz). 
 
Figure S37 1H NMR spectrum of 11a3 in CD3OD (500MHz). 
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Figure S38 1H NMR spectrum of 12a3 in CD3OD (500MHz). 
 
Figure S39 1H NMR spectrum of 13a3 in CD3OD (500MHz). 
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Figure S40 1H NMR spectrum of 1b3 in CDCl3 (500MHz). 
 
Figure S41 1H NMR spectrum of 5b3 in CDCl3 (500MHz). 
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Figure S42 1H NMR spectrum of 10b3 in CDCl3 (500MHz). 
 
Figure S43 1H NMR spectrum of 14b3 in CDCl3 (500MHz). 
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Figure S44 1H NMR spectrum of 1a4 in CDCl3 (500MHz). 
 
Figure S45 1H NMR spectrum of 1a4 in CD3COCD3 (500MHz). 
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Figure S46 1H NMR spectrum of 1a5 in CD3COCD3 (500MHz). 
 
Figure S47 1H NMR spectrum of 1a6 in CD3COCD3 (500MHz). 
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Figure S48 1H NMR spectrum of 1a6 in CDCl3 (500MHz). 
 
Figure S49 1H NMR spectrum of 5a6 in CDCl3 (500MHz). 
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Figure S50 1H NMR spectrum of 14a6 in CDCl3 (500MHz). 
 
Figure S51 1H NMR spectrum of 15a6 in CDCl3 (500MHz). 
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Figure S52 1H NMR spectrum of 1a7 in CDCl3 (500MHz). 
 
Figure S53 1H NMR spectrum of 1a7 in CD3COCD3 (500MHz). 
 SUPPORTING INFORMATION          
55 
 
 
Figure S54 1H NMR spectrum of 10a7 in CDCl3 (500MHz). 
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Structure-based protein engineering enables
prenyl donor switching of a fungal aromatic
prenyltransferase†
Peter Mai,a Georg Zocher,b Thilo Stehle*b and Shu-Ming Li *a
Microorganisms provide valuable enzyme machinery to assemble complex molecules. Fungal prenyltrans-
ferases (PTs) typically catalyse highly regiospecific prenylation reactions that are of significant pharma-
ceutical interest. While the majority of PTs accepts dimethylallyl diphosphate (DMAPP), very few such
enzymes can use geranyl diphosphate (GPP) or farnesyl diphosphate (FPP) as donors. This catalytic gap
prohibits the wide application of PTs for structural diversification. Structure-guided molecular modelling
and site-directed mutagenesis of FgaPT2 from Aspergillus fumigatus led to the identification of the gate-
keeping residue Met328 responsible for the prenyl selectivity and sets the basis for creation of GPP- and
FPP-accepting enzymes. Site-saturation mutagenesis of the gatekeeping residue at position 328 in
FgaPT2 revealed that the size of this side chain is the determining factor for prenyl selectivity, while its
hydrophobicity is crucial for allowing DMAPP and GPP to bind.
Introduction
Natural products from plants and microorganisms are impor-
tant sources of drugs.1–3 Diverse enzymes are involved in the
biosynthesis of these compounds.4 Prenyltransferases (PTs)
catalyse transfer reactions of prenyl (nxC5) moieties onto ali-
phatic or aromatic acceptors.5 Nature provides an impressive
repertoire of functionally versatile PTs in diverse metabolic
pathways. Prenylation often increases the hydrophobic charac-
ter of the target structures and enables or enhances their inter-
action with biomolecules. For example, protein prenylation
can be an essential posttranslational modification for specific
protein–protein and protein–membrane interactions in cell
signalling cascades across species.6 In bacteria, special
peptide pheromones obtain their functionality as signalling
molecules by prenylation of tryptophan residues.7,8 Discovery
of prenylated t-RNA underlines the crucial role of nucleic acid
PTs in causing an impact on translation processes.9
Over the last two decades, the progress in genome sequen-
cing and mining has enabled the prediction of metabolites
from genetic potentials. The rich availability of biologically
active metabolites in ascomycetous fungi has led to tremen-
dous efforts in structural and mechanistic investigations of
enzyme machinery, as exemplified by the biosynthesis of
indole alkaloids.10 Fungal PTs are found to either initialise
biosynthetic pathways or tailor assembled scaffolds, providing
particular benefits to the structural diversity of metabolites.11
To date, about fifty PTs from fungi and bacteria belonging to
the dimethylallyltryptophan synthase (DMATS) superfamily
have been characterized biochemically.5 Crystal structures of
the DMATS-type PTs show a conserved PT barrel fold com-
posed of five ααββ repeating units with ten circularly arranged
antiparallel β-strands surrounded by ten α-helices. This ABBA-
type architecture was initially observed for the bacterial PT
NphB12 and for the fungal C4-dimethylallyltryptophan
synthase FgaPT2, although the two enzymes share little
sequence similarity with each other.13 DMATS-type PTs usually
use dimethylallyl diphosphate (DMAPP, C5) as a prenyl donor
and catalyse metal ion-independent Friedel–Crafts alkylation
on their aromatic substrates. The enzymatically generated di-
methylallyl carbocation is attacked by electron-rich atoms, e.g.
C–C double bond, N-atom, or O-atom, at its C-1 or C-3 posi-
tion, resulting in regular and reverse prenylation, respectively.5
Biochemical investigations of DMATS-type PTs revealed
their clear promiscuity towards aromatic acceptors. However,
the majority of these PTs displays high specificity for DMAPP
and low or no activity towards longer donors like geranyl di-
phosphate (GPP, C10) or farnesyl diphosphate (FPP, C15). VrtC
and TleC are two examples of the DMATS superfamily that
†Electronic supplementary information (ESI) available: Primers, NMR spectra
with assignments, MS data, and determination of kinetic parameters (PDF). See
DOI: 10.1039/c8ob02037j
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require GPP for activity.14 A minority of DMATSs, e.g. AtaPT,
MpnD, TleC, BAE61387, and AstPT, can utilize a range of
prenyl donors.15–18 The high specificity for a prenyl donor
limits their application for structural diversification.
The particular importance and necessity of GPP- and FPP-
accepting enzymes as biocatalytic tools led us to perform a
directed evolution study. The selected tryptophan PT FgaPT2
from Aspergillus fumigatus utilizes DMAPP as a natural prenyl
donor and catalyses the C4-prenylation of L-tryptophan (1) to
yield 4-dimethylallyltryptophan (2)19 (Fig. 1A). The availability
of structures for several DMATS-type PTs such as FgaPT2,13
FtmPT1,20 CdpNPT,21 AnaPT,22 AtaPT,15 TleC, and MpnD16
provides a molecular basis for understanding the reaction
mechanisms and enables structure-based protein design and
engineering.
In this study, we genetically engineered the PT FgaPT2
based on its crystal structure13 by molecular modelling and
identified a gatekeeping residue for the prenyl donor specificity.
Furthermore, site-saturation mutagenesis at the gatekeeping
residue provides insights into the molecular effects of the
interactions between various prenyl donors and altering amino
acids.
Results and discussion
Methionine 328 in FgaPT2 controls the prenyl donor gateway
To confirm the preference for DMAPP observed in a previous
study, we synthesized chemically DMAPP, GPP and FPP23 and
confirmed their integrity by NMR analysis (Fig. S1–S6†).
FgaPT2 (10 µg) was then incubated with 1 mM 1 in the pres-
ence of 1 mM DMAPP, GPP or FPP at 37 °C for 90 min. The
reaction mixtures were subsequently analysed by LC-MS. 2,
with a conversion of 81.7%, was detected in the incubation
mixture with DMAPP. When GPP was used as a prenyl donor,
the geranylated product 3 showed a drastically reduced conver-
sion of only 3.8% (Fig. 1B and Fig. 2) and no conversion at all
when 1 was incubated with FgaPT2 in the presence of FPP
(Fig. 3).
Structure-based molecular modelling led to the identifi-
cation of Met328 in FgaPT2 as a putative gatekeeping residue.
The side chain of Met328 seals the active site of the prenyl
donor, closing the cavity from one side to form a hydrophobic
pocket that is well suited to accommodate DMAPP. Any prenyl
donor larger than DMAPP would clash with the bulky side
chain of Met328. Altering this residue therefore represents an
attractive strategy to enable the accommodation of GPP and
FPP (Fig. 4).
Therefore, the mutant M328G was generated by site-
directed mutagenesis and assayed with 1 in the presence of
DMAPP, GPP or FPP under the same conditions as for FgaPT2.
M328G showed a strongly reduced acceptance of DMAPP with
a conversion of 6.0%. In contrast, it has an almost tenfold
higher GPP acceptance than FgaPT2 (from 3.8% to 36.0%)
(Fig. 1B and 2), highlighting the importance of Gly328 in redu-
cing the steric hindrance for GPP-binding. Furthermore, a far-
nesylated product was clearly detected for M328G with FPP
(Fig. 3). These results clearly identify residue 328 in FgaPT2 as
a key position for prenyl donor selectivity and the mutation of
this residue to glycine enables the acceptance of GPP.
A comparison of the ternary crystal structure of FgaPT2
with those of FtmPT120 and CdpNPT21 led to the identification
of Met364 in FtmPT1 and Met349 in CdpNPT to be the corres-
ponding residues of Met328 in FgaPT2. As the structures of
5-DMATS24 and BrePT25 are not available, we generated com-
putational models on the basis of HHPRED26 alignments and
3D modelling using MODELLER (https://salilab.org/modeller).
Manual inspection of the superposition yielded the align-
ments illustrated in Fig. 5. The corresponding gatekeeping
residues were identified as Leu327 in 5-DMATS and Ile337 in
BrePT, which are comparable in size to methionine. Mutation
of the mentioned residues to glycine resulted in the formation
of mutants with significantly increased activities towards GPP
(data not shown).
Recently, the Aspergillus terreus prenyltransferase AtaPT was
demonstrated to utilize various prenyl donors, with relatively
low tolerance against DMAPP. The mutant AtaPT_G326M
showed lower acceptance of GPP and FPP, but it was more
Fig. 1 Prenylation of L-tryptophan by FgaPT2 and its M328 mutants in the presence of DMAPP (blue) and GPP (red). (A) Enzyme products and (B)
absolute conversion yields.
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active towards DMAPP.15 The reduced activity toward DMAPP
by FgaPT2_M328G and AtaPT wild-type is unexpected initially,
because these enzymes display a clear preference for prenyl
donors longer than DMAPP. We conclude that, in addition to
steric restraints, subtle changes in the active site can also have
a major impact on the specificity. Mutation of Met328 in
FgaPT2 to glycine increases the size of the active site cavity. As
a result, the mobility of the dimethylallyl entity in the active
site is increased during catalysis. This enables the prenyl
donor to adopt slightly different conformations, which ulti-
mately yield to a catalytic attack at different positions of the
aromatic ring system. The resulting flexibility of the substrate
DMAPP in the active site therefore reduces its activity in the
reaction catalysed by the wild-type enzyme.
Structure elucidation of the new enzyme product
4-geranyltryptophan
For structure confirmation, the enzyme product 3 was isolated
from an up-scaled incubation mixture of M328G with 1 and
GPP and subsequently subjected to NMR and MS analyses
(Fig. S7 and S8†). In the 1H NMR spectrum, two characteristic
signals appeared as broad triplets at δH 5.36 (1H) and
5.12 ppm (1H), confirming the regular attachment of the
geranyl moiety with its C-1 atom. Additional signals from the
geranyl moiety were observed at δH 3.81 (2H) and 2.07–2.13
(4H), and those of the three methyl groups in the up-field
region of δH 1.58–1.76 ppm (9H). Signals for four instead of
five aromatic protons appeared in the down-field region,
which verifies the prenylation at the indole ring. A comparison
of the 1H NMR spectrum of the GPP product (Fig. S7†) with
that of the C4-prenylated L-tryptophan 219,27 revealed almost
identical chemical shifts and coupling patterns for the four
aromatic protons in both spectra, which unequivocally con-
firms the formation of 4-geranyltryptophan (3). These results
clearly demonstrate that the targeted PT is redesigned from a
4-dimethylallyltryptophan synthase to a 4-geranyltryptophan
synthase by a single point mutation.
Position 328 in FgaPT2 controls the donor selectivity
As demonstrated above, Met328 in FgaPT2 is the gatekeeping
residue for controlling the prenyl donor selectivity. This amino
acid residue protrudes into the active centre, and it is therefore
likely that steric effects prevent the acceptance of GPP and FPP
(Fig. 4). Obviously, the replacement of Met328 with glycine
strongly decreased the steric hindrance, enabling the utiliz-
ation of GPP and FPP for prenylations. The engineered enzyme
also displays reduced activity toward DMAPP from 81.7% with
FgaPT2 to 6.0% with M328G. The reduced activity indicates
that besides steric restraints other molecular effects also influ-
ence the interaction with DMAPP. To uncover the molecular
interactions between the prenyl donors and the key residue
328 in FgaPT2, we performed site-saturation mutagenesis to
obtain mutants with the remaining 18 amino acids.
FgaPT2 and the nineteen M328X mutants were assayed
with 1 in the presence of DMAPP, GPP or FPP and analysed via
LC-MS (Fig. 2). Our results show that the steric hindrance in
the active centre is mainly responsible for the low GPP activity.
The side chains of the mutants M328L, M328I, M328F,
M328Q, and M328H are comparable in size to that of Met328
in the wild-type protein. These residues are located in the reac-
tion cavity in a similar manner (Fig. 6) and therefore show
catalytic activities as demonstrated for Met328. Absolute con-
Fig. 2 Activities of FgaPT2 and M328 mutants toward DMAPP and GPP. The extracted ion chromatograms (EICs) of their incubation mixtures with 1
and DMAPP (blue) or GPP (red) are presented.
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versions of 1 were determined for these mutants in the ranges
of 81.3–84.3% with DMAPP and 0.4–3.3% with GPP (Fig. 1B).
No product formation was detected with FPP.
Amino acid residues with smaller side chains than meth-
ionine (M328A, M328V, M328T, M328G, M328S, M328C, and
M328N) show strongly enhanced catalytic activity toward GPP,
with conversion rates in the range of 10.7–50.7% (Fig. 1B).
Their acceptances of DMAPP differ substantially from each
other, from nearly no changes in comparison with the wild-
type enzyme as in the cases of M328V, M328T, and M328N, to
strongly reduced activities as in the cases of M328G, M328S,
and M328A. Mutants M328T and M328C show similar
enhanced activities for GPP and clear acceptance of DMAPP.
M328C yielded the highest conversion of 50.7% with GPP.
However, this mutant still exhibits a relatively high acceptance
of DMAPP with a conversion of 40%. The best acceptance
ratios of GPP to DMAPP were observed for M328G, M328S, and
M328A, with conversions of 35.9, 42.9, and 47.1% for GPP
and 6.0, 12.7, and 8.6% for DMAPP, respectively (Fig. 1B).
Furthermore, the mutants with the smallest side chains, i.e.
M328A, M328G, M328S, and M328C, show clear acceptance of
FPP among the single mutants (Fig. 3).
The amino acid residues of M328T, M328V, and M328N
would allow for the interaction with GPP, and their polar
nature could also facilitate an interaction with DMAPP. As a
consequence, mutants M328T, M328V, and M328N display a
high acceptance of DMAPP with conversion rates of 81.2, 83.5,
and 76.9%, respectively. This is comparable to the wild-type
enzyme. However, they also show high tolerance towards GPP
with conversion rates of 44.6, 26.7, and 10.7%, respectively
(Fig. 1B).
The mutants M328Y, M328W, M328E, and M328K exhibit
absolute conversions of 82.2, 77.4, 66.1, and 34.9% with
DMAPP, respectively (Fig. 1B), and they are inactive toward
GPP and FPP. The aromatic character of the side chains of
M328Y and M328W probably explains the high activities of
these mutants toward DMAPP. Although π–π-interactions with
the prenyl donor seem impossible due to the perpendicular
orientation of the π-systems, the aromatic side chains of
M328W and M238Y interact perfectly with the hydrophobic
and aliphatic group of DMAPP. On the other hand, the
bulky side chains do not allow the incorporation of prenyl
donors larger than DMAPP because of steric hindrance, likely
preventing GPP and FPP from entering the reaction cavity or
blocking the binding of the prenyl donor. These findings are
in general agreement with the observed catalytic rates of the
aromatic amino acid residues of M328F and M328H, which
show similar activities toward DMAPP. Since the two side
chains are less bulky in comparison with M328Y and M328W,
they still display low acceptance of GPP. The acidic amino acid
residue of M328E and the basic character of M328K signifi-
cantly reduce the utilization of DMAPP (Fig. 1B). The amino
acid residues proline and aspartic acid at the 328 position
revealed very similar behaviours toward the prenyl donors.
They strongly reduced DMAPP and showed low GPP accep-
tance. The replacement of Met328 with arginine nearly abol-
ished the acceptance of DMAPP, probably due to steric and
polarity effects (Fig. 1B). We could not observe any activities
for GPP or FPP with the M328R mutant.
In order to verify the geranylation position of 1 by M328S,
M328A, M328C, M328T, M328V, and M328N mutants, the
enzyme products were isolated and subjected to 1H NMR ana-
lysis. A comparison of their spectra with that of 3 confirmed
the same enzyme product in their reaction mixtures.
Site-saturation mutagenesis at position 328 in FgaPT2
revealed that the size of the amino acid residue at this position
Fig. 3 Farnesylation of L-tryptophan by FgaPT2 and mutants thereof.
(A) EICs and (B) relative activities.
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determines the prenyl donor selectivity. However, polarity
effects also appear crucial for binding DMAPP and GPP for
prenyl transfer reactions. Molecular modelling (Fig. 4 and 6)
revealed that any large and rigid amino acid side chain at posi-
tion 328 would interfere with GPP prenylation, which is in
agreement with our active site model. In contrast, high GPP
conversions were found with very small side chain amino
acids. M328A showed a high conversion yield of 47.1% with
GPP and a low activity with DMAPP (8.6%) and therefore could
be applied for in vivo production of specifically geranylated
products in engineered organisms.
We conclude that, on the one hand, M328G, M328S,
M328A, and M328C are particularly effective in reducing the
steric hindrance for GPP acceptance. On the other hand, they
eliminate hydrophobic contacts that are crucial for optimal
fitting of DMAPP. The alanine residue of M328A provides the
second highest conversion of 47.1% with GPP and the second
lowest activity with DMAPP (8.6%) of the mutants that can
Fig. 4 Model of FgaPT2 catalysis. GPP (light green) and FPP (dark green) were modelled into the crystal structure of FgaPT2 (pdb entry: 3I4X) with
dimethylallyl S-thiolodiphosphate (DMSPP, orange) after mutating M328 to glycine using FoldX. The isoprenoids are docked into the cavity on the
basis of the DMAPP conformation. The pyrophosphate positions were kept fixed as the binding site, which is structurally conserved in all fungal
prenyl transferases. Potential clashes between GPP/FPP and the protein are indicated by spheres (pink). Smaller spheres indicate clashes that might
be compensated by side chain reorientation. The closest distances to L263 and R244 are 2.8 Å and 3.0 Å, respectively.
Fig. 5 Structure-based sequence alignments of five selected prenyltransferases. Labelled residues are suggested to be involved in the interactions
with the pyrophosphate entity (red), the prenyl acceptor (blue, cyan) and the dimethylallyl moiety (green). Residues corresponding to M328 of
FgaPT2 are labelled with * (M, L, I).
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utilize GPP. To the best of our knowledge, this catalytic behav-
iour is unique, because M328A offers enough space and hydro-
phobic interactions for optimal GPP and FPP binding and
therefore also shows the highest acceptance of FPP (Fig. 3). It
appears that the increased size of the active site in the mutant
introduces a higher degree of substrate mobility for the small
dimethylallyl entity inside the reaction chamber. This likely
hampers the correct positioning of the prenyl acceptor and
leads to decreased C4-prenylation.
The influence of polarity effects that distinguish between
DMAPP and GPP can be verified through a comparison of the
reactivities of M328V and M328T, and those of M328S and
M328C. Despite the equal sizes of the side chains of M328T
and M328V, M328T exhibits a significantly higher conversion
rate with GPP than M328V, whereas the DMAPP acceptance is
comparable for both enzymes. The two amino acid residues
differ only in their substitutions at β-carbon. The hydroxyl
group at the β-carbon of M328T enhances GPP turnover in
comparison with the methyl group at the β-carbon of M328V.
The amino acids in M328S and M328C differ also in their sub-
stitutions at the β-carbon. Considering the observed conver-
sions, the thiol group in M328C and the hydroxyl group in
M328S show similar effects on their acceptance of GPP, but
differ significantly in their DMAPP catalysis. Polarity effects
also appear crucial for binding DMAPP and GPP for prenyl
transfer reactions. The side chains of M328C and M328S differ
only slightly in their sizes. The atomic radii are 66 for oxygen
and 104 pm for sulphur, respectively. But the softer character
of the thiol group possessing a polarizable electron shell can
compensate for the increased cavity size of the active centre
that yielded to a decreased DMAPP turnover by variant M328S,
thereby enhancing the DMAPP turnover in M328C.
Determination of kinetic parameters
To obtain insights into the catalytic efficiency, Michaelis–
Menten kinetics of FgaPT2 and seven mutants with the best
acceptance of GPP (M328C, M328A, M328T, M328S, M328G,
M328V, and M328N) (Fig. S9†) was determined by using the
software GraphPad Prism 5.0 with a nonlinear regression. As
shown in Table 1, these mutants exhibit KM values for GPP in
the range of 0.078–0.48 mM and turnover numbers (kcat) in the
range of 0.0037–0.11 s−1. The calculated catalytic efficiencies
(kcat/KM) in the range of 181–317 s
−1 M−1 are comparable for
the first five mutants. Significantly lower catalytic efficiencies
were observed for M328V and M328N with GPP. These results
are in good agreement with those presented in Fig. 1B.
In summary, absolute conversion yields of up to 50%, i.e.
50–60% of that of the wild-type enzyme with DMAPP, were
detected with five mutants (Fig. 1B). The turnover number of
the best mutant towards GPP was determined as 0.11 s−1, i.e.
25% of that of the wild-type enzyme with DMAPP. The kcat/KM
values of the mutants for GPP are, however, significantly lower
than that of the wild-type enzyme with DMAPP. This is due to
the extremely unusually low KM value of the wild-type enzyme
towards DMAPP at 4 µM, although the KM values of the
Fig. 6 Mutations switching the specificity of FgaPT2 containing
L-tryptophan (sky blue) from DMAPP (orange) to GPP (cyan). In silico
models of selected FgaPT2 variants at position M328 (side chain shown
in pink) emphasizing the importance of the gatekeeper residue for the
acceptance of GPP and FPP. All FgaPT2 variants were calculated using
FoldX. Mutant M328P is not shown as this mutant might interfere with
the folding of the backbone. Large amino acid side chains would result
in a clash with the prenyl entity thereby excluding GPP and FPP as
prenyl donors. For DMAPP, the mutation to M328G seems to introduce
high flexibility in the active site thereby reducing the turnover.
Table 1 Kinetic parameters of FgaPT2 and mutants toward DMAPP and
GPP in the presence of 1
Enzyme kM [mM] kcat [s
−1] kcat/kM [s
−1 M−1]
DMAPP
FgaPT2 wild type 0.0040 0.44 110 000
GPP
FgaPT2_M328C 0.48 0.11 229
FgaPT2_M328A 0.20 0.050 250
FgaPT2_M328T 0.31 0.056 181
FgaPT2_M328S 0.18 0.057 317
FgaPT2_M328G 0.12 0.032 267
FgaPT2_M328V 0.13 0.0095 73
FgaPT2_M328N 0.078 0.0037 47
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mutants with GPP are in the normal range of many secondary
metabolite enzymes. Therefore, the obtained mutants can be
considered as effective biocatalysts.
Enhancing farnesylation activity
Our saturation mutagenesis results on M328 demonstrate that
this key residue is crucial to turn on the GPP and FPP activities
(Fig. 1–3). The low turnover observed for FPP indicates that
additional amino acid residues are also involved in FPP-
binding. Molecular modelling revealed that Leu263 and
Tyr398 could contribute as additional positions for FPP-activity
(Fig. 4). The modelling shows that these amino acids most
likely sterically interfere with the terminal isoprenyl entity of
FPP. As a side effect, this might hamper the accommodation
of the prenyl acceptor in the binding site. We therefore
mutated them to amino acids bearing smaller side chains. As
M328A has the highest activity toward FPP, we chose this
mutant for further mutagenesis experiments and created
L263A_M328A as a double and L263A_M328A_Y398F as a
triple mutant. Both engineered enzymes exhibited increased
activity toward DMAPP (approximately 15%) and simul-
taneously decreased activity toward GPP (also 15%), compared
to M328A. A clear enhancement of the activity towards FPP
was observed for the double (1.4%) and triple mutants (1.1%),
in comparison with 0.7% with M328A and no product for-
mation with FgaPT2 (Fig. 3).
Although our model shows that farnesylation would be
possible by the mutation of the gatekeeping residue M328 in
FgaPT2 to glycine, the turnover rates remain low for this bulky
prenyl donor. Plausible reasons for this observation are the
difficulty faced by the hydrophobic and long FPP molecule to
enter the active site and steric pressure at the end of the prenyl
tail with the residues R244, L263 or Y398. Additionally, it
seems possible that the very long tail of the prenyl donor
might interact with the correct position of the prenyl acceptor,
thereby reducing the enzyme activity with the FPP substrate.
Through the mutation of a second residue, L263A, we were
able to achieve a product yield of 1.4% with 1 and FPP with
L263A_M328A. Although this reaction rate is obviously too low
for the use of the double mutant as a farnesyltransferase, it
still shows that our design has potential because wild-type
FgaPT2 does not accept FPP at all.
Experimental
Chemicals and strains
DMAPP, GPP and FPP were synthesized according to the pro-
cedure described for GPP by Woodside et al.23 1-Chloro-3-
methyl-2-butene, geranyl chloride, or farnesyl chloride in
acetonitrile was stirred with tris(tetrabutyl ammonium) hydro-
gen pyrophosphate at room temperature for 2 h. After the
removal of the tetrabutyl ammonium salt by passing over a
Dowex AG 50W-X8 column, the resulting prenyl diphosphate
was extracted with a mixture of acetonitrile : 2-propanol (1 : 1)
and ammonium bicarbonate (0.05 M). The supernatants were
combined and the organic solvents were removed with a rotary
evaporator under reduced pressure. The aqueous residue was
subsequently lyophilized. L-Tryptophan was purchased from
Roth (Karlsruhe, Germany). E. coli XL1-Blue MRF′ (Stratagene)
and BL21(DE3) pLysS (Invitrogen, Karlsruhe, Germany) were
used for propagation of transformed plasmids and overproduc-
tion of recombinant proteins, respectively. Terrific Broth
medium supplemented with 50 µg mL−1 carbenicillin or
25 µg mL−1 kanamycin was used for cultivation of recombi-
nant E. coli strains. Primer sequences used in this study are
listed in Table S1.†
Site-directed and site-saturation mutagenesis
The plasmid harboring fgaPT2 was applied as a DNA template
for mutagenesis by PCR. To obtain specific or all variants of
mutations at the desired gene position (degenerated) primers
were designed as described by the optimized site-directed
mutagenesis protocols28,29 and synthesized by Eurofins
Genomics GmbH (Ebersberg, Germany) or Seqlab GmbH
(Göttingen, Germany). An Expand Long Template PCR System
(Roche Diagnostics GmbH, Mannheim) was used for PCR
amplification. An annealing temperature of 62 °C and an
elongation time of 8 min for fgaPT2 were adjusted to the
thermal profile.
Heterologous overexpression and purification of recombinant
proteins
The recombinant histidine-tagged PT His8-FgaPT2 and the
corresponding engineered proteins were overproduced in
E. coli and purified by Ni-NTA affinity chromatography
(Qiagen, Hilden) according to a published procedure.27
Protein concentrations were measured at 280 nm with a
NanoDrop 2000c UV-VIS spectrophotometer setting the protein
specific extinction coefficient and molecular weight. To ensure
an accurate concentration, proteins were further analysed by
SDS-PAGE. Intensities of the Coomassie stained proteins were
compared with those of the standardized markers.
Enzyme activity assays
Each reaction mixture contained 10 µg of a purified recombi-
nant protein, 1.0 mM 1, 1.0 mM DMAPP, GPP or FPP as a
prenyl donor, 10 mM CaCl2, up to 10% (v/v) glycerol, and up to
5% (v/v) DMSO. All enzyme assays were performed in duplicate
adjusting with 50 mM Tris-HCl (pH 7.5) to a total volume of
50 µL. After careful mixing, the reaction mixtures were incu-
bated at 37 °C for 90 min, stopped with an equal volume of
methanol and vortexed vigorously. Before injecting into a
LC-MS system, the mixtures were centrifuged at 13 300 rpm for
20 min to yield a clear supernatant.
LC-MS analysis
A sample volume of 5 µL was injected and analysed on an
Agilent HPLC 1260 series system (Agilent Technologies,
Böblingen, Germany) connected to a Bruker microTOF QIII
mass spectrometer with an ESI-source (Bruker, Bremen,
Germany). An Agilent Eclipse XDB-C18, 5 µm, 4.6 × 150 mm
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column was used for the separation of the enzyme products.
Solvent A (H2O) and solvent B (MeCN), both adjusted to 0.1%
formic acid, were run with a flow rate of 0.5 mL min−1 and a
linear gradient from 5% to 100% of solvent B over 40 min for
analysing the prenylated products. The column was washed for
5 min with 100% B prior to equilibrating for further 5 min
to the initial solvent composition of 5% B and 95%
A. Electrospray ionization positive ion mode was selected for
determining the masses. Sodium formate was used in each
run for mass calibration. The masses were scanned in the
range of 100–1500 m/z. The capillary voltage was set to 4.5 kV
and the collision energy was 8.0 eV. Data were evaluated with
the Compass Data Analysis 4.2 software (Bruker Daltonik,
Bremen, Germany).
Upscaling enzyme reactions and HPLC-based product
isolation
Structure elucidation via 1H NMR needed an upscaling of the
enzyme reactions to a total volume of up to 7.0 mL. The appro-
priate product amount was achieved with enzyme assays con-
taining 1.0 mM of 1, 2.0 mM DMAPP or GPP, 10 mM CaCl2, up
to 10% (v/v) glycerol, up to 5.0% (v/v) DMSO, 50 mM Tris HCl
(pH 7.5), and up to 1.38 mg of purified recombinant proteins.
The reaction mixtures were slightly agitated at 37 °C for 16 h.
An equal volume of methanol was added to the incubation
mixtures to terminate the reactions with a subsequent vigorous
mixing for several minutes. To remove the proteins, a centrifu-
gation step followed at 6000 rpm for 20 min. The clear super-
natant was transferred to a pear shaped flask and evaporated
to dryness and dissolved in an appropriate volume of DMSO
and/or methanol. Prior to isolation via HPLC, the samples
were centrifuged at 13 300 rpm for 20 min. The prenylated pro-
ducts were isolated on an Agilent HPLC 1200 series system
(Böblingen, Germany) equipped with a semi-preparative
Agilent ZORBAX Eclipse XDB C18 HPLC column (9.4 ×
250 mm, 5 µm) at a flow rate of 2.5 mL min−1. A linear gradi-
ent from 40% to 100% MeCN over 40 min was applied to
isolate geranylated 3.
NMR analysis
The isolated product was dissolved in CD3OD and measured
on a JEOL ECA-500 MHz spectrometer (JEOL Germany GmbH,
Munich, Germany). The recorded 1H NMR spectrum was pro-
cessed and evaluated using MestReNova Version: 6.0.2-5475
software (Mestrelab Research S.L.). As an internal reference,
the solvent signal was set at 3.31 ppm.
1H NMR data of 3 in CD3OD: δppm (multi, Hz) 7.20 (dd, 8.1,
0.7, 1H), 7.16 (s, 1H), 7.00 (dd, 8.1, 7.3, 1H), 6.81 (dd, 7.3, 0.7,
1H), 5.36 (tq, 6.9, 1.2, 1H), 5.12 (tsept, 6.9, 1.3, 1H), 3.81 (m,
4H, overlapping with solvent signals), 3.14 (m, 1H), 2.13 (m,
2H), 2.07 (m, 2H), 1.76 (d, 0.8, 3H), 1.65 (d, 1.0, 3H), 1.58 (d,
0.6, 3H).
Determination of kinetic parameters
Kinetic parameters were determined by incubation of an
appropriate amount of purified recombinant FgaPT2 or a
mutant with 1 mM of 1 and varied concentrations of DMAPP
or GPP as prenyl donors at 37 °C. The optimal protein amount
and incubation time were determined by measuring protein
and time dependency. The enzyme assays were performed in
duplicate. A protein concentration of 0.1 µM for FgaPT2 and
an incubation time of 2 min were applied to determine the
enzyme kinetics for DMAPP. To determine the kinetic para-
meters of FgaPT2 mutants for GPP, 1.9 µM of M328X (X = C, A,
T, S, G and V) and 3.8 µM of M328N were incubated for
20 min. In a total volume of 50 µL, each reaction mixture con-
tained DMAPP or GPP in concentrations up to 0.5 or 1.0 mM,
1.0 mM of 1, 10 mM CaCl2, up to 3.6% (v/v) glycerol, and
50 mM Tris-HCl (pH 7.5). The reactions were terminated with
50 µL MeOH and subsequently centrifuged at 13 300 rpm for
20 min. A volume of 80 µL supernatant was injected and ana-
lysed by HPLC.
Molecular modelling and docking
The conformations of the mutants were calculated in silico
using Foldx.30,31 Substrate docking was done manually for GPP
and FPP using COOT32 and DMAPP of FgaPT2 (PDB code:
3I4X) as a template. The conformation of the prenyl donors
were energetically optimized. Docking of 1 was performed by
in silico docking using Vina.33 The possible docking poses
were analysed and verified for the chemical sense of the
observed catalytic reaction. Figures were generated with PyMol
(The PyMOL Molecular Graphics System, Version 1.8
Schrödinger, LLC.).
Conclusions
In summary, we demonstrated a convenient approach to
obtain modified enzymes whose substrate specificities differ
clearly from that of the wild-type enzyme and from each other.
By structure-based modelling of the tryptophan C4-dimethyl-
allyl transferase FgaPT2, we are able to increase GPP and FPP
acceptance by the mutation of gatekeeping residues. To the
best of our knowledge, a natural or unnatural geranyl transfer-
ase or farnesyltransferase for tryptophan as a free amino acid
has not been reported prior to this study. Our results provide
evidence that a switch of the prenyl donor acceptance is not
only possible for enzymes with high flexibility for these sub-
strates such as AtaPT, MpnD and TleC,15,16 but can also be
applied for enzymes which are practically limited to the use of
DMAPP as a donor. Several mutants show high activity towards
GPP and could be used as geranyl transferases for chemoenzy-
matic synthesis and synthetic biology. Our findings should
encourage the PT community to manipulate additional PTs
among the approximately 45 DMATS-type PTs, which mainly
use DMAPP as the prenyl donor.5 The farnesyltransferase
activities are necessary to be optimized by identification of
other important factors and additional mutations. This would
require additional structural data, e.g. of the engineered
enzymes.
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Table S1 Primers used in this study and protein yields 
* The purity of the recombinant proteins was determined at 75% − 80%. The protein yields were calculated by taking the impurities into 
consideration.  
Mutant Primer  Sequence (5`3`) Yield [mg/L]* 
fgaPT2    3.3 
M328A 
328_GNW_f 
328_GNW_r 
 
TGCCGCTTGCAGCCAATTTCACCCTGCACCAGAATGACC 
AATTGGCTGCAAGCGGCAGCCTCTCGTCTGGGATAACC 2.1 
M328V 
328_NNN_f 
328_NNN_r 
 
TGCCGCTTGTGGCCAATTTCACCCTGCACCAGAATGACC 
AATTGGCCACAAGCGGCAGCCTCTCGTCTGGGATAACC 1.5 
M328L 
328_CTA_f 
328_CTA_r 
 
TGCCGCTTCTAGCCAATTTCACCCTGCACCAGAATGACC 
AATTGGCTAGAAGCGGCAGCCTCTCGTCTGGGATAACC 1.6 
M328I 
328_AWW_f 
328_AWW_r 
 
TGCCGCTTATTGCCAATTTCACCCTGCACCAGAATGACC 
AATTGGCAATAAGCGGCAGCCTCTCGTCTGGGATAACC 1.6 
M328P 
328_NNN_f 
328_NNN_r 
 
TGCCGCTTCCTGCCAATTTCACCCTGCACCAGAATGACC 
AATTGGCAGGAAGCGGCAGCCTCTCGTCTGGGATAACC 1.8 
M328W 
328_NNN_f 
328_NNN_r 
 
TGCCGCTTTGGGCCAATTTCACCCTGCACCAGAATGACC 
AATTGGCCCAAAGCGGCAGCCTCTCGTCTGGGATAACC 2.7 
M328F 
328_TTT_f 
328_TTT_r 
 
TGCCGCTTTTTGCCAATTTCACCCTGCACCAGAATGACC’ 
AATTGGCAAAAAGCGGCAGCCTCTCGTCTGGGATAACC 1.5 
M328Y 
328_TNT_f 
328_TNT_r 
 
TGCCGCTTTATGCCAATTTCACCCTGCACCAGAATGACC 
AATTGGCATAAAGCGGCAGCCTCTCGTCTGGGATAACC 2.5 
M328T 
328_NNN_f 
328_NNN_r 
 
TGCCGCTTACGGCCAATTTCACCCTGCACCAGAATGACC 
AATTGGCCGTAAGCGGCAGCCTCTCGTCTGGGATAACC 2.0 
M328Q 
328_NNN_f 
328_NNN_r 
 
TGCCGCTTCAAGCCAATTTCACCCTGCACCAGAATGACC 
AATTGGCTTGAAGCGGCAGCCTCTCGTCTGGGATAACC 1.6 
M328G 
328_NNN_f 
328_NNN_r 
 
TGCCGCTTGGGGCCAATTTCACCCTGCACCAGAATGACC 
AATTGGCCCCAAGCGGCAGCCTCTCGTCTGGGATAACC 2.2 
M328S 
328_NNN_f 
328_NNN_r 
 
TGCCGCTTTCTGCCAATTTCACCCTGCACCAGAATGACC 
AATTGGCAGAAAGCGGCAGCCTCTCGTCTGGGATAACC 1.6 
M328C 
328_TNT_f 
328_TNT_r 
 
TGCCGCTTTGTGCCAATTTCACCCTGCACCAGAATGACC 
AATTGGCACAAAGCGGCAGCCTCTCGTCTGGGATAACC 2.6 
M328N 
328_AWW_f 
328_AWW_r 
 
TGCCGCTTAATGCCAATTTCACCCTGCACCAGAATGACC 
AATTGGCATTAAGCGGCAGCCTCTCGTCTGGGATAACC 3.2 
M328K 
328_AWW_f 
328_AWW_r 
 
TGCCGCTTAAAGCCAATTTCACCCTGCACCAGAATGACC 
AATTGGCTTTAAGCGGCAGCCTCTCGTCTGGGATAACC 2.7 
M328R 
328_NNN_f 
328_NNN_r 
 
TGCCGCTTCGGGCCAATTTCACCCTGCACCAGAATGACC 
AATTGGCCCGAAGCGGCAGCCTCTCGTCTGGGATAACC 1.7 
M328H 
328_CAT_f 
328_CAT_r 
 
TGCCGCTTCATGCCAATTTCACCCTGCACCAGAATGACC 
AATTGGCATGAAGCGGCAGCCTCTCGTCTGGGATAACC 3.1 
M328E 
328_GNW_f 
328_GNW_r 
 
TGCCGCTTGAAGCCAATTTCACCCTGCACCAGAATGACC 
AATTGGCTTCAAGCGGCAGCCTCTCGTCTGGGATAACC 2.0 
M328D 
328_GAC_f 
328_GAC_r 
 
TGCCGCTTGACGCCAATTTCACCCTGCACCAGAATGACC 
AATTGGCGTCAAGCGGCAGCCTCTCGTCTGGGATAACC 1.5 
L263A_M328A 
L263A_f 
L263A_r 
 
CTACCTGGCAGAGCAGATGGTTTCACTAGAAGCCATGGAGG 
TCTGCTCTGCCAGGTAGATCTTGATTCTCGACTTGGCAGG 1.3 
L263A_M328A_Y398F 
Y398F_f 
Y398F_r 
 
CCACGCCTTTATATCCTTCTCCTACAGGGACCGTACC 
AAGGATATAAAGGCGTGGAGGTAGTTAAGTTTGTCATGATCCG 1.3 
S3 
 
Figure S1 1H NMR spectrum of dimethylallyl diphosphate (DMAPP) (500 MHz, D2O) 
 
 
Figure S2 31P NMR spectrum of dimethylallyl diphosphate (DMAPP) (200 MHz, D2O) 
S4 
 
Figure S3 1H NMR spectrum of geranyl diphosphate (GPP) (500 MHz, D2O) 
 
 
Figure S4 31P NMR spectrum of geranyl diphosphate (GPP) (200 MHz, D2O)  
S5 
 
Figure S5 1H NMR spectrum of farnesyl diphosphate (FPP) (500 MHz, D2O) 
 
 
Figure S6 31P NMR spectrum of farnesyl diphosphate (FPP) (200 MHz, D2O)  
S6 
 
Figure S7 1H NMR spectrum of 4-geranyltryptophan (3) (500 MHz, CD3OD) 
 
 
 
Figure S8 Positive HR-ESI-MS spectrum of 4-geranyltryptophan (3) 
  
S7 
 
Figure S9 Kinetic parameters of FgaPT2 wild type and FgaPT2_M328 mutants toward DMAPP and 
GPP with 1 
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Switching a regular tryptophan
C4-prenyltransferase to a reverse tryptophan-
containing cyclic dipeptide C3-prenyltransferase
by sequential site-directed mutagenesis†
Liujuan Zheng,‡ Peter Mai,‡ Aili Fan§ and Shu-Ming Li *
FgaPT2 from Aspergillus fumigatus catalyzes a regular C4- and its mutant K174A a reverse C3-prenyla-
tion of L-tryptophan in the presence of dimethylallyl diphosphate. FgaPT2 also uses tryptophan-con-
taining cyclic dipeptides for C4-prenylation, while FgaPT2_K174A showed almost no activity toward
these substrates. In contrast, Arg244 mutants of FgaPT2 accept very well cyclic dipeptides for regular
C4-prenylation. In this study, we demonstrate that FgaPT2_K174F, which catalyzes a regular C3-preny-
lation on tyrosine, can also use cyclo-L-Trp-L-Ala, cyclo-L-Trp-L-Trp, cyclo-L-Trp-Gly, cyclo-L-Trp-L-
Phe, cyclo-L-Trp-L-Pro, and cyclo-L-Trp-L-Tyr as substrates, but only with low activity. Combinational
mutation on Lys174 and Arg244 increases significantly the acceptance of these cyclic dipeptides. With
the exception of cyclo-L-Trp-L-Trp, the tested dipeptides were much better accepted by
FgaPT2_K174F_R244X (X = L, N, Q, Y) than FgaPT2, with an increase of two- to six-fold activity. In com-
parison to FgaPT2_K174F, even two- to ten-fold conversion yields were calculated for the double
mutants. Isolation and structural elucidation of the enzyme products revealed stereospecific reverse
C3-prenylation on the indole ring, resulting in the formation of syn–cis configured hexahydropyrroloin-
dole derivatives. The results presented in this study highlight the convenience of site-directed mutagen-
esis for creating new biocatalysts.
Introduction
Cyclic dipeptides (CDPs) and derivatives are widely distributed
in microorganisms and exhibit diverse biological and pharma-
cological activities.1–3 In nature, these dipeptides are bio-
synthesized by bimodular non-ribosomal peptide synthetases
or cyclodipeptide synthases.4–6 Due to the various modification
possibilities on the indole ring, tryptophan-containing CDPs
are the richest precursors of natural products with pharma-
ceutical interest.2,3 These dipeptides are frequently modified
by methylation, hydroxylation, prenylation, dimerization, and
further cyclization.2,3,7,8 Chart 1 lists several examples of CDP
derivatives such as the antitumor active rugulosuvine A from
Penicillium species,9 the sterol O-acyltransferase inhibitor
amauromine from Nocardiopsis sp.,10,11 and the two myco-
toxins roquefortine C and acetylaszonalenin from different
fungal strains.3,12,13 They are modification products of CDPs
obtained by tailoring enzymes including prenyltransferases
(PTs).3,14
Chart 1 Examples of CDP derivatives.
†Electronic supplementary information (ESI) available: Primers and constructs,
NMR data and spectra as well as determination of kinetic parameters. See DOI:
10.1039/c8ob01735b
‡These authors contributed equally to this work.
§Present address: Beijing Advanced Innovation Center for Soft Matter Science
and Engineering, Beijing Key Laboratory of Bioprocess, Beijing University of
Chemical Technology, Beijing, 100029, People’s Republic of China.
Institut für Pharmazeutische Biologie und Biotechnologie, Philipps-Universität
Marburg, Robert-Koch-Straße 4, 35037 Marburg, Germany.
E-mail: shuming.li@staff.uni-marburg.de
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Prenyltransferases belong to one of the important modify-
ing enzymes of CDPs and catalyze the transfer reactions of
prenyl units (n × C5, n = 1, 2, 3, 4 etc.) from prenyl dipho-
sphates to different aliphatic and aromatic acceptors.14
Members of the most biochemically and structurally investi-
gated PT group share meaningful sequence identities with the
dimethylallyltryptophan synthase in the biosynthesis of ergot
alkaloids and are therefore termed DMATS enzymes.8,14–16
Most PTs of the DMATS superfamily use dimethylallyl dipho-
sphate (DMAPP) as a donor and L-tryptophan or tryptophan-
containing cyclic dipeptides as acceptors and are involved in
the biosynthesis of diverse indole alkaloids.8,14 The dimethyl-
allyl moieties are attached to N-1, C-2, C-3, C-4, C-5, C-6, or C-7
of the indole ring in a regular or reverse manner. For the
regular prenylation, DMAPP was proposed to form a dimethyl-
allyl cation/pyrophosphate ion pair. The primary center of
DMAPP is attacked by the electron-rich aromatic ring with a
concerted displacement of pyrophosphate to form the arenium
ion intermediate, which re-aromatizes by deprotonation to
form the final product.17–19 For the reverse prenylation, the
nucleophilic attack takes place at the tertiary center instead of
the primary center of the dimethylallyl carbocation. Reverse
prenylation on the indole ring takes place mainly at C-2 and
C-3 of the cyclic dipeptides, like those of cyclo-L-Trp-L-Pro cata-
lyzed by NotF and BrePT,20,21 cyclo-L-Trp-L-Ala by EchPT1,22
cyclo-L-Trp-Ant by AnaPT,12 and cyclo-L-Trp-L-Leu by
CdpC3PT.23 L-Tryptophan is usually regularly prenylated at C-4,
C-5, C-6, and C-7, as demonstrated for FgaPT2,24 5-DMATS,25
6-DMATS,26 and 7-DMATS, respectively.27
FgaPT2 from Aspergillus fumigatus was identified as a
C4-DMATS, which initiates the biosynthesis of the ergot alka-
loids fumigaclavines.24 The crystal structure of FgaPT2 con-
tains a rare β/α fold (PT barrel) and serves as a basis for under-
standing the prenylation mechanism and for enzyme
design.18,19 Structure-based molecular modelling and site-
directed mutagenesis revealed that Lys174 facilitates the
entrance of substrates in the reactive center and Ile80, Leu81,
Tyr191, and Arg244 anchor the polar side chain of
L-tryptophan.19
Mutation of Lys174 to Phe switches FgaPT2 to a tyrosine
C3-prenyltransferase FgaPT2_K174F.28 Arg244 mutants
enhance significantly the catalytic ability of FgaPT2 toward
tryptophan-containing CDPs and keep the prenylation position
at C-4.29 Luk et al.30 demonstrated that FgaPT2_K174A can
prenylate L-tryptophan at both C-3 and C-4 positions and pro-
posed the C4-prenylated derivative to be the result of the
Cope rearrangement of a C3-prenylated derivative.
Acceptance of tryptophan-containing CDPs by FgaPT2_K174A
has not been tested before, while FgaPT2 was also demon-
strated to prenylate these compounds at C-4, i.e. the same
position as for the natural substrate L-tryptophan (Scheme 1).
All these results proved FgaPT2 as an excellent model for
enzyme design by site-directed mutagenesis. In this study, we
describe the creation of a reverse C3-prenyltransferase for
tryptophan-containing CDPs by two step-mutations on
Lys174 and Arg244.
Results and discussion
Acceptance of tryptophan-containing cyclic dipeptides by
FgaPT2_K174F
To prove the acceptance toward tryptophan-containing CDPs,
we constructed the plasmid pLZ1 for overproduction of
FgaPT2_K174A (Table S1†). One predominant protein band
with the expected size was detected using SDS-PAGE analysis
for the purified FgaPT2_K174A (Fig. S1†), which was used for
incubation with L-tryptophan and DMAPP. LC-MS analysis of
the reaction mixture revealed the presence of two product
peaks at 7.3 and 8.0 min. The peak at 8.0 min was identified
as the C4-prenylated derivative by comparison of its retention
time, UV (λmax 278 nm), and MS data with those of the FgaPT2
product (Fig. S2†). The peak at 7.3 min showed the same [M +
H]+ ion, but a clearly different UV spectrum (λmax at 240 and
294 nm) as the peak at 8.0 min. These data would correspond
to those of the C3-prenylated L-tryptophan reported for
FgaPT2_K174A.30 After proof of its functionality, the overpro-
duced FgaPT2_K174A was incubated with six L-tryptophan-con-
taining cyclic dipeptides, i.e. cyclo-L-Trp-L-Ala (1), cyclo-L-Trp-L-
Trp (2), cyclo-L-Trp-Gly (3), cyclo-L-Trp-L-Phe (4), cyclo-L-Trp-L-
Pro (5), and cyclo-L-Trp-L-Tyr (6) in the presence of DMAPP at
37 °C for 3 h. HPLC analysis of the incubation mixtures indi-
cated no product formation in all enzyme assays under the
tested conditions (Fig. 1). LC-MS analysis with EIC detection
for the [M + H]+ ion of monoprenylated products showed
product peaks with very low intensity (Fig. S3†).
In contrast, the cyclic dipeptides 1–6 were accepted by the
wildtype FgaPT2 with product yields in the range from 6.6 to
29.5% (Fig. 1). With the exception for 2, one product peak
each (1a or 3a–6a) was observed. These products showed a
typical UV λmax peak at 278 nm for the indole system and have
[M + H]+ ions, which are 68 Daltons larger than the respective
substrate (Fig. S3†), indicating the presence of an indole
chromophore and corresponding to the C4-prenylation of
cyclic dipeptides by FgaPT2 (Scheme 1).31 In the case of 2, two
products 2a and 2a* were detected, with [M + H]+ ions, which
are 68 and 136 Daltons larger than that of 2, indicating a
mono- and diprenylation, respectively (Fig. S3†).
In a previous study, we demonstrated that Lys174 also plays
an important role in aromatic substrate selection.
Scheme 1 Prenylation of cyclic dipeptides by FgaPT2 and its mutants.
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FgaPT2_K174F accepts L-tryptophan only with a 240-fold
decreased activity compared to FgaPT2, while its catalytic
ability for L-tyrosine increased 28-fold.28 We proved therefore
its behavior toward cyclic dipeptides 1–6 under the same con-
ditions used for FgaPT2_K174A. As shown in Fig. 1, all six sub-
strates were accepted by FgaPT2_K174F with product yields of
2.5 to 6.5%. Detailed inspection of the HPLC chromatograms
revealed the presence of one product each (1b–6b) with slightly
Fig. 1 HPLC analysis of incubation mixtures of FgaPT2 and its mutants with cyclic dipeptides.
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delayed retention times and clear different UV spectra com-
pared to 1a–6a.
The UV absorption maxima of 1b–6b at 240 and 294 nm
indicated the disruption of the indole and the presence of a
hexahydropyrroloindole system by C3-prenylation.
LC-ESI-HRMS analysis of the incubation mixtures of
FgaPT2_K174F with 1–6 confirmed the monoprenylation in
1b–6b by detection of [M + H]+ ions, which are 68 Daltons
larger than those of the respective substrates (Fig. S3†). We
speculated that 1–6 were converted to C3-prenylated derivatives
by FgaPT2_K174F. However, the conversion yields are too low
to be used as convenient biocatalyst for CDP prenylation.10,30
In the case of 2, a diprenylated product was also detected
using LC-MS analysis (Fig. S3†).
Enhancing the conversion of tryptophan-containing cyclic
dipeptides by combinational mutation on Lys174 and Arg244
We demonstrated previously that Arg244 mutants, especially
R244N, R244Q, R244Y, and R244L, showed strongly increased
activities toward tryptophan-containing cyclic dipeptides,
while L-tryptophan was less accepted by these mutants than
the wildtype FgaPT2.29 The prenylation position remained at
C-4 of the indole ring. To increase the conversion yields of
cyclic dipeptides for potential C3-prenylation, we created
double mutants by site-directed mutagenesis of Lys174 to Phe
and Arg244 to Leu, Asn, Gln, and Tyr, resulting in the four
double mutants FgaPT2_K174F_R244L, FgaPT2_K174F_R244N,
FgaPT2_K174F_R244Q, and FgaPT2_K174F_R244Y (Table S1†).
The overproduced proteins with yields of 1.2 –2.3 mg per liter
culture were purified to apparent homogeneity (Fig. S1†) and
exploited to enzyme assays with 1–6 under the conditions used
for FgaPT2_K174F.
HPLC analysis of the reaction mixtures delivered remark-
able results (Fig. 1 and 2). (i) Product formation was detected
in all the enzyme assays (Fig. 1, for simplification, only the
result of the best mutant for a given substrate is illustrated).
(ii) All double mutants exhibited increased activities toward all
the tested substrates (Fig. 2). Total product yields of 20.3 to
41.4% were calculated for the best mutant with a given
substrate, i.e. FgaPT2_K174F_R244N for 1–4 and
FgaPT2_K174F_R244L for 5 and 6. This means an activity
increase of two- to ten-fold, in comparison with those with
FgaPT2_K174F. (iii) The products have the same retention
times and UV spectra as those of the FgaPT2_K174F for a
given substrate (1b–6b). (iv) The corresponding products also
have almost the same [M + H]+ ions from LC-MS analysis
(Fig. S3†). In the case of 2, the additional peak 2b* with a [M +
H]+ ion for a diprenylated derivative was detected. All these
data underline successful mutational combinations for accep-
tance of tryptophan-containing CDPs.
Structure elucidation of the enzyme products with
FgaPT2_K174F_R244X
To elucidate the structures, the enzyme products of 1–4 were
isolated from incubation mixtures with FgaPT2_K174F_R244N
and those of 5 and 6 with FgaPT2_K174F_R244L. HRMS data
(Table 1) confirmed the monoprenylation in 1b–6b and dipre-
nylation in 2b*. Inspection of the 1H NMR spectra of 1b–6b
(Fig. S4–S9†) revealed the presence of signals for a reverse
prenyl moiety each at δh 4.97–5.13 (dd, 1H), 5.05–5.09 (dd, 1H),
5.76–5.98 (dd, 1H), 0.93–1.11 (s, 3H), and 0.79–1.01 (s, 3H)
Fig. 2 Yields of 1b–6b with Lys174 and Arg244 mutants. The com-
ponents and incubation conditions are identical to those of Fig. 1.
Table 1 ESI-HRMS data of the enzyme products
Compound Formula
[M + H]+
Deviation (ppm)Measured Calculated
1b C19H24N3O2 326.1858 326.1863 1.5
2b C27H29N4O2 441.2292 441.2285 −1.6
2b* C32H36N4O2 509.2927 509.2911 −3.1
3b C18H22N3O2 312.1719 312.1707 −3.8
4b C25H28N3O2 402.2187 402.2176 −2.7
5b C21H26N3O2 352.2029 352.2020 −2.6
6b C25H28N3O3 418.2138 418.2125 −3.1
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ppm (Table S2†). The signals of H-2 at the original indole
rings are significantly up-field shifted to 5.32–5.55 ppm, indi-
cating the disruption of the indole and formation of a hexahy-
dropyrroloindole system caused by a C3-prenylation.10,23 The
signals of H-11 appear as double doublets of doublets with
coupling constants of approximately 11, 6.0, and 2.0 Hz,
proving the 3β-prenylation of the L-configured tryptophanyl
moiety, i.e. syn–cis configuration (2S, 3R, 11S).10 A literature
search confirmed the structures 1b–6b (Scheme 1) as reported
previously.10,23 They were obtained as enzyme products of the
prenyltransferase CdpC3PT from Neosartorya fischeri.10,23 In
the case of 2b*, the structure cannot be confirmed using NMR
analysis, due to the low quantity. We speculated here C3-preny-
lation at both the indole rings, as observed for other C3-prenyl-
transferases with cyclo-L-Trp-L-Trp.14
To get detailed insights into the reaction mechanism, we
carried out molecular docking using the program AutoDock
Vina.32 The models of FgaPT2_K174A, FgaPT2_K174F, and
FgaPT2_K174F_R244L were created from the FgaPT2 structure
(PDB code: 3I4X) using SWISS-MODEL. The tested cyclic di-
peptides and DMAPP were docked in silico into the models of
FgaPT2 and its mutants. Unfortunately, the observed enzyme
activities and prenylation positions can be explained neither by
the distances of C-1/C-3 of DMAPP to C-3/C-4 of the indole ring
of the cyclic dipeptides, nor by π–π or van der Waals force inter-
action (data not shown). Therefore, crystal structures of the
mutants are needed for understanding the observed results pre-
sented in this study, which should be explored in the near future.
Determination of kinetic parameters
Kinetic parameters including Michaelis Menten constants (KM)
and turnover numbers (kcat) were determined at pH 7.5 for
the two best mutants in the presence of DMAPP, i.e.
FgaPT2_K174F_R244N with 1–4 as well as
FgaPT2_K174F_R244L with 5 and 6. The reactions catalyzed by
both mutants apparently followed the Michaelis Menten kine-
tics (Fig. S10–S15†). With the exception of 3, KM values in the
range of 0.15 to 0.79 mM were determined (Table 2). The high
catalytic efficiencies of FgaPT2_K174F_R244N for 4 and
FgaPT2_K174F_R244L for 5 and 6 confirmed their high con-
versions illustrated in Fig. 1.
Experimental
Chemicals
DMAPP was synthesized according to the method described
for geranyl diphosphate reported previously.33 Substrates used
for the enzyme assays were purchased from Bachem
(Bubendorf, Switzerland) or synthesized as described
previously.34
Bacterial strains, plasmids, and culture conditions
E. coli BL21 (DE3) pLysS (Invitrogen, Karlsruhe, Germany) and
SoluBL21 (Novagen, Darmstadt, Germany) were used for
expression experiments. pIU18 was used as a DNA template for
the creation of FgaPT2_K174A. pES26 containing the mutation
for FgaPT2_K174F28 was used as a template for the cons-
truction of the double mutants FgaPT2_K174F_R244L,
FgaPT2_K174F_R244N, FgaPT2_K174F_R244Q, and
FgaPT2_K174F_R244Y. E. coli cells harboring plasmids were
grown in liquid Lysogeny Broth (LB) or Terrific Broth (TB)
medium and on solid LB medium with 2% (w/v) agar at 37 °C.
Kanamycin (50 μg mL−1) was used for the selection of recombi-
nant E. coli strains.
Site-directed mutagenesis, overproduction and purification of
the recombinant proteins
The Expand™ Long Template PCR system (Roche Diagnostic,
Mannheim, Germany) was used for the construction of plas-
mids listed in Table S1.† The primers are given in Table S1.†
The obtained plasmids were sequenced by Seqlab Sequence
Laboratories (Göttingen, Germany) to confirm the desired
mutations in the respective constructs. FgaPT2 and its
mutated derivatives were overproduced and purified as
described previously.28,35
Enzyme assays with purified recombinant proteins
To test the enzyme activity, the reaction mixtures (50 μL) con-
taining 50 mM Tris-HCl (pH 7.5), 10 mM CaCl2, 0.5 mM cyclic
dipeptide, 1 mM DMAPP, and 10 μg of the purified recombi-
nant protein were incubated at 37 °C for 3 h. The reactions
were terminated by the addition of 50 μL methanol. After
removal of the precipitated protein by centrifugation at
13 000g for 30 min, 20 μL supernatant was subjected to HPLC
or LC-HRMS analysis.
Enzyme assays for the determination of kinetic
parameters (50 μL) contained 1 mM DMAPP, 5–10 µg
FgaPT2_K174F_R244N or FgaPT2_K174F_R244L and the aro-
matic substrates at final concentrations from 0.025 to 5 mM.
The incubations were carried out at 37 °C for 30 min. After
addition of MeOH and centrifugation, the supernatants were
analyzed on a HPLC system.
HPLC analysis of enzyme assays
Enzyme assays were analyzed on an Agilent HPLC series 1200
system (Agilent Technologies) equipped with an Agilent
Eclipse XDB-C18 column (5 μm, 4.6 × 150 mm). A linear gradi-
ent from 10 to 90% CH3CN in H2O in 20 min was used. The
Table 2 Kinetic parameters of FgaPT2_K174F_R244N and
FgaPT2_K174F_R244L
S
FgaPT2_K174F_R244N FgaPT2_K174F_R244L
KM
[mM]
kcat
[s−1]
kcat/KM
[s−1 M−1]
KM
[mM]
kcat
[s−1]
kcat/KM
[s−1 M−1]
1 0.36 0.012 33.3 — — —
2 0.79 0.13 164.6 — — —
3 3.10 0.19 61.3 — — —
4 0.15 0.03 200.0 — — —
5 — — — 0.41 0.15 365.9
6 — — — 0.62 0.25 403.2
S: substrate.
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column was then washed with 100% CH3CN for 5 min and
equilibrated with 10% CH3CN in H2O for another 5 min.
Detection was carried out with a photodiode array detector
and absorptions at 254 nm were illustrated in this study.
Isolation of the enzyme products
For isolation of the enzyme products, the assays (10 mL)
contained 50 mM Tris-HCl (pH 7.5), 5 mM CaCl2, 1 mM
cyclic dipeptide, 1 mM DMAPP, and 0.2–0.5 mg mL−1 recom-
binant protein. After incubation at 37 °C for 24 h, the reac-
tion mixtures were extracted with equal volume of EtOAc for
three times. The extracts were concentrated on a rotating
vacuum evaporator at 30 °C and the residues are dissolved
in 1 mL MeOH for isolation on a HPLC system. A semipre-
parative Multospher 120 RP-18 column (5 μm, 10 × 250 mm)
was used for isolation of the enzyme products on the same
HPLC system mentioned above with the same solvents at a
flow rate of 2.5 mL min−1. Separation was done by isocratic
elution with 40–70% CH3CN for 10–20 min. The fractions of
interest were collected, combined, and concentrated to
dryness on a rotating vacuum evaporator at 30 °C. The iso-
lated enzyme products were then subjected to NMR and MS
analyses.
LC-MS and MS analysis
Enzyme products were also analyzed on an Agilent HPLC 1260
series system equipped with a Bruker microTOF QIII mass
spectrometer using the Multospher 120 RP-18 column (5 μm,
2 × 250 mm). Separation was performed at a flow rate of
0.5 mL min−1 with a 10 min linear gradient from 5 to 100%
CH3CN in H2O, both containing 0.1% (v/v) formic acid. The
column was then washed with 100% CH3CN for 5 min and
equilibrated for 5 min. The parameters of the spectrometer
were set as the following: electrospray positive ion mode for
ionization, capillary voltage with 4.5 kV, collision energy with
8.0 eV.
NMR analysis
NMR spectra of the isolated enzyme products were recorded
at room temperature on a JEOL ECA-500 system (JEOL,
Akishima, Tokyo, Japan). The samples were dissolved in
DMSO-d6 or CDCl3. All spectra were processed with
MestReNov.6.1.0 (Mestrelab Research, Santiago de
Compostella, Spain).
Conclusions
In summary, we demonstrated that FgaPT2_K174F catalyzes a
reverse C3-prenylation of cyclic dipeptides, instead of C4-pre-
nylation by the non-mutated enzyme, but only with low
activity. Significant increase of the reaction velocity was
achieved by additional mutation on Arg244. Our results
provide an excellent example of protein engineering by site-
directed mutagenesis on the basis of structural information.
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Table S1 Construction of expression plasmids 
 
Mutants Primer name Primer sequence for PCR amplification (5’-3’) Plasmid name Protein yield 
(mg/L culture) 
FgaPT2_K174A 
FgaPT2_K174A_f CAGAACGCACTCGCGCTCGATCTGAAGGATGGCCGCTTTGC 
pLZ1 1.2 
FgaPT2_K174A_r GAGCGCGAGTGCGTTCTGCGTCCTGATAGTGCCGCCCA 
FgaPT2_K174F_R244Q 
FgaPT2_R244Q_f GCCAGTCCCCAACTAGTGTCCTGTGAT 
pALF56 
2.3 
FgaPT2_R244Q_r GGACACTAGTTGGGGACTGGCAGTGCT 
FgaPT2_K174F_R244N 
FgaPT2_R244N_f GCCAGTCCC(A/G)ATCTAGTGTCCTGTGAT 
pALF55 1.5 
FgaPT2_R244N_r GGACACTAGATYGGGACTGGCAGTGCT 
FgaPT2_K174F_R244Y 
FgaPT2_R244Y_f CAGAACTTTCTCGCGCTCGATCTGAAGGATGGCCGCTTTGC 
pPM72 2.0 
FgaPT2_R244Y_r GAGCGCGAGAAAGTTCTGCGTCCTGATAGTGCCGCCCA 
FgaPT2_K174F_R244L 
FgaPT2_R244L_f CAGAACTTTCTCGCGCTCGATCTGAAGGATGGCCGCTTTGC 
pPM71 2.2 
FgaPT2_R244L_r GAGCGCGAGAAAGTTCTGCGTCCTGATAGTGCCGCCCA 
 
pIU181 was used as template for creation of FgaPT2_K174A and pES26 containing the K174F mutation2 for creation of double mutants  
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Table S2 1H NMR (500 MHz) Data for 1b-5b in CDCl3 and 6b in DMSO-d6 
 
NH
N
NH
O
O
1 2
39
4
5
6
7
8
10
5'3'4'
2' 1'
11 16
15
12
13
14H 17 1b 
NH
N
NH
O
O
1 2
39
4
5
6
7
8
10
5'3'4'
2' 1'
11 16
15
12
13
14H
HN
17
18
19 20
26 25
24
23
22
21
2b 
NH
N
NH
O
O
1 2
39
4
5
6
7
8
10
5'3'4'
2' 1'
11 16
15
12
13
14H
 3b 
no δH, mult., (J in Hz) δH, mult, (J in Hz) δH, mult, (J in Hz) 
2 5.50, s 5.55, s 5.55, s 
4 7.16, dd (7.5, 0.7) 7.14 a  7.16, ddd (7.5, 1.2, 0.5) 
5 6.77, td (7.5, 1.0) 6.75, td (7.5, 1.0) 6.77, td (7.5, 1.0) 
6 7.11, td (7.5, 1.0) 7.11a 7.11, td (7.6, 1.0) 
7 6.58, d (7.8) 6.61, d (7.8) 6.59, ddd (7.6, 1.0, 0.5) 
10 2.47, dd (12.7, 11.0) 2.42, dd (12.5, 11.2) 2.45, dd (12.7, 11.2) 
 2.55, dd (12.8, 6.5) 2.52, dd (12.5, 6.2) 2.56, dd (12.7, 6.2) 
11 3.96, ddd (10.9, 6.4, 1.7) 3.92, ddd(10.9, 6.3, 1.7) 3.95, ddd (11.2, 6.2, 1.6) 
14 4.05, qd (6.9, 1.6) 4.31, ddd (10.9, 3.6, 1.8) 4.04, dd (17.0, 2.0) 
 - - 3.87, dd (17.0, 4.1) 
15 - 5.65, s - 
17 1.46, d (6.9) 3.75, ddd (15.2, 3.7, 0.9) - 
 - 2.97, dd (15.1, 11.0) - 
19 - 7.11a - 
20 - 8.13, s - 
22 - 7.39, dt (8.3, 0.9) - 
23 - 7.23, td (7.7, 0.9) - 
24 - 7.13 a - 
25 - 7.55, d (7.9) - 
1' 5.13, dd (10.8, 1.1) 5.13, dd (10.8, 1.1) 5.13, dd (10.8, 1.1) 
 5.08, dd (17.4, 1.1) 5.08, dd (17.4, 1.1) 5.09, dd (17.4, 1.1) 
2' 5.98, dd (17.4, 10.8) 5.97, dd (17.4, 10.8) 5.98, dd (17.4, 10.8) 
4' 1.12, s 1.11, s 1.12, s 
5' 1.01, s 1.01, s 1.01, s 
 
NH
N
NH
O
O
1 2
39
4
5
6
7
8
10
5'3'4'
2' 1'
11 16
12
13
14 17
18 19H
15
20
2122
23
4b 
NH
N
N
O
O
1 2
39
4
5
6
7
8
10
5'3'4'
2' 1'
11 1615
12
13
14
17
18
19
H 5b 
NH
N
NH
OH
O
O
1 2
39
4
5
6
7
8
10
5'3'4'
2' 1'
11 16
15
12
13
14 17
18
23 22
19 20
21
H
6b 
no. δH, mult., (J in Hz) δH, mult., (J in Hz) δH, mult., (J in Hz) 
2 5.54, s 5.46, s 5.32, d (1.1) 
4 7.14, d (7.5) 7.16, dd, (7.5, 1.0) 7.09, d (7.0) 
5 6.76, d (7.5) 6.77, td, (7.5, 1.0) 6.59, t (7.4) 
6 7.11, t (7.7) 7.11, td (7.5,1.0) 6.98, t (7.4) 
7 6.59, d (7.7) 6.59, d (7.5) 6.49, d (7.0) 
10 2.40, t (1.9) 2.49, dd (12.9, 10.8) 2.50b 
 2.52,dd (12.8, 6.2) 2.54, dd (12.9, 6.7)  
11 3.93, ddd (11.3, 6.2, 1.8) 3.98, dd (10.8, 6.7) 3.67, ddd (11.6, 5.7, 1.8) 
14 4.21, ddd (10.8, 3.6, 1.8) 4.05, t (8.3) 4.07, m 
15 5.50, s  - 
 - 2.12, m - 
16 - 3.56, m - 
 - 3.50, m - 
17 3.60, dd (14.4, 3.6) 2.04, m 3.06, dd (14.0, 3.8) 
 2.78, dd (14.4, 10.8) 1.89, m 2.84, dd (14.0, 5.0) 
18  2.32, dtd (9.1, 6.7, 2.5)  
19 7.19, d (7.1) - 7.01, d (8.4) 
20 7.34, t (7.3) - 6.66, m (8.4) 
21 7.29, t (7.4) - 9.17, s (OH) 
22 7.34, t (7.3) - 6.66, m (8.4) 
23 7.19, d (7.1) - 7.01, d (8.4) 
1' 5.13 ,dd (10.8, 1.0) 5.07, dd (17.4, 1.1) 4.97, dd (17.3, 1.4) 
 5.08, dd (17.4, 10) 5.05, dd (10.8, 1.1) 5.05, dd (10.8, 1.4) 
2' 5.96, dd (17.3, 10.8) 5.99, dd (17.4, 10.8) 5.76, dd (17.3, 10.8) 
4' 1.11, s 1.11, s 0.93, s 
5' 1.01, s 1.00, s 0.79, s 
a Signals overlapping with each other. b signals overlapping with those of solvent. The data of 1b – 6b correspond 
well to those of published previously.3,4  
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Fig. S1 SDS-PAGE analysis of the purified proteins. 
The proteins were separated on a 12% polyacrylamide gel and stained with 
Coomassie brilliant blue R-250 
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Fig. S2 LC-HRMS analysis of FgaPT2 and FgaPT2_K174A reactions with 
L-tryptophan in the presence of DMAPP.  
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Fig. S3  LC-MS analysis of the incubation mixtures of cyclic dipeptides with 
FgaPT2 and its mutants 
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 Fig. S4 1H NMR (500 MHz) spectrum of 1b in CDCl3 
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 Fig. S5 1H NMR (500 MHz) spectrum of 2b in CDCl3 
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 Fig. S6 1H NMR (500 MHz) spectrum of 3b in CDCl3 
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 Fig. S7 1H NMR (500 MHz) spectrum of 4b in CDCl3 
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 Fig. S8 1H NMR (500 MHz) spectrum of 5b in CDCl3 
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 Fig. S9 1H NMR(500 MHz) spectrum of compound 6b in DMSO-d6 
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Fig. S10 Determination of the kinetic parameters of the FgaPT2_K174F_R244N 
reaction toward 1 in the presence of DMAPP. 
 
 Fig. S11 Determination of the kinetic parameters of the FgaPT2_K174F_R244N 
reaction toward 2 in the presence of DMAPP. 
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Fig. S12 Determination of the kinetic parameters of the FgaPT2_K174F_R244N 
reaction toward 3 in the presence of DMAPP. 
 
 
 
 
Fig. S13 Determination of the kinetic parameters of the FgaPT2_K174F_R244N 
reaction toward 4 in the presence of DMAPP. 
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Fig. S14 Determination of the kinetic parameters of the FgaPT2_K174F_R244L 
reaction toward 5 in the presence of DMAPP. 
 
 
 
Fig. S15 Determination of the kinetic parameters of the FgaPT2_K174F_R244L 
reaction toward 6 in the presence of DMAPP. 
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Abstract: Dimethylallyltryptophan synthases
(DMATSs) catalyze regiospecific transfer reactions
of a prenyl moiety from dimethylallyl diphosphate to
various positions of the indole ring of tryptophan.
For example, FgaPT2, 5-DMATS, and 7-DMATS
from Aspergillus fungi catalyze tryptophan prenyla-
tion at C-4, C-5, and C-7, while 5-DMATSSc and 6-
DMATSSa from Streptomyces strains are tryptophan
C-5 and C-6 prenyltransferases, respectively. In this
study, our objective is to demonstrate the possibility
of producing prenylated analogues of ardeemin fumi-
quinazoline (FQ) (1a), a precursor of the multidrug
resistance (MDR) export pump inhibitor ardeemin,
by using DMATSs. All ardeemin FQ stereoisomers
were chemically synthesized and used as substrates
for enzyme assays with DMATSs. Biochemical inves-
tigations revealed different features of these enzymes
toward ardeemin FQ analogues, regarding activity
and prenylation position. Isolation and structural elu-
cidation showed that 7-DMATS catalyzed mainly re-
giospecific prenylation at C-7, which is also observed
for its natural substrate l-tryptophan. Up to four
prenylated derivatives were identified in the reaction
mixtures of other enzymes. In total, 18 new prenylat-
ed ardeemin FQ analogues were obtained in this
study. Molecular modelling of ardeemin FQ ana-
logues with the crystal structure of FgaPT2 led to
the identification of two potential amino acid resi-
dues for guidance of the prenylation position. The
two generated mutants FgaPT2_M328L and FgaP-
T2_Y398F showed significant prenylation shifts with
1a.
Keywords: C¢C bond formation; chemoenzymatic
synthesis; dimethylallyltryptophan synthase; enzyme
catalysis; molecular modelling; prenylation
Introduction
Naturally occurring prenylated indole alkaloids de-
rived from l-tryptophan and dimethylallyl diphos-
phate (DMAPP) are secondary metabolites of tre-
mendous importance as toxins, drugs, and drug candi-
dates. Their interactions with mammalian receptors
provide a useful basis for pharmacological and medic-
inal applications.[1] Such compounds are mainly found
in plants and microorganisms, especially in fungi of
the genera of Aspergillus and Penicillium of Ascomy-
cota.[1,2] Identification of the prenylated tripeptide de-
rivative 5-N-acetylardeemin[3,4] awakened the interest
of different research areas including natural product
chemistry and chemical synthesis.[5–9] This compound
exhibits significant interaction with a membrane P-
glycoprotein (Pgp) that acts as a multidrug resistance
(MDR) export pump.[10,11] The binding of ardeemins
to Pgp reduces the resistance against antitumour
drugs such as Vinca alkaloids.[12] Later, ardeemin and
several derivatives were isolated from natural sources
(Figure 1A).[3,4;13–15] Furthermore, modified 5-N-acetyl-
ardeemins with substitutions at both tryptophanyl and
anthranyl moieties as well as 5-N-formylardeemin
have been chemically synthesized (Figure 1B).[16,17]
Ardeemin FQ and stereoisomers with prenyl moieties
at the indole ring have not been reported prior to this
study.
Genome sequencing and identification of the 5-N-
acetylardeemin gene cluster in Aspergillus fischeri
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provided a solid basis for understanding its formation
in nature.[18] The identified gene cluster ardABC com-
prises genes encoding a trimodular non-ribosomal
peptide synthetase (NRPS) termed ArdA, a prenyl-
transferase ArdB, and an acetyltransferase ArdC.
ArdA assembles anthranilic acid, l-alanine, and l-
tryptophan to the tripeptide derivative ardeemin fu-
miquinazoline (FQ) (1a). The reverse C-3 prenylation
of the tryptophanyl moiety in ardeemin FQ by ArdB
activates bridging of the indole to the N-atom of the
fumiquinazoline ring, resulting in the formation of the
pharmacological active hexacyclic ardeemin.[18] ArdC
is presumably responsible for the acetylation at the
indolyl N-atom, leading to 5-N-acetylardeemin. ArdB
belongs to the dimethylallyltryptophan synthase
(DMATS) superfamily[19] and shares amino acid se-
quence identities of 35, 34, and 27% with the trypto-
phan prenyltransferases FgaPT2, 5-DMATS, and 7-
DMATS from other Aspergillus strains, respective-
ly.[20–22] The importance of ardeemin FQ derivatives
and the observation that 1a serves as a substrate for
a prenyltransferase from the DMATS superfamily
raised our interest to investigate the acceptance of
this tripeptide derivative and its analogues by trypto-
phan prenyltransferases such as FgaPT2,[22] 5-
DMATS,[20] 5-DMATSSc,
[23,24] 6-DMATSSa,
[25] and 7-
DMATS.[21] These enzymes participate in the biosyn-
thesis of various natural products from different mi-
croorganisms (Scheme 1). They use the same sub-
strates, i.e. , l-tryptophan and DMAPP, but catalyze
different regiospecific prenylations at the indole ring.
As shown in Scheme 1, FgaPT2 from Aspergillus fu-
migatus is involved in the biosynthesis of the ergot al-
kaloid fumigaclavine C and responsible for C-4 preny-
lation of l-tryptophan.[22;26] The C-5 prenyltransferase
5-DMATS from Aspergillus clavatus participates in
the biosynthesis of an unknown product.[20] 5-
DMATSSc from Streptomyces coelicolor acts as a tryp-
tophan C-5 prenyltransferase and is involved in the
biosynthesis of 5-dimethylallylindole-3-acetoni-
trile.[23,24] 6-DMATSSa from Streptomyces ambofaciens
was identified and characterized as a tryptophan C-6
prenyltransferase and is probably involved in the bio-
synthesis of 6-prenyltryptophanol.[23,25] The tryptophan
C-7 prenyltransferase 7-DMATS from Aspergillus fu-
migatus is a member of the astechrome biosynthetic
pathway.[27]
Previous studies have shown that FgaPT2, 5-
DMATS, 5-DMATSSc, 6-DMATSSa, and 7-DMATS
also accepted simple indole derivatives as prenyl ac-
ceptors, and catalyze the same regiospecific prenyla-
tions as observed for their natural substrate l-trypto-
phan.[20,23,25,28–31] In the case of FgaPT2, C-4 prenyla-
tion of tryptophan-containing diketopiperazines has
also been demonstrated.[32] Partial or complete shifts
in the alkylation or benzylation position of trypto-
phan and derivatives were observed after incubation
of DMATSs in the presence of non-natural alkyl or
benzyl donors.[28,33,34]
Figure 1. (A) Naturally occurring and (B) chemically synthesized ardeemin derivatives containing a reverse prenyl moiety
(blue).
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In this work, we characterize the actions of the five
DMATSs shown in Scheme 1 and two FgaPT2 mu-
tants toward ardeemin FQ (1a) and its three stereo-
isomers ent-ardeemin FQ (2a), dia-ardeemin FQ (3a),
and dia,ent-ardeemin FQ (4a) and have produced 18
new compounds for further investigations.
Results and Discussion
Chemical Synthesis of Ardeemin FQ and its
Stereoisomers
The synthesis of 1a was performed in a microwave ap-
paratus by using anthranilic acid, d-alanine methyl
ester and N-BOC protected l-tryptophan as reactants
according to the protocol described by Haynes
et al.[18] This reaction also led to the formation of its
enantiomer 2a and two additional diastereomers 3a
and 4a due to the epimerization of the two chiral cen-
ters (Figure 2). Column chromatography of the reac-
tion mixture on silica gel resulted in two fractions
containing the enantiomeric pairs 1a with 2a and 3a
with 4a. To provide a basis for structure elucidation
of the enzyme products, HR-MS data (see the Sup-
porting Information, Table S1), 1H NMR, 13C NMR,
and 2D NMR spectra were acquired for the two enan-
tiomeric pairs, followed by exact assignments for the
signals (see the Supporting Information, Figures S1–
S20).
Further purification of both fractions on HPLC
with a chiral reverse-phase column provided 1a–4a in
pure form (see the Experimental Section for details),
which was confirmed by determination of their optical
rotation values.
Different Prenylations of Ardeemin FQ and its
Stereoisomers by FgaPT2
To test the acceptance for 1a with an (11S,14R) con-
figuration, FgaPT2 from the ascomycetous fungus As-
pergillus fumigatus was overproduced in E.coli and
purified to near homogeneity as described previous-
ly.[31] 3.8 mM of FgaPT2 were incubated with 0.5 mM
1a and 2 mM DMAPP at 37 8C for 4 h. LC-MS analy-
sis of the reaction mixture revealed the presence of
two product peaks 1b and 1c with retention times (tR)
at 22.0 and 19.0 min and conversion yields of 14.2 and
2.5%, respectively (Figure 3). The extracted ions at
m/z=427.2113 for 1b and 427.2111 for 1c correspond-
ed well to the [M+H]+ ions of monoprenylated deriv-
Scheme 1. Involvement of DMATSs in different pathways.
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atives of 1a (see the Supporting Information,
Table S1). For structure elucidation, the enzyme prod-
ucts 1b and 1c were isolated on HPLC from an up-
scaled assay and subjected to NMR analysis. In com-
parison to that of 1a, additional signals for a dimethyl-
allyl moiety were indeed observed in the 1H NMR
spectrum of 1b (see the Supporting Information, Fig-
ures S1 and S21). Correspondingly, signals for four in-
stead of five aromatic protons were observed for the
indole ring (to simplify the description, we ignore the
NMR signal of indole NH for structure elucidation).
By comparison with those of different prenylated
tryptophan derivatives,[20,25,30,31] the four indolyl pro-
tons were assigned to H-2, H-5, H-6, and H-7, which
unequivocally proved 1b as 4-dimethylallylardeemin
FQ (Scheme 2). Due to the low quantity, it was not
possible to get a satisfactory NMR spectrum for the
isolated peak 1c from the FgaPT2 assay for structure
elucidation. However, most ardeemin FQ and ana-
logues with prenyl moieties at different positions of
the indole ring can be distinguished under the HPLC
conditions used in this study. Therefore, the product
1c was assigned to 5-dimethylallylardeemin FQ by
comparison of its retention time to that of the product
1c from the enzyme assay of 1a with 5-DMATSSc and
6-DMATSSa (see below). The results of FgaPT2 with
1a have demonstrated the ability of a tryptophan pre-
nyltransferase to prenylate a tripeptide derivative,
which was not observed prior to this study.
We were then curious to assess the reactivity of
FgaPT2 toward the enantiomer 2a with the configura-
tion of (11R,14S). Incubation of FgaPT2 with 2a and
DMAPP under the same condition as for 1a and LC-
MS analysis of the enzyme assay led to detection of
a dominant product peak 2c with a slightly lower
product yield of 12.2% and a tR of 19.0 min
(Figure 3). That is 3.0 min shorter than that of 1b.
This indicated a different prenylation position and/or
pattern for 2c than for 1b, because the same retention
time is expected for products with the same prenyla-
tion of the enantiomer pair 1a and 2a on a reverse
phase column without a chiral selector. Monoprenyla-
tion was confirmed for the isolated peak 2c by MS
(see the Supporting Information, Table S1) and
1H NMR data. The chemical shifts and coupling pat-
terns of the signals for the four aromatic protons on
the indole ring of 2c are clearly distinguished from
those of the C-4 prenylated derivative 1b. The charac-
teristic coupling patterns of C-5 prenylated trypto-
phan and derivatives[20] were found in the spectrum of
Figure 2. Synthesis of ardeemin FQ (1a) and its stereoisomers (2a–4a).
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2c (see the Supporting Information, Figure S22), veri-
fying the C-5 prenylation of 2a by FgaPT2 as the
main reaction (Scheme 2). The prenylation shift of
FgaPT2 reaction from C-4 to C-5 was previously ob-
served for non-natural alkyl or benzyl donors, but not
for DMAPP itself.[33,34] Two minor monoprenylated
products of 2a, namely 2d and 2b, with tR at 21.3 and
22.0 min and conversion yields of 0.7 and 2.0% were
also observed. They were more clearly detected in the
EIC trace chromatogram than in UV absorption
(Figure 3). These enzyme products have been as-
signed to 4-dimethylallyl-ent-ardeemin FQ (2b) and 6-
dimethylallyl-ent-ardeemin FQ (2d) by comparison of
their retention times with those from the enzyme
assays of 2a with 5-DMATSSc and 6-DMATSSa (see
below).
The enantiomer pair 1a and 2a were converted by
FgaPT2 with comparable yields to different products.
These results encouraged us to investigate the accept-
ance and prenylation position of another enantiomer
pair, 3a (11S,14S) and 4a (11R,14R), by this enzyme.
Surprisingly, FgaPT2 clearly showed different activi-
ties toward these substrates. 3a was converted to two
product peaks 3b and 3c with conversion yields of 4.6
and 16.1%, respectively, while 4a was almost not ac-
cepted by FgaPT2, only with a conversion yield of
less than 1.0%. In analogy to those of 1b and 2c, the
structures of 3b and 3c were determined to be 4- and
5-dimethylallyl-dia-ardeemin FQ, respectively
(Scheme 2, see the Supporting Information, Figur-
es S23 and S24). Obviously, the stereochemistries of
these compounds have a strong influence on their ac-
ceptance and prenylation reactions by FgaPT2. The
two minor product peaks 4b and 4c in the incubation
mixture of 4a had the same tR as those of 3b and 3c,
indicating a plausible C-4 and C-5 prenylation as well.
Predominant C-7 Prenylation of Ardeemin FQ and
its Stereoisomers by the Tryptophan C-7
Prenyltransferase 7-DMATS
The fungal C-4 prenyltransferase FgaPT2 showed rel-
atively high levels for C-4 prenylation of 1a and C-5
prenylation of 2a and 3a, while 4a was almost not ac-
cepted by FgaPT2. This phenomenon raised our inter-
est to test the acceptance of 1a–4a by additional
fungal tryptophan prenyltransferases. 7-DMATS from
Figure 3. LC-MS analysis of incubation mixtures of FgaPT2, 5-DMATS, 5-DMATSSc, 6-DMATSSa, and 7-DMATS with ar-
deemin FQ (1a) and its stereoisomers ent-ardeemin FQ (2a); dia-ardeemin FQ (3a) and dia,ent-ardeemin FQ (4a) at 37 8C
for 4 h. The absorption at 274 nm and EIC at m/z=427.2034–427.2234 and 495.2660–495.2860 are illustrated.
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Scheme 2. Prenylation of A) ardeemin FQ (1a), B) ent-ardeemin FQ (2a), C) dia-ardeemin FQ (3a) and D) dia,ent-ardeemin
FQ (4a) catalyzed by tryptophan prenyltransferases.
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the same fungus as FgaPT2, Aspergillus fumigatus,
shared a sequence identity of 27% with ArdB and
31% with FgaPT2 on the amino acid level. Despite
the low sequence homology with FgaPT2, 7-DMATS
also uses DMAPP as the prenyl donor and l-trypto-
phan as the acceptor. In contrast to FgaPT2, 7-
DMATS catalyzes regiospecific C-7 prenylations of l-
tryptophan and a large number of derivatives there-
of.[21,30]
Compounds 1a and 2a were incubated with 3.8 mM
of 7-DMATS in the presence of DMAPP at 37 8C for
4 h. LC-MS analysis of the reaction mixtures revealed
the presence of one product peak each with the same
tR of 21.8 min (Figure 3). The product yields of 50.2%
for 1a and 54.0% for 2a are much higher than those
with FgaPT2. HR-MS data of the isolated peaks con-
firmed the monoprenylation in both cases (see the
Supporting Information, Table S1). Inspection of the
1H NMR spectra revealed the presence of signals for
two products 1d and 1e with a ratio of 1:32 from the
reaction mixture of 1a and only one product 2e from
that of 2a (see the Supporting Information, Fig-
ures S25 and S26). Compounds 1e and 2e had almost
identical signals, indicating the enantiomeric feature
of both products. This would be the case if prenyla-
tions of both enantiomers 1a and 2a have taken place
at the same position. Analysis and comparison of
their NMR data with those of known prenylated
indole derivatives[20,25,30,31] allowed us to assign 1e to 7-
dimethylallylardeemin FQ and 2e to 7-dimethylallyl-
ent-ardeemin FQ (Scheme 2). This confirmed the
highly regiospecific C-7 prenylation of the tripeptide
derivatives 1a and 2a by 7-DMATS. Compound 1d
was identified as the C-6 prenylated derivative by
comparison of its spectrum with that obtained from
the incubation mixture of 1a with 6-DMATSSa (see
below).
Next, 7-DMATS was incubated with another enan-
tiomer pair 3a and 4a and the reaction mixtures were
analyzed on LC-MS (Figure 3). Compounds 3a and 4a
were accepted with conversion yields of 72.0 and
18.9%, significantly higher than those with FgaPT2.
Similar to the incubation mixtures with 1a and 2a,
only one product peak each was observed. Isolation
and structure elucidation with the help of MS and
NMR analyses (see the Supporting Information,
Table S1 and Figure S27) verified 7-dimethylallyl-dia-
ardeemin FQ (3e) as the main product of 3a with
a product yield of 66.7%, accompanied by 6-dimethyl-
allyl-dia-ardeemin FQ (3d) as a minor product with
a yield of 5.3% (Scheme 2). Interestingly, 6-dimethyl-
allyl-dia,ent-ardeemin FQ (4d) with a product yield of
13.5% was identified as a main and 7-dimethylallyl-
dia,ent-ardeemin FQ (4e) with a yield of 5.4% as
a minor product of 4a with 7-DMATS (see the Sup-
porting Information, Figure S28).
Different Substrate Preference and Low
Regioselectivity of the Two Tryptophan C-5
Prenyltransferases 5-DMATS and 5-DMATSSc
Incubation of 1a–4a with FgaPT2 and 7-DMATS
showed that they clearly differed from each other re-
garding the prenylation positions. We extended our
investigations to 5-DMATS from the fungus Aspergil-
lus clavatus and 5-DMATSSc (SCO7467) from the
Gram-positive soil bacterium Streptomyces coelicolor
A3(2).[28] 5-DMATS shares a sequence identity of
34% with ArdB on the amino acid level and has prac-
tically no sequence similarity with 5-DMATSSc. Both
5-DMATS and 5-DMATSSc catalyze tryptophan C-5
prenylation in the presence of DMAPP.[20,28] LC-MS
analysis of the incubation mixtures of 1a–4a with 5-
DMATS and 5-DMATSSc clearly revealed different
acceptances of the four stereoisomers by the two tryp-
tophan C-5 prenyltransferases. 5-DMATS converted
these substances to their monoprenylated derivatives
with low, but comparable product yields of 5 to 12%,
while 5-DMATSSc showed a clear preference for 1a
and 2a with comparable total product yields of about
36%. Compounds 3a and 4a were poorly accepted by
5-DMATSSc with product yields of about 3%
(Figure 3). At least two product peaks each, 1c and
1d, 2c and 2d, 3c and 3d or 4c and 4d, were detected
in the incubation mixtures of 1a–4a with 5-DMATS.
By comparison of their retention times with those
from enzyme assays with FgaPT2, 5-DMATSSc, and 6-
DMATSSa, these products were identified as C-5 and
C-6 prenylated derivatives, respectively (Figure 3).
Due to low conversion, one predominant product
each, 3d or 4d, was observed in the LC-MS chromato-
gram of 3a or 4a with 5-DMATSSc and identified to
be the C-6 prenylated derivative by comparison with
the products of 3a and 4a with 6-DMATSSa. In the
enzyme assays of 1a and 2a with 5-DMATSSc, four
product peaks each were detected (Figure 3).
For structure elucidation, the product peaks of the
incubation mixtures of 1a and 2a with 5-DMATSSc
were isolated and subjected to MS and NMR analy-
ses. HR-MS confirmed the presence of monoprenylat-
ed products in the first (1c, tR=19.0 min), second (1d,
tR=21.3 min) and third peaks (1e, tR=21.7 min). In-
terestingly, an [M+H]+ ion at m/z=495.2769 was de-
termined for the fourth product (1f, tR=32.7 min),
which is 136 Da larger than that of 1a and corre-
sponds to that of a diprenylated derivative (see the
Supporting Information, Table S1). The 1H NMR
spectrum of the first peak 1c (see the Supporting In-
formation, Figure S29) was found to be identical to
that of 2c obtained from the incubation of FgaPT2
with 2a. This verified the structure of 1c as 5-
dimethylallylardeemin FQ (Scheme 2), corresponding
to the prenylation position of tryptophan by 5-
DMATSSc. However, the product yield of 1c was only
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6.4%. A yield of 10.5% was calculated for 1d and
17.2% for 1e at 21.7 min. By NMR analysis, 1d was
identified to be 6- and 1e 7-dimethylallylardeemin FQ
(Scheme 2). Product 1f at 32.7 min with a yield of
2.4% was confirmed as 5,6-bis(dimethylallyl)ardeemin
FQ (Scheme 2) by the presence of three characteristic
singlets for H-2, H-4, and H-6 in the 1H NMR spec-
trum (see the Supporting Information, Figure S30).
Identification of three monoprenylated and one dipre-
nylated compounds demonstrated the reduced regio-
selectivity of 5-DMATSSc toward 1a. This is also true
for the enzyme reaction of 5-DMATSSc with 2a. 5-
(2c), 6- (2d), 7-monoprenylated (2e) and the 5,6-di-
prenylated derivatives (2f) (see the Supporting Infor-
mation, Figure S31) in a ratio of 1.6:1.0:1.3:1.1 were
isolated from the reaction mixture and identified by
MS (see the Supporting Information, Table S1) and
NMR analyses. In summary, 5-DMATSSc accepted
both enantiomers 1a and 2a with comparable activi-
ties and strongly reduced regioselectivity. They dif-
fered from each other solely by the ratio of the
enzyme products.
C-6 Prenylated Derivatives Remain the Main
Products of the Tryptophan C-6 Prenyltransferase 6-
DMATSSa
The results obtained for 5-DMATSSc clearly differed
from those for FgaPT2 and 7-DMATS, which prompt-
ed an investigation of a tryptophan C-6 prenyltrans-
ferase, e.g., 6-DMATSSa from Streptomyces ambofa-
ciens. This enzyme catalyzes regiospecific C-6 prenyla-
tion of tryptophan, even in the presence of non-natu-
ral prenyl or benzyl donors.[25,28] Neither 5-DMATSSc,
nor 6-DMATSSa shares significant sequence homology
with ArdB from Aspergillus fischeri.[18]
LC-MS analysis of the incubation mixtures of 6-
DMATSSa with 1a–4a and DMAPP showed very good
acceptance of all four stereoisomers, with total con-
version yields of 51, 53.1, 28.9, and 20.6% for 1a, 2a,
3a, and 4a, respectively. One predominant peak (1d,
2d, 3d or 4d) was detected in each incubation mixture.
One minor peak each (1c, 2c, 3c or 4c) with a smaller
retention time than that of the d series product was
also detected. The ratios of the yields of 1c to 1d, 2c
to 2d, 3c to 3d, and 4c to 4d were calculated to be
1:0.24, 1:0.42, 1:0.3, and 1:0.05, respectively. Further-
more, an additional peak with the same retention
time as 2f from the incubation mixture with 5-
DMATSSc and a conversion yield of approximate
2.0% was detected in the reaction mixture of 2a with
6-DMATSSa (Figure 3).
For structure elucidation, the enzyme products 1c,
1d, 2c, 2d, 3c, 3d, and 4d were isolated using HPLC
and subjected to NMR and MS analyses. HR-MS con-
firmed the monoprenylation in the structures of these
products (see the Supporting Information, Table S1).
Comparison of their NMR data with those of the
products from incubation mixtures of FgaPT2 and 5-
DMATSSc as well as those of the known prenylated
tryptophan derivatives[20,25,28] led to the identification
of 1c, 2c and 3c as C-5 prenylated and 1d, 2d, 3d and
4d (see the Supporting Information, Figures S32–S35)
as C-6 prenylated derivatives. Based on the same re-
tention time as that of 2f from the incubation mixture
of 2a with 5-DMATSSc and the fact that both C-5 (2c)
and C-6 prenylated derivatives (2d) were identified as
enzyme products, the minor product peak with a tR at
32.7 min was assigned to be C-5, C-6 diprenylated 2a.
This proved that 6-DMATSSa catalyzes mainly the C-6
prenylation of ardeemin FQ and its analogues.
Determination of the Kinetic Parameters
To obtain insights into the catalytic efficiency, kinetic
parameters including Michaelis–Menten constants
(KM) and turnover numbers (kcat) were determined
for the FgaPT2, 5-DMATSSc, 6-DMATSSa, and 7-
DMATS reactions with 1a–4a by Hanes–Woolf,
Eadie–Hofstee, and Lineweaver—Burk plots (see the
Supporting Information, Figures S36-S48).
As listed in Table 1, KM values for these reactions
were found in the range of 0.1 for 7-DMATS with 1a
to 0.84 mM for 6-DMATSSa with 4a. Turnover num-
bers were found between 0.0016 for FgaPT2 with 2a
and 0.23 s¢1 for 6-DMATSSa with 2a. All of the en-
zymes showed a higher affinity to 1a and 2a than to
3a and 4a. Surprisingly, the turnover numbers of 6-
DMATSSa with 1a and 2a are much higher than those
of 7-DMATS with both substrates, which is in disa-
Table 1. Kinetic parameters of investigated tryptophan prenyltransferases with ardeemin FQ (1a) and its stereoisomers (2a–
4a) as substrates
Ardeemin FQ (1a) ent-Ardeemin FQ (2a) dia-Ardeemin FQ (3a) dia,ent-Ardeemin FQ (4a)
KM [mM] kcat [s
¢1] KM [mM] kcat [s
¢1] KM [mM] kcat [s
¢1] KM [mM] kcat [s
¢1]
FgaPT2 0.32 0.009 0.11 0.0016 0.55 0.009 – –
5-DMATSSc 0.21 0.027 0.20 0.022 – – – –
6-DMATSSa 0.12 0.19 0.11 0.23 0.51 0.018 0.84 0.016
7-DMATS 0.10 0.079 0.14 0.059 0.18 0.053 0.34 0.002
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greement with their higher conversion by 7-DMATS
(Figure 3). To find out the reason for this discrepancy,
we investigated the stability of the recombinant
DMATSs by incubating them at 37 8C for different
times. 20 mg of the pre-incubated enzymes were then
incubated with 1a at 37 8C for 30 min. As shown in
Figure 4, 7-DMATS was more stable than the other
enzymes. 87.0% of the original enzyme activity was
recovered for the incubation mixture with 4 h pre-in-
cubated protein. In contrast, the enzyme activities of
5-DMATSSc and 6-DMATSSa have almost been lost
after pre-incubation for 2 h. This could be the reason
for the observed higher turnover numbers, but lower
product yields of 6-DMATSSa with 1a and 2a than the
values obtained for 7-DMATS reactions (Figure 3).
Docking Experiments of FgaPT2 with Ardeemin FQ
and its Stereoisomers
To explain the dependency of the regioselective pre-
nylations on the substrate configuration, we per-
formed molecular docking experiments for FgaPT2
reactions with 1a–4a. The ternary complex of the
FgaPT2 crystal structure with l-tryptophan and the
DMAPP analogue dimethylallyl S-thiolodiphosphate
(DMSPP) as ligands[35] was used as basis for computa-
tional analyses. As reported for l-tryptophan, the co-
ordination of the carboxylate group of E89 to the
indole N-1¢H should facilitate the electrophilic
proton abstraction for subsequent prenylation by re-
ducing the positive charge of the intermediary s-com-
Figure 4. Stability of the recombinant enzymes. The proteins
were pre-incubated at 37 8C for different times and used for
incubation with 1a and DMAPP (37 8C, 30 min).
Figure 5. Docking results of FgaPT2 with A) 1a and 3a and B) 2a and 4a. The catalytic center of FgaPT2 including the natu-
ral substrates (blue) are shown in a stick representation. Amino acids M328 and Y398 (green) were modified in this study.
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plex. As shown in Figure 5, 1a–4a can be superim-
posed into the FgaPT2 structure. The distances be-
tween N-1¢H of 1a–4a to the carboxyl group of E89
are very similar (2.8 è to 3.2 è), but molecular dock-
ing showed that steric restrictions resulted in a tilt of
the indole entity of substrates 2a and 4a. This tilt pro-
duces an orientation that disfavours the stabilizing
effect of hydrogen bonds. Moreover, substrates with
an 11S configuration bind the anthranyl moiety in
a pocket that showed less steric pressure, and a p–p
stacking to R244 seems to enhance the binding of
these substrates.
The data support the observations that 1a and 3a
serve as better substrates for FgaPT2 prenylation.
The poor acceptance of 4a can be explained by the
steric restrictions of the methyl at C-14 to Tyr398,
which is avoided in 2a due to the 14S configuration.
The preference of 1a and 3a is moreover in good
agreement with the calculated binding energy of these
substrates showing a substantial energy gain (approx.
¢4.5 kcalmol¢1) over 2a and 4a.
The regiospecific C-4 prenylation of l-tryptophan
by FgaPT2 has been explained by steric restraints of
other positions (C-5, C-6, and C-7) that prevent an in-
teraction with the amino acid responsible for proton
abstraction at these positions. The basic K174 has
been identified as a key amino acid for abstracting H-
4 from the indole s-complex. Our docking calcula-
tions data showed that the indole entity of 2a and 3a
is slightly shifted in the tryptophan binding pocket. It
is not clear whether this shift is sufficient for the ob-
served regioselectivity or if this is accompanied by the
destabilization of the hydrogen bond to E89.
Influence of Prenylation Position by Site-Directed
Mutagenesis
From the molecular modelling data (Figure 5), it
seems that Met328 and Tyr398 play important roles in
the prenyl orientation. Both residues interact with the
anthranyl entity and therefore modifications at these
sites may shift the indole moiety within the binding
cavity to result in a shift of the prenylation position of
1a from C-4 to C-5. For this purpose, two mutants
FgaPT2_M328L and FgaPT2_Y398F were suggested
and constructed. Both mutations aimed to relieve the
steric stress. Moreover, FgaPT2_Y398F is hydropho-
bic and should therefore fit better to the substrate as
suggested by the docking model. We assayed mutants
FgaPT2_M328L and FgaPT2_Y398F with 1a and ana-
lyzed the product formation by LC-MS, quantified
the C-4 and C-5 prenylated products and compared
them with those of non-mutated FgaPT2 (Figure 6).
In comparison to FgaPT2, drastic reduction of
enzyme activity was observed for both mutants. The
product yield of the C-4 prenylated derivative 1b was
reduced from 14.2% in FgaPT2 to 5.2% in
FgaPT2_M328L and to 1.8% in FgaPT2_Y398F. The
reduction of enzyme activity was not observed for the
C-5 prenylated derivative 1c. The product yield of 1c
was even increased from 2.5% in FgaPT2 to 3.5% in
FgaPT2_M328L. This indicated that prenylation redi-
rection was possible, but additional mutations are
necessary to increase the enzyme activity for C-5 pre-
nylation of 1a.
Conclusions
We demonstrate in this study that tryptophan prenyl-
transferases can also use tripeptide derivatives 1a–4a
as prenylation substrates, which was not observed
Figure 6. LC-MS analysis of incubation mixtures of 1a with
FgaPT2; FgaPT2_M328L and FgaPT2_Y398F (37 8C and
4 h). The absorption at 274 nm and EIC at m/z=427.2034-
427.2234 are illustrated.
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prior to this study and provides a possibility for the
synthesis of prenylated ardeemin FQ and derivatives
thereof. The stereochemistries at C-11 and C-14 of 1a,
2a, 3a, and 4a have a strong influence on the activity
and regioselectivity of these enzymes. Substrates 1a
and 2a were converted by most of the investigated en-
zymes to prenylated products. A low product forma-
tion was observed for 1a–4a with 5-DMATS, 3a and
4a with 5-DMATSSc, and 4a with FgaPT2 (Figure 3
and Scheme 2). Compound 1a was alkylated by
FgaPT2 and 7-DMATS predominantly at the same
position as verified for their natural substrate l-tryp-
tophan. As an exception, the C-6 prenylated deriva-
tive 4d was identified as the major product of 4a with
7-DMATS. Incubation of 2a with FgaPT2 resulted in
a prenylation shift from C-4 to C-5. This highlights
the influence of chiral centers on the alkylation posi-
tion. Prenylations at both C-4 and C-5 on the indole
ring of 3a were observed with FgaPT2. 5-DMATS
from Aspergillus clavatus catalyzed both C-5 and C-6
prenylation of 1a–4a, but with very low conversion
yields. Interestingly, 5-DMATSSc from Streptomyces
coelicolor converted 1a to C-5 (minor), C-6, C-7
(major) monoprenylated and C-5,C-6 diprenylated
products. A similar behaviour was also observed for
5-DMATSSc toward the enantiomer 2a, but with C-5
prenylation as major reaction. 6-DMATSSa prenylated
1a–4a at C-6 as major reaction. C-5 Prenylated deriv-
atives were also identified as minor products in the
reaction mixtures of 6-DMATSSa with 1a–3a.
Our data provide evidence that these enzymes can
be used complementarily for the production of de-
signed compounds. In total, 18 new prenylated deriva-
tives were obtained from incubation mixtures of 1a,
2a, 3a, and 4a with tryptophan prenyltransferases.
Their biological activities including MDR reversing
activity will be evaluated in the future. Therefore, this
study also expands the potential application of such
enzymes for the generation of substances with phar-
macological relevance by chemoenzymatic synthesis
and synthetic biology.
Our data obtained for the FgaPT2_M328L and
FgaPT2_Y398F reactions with 1a indicated that pre-
nylation position can be altered by molecular model-
ling-guided site-directed mutagenesis. Additional ef-
forts such as crystal structures with different ligands
are needed for optimization in the future.
Experimental Section
Chemicals and General Experimental Methods
Anthranilic acid was purchased from Sigma–Aldrich (Stein-
heim, Germany), N-(tert-butoxycarbonyl)-l-tryptophan and
d-alanine methyl ester hydrochloride from Acros (Geel,
Belgium). The Discover SP CEM synthesis reactor was ap-
plied for the microwave and permitted condensation reac-
tions. DMAPP was synthesized in analogy to the method de-
scribed for geranyl diphosphate by Woodside et al.[36] The
optical rotation was measured with the polarimeter Jasco
DIP-370 equipped with a cuvette of 1 mL volume and 10 cm
path length. Enzyme product formation was analyzed on
a high performance liquid chromatography system (Agilent
series 1260, Agilent Technologies, Bçblingen, Germany)
equipped with a mass spectrometer (micrOTOF-Q III,
Bruker, Germany). NMR spectra were recorded on a JEOL
ECA-500 MHz spectrometer (JEOL Germany GmbH,
Munich, Germany) and processed by using MestReNova
Version: 6.0.2-5475 software. The CHCl3 signal at 7.26 ppm
in 1H NMR and CDCl3 signal at 77.16 ppm act as internal
standards.
Synthesis and Separation of Ardeemin FQ and its
Stereoisomers
Synthesis of 1a–4a from anthranilic acid, d-alanine methyl
ester and N-BOC protected l-tryptophan was performed in
a microwave apparatus according to a protocol described by
Haynes et al.[18] The crude reaction mixture was purified on
a silica gel column with CH2Cl2 :EtOAc:MeOH (50:48:2) as
elution solvents, resulting in two fractions containing 1a plus
2a and 3a plus 4a, respectively.
Further purification of the enantiomers 1a and 2a as well
as 3a and 4a was achieved on an Agilent HPLC series 1200
Infinity system equipped with a Multohigh chiral AM-RP
column (250×10 mm, Chromatographie Service, Langer-
wehe, Germany). A gradient from 30 to 45% MeCN in H2O
over 30 min was used for separation. The flow rate was set
to 4 mLmin¢1 and detection at 277 nm. The column was
then washed with MeCN for 5 min and equilibrated with
30% MeCN in H2O for another 5 min. Under these condi-
tions 1a, 2a, 3a, and 4a were detected at 21.8, 26.5, 13.2, and
9.5 min, respectively.
Measurement of Optical Rotations
The optical rotation measurement of the isolated 1a–4a was
conducted at 25 8C using the D-line of the sodium lamp at
l=589.3 nm. Prior to the measurement, the polarimeter was
calibrated with chloroform as solvent. The values below are
means of triple measurements. 1a : [a]25D : ¢74.78 (c 0.07,
CHCl3), 2a : [a]
25
D : +75.88 (c 0.07, CHCl3), 3a : [a]
25
D : +43.58
(c 0.08, CHCl3) and 4a : [a]
25
D : ¢63.58 (c 0.18, CHCl3). As-
signment of the stereoisomers was achieved by comparison
of their chromatographic behaviours on chiral columns and
directions of the optical values with literature data.[18,37]
Overproduction and Purification of the Tryptophan
Prenyltransferases
The recombinant tryptophan prenyltransferases His8-
FgaPT2, 5-DMATS-His6, His8-5-DMATSSc, 6-DMATSSa-
His6, and His6-7-DMATS were overproduced and purified
according to published procedures.[20,21,25,28,31]
Enzyme Assays
To determine the enzyme activities, reaction mixtures in
total volumes of 100 mL contained 0.5 mM substrate (1a, 2a,
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3a or 4a), 2 mM DMAPP, 10 mM CaCl2, 0.5–10% (v/v) glyc-
erol, 2.5% (v/v) DMSO, 50 mM Tris-HCl (pH 7.5) and 20 mg
purified recombinant enzymes. After incubation at 37 8C for
4 h, the reaction mixtures were extracted twice with 200 mL
ethyl acetate and evaporated to dryness. The yellow pellets
were dissolved in 150 mL acetonitrile. 5 mL were then ana-
lyzed on the LC-MS system described below.
The enzyme assays to determine the kinetic parameters of
the tryptophan prenyltransferases for 1a–4a were performed
in duplicate. The reaction mixtures contained the respective
aromatic substrate in concentrations of up to 1.0 mM, 2 mM
DMAPP, 10 mM CaCl2, 0.5–10.0% (v/v) glycerol, 5.0% (v/v)
DMSO, 50 mM Tris-HCl (pH 7.5) and different protein
amounts were incubated at 37 8C for different times. 3.8 mM
FgaPT2 and an incubation time of 30 min were applied for
1a, 2a, and 3a. 4.8 mM 5-DMATSSc and 20 min incubation
time were used for 1a and 2a. In the case of 6-DMATSSa, 1a
and 2a were incubated with 1.25 mM protein for 5 min. 3a
and 4a were assayed with 5.0 mM 6-DMATSSa for 20 min. 1a,
2a, and 3a were incubated with 0.95 mM 7-DMATS for
20 min. The protein amount was increased to 1.9 mM 7-
DMATS and incubation time to 45 min for 4a. The reactions
were then quenched by addition of 100 mL MeOH. After
centrifugation at 17.000×g for 15 min, 100 mL were analyzed
on HPLC.
Enzyme assays for product isolation were scaled up to
a volume of 2 to 15 mL. The reaction mixtures contained
0.5 mM of 1a, 2a, 3a or 4a, 2 mM DMAPP, 10 mM CaCl2,
0.5–10% (v/v) glycerol, 2.5% (v/v) DMSO, 50 mM Tris-HCl
(pH 7.5) and 1 to 6 mg of purified proteins. The enzyme
assays were incubated at 37 8C for 16 h and extracted twice
with the double volume of ethyl acetate. The extracts were
combined and evaporated to dryness and the residue dis-
solved in 0.7 mL DMSO-d6. The conversion rates were cal-
culated by signals of the products and substrates in the
1H NMR spectrum of these extracts. The samples after
1H NMR analysis were quantified on HPLC and also used
for product isolation.
LC-MS Analysis of Enzymatic Activities and
Isolation of the Enzyme Products
The enzyme products were analyzed on an Agilent HPLC
1260 series system equipped with a photodiode array detec-
tor and a Bruker micrOTOF-Q III mass spectrometer by
using an Agilent Eclipse XDB-C18, 5 mm, 4.6×150 mm
column. H2O (solvent A) and MeCN (B), both containing
0.1 (v/v) formic acid, were adjusted to a flow rate of
0.5 mLmin¢1. The separation began with a linear gradient
from 45% to 80% MeCN over 30 min, followed by a linear
gradient from 80% to 100% MeCN in 5 min. The column
was then washed by 100% B for 10 min and subsequently
equilibrated with 45% MeCN for 5 min. The mass spectra
were extracted from the LC-MS analysis and are provided
in the Supporting Information (see the Supporting Informa-
tion, Figures S49–S70).
The up-scaled enzyme products were isolated with an
Agilent HPLC 1200 series system with a semipreparative
Multospher 120 RP-18 column (250×10 mm×5 mm, C+S-
Chromatographie Service, Langerwehe, Germany) at a flow
rate of 2.5 mLmin¢1. A linear gradient from 60% to 100%
MeCN over 40 min was used.
NMR and MS data
Compound 1a: 1H NMR (chloroform-d, 500 MHz): d=8.40
(br s, NH-1), 8.31 (dd, J=8.1, 1.3 Hz, H-21), 7.82 (ddd, J=
8.0, 7.0, 1.3 Hz, H-19), 7.78 (d, J=8.0 Hz, H-18), 7.65 (d, J=
7.9 Hz, H-4), 7.54 (ddd, J=8.1, 7.0, 1.2 Hz, H-20), 7.44 (d,
J=8.2 Hz, H-7), 7.26 (H-6, signals overlapping with that of
solvent), 7.19 (d, J=1.8 Hz, H-2), 7.16 (dd, J=7.9, 7.3 Hz,
H-5), 6.09 (br s, NH-12), 5.44 (q, J=7.2 Hz, H-14), 4.90 (dd,
J=10.4, 3.7 Hz, H-11), 4.26 (dd, J=15.0, 3.7 Hz, H-10), 3.17
(dd, J=15.0, 10.4 Hz, H-10), 1.58 (d, J=7.2 Hz, 3H-25);
13C NMR (chloroform-d, 125 MHz): d=169.25 (C-13),
160.52 (C-24), 150.08 (C-16), 147.12 (C-23), 136.88 (C-8),
134.89 (C-19), 127.69 (C-20), 127.56 (C-18), 127.02 (C-21),
126.90 (C-9), 123.88 (C-2), 123.07 (C-6), 120.68 (C-5), 120.28
(C-22), 118.54 (C-4), 111.88 (C-7), 109.53 (C-3), 52.54 (C-
11), 52.39 (C-14), 28.40 (C-10), 17.08 (C-25); HR-ESI-MS:
m/z=359.1505, calcd. for [M+H]+: 359.1503.
Compound 1b: 1H NMR (chloroform-d, 500 MHz): d=
8.32 (ddd, J=8.0, 1.5, 0.6 Hz, H-21), 8.23 (br s, NH-1), 7.81
(ddd, J=8.1, 7.0, 1.5 Hz, H-19), 7.76 (dd, J=8.1, 1.3 Hz, H-
18), 7.54 (ddd, J=8.0, 7.0, 1.3 Hz, H-20), 7.30 (dd, J=8.2,
0.9 Hz, H-7), 7.20 (dd, J=8.2, 7.2 Hz, H-6), 7.16 (d, J=
2.3 Hz, H-2), 6.98 (dd, J=7.2, 0.9 Hz, H-5), 6.05 (br s, NH-
12), 5.48 (qd, J=7.3, 0.9 Hz, H-14), 5.35 (tsept, J=6.5,
1.4 Hz, H-2’), 4.83 (dd, J=10.9, 3.4 Hz, H-11) 4.50 (ddd, J=
15.3, 3.4, 0.9 Hz, H-10), 3.77 (d, J=6.5 Hz, 2H-1’), 3.13 (dd,
J=15.3, 10.9 Hz, H-10), 1.70 (d, J=1.4 Hz, 3H-4’), 1.67 (d,
J=0.8 Hz, 3H-5’); 1.58 (d, J=7.3 Hz, 3H-25); HR-ESI-MS:
m/z=427.2113, calcd. for [M+H]+: 427.2129.
Compound 1c: 1H NMR (chloroform-d, 500 MHz): d=
8.32 (ddd, J=8.0, 1.4, 0.6 Hz, H-21), 8.16 (br s, NH-1), 7.82
(ddd, J=8.1, 6.9, 1.4 Hz, H-19), 7.79 (dd, J=8.1, 1.4 Hz, H-
18), 7.54 (ddd, J=8.0, 6.9, 1.4 Hz, H-20), 7.41 (s, H-4), 7.36
(d, J=8.4 Hz, H-7), 7.16 (d, J=2.0 Hz, H-2), 7.11 (dd, J=
8.4, 1.5 Hz, H-6), 5.99 (br s, NH-12), 5.44 (qd, J=7.2,
0.7 Hz, H-14), 5.37 (tsept, J=7.3, 1.4 Hz, H-2’), 4.90 (dd, J=
10.5, 3.7 Hz, H-11), 4.22 (ddd, J=15.0, 3.6, 0.8 Hz, H-10),
3.43 (d, J=7.3 Hz, 2H-1’), 3.16 (dd, J=15.0, 10.5 Hz, H-10),
1.74 (d, J=0.8 Hz, 3H-4’), 1.73 (d, J=1.2 Hz, 3H-5’), 1.59
(d, J=7.2 Hz, 3H-25); HR-ESI-MS: m/z=427.2111, calcd.
for [M+H]+: 427.2129.
Compound 1d: 1H NMR (chloroform-d, 500 MHz): d=
8.32 (dd, J=8.0, 1.4 Hz, H-21), 8.12 (br s, NH-1), 7.82 (ddd,
J=8.2, 6.9, 1.4 Hz, H-19), 7.78 (dd, J=8.2, 1.3 Hz, H-18),
7.56 (d, J=8.1 Hz, H-4), 7.54 (ddd, J=8.0, 6.9, 1.3 Hz, H-
20), 7.24 (s, H-7), 7.14 (d, J=2.0 Hz, H-2), 7.02 (dd, J=8.1,
1.3 Hz, H-5), 5.97 (br s, NH-12), 5.45 (q, J=7.2 Hz, H-14),
5.39 (tsept, J=7.4, 1.4 Hz, H-2’), 4.89 (dd, J=10.7, 3.7 Hz,
H-11), 4.24 (ddd, J=14.9, 3.6, 0.8 Hz, H-10), 3.47 (d, J=
7.3 Hz, 2H-1’), 3.13 (dd, J=14.9, 10.7 Hz, H-10), 1.77 (d, J=
0.9 Hz, 3H-4’), 1.76 (s, 3H-5’), 1.58 (d, J=7.2 Hz, 3H-25);
HR-ESI-MS: m/z=427.2137, calcd. for [M+H]+: 427.2129.
Compound 1e: 1H NMR (chloroform-d, 500 MHz): d=
8.32 (ddd, J=8.0, 1.4, 0.5 Hz, H-21), 8.19 (br s, NH-1), 7.82
(ddd, J=8.1, 6.9, 1.4 Hz, H-19), 7.78 (dd, J=8.1, 1.3 Hz, H-
18), 7.54 (ddd, J=8.0, 6.9, 1.3 Hz, H-20), 7.52 (d, J=7.3 Hz,
H-4), 7.18 (d, J=2.2 Hz, H-2), 7.12 (t, J=7.3 Hz, H-5), 7.09
(dd, J=7.3, 1.2 Hz, H-6), 5.94 (br s, NH-12), 5.45 (qd, J=
7.3, 0.6 Hz, H-14), 5.43 (tsept, J=7.1, 1.4 Hz, H-2’), 4.90 (dd,
J=10.7, 3.7 Hz, H-11), 4.26 (ddd, J=14.9, 3.7, 0.9 Hz, H-10),
3.60 (m, 2H-1’), 3.16 (dd, J=14.9; 10.7 Hz, H-10), 1.85 (d,
J=0.6 Hz, 3H-4’), 1.81 (d, J=1.2 Hz, 3H-5’), 1.58 (d, J=
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7.3 Hz, 3H-25); HR-ESI-MS: m/z=427.2138, calcd. for
[M+H]+: 427.2129.
Compound 1f: 1H NMR (chloroform-d, 500 MHz): d=
8.32 (dd, J=8.0, 1.4 Hz, H-21), 8.05 (br s, NH-1), 7.82 (ddd,
J=8.0, 6.9, 1.4 Hz, H-19), 7.79 (dd, J=8.0, 1.4 Hz, H-18),
7.54 (ddd, J=8.0, 6.9, 1.4 Hz, H-20), 7.39 (s, H-4), 7.23 (H-7,
signals overlapping with that of solvent,), 7.10 (d, J=2.1 Hz,
H-2), 5.96 (br s, NH-12), 5.45 (q, J=7.1 Hz, H-14), 5.33 (br
t, J=7.3 Hz, H-2’), 5.27 (br t, J=6.6 Hz, H-2’’), 4.89 (dd, J=
10.6, 3.8 Hz, H-11), 4.21 (dd, J=15.0, 3.8 Hz, H-10), 3.435
(m, 2H-1’), 3.425 (m, 2H-1’’), 3.14 (dd, J=15.0, 10.6 Hz, H-
10), 1.78 (s, 3H-4’), 1.73 (s, 3H-5’ and 3H-4’’), 1.72 (s, 3H-
5’’), 1.59 (3H-25, signals overlapping with those of H2O);
HR-ESI-MS: m/z=495.2770, calcd. for [M+H]+: 495.2755.
Compound 2a: 1H NMR (chloroform-d, 500 MHz): d=
8.40 (br s, NH-1), 8.31 (dd, J=8.1, 1.3 Hz, H-21), 7.82 (ddd,
J=8.0, 7.0, 1.3 Hz, H-19), 7.78 (d, J=8.0 Hz, H-18), 7.65 (d,
J=7.9 Hz, H-4), 7.54 (ddd, J=8.1, 7.0, 1.2 Hz, H-20), 7.44
(d, J=8.2 Hz, H-7), 7.26 (H-6, signals overlapping with that
of solvent), 7.19 (d, J=1.8 Hz, H-2), 7.16 (dd, J=7.9, 7.3 Hz,
H-5), 6.09 (br s, NH-12), 5.44 (q, J=7.2 Hz, H-14), 4.90 (dd,
J=10.4, 3.7 Hz, H-11), 4.26 (dd, J=15.0, 3.7 Hz, H-10), 3.17
(dd, J=15.0, 10.4 Hz, H-10), 1.58 (d, J=7.2 Hz, 3H-25);
13C NMR (chloroform-d, 125 MHz): d=169.25 (C-13),
160.52 (C-24), 150.08 (C-16), 147.12 (C-23), 136.88 (C-8),
134.89 (C-19), 127.69 (C-20), 127.56 (C-18), 127.02 (C-21),
126.90 (C-9), 123.88 (C-2), 123.07 (C-6), 120.68 (C-5), 120.28
(C-22), 118.54 (C-4), 111.88 (C-7), 109.53 (C-3), 52.54 (C-
11), 52.39 (C-14), 28.40 (C-10), 17.08 (C-25); HR-ESI-MS:
m/z=359.1507, calcd. for [M+H]+: 359.1503.
Compound 2c: 1H NMR (chloroform-d, 500 MHz): d=
8.32 (dd, J=8.0, 1.4 Hz, H-21), 8.14 (br s, NH-1), 7.82 (ddd,
J=8.2, 6.8, 1.4 Hz, H-19), 7.79 (dd, J=8.2, 1.4 Hz, H-18),
7.54 (ddd, J=8.0, 6.8, 1.4 Hz, H-20), 7.41 (s, H-4), 7.36 (d,
J=8.4 Hz, H-7), 7.17 (d, J=2.2 Hz, H-2), 7.11 (dd, J=8.4,
1.5 Hz, H-6), 5.96 (br s, NH-12), 5.44 (qd, J=7.2, 0.8 Hz, H-
14), 5.37 (tsept, J=7.2, 1.4 Hz, H-2’), 4.90 (dd, J=10.5,
3.7 Hz, H-11), 4.22 (ddd, J=15.0, 3.7, 1.0 Hz, H-10), 3.44 (d,
J=6.9 Hz, 2H-1’), 3.16 (dd, J=15.0, 10.5 Hz, H-10), 1.74 (s,
3H-4’), 1.73 (d, J=1.1 Hz, 3H-5’), 1.59 (d, J=7.3 Hz, 3H-
25); HR-ESI-MS: m/z=427.2125, calcd. for [M+H]+:
427.2129.
Compound 2d: 1H NMR (chloroform-d, 500 MHz): d=
8.32 (dd, J=8.0, 1.4 Hz, H-21), 8.10 (br s, NH-1), 7.82 (ddd,
J=8.1, 7.0, 1.4 Hz, H-19), 7.78 (dd, J=8.1, 1.3 Hz, H-18),
7.56 (d, J=8.1 Hz, H-4), 7.54 (ddd, J=8.0, 7.0, 1.3 Hz, H-
20), 7.24 (s, H-7), 7.14 (d, J=2.2 Hz, H-2), 7.02 (dd, J=8.1,
1.2 Hz, H-5), 5.96 (br s, NH-12), 5.45 (q, J=7.3 Hz, H-14),
5.39 (tsept, J=7.4, 1.4 Hz, H-2’), 4.89 (dd, J=10.7, 3.6 Hz,
H-11), 4.24 (ddd, J=15.0, 3.6, 0.6 Hz, H-10), 3.47 (d, J=
7.3 Hz, 2H-1’), 3.13 (dd, J=15.0, 10.7 Hz, H-10), 1.77 (d, J=
0.8 Hz, 3H-4’), 1.76 (s, 3H-5’), 1.58 (d, J=7.3 Hz, 3H-25);
HR-ESI-MS: m/z=427.2122, calcd. for [M+H]+: 427.2129.
Compound 2e: 1H NMR (chloroform-d, 500 MHz): d=
8.32 (ddd, J=8.0, 1.4, 0.5 Hz, H-21), 8.20 (br s, NH-1), 7.82
(ddd, J=8.2, 6.9, 1.4 Hz, H-19), 7.78 (ddd, J=8.2, 1.4,
0.5 Hz, H-18), 7.54 (ddd, J=8.0, 6.9, 1.4 Hz, H-20), 7.52 (dd,
J=7.6, 1.0 Hz, H-4), 7.19 (d, J=2.0 Hz, H-2), 7.12 (dd, J=
7.6, 7.2 Hz, H-5), 7.09 (dd, J=7.2, 1.0 Hz, H-6), 5.94 (br s,
NH-12), 5.45 (qd, J=7.2, 0.9 Hz, H-14), 5.43 (tsept, J=7.2,
1.4 Hz, H-2’), 4.90 (dd, J=10.7, 3.7 Hz, H-11), 4.26 (ddd, J=
14.9, 3.7, 1.0 Hz, H-10), 3.60 (m, 2H-1’), 3.16 (dd, J=14.9,
10.7 Hz, H-10), 1.85 (d, J=0.7 Hz, 3H-4’), 1.81 (d, J=
1.3 Hz, 3H-5’), 1.58 (d, J=7.2 Hz, 3H-25); HR-ESI-MS:
m/z=427.2127, calcd. for [M+H]+: 427.2129.
Compound 2f: 1H NMR (chloroform-d, 500 MHz): d=
8.32 (dd, J=8.0, 1.4 Hz, H-21), 8.04 (br s, NH-1), 7.82 (ddd,
J=8.1, 7.0, 1.4 Hz, H-19), 7.78 (dd, J=8.1, 1.4 Hz, H-18),
7.54 (ddd, J=8.0, 7.0, 1.4 Hz, H-20), 7.39 (s, H-4), 7.24 (s, H-
7), 7.10 (d, J=2.2 Hz, H-2), 5.96 (br s, NH-12), 5.45 (q, J=
7.3 Hz, H-14), 5.33 (tsept, J=7.2, 1.4 Hz, H-2’), 5.27 (tsept,
J=6.9, 1.3 Hz, H-2’’), 4.89 (dd, J=10.7, 3.7 Hz, H-11), 4.21
(ddd, J=15.0, 3.7, 0.7 Hz, H-10), 3.435 (m, 2H-1’), 3.415 (m,
2H-1’’), 3.13 (dd, J=15.0, 10.7 Hz, H-10), 1.78 (d, J=0.8 Hz,
3H-4’), 1.73 (s, 3H-5’ and 3H-4’’), 1.72 (d, J=1.0 Hz, 3H-
5’’), 1.58 (d, 7.3 Hz, 3H-25); HR-ESI-MS: m/z=495.2748,
calcd. for [M+H]+: 495.2755.
Compound 3a: 1H NMR (chloroform-d, 500 MHz): d=
8.46 (br s, NH-1), 8.29 (dd, J=8.0, 1.4 Hz, H-21), 7.83 (ddd,
J=8.2, 7.0, 1.4 Hz, H-19), 7.77 (dd, J=8.2, 1.1 Hz, H-18),
7.55 (d, J=7.9 Hz, H-4), 7.52 (ddd, J=8.0, 7.0, 1.1 Hz, H-
20), 7.30 (d, J=8.1 Hz, H-7), 7.13 (ddd, J=8.1, 7.1, 0.9 Hz,
H-6), 7.07 (d, J=2.3 Hz, H-2), 7.04 (ddd, J=7.9, 7.1, 1.0 Hz,
H-5), 6.82 (br s, NH-12), 5.21 (q, J=7.1 Hz, H-14), 4.82 (dt,
J=10.0, 3.6 Hz, H-11), 3.61 (dd, J=14.5, 3.6 Hz, H-10), 3.29
(dd, J=14.5, 10.0 Hz, H-10), 1.52 (d, J=7.1 Hz, 3H-25);
13C NMR (chloroform-d, 125 MHz): d=169.21 (C-13),
160.65 (C-24), 150.32 (C-16), 147.44 (C-23), 136.42 (C-8),
134.99 (C-19), 127.25 (C-20), 127.10 (C-18), 127.06 (C-21),
126.97 (C-9), 123.88 (C-2), 122.65 (C-6), 120.38 (C-5), 120.17
(C-22), 118.58 (C-4), 111.61 (C-7), 109.49 (C-3), 57.56 (C-
11), 51.94 (C-14), 34.66 (C-10), 19.14 (C-25); HR-ESI-MS:
m/z=359.1509, calcd. for [M+H]+: 359.1503.
Compound 3b: 1H NMR (chloroform-d, 500 MHz): d=
8.31 (dd, J=8.0, 1.5 Hz, H-21), 8.25 (br s, NH-1), 7.80 (ddd,
J=8.3, 7.1, 1.5 Hz, H-19), 7.69 (dd, J=8.3, 1.0 Hz, H-18),
7.52 (ddd, J=8.0, 7.1, 1.0 Hz, H-20), 7.29 (d, J=8.1 Hz, H-
7), 7.18 (dd, J=8.1, 7.3 Hz, H-6), 7.14 (d, J=2.4 Hz, H-2),
6.99 (dd, J=7.3, 0.5 Hz, H-5), 6.05 (d, J=3.2 Hz, NH-12),
5.37 (tsept, J=6.5, 1.4 Hz, H-2’), 5.35 (q, J=7.2 Hz, H-14),
4.78 (dt, J=11.3, 3.3 Hz, H-11), 4.03 (dd, J=16.0, 6.4 Hz, H-
1’), 3.96 (dd, J=14.5, 3.3 Hz, H-10), 3.88 (dd, J=16.0,
6.4 Hz, H-1’), 3.19 (dd, J=14.5, 11.3 Hz, H-10), 1.88 (s, 3H-
4’), 1.77 (d, J=7.2 Hz, 3H-25), 1.76 (d, J=1.4 Hz, 3H-5’);
HR-ESI-MS: m/z=427.2139, calcd. for [M+H]+: 427.2129.
Compound 3c: 1H NMR (chloroform-d, 500 MHz): d=
8.30 (dd, J=8.0, 1.4 Hz, H-21), 8.11 (br s, NH-1), 7.83 (ddd,
J=8.1, 7.1, 1.4 Hz, H-19), 7.78 (d, J=8.1 Hz, H-18), 7.53
(ddd, J=8.0, 7.1, 1.2 Hz, H-20), 7.34 (s, H-4), 7.30 (d, J=
8.3 Hz, H-7), 7.13 (d, J=2.3 Hz, H-2), 7.04 (dd, J=8.3,
1.4 Hz, H-6), 6.08 (d, J=3.1 Hz, NH-12), 5.29 (tsept, J=7.3,
1.4 Hz, H-2’), 5.24 (q, J=7.1 Hz, H-14), 4.88 (dt, J=9.7,
3.6 Hz, H-11), 3.61 (dd, J=14.4, 3.6 Hz, H-10), 3.34 (dd, J=
14.4, 9.7 Hz, H-10), 3.31 (d, J=7.3 Hz, 2H-1’), 1.74 (s, 3H-4’
and 3H-5’), 1.50 (d, J=7.1 Hz, 3H-25); HR-ESI-MS: m/z=
427.2140, calcd. for [M+H]+: 427.2129.
Compound 3d: 1H NMR (chloroform-d, 500 MHz): d=
8.30 (dd, J=8.0, 1.4 Hz, H-21), 8.09 (br s, NH-1), 7.82 (ddd,
J=8.2, 7.0, 1.4 Hz, H-19), 7.76 (dd, J=8.2, 1.1 Hz, H-18),
7.55 (d, J=8.1 Hz, H-4), 7.52 (ddd, J=8.0, 7.0, 1.1 Hz, H-
20), 7.20 (s, H-7), 7.10 (d, J=2.3 Hz, H-2), 6.99 (dd, J=8.1,
1.3 Hz, H-5), 6.05 (d, J=3.5 Hz, NH-12), 5.37 (tsept, J=7.4,
1.2 Hz, H-2’), 5.29 (q, J=7.1 Hz, H-14), 4.84 (dt, J=10.6,
3.5 Hz, H-11), 3.66 (dd, J=14.3, 3.5 Hz, H-10), 3.45 (d, J=
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7.4 Hz, 2H-1’), 3.24 (dd, J=14.3, 10.6 Hz, H-10), 1.76 (d, J=
1.2 Hz, 3H-4’), 1.75 (s, 3H-5’), 1.62 (d, J=7.1 Hz, 3H-25);
HR-ESI-MS: m/z=427.2145, calcd. for [M+H]+: 427.2129.
Compound 3e: 1H NMR (chloroform-d, 500 MHz): d=
8.31 (dd, J=8.0, 1.4 Hz, H-21), 8.17 (br s, NH-1), 7.83 (ddd,
J=8.2, 7.1, 1.4 Hz, H-19), 7.77 (dd, J=8.2, 1.1 Hz, H-18),
7.54 (d, J=7.6 Hz, H-4), 7.53 (ddd, J=8.0, 7.1, 1.1 Hz, H-
20), 7.15 (d, J=2.5 Hz, H-2), 7.09 (dd, J=7.6, 7.4 Hz, H-5),
7.05 (d, J=7.4 Hz, H-6), 5.98 (d, J=3.2 Hz, NH-12), 5.39
(tsept, J=7.1, 1.4 Hz, H-2’), 5.29 (q, 7.1 Hz, H-14), 4.86 (dt,
J=10.5, 3.6 Hz, H-11), 3.69 (dd, J=14.3, 3.6 Hz, H-10), 3.58
(d, J=7.1 Hz, 2H-1’), 3.26 (dd, J=14.3, 10.5 Hz, H-10), 1.83
(s, 3H-4’), 1.79 (d, J=1.1 Hz, 3H-5’), 1.63 (d, J=7.1 Hz,
3H-25); HR-ESI-MS: m/z=427.2141, calcd. for [M+H]+:
427.2129.
Compound 4a: 1H NMR (chloroform-d, 500 MHz): d=
8.46 (br s, NH-1), 8.29 (dd, J=8.0, 1.4 Hz, H-21), 7.83 (ddd,
J=8.2, 7.0, 1.4 Hz, H-19), 7.77 (dd, J=8.2, 1.1 Hz, H-18),
7.55 (d, J=7.9 Hz, H-4), 7.52 (ddd, J=8.0, 7.0, 1.1 Hz, H-
20), 7.30 (d, J=8.1 Hz, H-7), 7.13 (ddd, J=8.1, 7.1, 0.9 Hz,
H-6), 7.07 (d, J=2.3 Hz, H-2), 7.04 (ddd, J=7.9, 7.1, 1.0 Hz,
H-5), 6.82 (br s, NH-12), 5.21 (q, J=7.1 Hz, H-14), 4.82 (dt,
J=10.0, 3.6 Hz, H-11), 3.61 (dd, J=14.5, 3.6 Hz, H-10), 3.29
(dd, J=14.5, 10.0 Hz, H-10), 1.52 (d, J=7.1 Hz, 3H-25);
13C NMR (chloroform-d, 125 MHz): d=169.21 (C-13),
160.65 (C-24), 150.32 (C-16), 147.44 (C-23), 136.42 (C-8),
134.99 (C-19), 127.25 (C-20), 127.10 (C-18), 127.06 (C-21),
126.97 (C-9), 123.88 (C-2), 122.65 (C-6), 120.38 (C-5), 120.17
(C-22), 118.58 (C-4), 111.61 (C-7), 109.49 (C-3), 57.56 (C-
11), 51.94 (C-14), 34.66 (C-10), 19.14 (C-25); HR-ESI-MS:
m/z=359.1512, calcd. for [M+H]+: 359.1503.
Compound 4d: 1H NMR (chloroform-d, 500 MHz): d=
8.31 (ddd, J=8.0, 1.4, 0.7 Hz, H-21), 8.09 (br s, NH-1), 7.83
(ddd, J=8.2, 7.0, 1.4 Hz, H-19), 7.77 (dd, J=8.2, 1.3 Hz, H-
18), 7.56 (d, J=8.1 Hz, H-4), 7.53 (ddd, J=8.0, 7.0, 1.4 Hz,
H-20), 7.20 (dd, J=1.4, 0.7 Hz, H-7), 7.10 (d, J=2.4 Hz, H-
2), 7.00 (dd, J=8.1, 1.4 Hz, H-5), 6.02 (d, J=3.3 Hz, NH-
12), 5.37 (tsept, J=7.3, 1.4 Hz, H-2’), 5.29 (q, J=7.1 Hz, H-
14), 4.85 (dt, J=10.5, 3.5 Hz, H-11), 3.67 (ddd, J=14.2, 3.5,
0.6 Hz, H-10), 3.45 (d, J=7.3 Hz, 2H-1’), 3.25 (dd, J=14.2,
10.5 Hz, H-10), 1.76 (d, J=1.1 Hz, 3H-4’), 1.75 (d, J=
0.7 Hz, 3H-5’), 1.63 (d, J=7.1 Hz, 3H-25); HR-ESI-MS:
m/z=427.2131, calcd. for [M+H]+: 427.2129.
Docking Experiments
For docking calculations with FgaPT2, the pdb coordinates
(3I4X) were modified by removal of l-tryptophan and the
surrounding water molecules. The prenylation agent (dime-
thylallyl S-thiolodiphosphate) was kept in the active site.
The substrates 1a–4a were docked into the tryptophan bind-
ing pocket using VINA.[38] Docking calculations were pre-
pared with ADT[39] using a grid that covers the complete
binding site. The results were visualized with PyMOL (the
PyMOL molecular Graphics System, version 1.5.0.4, Schrç-
dinger, LLC, New York) and verified for chemical sense.
Docking solutions contradicting the observed chemical reac-
tion were discarded.
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Structure elucidation by NMR analyses 
1H NMR, 13C NMR and two-dimensional NMR spectra including HMBC, HSQC, and 1H-1H COSY 
have been recorded for the mixture of 1a with its enantiomer 2a as well as of 3a with its enantiomer 4a. 
The detailed assignments for proton signals in 1a-4a facilitated the structure elucidation of their 
prenylated products. The correlations of H-10 in 1a+2a at δH 3.17 and 4.26 ppm to C-11 (52.54 ppm), 
C-3 (109.53 ppm), C-2 (123.88 ppm), C-9 (126.90 ppm), and C-16 (150.08 ppm) were clearly observed 
in their HMBC spectra. Connectivities in HSQC and 1H-1H COSY enabled the assignments of the 
chemical shifts for aromatic protons. The signals for indole protons of 1a+2a have been assigned to H-
2 (7.19 ppm, d, 1.8), H-4 (7.65 ppm, d, 7.9), H-5 (7.16 ppm, dd, 7.9, 7.3), H-6 (7.26 ppm, overlapping 
with solvent), and H-7 (7.44 ppm, d, 8.2). The signals of the anthranyl protons were found at 7.78 (d, 
8.0, H-18), 7.82 (ddd, 8.0, 7.0, 1.3, H-19), 7.54 (ddd, 8.1, 7.0, 1.2, H-20), and 8.31 ppm (dd, 8.1, 1.3, 
H-21). In the case of 3a+4a, HMBC connectivities were observed for H-10 at δH 3.29 and δH 3.61 ppm 
to C-11 (57.56 ppm), C-3 (109.49 ppm), C-2 (123.88 ppm), C-9 (126.97 ppm), and C-16 (150.32 ppm). 
Furthermore, the HMBC correlations for the indole and anthranyl moieties as well as the HSQC and 1H-
1H COSY spectra allowed the exact assignments of the proton signals in the 1H NMR spectra. In the 1H 
NMR spectra of 3a and 4a, signals of indole protons have been assigned to H-2 (7.07 ppm, d, 2.3), H-4 
(7.55 ppm, d, 7.9), H-5 (7.04 ppm, ddd, 7.9, 7.1, 1.0), H-6 (7.13 ppm, ddd, 8.1, 7.1, 0.9), and H-7 (7.30 
ppm, d, 8.1). The protons of anthranyl moiety in 3a and 4a displayed chemical shifts at 7.77 (dd, 8.2, 
1.1, H-18), 7.83 (ddd, 8.2, 7.0, 1.4, H-19), 7.52 (ddd, 8.0, 7.0, 1.1, H-20), and 8.29 ppm (dd, 8.0, 1.4, 
H-21). 
 
1H NMR data of C4-, C5-, C6-, and C7-prenylated L-tryptophan and derivatives as well as 
diketopiperazine derivatives provide characteristic coupling patterns for each prenylation position,[1-5] 
which are used for comparison with and identification of the prenylated products of 1a-4a. The signals 
for the protons of the indole moiety in the 1H NMR spectrum of 1b were found at δH 8.23 (1H, br s), δH 
7.30 (1H, dd, 8.2, 0.9), δH 7.20 (1H, dd, 8.2, 7.2), δH 7.16 (1H, d, 2.3), and δH 6.98 ppm (1H, dd, 7.2, 
0.9), and for those of 3b at δH 8.25 (1H, br s), δH 7.29 (1H, d, 8.1), δH 7.18 (1H, dd, 8.1, 7.3), δH 7.14 
(1H, d, 2.4), and δH 6.99 ppm (1H, dd, 7.3, 0.5). They were compared with C4-prenylated 
cyclodipeptides such as cyclo-L-4-DMAT-L-Trp or cyclo-L-4-DMAT-L-Pro[6]. Despite the structure 
difference, the coupling patterns of the indole protons of cyclo-L-4-DMAT-L-Pro at δH 8.16 (br s), δH 
7.25 (1H, d, 7.4), δH 7.15 (1H, t, 7.4), δH 7.08 (1H, d, 2.0), and δH 6.93 ppm (1H, d, 7.4) display 
equivalent order and coupling patterns as observed for 1b and 3b. The absence of one indole proton in 
the 1H NMR spectra of 1b and 3b as well as the presence of the signals for H-1’, H-2’, H-4’ and H-5’ of 
a prenyl moiety verified 1b as C4-prenylated 4-dimethylallylardeemin FQ and 3b as 4-dimethylallyl-
dia-ardeemin FQ.  
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The 1H NMR spectra of 1c, 2c, and 3c showed also the characteristic signals for a regular prenyl moiety 
each and the absence of a signal for one indole proton. The observation of one singlet for one proton at 
the tryptophanyl moiety in 1c (7.41 ppm), 2c (7.41 ppm) or 3c (7.34 ppm) indicated that the prenylation 
took place at C-5 or C-6 position of 1a, 2a, or 3a. The available 1H NMR data of C5- and C6-prenylated 
L-tryptophan, L-tryptophan derivatives,[2;3] and cyclo-L-homotryptophan-D-valine[7] enabled the 
assignments of 1c, 2c, and 3c to the C5-prenylated products 5-dimetyhlallylardeemin FQ (1c), 5-
dimethylallyl-ent-ardeemin FQ (2c), and 5-dimethylallyl-dia-ardeemin FQ (3c). In the 1H NMR spectra 
of C5- prenylated substances, the singlet for H-4 is strongly down-field shifted, followed by the doublet 
for H-7 and the signal (doublet or doublet of doublet) for H-6. In the 1H NMR spectra of C6- prenylated 
products, the doublet for H-4 is more down-field shifted than those for other indole protons followed by 
the singlet of H-7. The signals of H-7 and H-5 are closer in C6-prenylated derivatives than those of H-
7 and H-6 in C5-prenylated derivatives. Based on the enantiomeric feature of 1a and 2a, the signals of 
their C5-prenylated products 1c and 2c are almost identical. The chemical shifts for the indole protons 
were found at δH 8.16 (1H, br s), δH 7.41 (1H, s), δH 7.36 (1H, d, 8.4), δH 7.16 (1H, d, 2.0), and 7.11 ppm 
(1H, dd, 8.4, 1.5) with a maximum deviation of 0.02 ppm. The signals of the indole protons of 3c at δH 
8.11 (1H, br s), δH 7.34 (1H, s), δH 7.30 (1H, d, 8.3) δH 7.13 (1H, d, 2.3), and δH 7.04 ppm (1H, dd, 8.3, 
1.4) show the same coupling patterns as observed for 1c and 2c, proving its C5-prenyltion.  
 
The nearly identical 1H NMR spectra of 1d and 2d differ clearly from those of 1c, 2c, and 3c. The 
observed singlet at δH 7.24 ppm for 1d and 2d indicated a prenylation at C-6 position of 1a and 2a. The 
coupling patterns of the signals for indole protons in 1d and 2d at δH 8.12 (1H, br s), δH 7.56 (1H, d, 
8.1), δH 7.24 (1H, s), δH 7.14 (1H, d, 2.0), and δH 7.02 ppm (1H, dd, 8.1, 1.3) corresponded well to those 
of the C-6-prenylated cyclo-L-homotryptophan-D-valine[7], proving 1d as 6-dimethylallylardeemin FQ 
and 2d as 6-dimethylallyl-ent-ardeemin FQ. In the 1H NMR spectra of 3d and 4d, the coupling patterns 
of the signals for indole protons corresponded well to that of 1d and 2d and therefore can be assigned 
to 6-dimethylallyl-dia-ardeemin FQ (3d) and 6-dimethylallyl-dia,ent-ardeemin FQ (4d), respectively.  
 
The signals of the indole moiety for 1e and 2e, the products of 7-DMATS with 1a and 2a, at δH 8.19 
(1H, br s), δH 7.52 (1H, d, 7.3), δH 7.18 (1H, d, 2.2) δH 7.12 (1H, t, 7.3), and δH 7.09 ppm (1H, dd, 7.3, 
1.2) are in consistence with C7-prenylated derivatives[7;8]. Similar coupling patterns were also observed 
for indole protons in 3e and 4e. 1e, 2e, 3e and 4e were identified as 7-dimethylallylardeemin FQ, 7-
dimethylallyl-ent-ardeemin FQ, 7-dimethylallyl-dia-ardeemin FQ, and 7-dimethylallyl-dia,ent-
ardeemin FQ, respectively.  
 
In the 1H NMR spectra of 1f and 2f, the detection of only four signals at δH 8.05 (1H, br s), δH 7.39 (1H, 
s), 7.23 (1H, s), and 7.10 ppm (1H, d, 2.1) proved the absence of two tryptophanyl protons and therefore 
verified the diprenylation of 1a and 2a catalyzed by 5-DMATSSc. In addition, the signals for two prenyl 
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moieties were observed. The presence of the signals of H-4 and H-7 as singlets proved unequivocally 
the C5-, C6-diprenylation in both structures. 
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Table S1. HR-ESI-MS data of substrates (1a-4a) and their enzymatic products 
compound 
      HR‐ESI‐MS([M+H]+)     
  chemical formula    calculated [Da]  measured [Da]    deviation [ppm] 
ardeemin FQ (1a)    C21H18N4O2    359.1503  359.1505    ‐0.7 
4‐dimethylallylardeemin FQ (1b)    C26H26N4O2    427.2129  427.2113    3.7 
5‐dimethylallylardeemin FQ (1c)    C26H26N4O2    427.2129  427.2111    4.0 
6‐dimethylallylardeemin FQ (1d)    C26H26N4O2    427.2129  427.2137    ‐1.9 
7‐dimethylallylardeemin FQ (1e)    C26H26N4O2    427.2129  427.2138    ‐2.2 
5,6‐dimethylallylardeemin FQ (1f)    C31H34N4O2    495.2755  495.2770    ‐3.2 
ent‐ardeemin FQ (2a)    C21H18N4O2    359.1503  359.1507    ‐1.2 
4‐dimethylallyl‐ent‐ardeemin FQ (2b)    C26H26N4O2    427.2129  427.2120    1.9 
5‐dimethylallyl‐ent‐ardeemin FQ (2c)    C26H26N4O2    427.2129  427.2125    0.7 
6‐dimethylallyl‐ent‐ardeemin FQ (2d)    C26H26N4O2    427.2129  427.2122    1.6 
7‐dimethylallyl‐ent‐ardeemin FQ (2e)    C26H26N4O2    427.2129  427.2127    0.2 
5,6‐dimethylallyl‐ent‐ardeemin FQ (2f)    C31H34N4O2    495.2755  495.2748    1.4 
dia‐ardeemin FQ (3a)    C21H18N4O2    359.1503  359.1509    ‐1.8 
4‐dimethylallyl‐dia‐ardeemin FQ (3b)    C26H26N4O2    427.2129  427.2139    ‐2.6 
5‐dimethylallyl‐dia‐ardeemin FQ (3c)    C26H26N4O2    427.2129  427.2140    ‐2.7 
6‐dimethylallyl‐dia‐ardeemin FQ (3d)    C26H26N4O2    427.2129  427.2145    ‐3.9 
7‐dimethylallyl‐dia‐ardeemin FQ (3e)    C26H26N4O2    427.2129  427.2141    ‐2.9 
dia,ent‐ardeemin FQ (4a)    C21H18N4O2    359.1503  359.1512    ‐2.7 
4‐dimethylallyl‐dia,ent‐ardeemin FQ (4b)    C26H26N4O2    427.2129  427.2120    1.9 
5‐dimethylallyl‐dia,ent‐ardeemin FQ (4c)    C26H26N4O2    427.2129  427.2115    3.1 
6‐dimethylallyl‐dia,ent‐ardeemin FQ (4d)    C26H26N4O2    427.2129  427.2131    ‐0.7 
7‐dimethylallyl‐dia,ent‐ardeemin FQ (4e)    C26H26N4O2    427.2129  427.2141    ‐2.9 
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Figure S1. 1H NMR spectra of ardeemin FQ (1a) and ent-ardeemin FQ (2a) as a mixture in CDCl3 (500 MHz)
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Figure S2. 13C NMR spectra of ardeemin FQ (1a) and ent-ardeemin FQ (2a) as a mixture in CDCl3 (125 MHz)
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Figure S3. 1H-1H COSY spectra of ardeemin FQ (1a) and ent-ardeemin FQ (2a) as a mixture in CDCl3
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Figure S4. Aromatic region of 1H-1H COSY spectra of ardeemin FQ (1a) and ent-ardeemin FQ (2a) as a mixture in CDCl3
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Figure S5. 1H-13C HSQC spectra of ardeemin FQ (1a) and ent-ardeemin FQ (2a) as a mixture in CDCl3
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Figure S6. Aromatic region of 1H-13C HSQC spectra of ardeemin FQ (1a) and ent-ardeemin FQ (2a) as a mixture in CDCl3
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Figure S7. 1H-13C HMBC spectra of ardeemin FQ (1a) and ent-ardeemin FQ (2a) as a mixture in CDCl3
S12 
Figure S8. Aromatic region of 1H-13C HMBC spectra of ardeemin FQ (1a) and ent-ardeemin FQ (2a) as a mixture in CDCl3
S13 
 
Figure S9. Selected 1H-1H COSY of ardeemin FQ (1a) and ent-ardeemin FQ (2a) as a mixture 
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Figure S10. Selected HMBC connectivities in ardeemin FQ (1a) and ent-ardeemin FQ (2a) as a mixture
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Figure S11. 1H NMR spectra of dia-ardeemin FQ (3a) and dia,ent-ardeemin FQ (4a) as a mixture in CDCl3 (500 MHz)
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Figure S12. 13C NMR spectra of ardeemin FQ (3a) and ent-ardeemin FQ (4a) as a mixture in CDCl3 (125 MHz)
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Figure S13. 1H-1H COSY spectra of dia-ardeemin FQ (3a) and dia,ent-ardeemin FQ (4a) as a mixture in CDCl3
S17 
Figure S14. Aromatic region of 1H-1H COSY spectra dia-ardeemin FQ (3a) and dia,ent-ardeemin FQ (4a) as a mixture in CDCl3
S18 
Figure S15. 1H-13C HSQC spectra dia-ardeemin FQ (3a) and dia,ent-ardeemin FQ (4a) as a mixture in CDCl3
S19 
Figure S16. Aromatic region of 1H-13C HSQC spectra dia-ardeemin FQ (3a) and dia,ent-ardeemin FQ (4a) as a mixture in CDCl3
S20 
Figure S17. 1H-13C HMBC spectra of dia-ardeemin FQ (3a) and dia,ent-ardeemin FQ (4a) as a mixture in CDCl3
S21 
Figure S18. Aromatic region of 1H-13C HMBC spectra of dia-ardeemin FQ (3a) and dia,ent-ardeemin FQ (4a) as a mixture in CDCl3
S22 
 
Figure S19. Selected 1H-1H COSY spectra of dia-ardeemin FQ (3a) and dia,ent-ardeemin FQ (4a) as a mixture 
 
 
 
Figure S20. Selected HMBC connectivities in dia-ardeemin FQ (3a) and dia,ent-ardeemin FQ (4a) as a mixture
S23 
Figure S21. 1H NMR spectrum of 4-dimethylallylardeemin FQ (1b) in CDCl3 (500 MHz)
S24 
Figure S22. 1H NMR spectrum of 5-dimethylallyl-ent-ardeemin FQ (2c) in CDCl3 (500 MHz)
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Figure S23. 1H NMR spectrum of 4-dimethylallyl-dia-ardeemin FQ (3b) in CDCl3 (500 MHz)
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Figure S24. 1H NMR spectrum of 5-dimethylallyl-dia-ardeemin FQ (3c) in CDCl3 (500 MHz)
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Figure S25. 1H NMR spectrum of 7-dimethylallylardeemin FQ (1e) in CDCl3 (500 MHz)
S28 
Figure S26. 1H NMR spectrum of 7-dimethylallyl-ent-ardeemin FQ (2e) in CDCl3 (500 MHz)
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Figure S27. 1H NMR spectrum of 7-dimethylallyl-dia-ardeemin FQ (3e) in CDCl3 (500 MHz)
S30 
Figure S28. 1H NMR spectrum of 6-dimethylallyl-dia,ent-ardeemin FQ (4d) and 7-dimethylallyl-dia,ent-ardeemin FQ (4e) as mixture in CDCl3 (500 MHz)
S31 
Figure S29. 1H NMR spectrum of 5-dimethylallylardeemin FQ (1c) in CDCl3 (500 MHz)
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Figure S30. 1H NMR spectrum of 5,6-dimethylallylardeemin FQ (1f) in CDCl3 (500 MHz)
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Figure S31. 1H NMR spectrum of 5,6-dimethylallyl-ent-ardeemin FQ (2f) in CDCl3 (500 MHz)
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Figure S32. 1H NMR spectrum of 6-dimethylallylardeemin FQ (1d) in CDCl3 (500 MHz)
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Figure S33. 1H NMR spectrum of 6-dimethylallyl-ent-ardeemin FQ (2d) in CDCl3 (500 MHz)
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Figure S34. 1H NMR spectrum of 6-dimethylallyl-dia-ardeemin FQ (3d) in CDCl3 (500 MHz)
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Figure S35. 1H NMR spectrum of 6-dimethylallyl-dia,ent-ardeemin FQ (4d) in CDCl3 (500 MHz)
S38 
Figure S36. Determination of kinetic parameters of FgaPT2 for ardeemin FQ (1a)
Figure S37. Determination of kinetic parameters of FgaPT2 for ent-ardeemin FQ (2a)
S39 
Figure S38. Determination of kinetic parameters of FgaPT2 for dia-ardeemin FQ (3a)
S40 
Figure S39. Determination of kinetic parameters of 5-DMATSSc for ardeemin FQ (1a)
Figure S40. Determination of kinetic parameters of 5-DMATSSc for ent-ardeemin FQ (2a)
S41 
Figure S41. Determination of kinetic parameters of 6-DMATSSa for ardeemin FQ (1a)
Figure S42. Determination of kinetic parameters of 6-DMATSSa for ent-ardeemin FQ (2a)
S42 
Figure S43. Determination of kinetic parameters of 6-DMATSSa for dia-ardeemin FQ (3a)
Figure S44. Determination of kinetic parameters of 6-DMATSSa for dia,ent-ardeemin FQ (4a)
S43 
Figure S45. Determination of kinetic parameters of 7-DMATS for ardeemin FQ (1a)
Figure S46. Determination of kinetic parameters of 7-DMATS for ent-ardeemin FQ (2a)
S44 
Figure S47. Determination of kinetic parameters of 7-DMATS for dia-ardeemin FQ (3a)
Figure S48. Determination of kinetic parameters of 7-DMATS for dia,ent-ardeemin FQ (4a)
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Figure S49. HR-MS spectrum of ardeemin FQ (1a) 
 
Figure S50. HR-MS spectrum of 4-dimethylallylardeemin FQ (1b) 
 
Figure S51. HR-MS spectrum of 5-dimethylallylardeemin FQ (1c) 
 
Figure S52. HR-MS spectrum of 6-dimethylallylardeemin FQ (1d)  
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Figure S53. HR-MS spectrum of 7-dimethylallylardeemin FQ (1e)  
 
Figure S54. HR-MS spectrum of 5,6-dimethylallylardeemin FQ (1f)  
 
Figure S55. HR-MS spectrum of ent-ardeemin FQ (2a)  
 
Figure S56. HR-MS spectrum of 4-dimethylallyl-ent-ardeemin FQ (2b)
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Figure S57. HR-MS spectrum of 5-dimethylallyl-ent-ardeemin FQ (2c)  
 
Figure S58. HR-MS spectrum of 6-dimethylallyl-ent-ardeemin FQ (2d) 
 
Figure S59. HR-MS spectrum of 7-dimethylallyl-ent-ardeemin FQ (2e) 
 
Figure S60. HR-MS spectrum of 5,6-dimethylallyl-ent-ardeemin FQ (2f)  
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Figure S61. HR-MS spectrum of dia-ardeemin FQ (3a) 
 
Figure S62. HR-MS spectrum of 4-dimethylallyl-dia-ardeemin FQ (3b) 
 
Figure S63. HR-MS spectrum of 5-dimethylallyl-dia-ardeemin FQ (3c) 
 
Figure S64. HR-MS spectrum of 6-dimethylallyl-dia-ardeemin FQ (3d)  
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Figure S65. HR-MS spectrum of 7-dimethylallyl-dia-ardeemin FQ (3e)  
Figure S66. HR-MS spectrum of dia,ent-ardeemin FQ (4a) 
 
Figure S67. HR-MS spectrum of 4-dimethylallyl-dia,ent-ardeemin FQ (4b) 
 
Figure S68. HR-MS spectrum of 5-dimethylallyl-dia,ent-ardeemin FQ (4c)  
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Figure S69. HR-MS spectrum of 6-dimethylallyl-dia,ent-ardeemin FQ (4d) 
 
Figure S70. HR-MS spectrum of 7-dimethylallyl-dia,ent-ardeemin FQ (4e) 
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Abstract
Ergot alkaloids are secondary metabolites with significantly toxicological and
pharmacological relevance and have been identified in different fungi of
Ascomycota and several families of higher plants. Lysergic acid amides
or peptides produced by the fungus Claviceps purpurea of the family
Clavicipitaceae, e.g., ergometrine, ergotamine, or ergotoxine, and their semi-
synthetic derivatives are widely used in modern medicine for treatment of diverse
diseases. Large-scale productions of ergot alkaloids for pharmaceutical applica-
tions have been achieved by biotechnological processes including field cultivation
of Claviceps purpurea on rye or in submerged cultures. Some members of the
fungal family of Trichocomaceae such as Aspergillus fumigatus and Penicillium
commune produce clavine-type ergot alkaloids. These substances consist merely
of the ergoline ring system as a common structure of most ergot alkaloids and lack
an amide or peptidyl moiety in comparison to ergoamides or ergopeptines. Diverse
analytical methods were developed for detection and determination of ergot
alkaloids as mycotoxins in foods, cereals, and livestock feeds. Significant progress
has also been achieved on the molecular biological and biochemical investigations
of ergot alkaloid biosynthesis in the last years. The reaction steps from prenylation
of tryptophan to formation of the ergoline ring system have been studied in detail.
Keywords
Aspergillus fumigatus • biosynthesis • Claviceps purpurea • ergot alkaloids •
mycotoxins • Penicillium commune • pharmaceuticals
Abbreviations
4-DMA-l-abrine N-methyl-4-dimethylallyltryptophan
4-l-DMAT 4-dimethylallyltryptophan
5-HT 5-hydroxytryptamine
A. fumigatus Aspergillus fumigatus
acetyl-CoA Acetyl coenzyme A
C. purpurea Claviceps purpurea
C. fusiformis Claviceps fusiformis
DMAPP Dimethylallyl diphosphate
DMATS Dimethylallyl tryptophan synthase
E. coli Escherichia coli
EA Ergot alkaloid
ELISA Enzyme-linked immunosorbent assay
GSH Reduced glutathione
HPLC High performance liquid chromatography
LSD Lysergic acid diethylamide
N. lolii Neotyphodium lolii
NADH Nicotinamide adenine mononucleotide-phosphate
NFkB Nuclear factor kB
NRPS Nonribosomal peptide synthetase
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P. commune Penicillium commune
SAM S-adenosyl methionine
TLC Thin-layer chromatography
TLR 4 Toll-like receptor 4
1 Introduction
Ergot alkaloids (EAs) are a complex family of naturally occurring secondary metab-
olites derived from the amino acid l-tryptophan 1 and dimethylallyl diphosphate
(DMAPP) [1–5]. The tetracyclic ergoline ring 2 is the common structural feature of
all EAs (Fig. 23.1). Based on their structures, EAs can be classified into clavine-type
alkaloids (clavines), ergoamides 3 and ergopeptines 4 with 2 as the common
structure [5]. Clavines consist merely of 2, while 3 and 4 are d-lysergic acid 5
derivatives linked with an alkyl amine or tripeptide at the carboxyl group [2, 5].
The fungus Claviceps purpurea (C. purpurea) of the family Clavicipitaceae rep-
resents themost important EAproducer, which parasitizesmainly on rye and forms the
so-called sclerotium as resting structure during its life cycle. EAs were also detected in
Aspergillus fumigatus (A. fumigatus) and Penicillium commune (P. commune) of the
fungal family of Trichocomaceae as well as in plants of the families Convolvulaceae,
R2
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R1
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CH3 CH3
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Poaceae, and Polygalaceae [1, 3, 5]. Recent investigation revealed however that the
plant-associated fungi are responsible for EA production in plants [6, 7].
Due to their pharmacological and toxicological properties, EAs have attracted
special attention as drugs in modern medicine, as mycotoxins in the food industry
and ecological systems. In the middle ages, the consumption of rye bread contam-
inated with EAs led to severe epidemics, which have become known as ergotism or
St. Anthony’s fire. Ergotism can be distinguished in two forms dependent on
observed symptoms. Ergotismus convulsivus is characterized by paranoia with
hallucinations and ergotismus gangraenosus, which can lead to the loss of infected
tissues [8]. The relationship between ergotism and infected rye was first recognized
by Tulasne in 1853 [4]. Ergotism has been occasionally observed in livestock today
[9]. Nowadays, EAs serve as important drugs in the modern medicine. They interact
with serotonin, dopamine, and adrenergic receptors of the central nervous system
and with adrenergic receptors of blood vessels. Natural and partial synthetic EAs
are used in the treatment of postpartum hemorrhage, as antihypertensive drugs, in
migraine therapy, in the treatment of Parkinson’s disease, and in controlling the
secretion of pituitary hormones such as prolactin [1, 4, 5, 10]. Infection of plants by
endophytic fungi resulted in most cases in increased ecological fitness of the host.
Infected plants show resistance to herbivores and extreme weather conditions such
as drought. In addition, increased growth and mineral uptake is observed [11, 12].
First insights into the biosynthesis of EAs have been achieved by feeding
experiments mainly carried out by the Gr€oger and Floss groups between the
1960s and 1990s [1, 3, 5, 13–15]. In 1999, the occurrence of EA biosynthetic
gene cluster in C. purpurea has been proven by genome walking with the dmaW
gene [16], which had been identified for the first pathway-specific enzyme
dimethylallyl tryptophan synthase (DMATS) 4 years before [17]. The next impor-
tant milestone in the research of EA biosynthesis was the identification of the
biosynthetic gene cluster of fumigaclavine C 6 from the genome sequence
of A. fumigatus Af293 by bioinformatic approaches [18, 19]. The identification of
this cluster provided a convenient way to identify homologue genes in C. purpurea
and A. fumigatus involved in the committed steps and different genes for specific
steps in both pathways. Seven homologous genes were identified in both gene
clusters and proposed for reactions from l-tryptophan to ergoline ring. In the last
7 years, the functions of most of these genes from both clusters were proven
molecular biologically and biochemically.
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2 Occurrence and Structures of Ergot Alkaloids
2.1 Ascomycota as Producers of Diverse Ergot Alkaloids
2.1.1 Fungi of the Family Trichocomaceae
Somemembers of the family Trichocomaceae, e.g., A. fumigatus [20] and P. commune
[21], produce clavines as the main EAs. Festuclavine 8, chanoclavine-I 9,
fumigaclavines A 10 or 11, B 12 or 13, and C 6 or 7 have been isolated from members
of the Trichocomaceae [20]. The accumulated EAs have been observed to be present
in or on conidia of A. fumigatus. No EAs were detected in the conidiation-deficient
strains of A. fumigatus by disruption of the gene brlA. Complementation of the
deficient strain with the wild-type allele of brlA by homologous recombination
restored conidiation and EA production [19]. In A. fumigatus, 6 is the end product of
EA biosynthesis, whereas in P. commune, the biosynthetic pathway ends with the
formation of 10 [22]. 12 or 13 as a precursor for 10 or 11was found in both Aspergillus
and Penicillium strains [21, 23–25]. The stereochemistry of fumigaclavines was not
given in the literature in most cases. Conversion of chanoclavine-I aldehyde 14 leads to
the formation of 8 in A. fumigatus as predominant product (see below) [26], while
Penicillium strains produce 8 as main and its stereoisomer pyroclavine 15 and
agroclavine 16 as minor products [21, 27–29].
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2.1.2 Fungi of the Family Clavicipitaceae
Fungi of the family Clavicipitaceae, e.g., Claviceps fusiformis (C. fusiformis),
Claviceps paspali, and Claviceps hirtella, were also reported to produce clavine-
type EAs [2]. In comparison to A. fumigatus and P. commune, 14 is mainly
converted to 16 in Claviceps species [30–34]. Claviceps hirtella produces clavines
as major compounds and ergometrine 17 as minor component [35]. C. fusiformis is
the sole exception of the family Clavicipitaceae, which produces clavines but no
d-lysergic acid 5 derivatives such as 3 or 4 [31]. The most important 3 and 4
producing fungus of the family Clavicipitaceae is represented by C. purpurea. In
this fungus, EAs are detected in the sclerotium [35]. In addition, C. purpurea strains
differ from each other in the spectrum of EAs [35]. The strain P1 produces
elymoclavine 18, ergocryptine consisting of a-ergocryptine 19 and b-ergocryptine 20,
ergosine 21 and ergotamine 22 as major component [36]. In comparison, 22 and
ergocristine 23were found as major and 17 as minor EAs in the strain ECC93 [37, 38].
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2.2 Accumulation of Ergot Alkaloids in Fungi-Associated Plants
It was assumed that not only fungi but also plants of the families Convolvulaceae,
Poaceae, and Polygalaceae can produce EAs. These plants should have obtained the
ability through a horizontal gene transfer from fungi during evolution [3, 6].
Investigations of four different EA-containing plants of the family Convolvulaceae
demonstrated however that EAs were only detectable in the presence of the
plant-associated fungi. Treatment of Ipomoea asarifolia (Convolvulaceae) with
fungicides resulted in complete abolishment of EA production [39]. In conclusion
plant-associated and mostly seed-transmitted fungi, not the plants themselves
produced EAs [40]. Comparison of the ribosomal DNA and dmaW, encoding the
first enzyme in the EA biosynthetic pathway, revealed that these clavicipitalean
fungi are closely related but not identical [41]. Recently, two new plant-associated
EA-producing fungi were described and named Periglandula ipomoeae and
Periglandula turbineae [42]. In Poaceen plants, sexual endophytic fungi of the
genus Epichloe¨ and their asexual counterparts Neotyphodium as well as the genus
Balansia are responsible for EA production [7]. Ergovaline 24 and simple lysergic
acid amides have been identified in Epichloe¨ festucae, which is determined to be
symbiotic with many grasses [7].
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2.3 Symbiotic Communities
Clavicipitalean fungi and higher plants of the family Convolvulaceae as well as
grasses of the family Poaceae exhibit often symbiotic communities. The endophytic
fungi benefit from its host by receiving nutrients, protection, and dissemination.
Plants have also advantages by associating with endophytic fungi, including
defense against herbivores, insects, and nematodes. Other benefits include
increased growth of the plant, resistance to drought, and nutrient status [43]. The
beneficial implications of EAs in endophyte-infected tall fescue have been analyzed
by application of root extracts including polyphenolic fraction, EAs, and loline
alkaloids to Pratylenchus scribneri, a nematode of tall fescue grasses. It has been
shown that P. scribneri affects endophyte-infected tall fescue in very low amount,
compared with noninfected tall fescue. The toxicological tests of EAs revealed that
19 and 24 were toxic to nematodes at concentrations of 5 and 50 mg ml1. Also 17
and ergocornine 25 showed nematistatic effects at most tested concentrations [44].
Another study revealed a putative biosynthetic gene cluster of 24 in Neotyphodium
lolii (N. lolii) by cloning and analysis of a nonribosomal peptide synthetase (NRPS)
gene. A monomodular NRPS and other genes have been identified, which are
orthologous to C. purpurea and A. fumigatus genes. Endophyte-associated grasses
expressed genes, which encode enzymes catalyzing the biosynthesis of 24, whereas
no formation of 24 was found in N. lolii mycelia from axenic culture. It was
proposed that plants associated with endophytes induce the gene expression by
special signal molecules [45]. EA occurrence was also analyzed in the symbiotic
community of a clavicipitalean fungus and Ipomoea asarifolia (Convolvulaceae).
The dmaW gene encoding the first EA biosynthesis specific step was identified in
clavicipitalean fungus, but not in Ipomoea asarifolia [40]. This demonstrates that
only the fungus possesses the genetic information for EA biosynthesis. Neverthe-
less, the produced EAs were only detectable in plants, while no alkaloids were
measured in the associated epibiotic fungus. A transport system is supposed to be
responsible for transferring EAs from fungus to its host [40]. In contrast, no
observed benefits have been achieved by symbiosis of native grass populations
and endophytes in a 4-year experiment. Neither advantages in growth nor seed
production or reproductive effort under full herbivory were detected in comparison
to grasses, which are not infected or infected but not producing EAs [46].
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3 Cultivation, Extraction, Purification, and Analyses of Ergot
Alkaloids
3.1 Cultivation of Penicillium commune as an Example for Ergot
Alkaloid Production in Fungi
The optimal cultivation conditions for EA production in fungi vary enormously. For
example, different conditions for EA production were described for C. purpurea
strains (see Sects. 6.2 and 6.3) [31–33, 47–49]. Here, we will just demonstrate the
principle for EA production in P. commune used in our laboratory. Glucose peptone
with soy flour medium (GPS) and wheat grains liquid media were inoculated with
1105 spores of P. commune per 100 ml medium and cultivated at 25 C for
14 days in the dark without shaking.
3.2 Extraction and Purification of Ergot Alkaloids
EAs are natural bases, due to the N-6 of 2. The solubility of EAs can be
therefore influenced by changing the pH value of the solution. At low pH value
(e.g., pH < 6), the N-6 will be protonated and easier soluble in water.
EAs exist, at high pH value (e.g., pH 9), in their free base and therefore are
soluble in organic solvents. Furthermore, the residues at C-8 of 2 contribute
to the different polarities of EAs. These properties are usually used in
the extraction and purification procedures of EAs [22, 26, 50]. Initially,
halogenated organic solvents such as chloroform or dichloromethane were
applied for extraction of EAs. Ethyl acetate and acetonitrile have been
demonstrated later to be alternatives to halogenated solvents [51]. Never-
theless, dichloromethane was better in certain extraction procedures.
Ammonium hydroxide or sodium hydroxide was often found as component
in the extraction agents for EAs as free bases [52–54]. As aforementioned,
EAs can be also extracted as EA salts by using polar solvents with acid,
e.g., methanol and 0.25% concentrated phosphoric acid (40/60) [55], acetonitrile
with phosphate-buffer pH 6.0 (60/40) [56], or 2-propanol, H2O, and lactic
acid (50/49/1, V/V). These systems were able to extract EAs with different
polarities [57].
Purification of the EA-containing extracts was performed either by liquid-liquid
extraction [53] or on solid-phase extraction using silica gel as normal phase or C18
as reverse phase [54, 58]. EAs with a wide range of polarities can be separated by
reverse phase HPLC (high performance liquid chromatography) using gradient
elution system beginning often with an aqueous solvent, e.g., 5% acetonitrile
in 50 mM ammonium acetate to a nonpolar solvent, e.g., 75% acetonitrile in
50 mM ammonium acetate [1]. Cation exchangers are often used for purification
after extraction of EAs with acids. Protonation of EAs at the N-6 enables them to
adsorb at the negatively charged material. Elution of EAs is performed by
deprotonating with basic solvents [51].
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3.2.1 Extraction of Ergot Alkaloids from Liquid Cultures of Penicillium
commune
The mycelia of P. commune are to be separated from media by filtration and the pH
value of the filtrate is adjusted to 8–9 with ammonium hydroxide. The filtrate is
subsequently extracted twice with equal volume of dichloromethane. The organic
phases are combined and evaporated to dryness in vacuum.
3.2.2 Extraction of Ergot Alkaloids from Cultures of Penicillium
commune on Wheat Grains
The solid cultures with wheat grains are suspended in 300 ml ethyl acetate and
shaked at 25 C for 4 h. The organic phase is obtained by filtration, subsequently
dried over sodium sulfate and evaporated to dryness in vacuum.
3.3 Analyses of Ergot Alkaloids in the Extracts
3.3.1 Colorimetric Assay
EAs can be identified by various analytical methods. The most important
colorimetric analysis is the reaction of EAs with van Urk’s reagent, a mixture of
p-dimethylaminobenzaldehyde, FeCl3, and H2SO4. This reagent is also used for
quantification of EAs by measurement of the absorbance at 580 nm of the reaction
products [59, 60].
3.3.2 Thin Layer Chromatography (TLC)
TLC was performed on silica gel alone, impregnated with sodium hydroxide or
formamide as well as aluminum oxide and used both for detection and separation of
EAs [22, 49, 60–62].
Detection of EAs on TLC was carried out by observation of their fluorescence or
colors of reaction products with spray reagents. The presence of the double bond
between C-9 and C-10 in EAs is prerequisite for a detection of their fluorescence
under UV light. Clavine-type alkaloids show no auto-fluorescence due to the
absence of the double bond in 2. Various spray reagents are explored to detect
clavine-type alkaloids or to distinguish between different EAs. Van Urk’s reagent
is also used as spray reagent to detect EAs [63]. To intensify the spots, TLC plates
can be sprayed with sodium nitrite solution [64]. 22 was determined as a blue
spot by using an acidic aqueous solution of 0.5% glyoxylic acid containing 0.05%
ferric chloride. In case of ergoamides 3 additional heating of the sprayed plate
at 110 C is necessary for displaying spots [65]. Different colors of 22 can
be achieved by spraying the TLC plates with p-acceptors such as 2, 3-dichloro-5,
6-dicyanobenzoquinone [66].
3.3.3 Enzyme-Linked Immunosorbent Assay (ELISA)
Specificity in the determination of EAs in immunoassays depends on the
applied antibodies [63]. Most ELISA techniques were only able to detect
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certain EAs [51]. A competitive inhibition ELISA was developed for specific
reaction of polyclonal antibodies with phenylalanine residues of EAs in 22, 23,
and ergostine 26 [67]. Development of a monoclonal antibody permitted the
detection of various EAs, e.g., 24 and clavine alkaloids [68]. Another competitive
ELISA was used for measuring dihydroergosine 27 in grain and animal feed. 27
conjugated to bovine serum albumin was recognized by specific mouse monoclo-
nal antibodies and rabbit polyclonal antibodies [69]. Furthermore, the
semiquantitative competitive ELISA is applied for the determination of EAs in
endophyte-infected plants by specific reaction of the monoclonal antibody with
the lysergic acid moiety [70].
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3.3.4 High Performance Liquid Chromatography (HPLC)
HPLC was proven to be the most important instrumental analytical method
for determination of EAs. Separation on HPLC and downstream detection
by fluorescence detector or tandem mass spectrometer was performed. In the
early 1970s, when the semisynthetic lysergic acid diethylamide 28 (LSD)
became available in the drug scene, there was the need of a suitable
analytical method for the detection of LSD. Since then, many HPLC analyses
have been developed for the detection of EAs. Initially, normal phase HPLC
was used for the determination of 4 with subsequent fluorescence detection.
Today, reversed phase with C18 column materials is used more frequently
for analysis of EAs [63, 71–73]. As mentioned before, EAs differ often in the
position of the double bond in ring D of the 2. Clavine-type EAs contain
sometimes a double bond at C-8 and C-9, whereas 3 and 4 carry a double
bond at C-9 and C-10 instead, which influences the chromophoric features
and is therefore a key parameter for the choice of excitation and emission
wavelength of fluorescence detection. Extract mixtures containing EAs
with a double bond at different positions (C-8 and C-9 or C-9 and C-10)
should be analyzed in two runs to ensure the detection and quantification of
the complete EAs. Another possibility is to use two fluorescence detectors
subsequently [74].
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4 Versatile Biological Activities of Ergot Alkaloids
4.1 Therapeutically Significant Ergot Alkaloids and Those as
Potential Pharmaceuticals
Comparison of the general ergoline structure of EAs with the neurotransmitters
noradrenaline, dopamine, and serotonin display structural similarities [75]
and accordingly explain their interaction with a-adrenergic receptors and
serotonin receptors as agonists, partial agonists, and antagonists [76]. In addition,
they act as agonists or partial agonists at dopamine receptors of the central
nervous system. In the modern medicine, natural EAs and their semisynthetic
derivatives are important therapeutic drugs. Due to the broad interaction with
receptors and some adverse effects, pharmacologically used compounds are
characterized as “dirty drugs.” To obtain desired affinity of EAs toward
the various receptors, chemical modifications on the substituents linked to the
carboxyl group of 5 were carried out [77].
4.1.1 Clavine-Type Alkaloids
An important compound with biological activity of clavines is represented by 6 as
end product of EA biosynthesis in A. fumigatus. In animal experiments using
rats, 6 exhibited vasorelaxant effects on isolated thoracic aortic rings independent
of endothelial mediators. Several mechanisms are proposed for the vasorelaxant
effect of 6. These results indicate that 6 has potential capacity in vascular
protection and may be used as therapeutic drug against cardiovascular diseases
[78]. Treatment of mice with induced liver damage and colitis with 6 showed
clear beneficial effects on these diseases [79, 80]. In addition, it has also been
demonstrated that 6 exhibits potential relevance as an antiatherosclerotic agent.
Inflammation processes like activation of toll-like receptor 4 (TLR 4) and
nuclear factor kB (NFkB) have been shown to be responsible in the development
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of atherosclerosis. 6 interferes with the TLR 4/NFkB signaling pathway leading to
a decrease of inflammatory factors [81]. Studies with other biologically active
clavine-type alkaloids, e.g., 8, 15, 16, and 18, revealed that these compounds act
as pure antagonists or partial agonists at 5HT2A (5-hydroxytyptamine) receptors
of rat tail artery and as antagonists at a1-adrenoceptors of rat aorta [82]. It has
been furthermore reported that clavines, e.g., 9-deacetoxyfumigaclavine C 29 and
9-deacetylfumigaclavine C 30 exhibit selective and potent cytotoxicity against
human leukemia cells [83].
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4.1.2 Ergoamides
17 and its semisynthetic derivative methylergometrine 31 are the main ergoamides
used in modern medicine. 17 and 31 are assembled from 5 and amidated with
2-aminopropanol and 2-aminobutanol, respectively. Their pharmacological effects
are based on the selective antagonistic interaction with 5-HT receptors on the
smooth muscles and as partial agonists or antagonists to 5-HT receptors of the
central nervous system. Additionally, they act on blood vessels as antagonists of
dopaminergic receptors and partial agonists of a-adrenergic receptors. 17 and 31
are used due to the direct stimulatory effect on uterine contraction in obstetrics and
for both prevention and treatment of postpartum hemorrhage [84]. 28 is also a
semisynthetic ergoamide and it should be mentioned here. Due to the strong
hallucinogenic side effects and abuse potential, 28 is no longer used for treatment
of psychiatric disorders [85, 86].
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4.1.3 Ergopeptines
Peptide alkaloids or ergopeptines 4 are composed of 5 with proline-
containing tripeptidyl residues attached to the carboxyl group resulting in the
formation of a tricyclic system. 22 is one of the therapeutically important peptide
alkaloids. 22 interacts as partial agonist and antagonist with 5-HT- and
a-adrenergic receptors in blood vessels and smooth muscles. The most significant
effect of 22 is based on the agonistic effect at 5-HT1B/1D receptors at the blood
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vessels in the central nervous system, where the constriction of intracranial
blood vessels leads to reduction of neurogenic inflammation in the trigemino-
vascular system. 22 is used for treatment of mild to severe migraine attacks
and cluster headache [87, 88]. The hydration of the double bond at C-9 and
C-10 of 22 results in the semisynthetic derivative dihydroergotamine 32, which
is also used in the therapy of migraine headache [89, 90] and furthermore in
the therapy of orthostatic hypotension [91]. The ergopeptine alkaloids 19, 20,
23, and 25 are components of ergotoxine, which were initially thought to be
a single compound. Dihydroergotoxine consisting of the semisynthetic deriv-
atives dihydroergocornine 33, dihydroergocristine 34, a-dihydroergocryptine
35, and b-dihydroergocryptine 36, also named ergoloid, is used for treatment of
age-related cerebral dysfunction like dementia [84, 92]. Furthermore 35 and
bromocryptine 37, a semisynthetic derivative of 19, as well as pergolide 38
and cabergoline 39, are used therapeutically for treatment of early-onset
Parkinson’s disease [93–95]. Their effects are based on their potent agonism
on dopamine (D2) receptors. Dopamine is a prolactin-inhibiting factor.
The agonistic effect of 37 and 39 to dopaminergic receptors results also
in inhibition on the release of the peptide hormone prolactin [96].
Therefore, they are also used in treatment of prolactin-related disorders such
as galactorrhea, prolactin-dependent mammary carcinoma, amenorrhea, and
acromegaly [97–99].
5 Biosynthesis of Ergot Alkaloids in Different Fungi
5.1 Biosynthesis of the Tetracyclic Ergoline as a General
Structure of Ergot Alkaloids
Different approaches have been carried out to investigate the biosynthesis of EAs.
Early feeding experiments with isotope-labeled precursors, e.g., [14C]-L- trypto-
phan 1, to rye ears infected with C. purpurea or to fermentation cultures of different
Claviceps species proved its incorporation into 2 [100–102]. Further biochemical
experiments with crude and purified enzyme extracts from producers revealed
the determinant step in the biosynthesis of EAs by the key enzyme
4-dimethylallyltransferase (4-DMATS) [103, 104], i.e., the prenylation of 1 at
C-4 position [17, 104, 105].
The gene dmaW encoding for the first pathway-specific DMATS was cloned
firstly from C. fusiformis [17]. This was done by PCR amplification using degen-
erate primers deduced from partial amino acid sequences obtained from purified
DMATS of C. fusiformis and cDNA (copy DNA) library from the same strain [17].
The identified nucleotide sequence of dmaW led later to detection of an EA gene
cluster in C. purpurea containing 14 genes by chromosome walking (Fig. 23.2)
[16]. This cluster was proven to be responsible for the biosynthesis of ergoamides,
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e.g., 17 and ergopeptines, e.g., 22 [35, 38, 106]. Blasting the genome sequence of
the first Aspergillus species, i.e., A. fumigatus Af293 [107] with dmaW sequence
from C. purpurea revealed the presence of an EA gene cluster in A. fumigatus
containing 11 genes on chromosome 2 [18] (Fig. 23.2). This cluster contains genes
necessary for the biosynthesis of the clavine alkaloid 6 lacking an amide or
a peptidyl moiety [5, 22]. To identify the biosynthetic gene cluster of 11,
a cosmid library with genomic DNA from P. commune NRRL2033
was constructed and screened with fgaPT, a homologous gene of dmaW from
P. commune NRRL2033. Sequencing and analysis of three positive cosmids
revealed a putative cluster consisting of nine genes for the biosynthesis of 11
(Fig. 23.2) [108].
Identification of the biosynthetic gene clusters for 6 and 11 as well as compar-
ison of the EA biosynthetic genes in C. purpurea, A. fumigatus, and P. commune
provided a convenient way to identify candidate genes for the formation of the
common structure 2 and for the specific steps in the three fungi [5, 18, 22].
Comparison of the gene clusters from C. purpurea, A. fumigatus, and P. commune
revealed the presence of seven orthologous/homologous genes (black arrows) in the
Claviceps purpurea P1
lpsC
lpsA1
Aspergillus fumigatus Af293
fgaOx3 fgaP450-1 fgaDH
fgaFS fgaPT1 fgaP450-2 fgaCat fgaOX1
fgaOx3pcfgaCatpcfgaOx1pcfgaDHpc
Penicillium commune NRRL2033
fgaATpc
fgaP450pc fgaPTpc fgaMTpc fgaFSpc
fgaAT fgaPT2 fgaMT 1 kb
easH2 lpsA2
easA lpsB easC easG easH1
dmaWeasFeasDcloA
ccsA/
easE
Fig. 23.2 EA gene clusters of C. purpurea, A. fumigatus, and P. commune. The black arrows
indicate the homologous genes of all clusters (Modified after [22, 35, 109])
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three clusters (Fig. 23.2), which were speculated to be responsible for the formation
of the ergoline scaffold 2 [5, 18, 22]. The NRPS genes lpsA1, lpsA2, lpsB, and lpsC
from the cluster of C. purpurea P1 will be needed for the biosynthesis and
attachment of the alcohol amine and peptidyl moiety to the carboxyl group of 5.
The presence of the putative acetyltransferase gene fgaAT in the cluster of 6 in A.
fumigatus or fgaATPc in the cluster of 11 in P. commune would be used for the
transfer of an acetyl group from acetyl-CoA to a hydroxyl group of 12 or 13. The
second prenyltransferase gene fgaPT1 in the cluster of A. fumigatus could be
assigned for the conversion of 10 to 6 [110]. This gene is absent in the cluster of
P. commune, indicating that 11 instead 7 is the end product of the gene cluster. This
was proven by isolation and identification of 11 as the main EA in P. commune
NRRL 2033 [22, 108, 110].
Functional proof of genes was carried out by knock-out experiments and
identification of the accumulated intermediates [111–115] or by biochemical
approaches using purified recombinant enzymes [18, 26, 50, 110, 116–119].
The biosynthesis of 2 begins with the prenylation of 1 by the enzyme 4-DMATS
(DmaW), e.g., FgaPT2 from A. fumigatus (Scheme 23.1). The essential role of
fgaPT2 for the biosynthesis of 6 in A. fumigatus has been proven by knock-out
experiments [113]. Incubation of 1 with recombinant FgaPT2 from Saccharomyces
cerevisiae in the presence of DMAPP and subsequent isolation and structure
elucidation of the enzyme product proved unequivocally its conversion to 4-
dimethylallyltryptophan (4-l-DMAT) 40 [18]. 40 was then converted to N-
methyl-4-dimethylallyltryptophan (4-DMA-l-abrine) 41 by a methyltransferase,
e.g., FgaMT from A. fumigatus, in the presence of S-adenosyl methionine, which
was verified by using the purified recombinant FgaMT [117]. Conversion of 41 to
the next detected intermediate 9 requires one decarboxylation and two oxidation
steps. The first proposed oxidation starts with the formation of a diene by hydrox-
ylation at C-9 resulting in formation of an unstable intermediate and subsequent
spontaneous dehydration [3]. The gene ccsA (also termed easE) encodes a flavin
adenine dinucleotide containing oxidoreductase, which plays an important role in
the biosynthesis of 9. Experiments with knock-out mutants of C. purpurea strain P1
lacking ccsA led to accumulation of 41 and traces of 40 [114]. In addition, the gene
easC has been proven to encode a catalase and plays also an essential role in the
biosynthesis of 9. Disruption of easC in A. fumigatus by homologous recombination
resulted in accumulation of 41 and abolishment of downstream EAs, similar to the
results obtained from disruption mutants of ccsA mentioned above [111]. Feeding
experiments with 9 to easC and easE mutants of A. fumigatus led to restoration of
EA biosynthesis, which proved that the conversion of 41 to 9 required both EasC
and EasE. Recombinant EasC from Escherichia coli (E. coli) showed catalase
activity in the presence of H2O2. It was therefore speculated that two different
classes of enzymes, a catalase and a flavin adenine dinucleotide-dependent
oxidoreductase are together responsible for the formation of 9 (Scheme 23.1).
Biochemical evidence for this hypothesis has to be provided in the future.
The common biosynthetic pathway of EA-producing fungi, e.g., Aspergillus,
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Penicillium, and Claviceps, ends with enzymatic formation of 14 (Scheme 23.1).
Earlier experiments in the 1970s and 1980s by feeding Claviceps cultures with
isotope-labeled precursors identified 14 as further intermediate in the conversion of
41 to 16 [13, 120]. Biochemical investigation showed that a short-chain dehydro-
genase FgaDH from A. fumigatus catalyzed the conversion of 9 to 14 in the
presence of nicotinamide adenine nucleotide (NAD+) [50]. The orthologous EasD
from C. purpurea and FgaDHPc from P. commune are expected to catalyze the same
reaction (Scheme 23.1).
14 was found to be the branch point in the biosynthesis of different EAs [112].
A lot of efforts have been made to investigate the conversion of 14 to downstream
intermediates. EasA from C. purpurea and its homologous fgaOx3 from
A. fumigatus and fgaOx3Pc from P. commune belong to the old yellow enzyme
family and encode for flavin adenine dinucleotide-dependent oxidoreductases.
Investigations with purified recombinant proteins showed that in A. fumigatus,
FgaOx3 catalyzed together with the festucalvine synthase the formation of 8 from
14 (Scheme 23.1) [26]. In the absence of FgaFS, FgaOx3 catalyzed the conversion
of 14 to two shunt product isomers [121]. It has been proposed that conversion of
14 to 8 consist of two reduction steps. The double bond between C-8 and C-9 would
be firstly reduced by FgaOx3 and the resulted dihydrochanoclavine-I aldehyde
would undergo spontaneous cyclization to an iminium intermediate, which is
subsequently reduced by FgaFS [26]. Similar to their orthologous FgaOx3 and
FgaFS in A. fumigatus, FgaOx3Pc and FgaFSPc from P. commune also catalyzed
the conversion of 14 to 8 [22]. Interestingly, 15 was found as the second
enzyme product in the incubation mixture of 14 with FgaOx3Pc and FgaFSPc.
Incubation with different enzyme combinations proved that the second reduction
catalyzed by FgaFS or FgaFSPc controlled the stereochemistry of the product,
i.e., those of 8 and 15 [22].
In contrast, EasA from C. purpurea was proven to be inactive and will be not
involved in the conversion of 14 to 16 [22, 116]. The agroclavine synthase EasG in
C. purpurea alone was responsible for conversion of 14 to 16, via a nonenzymatic
adduct with reduced glutathione (GSH) (Scheme 23.1). GSH was necessary for the
isomerization of 14 to form isochanoclavine-I aldehyde, which would undergo
spontaneous cyclization to an iminium intermediate. This imine is subsequently
reduced by EasG, as in the case of FgaFS [116]. 8, 15, and 16 serve as precursors
for 6 in A. fumigatus, 11 in P. commune, and lysergic acid 5 in C. purpurea,
respectively.
5.2 Biosynthesis of Fumigaclavines
The first main tetracyclic intermediate with an ergoline 2 scaffold in the biosyn-
thesis of fumigaclavines was detected as 8 in A. fumigatus, whereas another
intermediate with tetracyclic scaffold was determined as 15 in P. commune. Both
structures contain a saturated d-ring, which are different in their stereochemistry
at C-8. In comparison, 8 and downstream enzymatic products of A. fumigatus,
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e.g., 6, 10, and 12 have S-configuration at C-8, while 15 and the subsequent
enzymatic products, e.g., 11 and 13 have R-configuration at C-8 position. In
addition, the biosynthetic pathway in A. fumigatus ends with the formation of 7,
whereas 11 is the last detectable product of P. commune. The difference of
structural features of 6 and 11 depends on the additional gene fgaPT1 encoding
for a second prenyltransferase in A. fumigatus biosynthetic gene cluster, while the
gene cluster of P. commune contains only one gene fgaPT encoding for
a dimethylallyl tryptophan synthase [22]. The comparison of the structures 6 and
8, which differ in an acetoxy group at position C-9 and a reverse prenyl moiety at
position C-2 of 6, indicates that three enzymatic reactions must be involved in the
formation of 6 from 8. These reactions must be hydroxylation, acetylation, and
prenylation. Three genes in the cluster of A. fumigatus, fgaP450-2, fgaAT, and
fgaPT1, encode a putative hydroxylase, acetyltransferase, and prenytransferase and
are proposed to be responsible for the enzymatic synthesis of 6 from 8. Two
reactions, i.e., hydroxylation and acetylation, are needed in the biosynthesis of 11
from 15 in P. commune. It can be expected that the orthologous enzymes catalyze
same reactions with different stereochemistry at C-9. Indeed, cloning of the puta-
tive genes fgaAT and fgaPT1 from A. fumigatus, overexpression in E. coli and
biochemical investigations revealed that FgaAT catalyzes the acetylation of 13
isolated from P. commune in the presence of acetyl-CoA, resulting in the formation
of 11 [122]. FgaPT1 catalyzes the attachment of a prenyl moiety to C-2 of 11
isolated from P. commune in the presence of DMAPP [110]. Until now, the
enzymatic conversion of 8 to 12 or 15 to 13 is not yet investigated. It is speculated
that this reaction is catalyzed by a cytochrome P450 monooxygenase
(Scheme 23.1).
5.3 Formation of d-Lysergic Acid
The conversion of 16 to 5, as the acyl component of 3 and 4 in C. purpurea, requires
two oxidation steps to form paspalic acid 42 via 18 and subsequent isomerization of
42 to 5. Disruption of cloA, encoding a cytochrome P450 monooxygenase in the EA
gene cluster of C. purpurea, resulted in the abolishment of 4 production, whereas
the immediate precursor of 16, 18, and 42 accumulated in the cloA deficient mutant.
Restoration of ergopeptine 4 biosynthesis was observed, on the one hand, by feeding
the cloA deficient mutant with 5 and, on the other hand, by complementation of the
mutant with intact cloA gene [123]. In addition, cross-complementation analyses of
cloA between C. pupurea and C. fusiformis confirmed the function of CloA as
elymoclavine oxidase. The EA biosynthesis in C. purpurea proceeds via 16, 18, and
42 to 5 and the ergopeptines 4, while C. fusiformis is only able to produce 16 and 18.
Due to mutations and rearrangements of cloA in C. fusiformis, the biosynthetic
pathway ends on the level of 18. Integration of intact cloA from C. purpurea into
C. fusiformis led to the production of 4. In summary, these experiments showed the
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catalytic role of CloA bridging the biosynthesis of clavine alkaloids and d-lysergic
acid-derived EAs in C. purpurea [115]. Until now, the conversion of 16 to 18 as
well as 42 to 5 is not investigated biochemically. No information on the structural
genes is available (Scheme 23.1).
5.4 Biosynthesis of Ergoamides and Ergopeptines
C. purpurea produces simple d-lysergic acid alkyl amides like 17 and ergopeptines
4. The tripeptidyl moiety of 4 in C. purpurea contains in the first and second
position variable unpolar amino acids and L-proline in the third position. Biochem-
ical investigations revealed that biosynthesis of 4 are catalyzed by two interacting
NRPSs. The biosynthetic gene cluster of EAs in C. purpurea includes four NRPS
genes, lpsA1, lpsA2, lpsB, and lpsC. The lysergyl peptidyl synthetases LPSA1 and
LPSA2, encoded by lpsA1 and lpsA2, contain both trimodular domains
(A1TC1A2TC2A3TC3). In contrast, LPSB and LPSC encoded by lpsB and lpsC
contain only monomodular domains (ATC). In addition, LPSC includes a further
domain termed as R-domain (reduction). The function of LPSA1 was investigated
by deletion experiments in C. purpurea strain P1, which produces 19, 20, and 22.
22, with a tripeptide moiety of phenylalanine, alanine, and proline, was absent in
the resulted deficient mutant, while 19 and 20, with a tripeptide moiety of valine,
proline, and leucine or isoleucine, were still produced by the mutant. These results
prove that LPSA1 is involved in the formation of the tripeptide moiety of 22, but not
in the formation of the tripeptide moiety of 19 and 20. In addition, these findings
indicate that the formation of 4 with altered peptidyl residues is determined by
NRPS specificity [37]. The second NRPS gene lpsB was investigated by several
approaches. Analysis of the lpsB disruption mutant in C. purpurea P1 showed
inability to produce any ergopeptines, whereas accumulation of 5 was observed.
After heterologous expression of lpsB in E. coli, the purified enzyme LPSB was
assayed with 5 and amino acids presented in the peptidyl moieties of 4. LPSB was
shown to be responsible only for 5 activation and incorporation into the
ergopeptine skeleton. The connection of 5 with the tripeptidyl residue containing
alanine, phenylalanine, and proline catalyzed by NRPSs is proposed to start with
activation of 5 by the A-domain of the monomodular LPSB and subsequent transfer
to the T-domain, which acts as peptidyl carrier protein binding d-lysergic acid as
thioester. In comparison, the trimodular LPSA1 catalyzes the activation of
alanine, phenylalanine, and proline by the A-domains and transfers them to
the 40-phosphopantetheinyl residues of the three T-domains. 5 is transferred to the
trimodular LPSA1 and is then incorporated to the d-lysergyl mono-, di-, and
tripeptides. It is presumed that the formation of the peptide bond between 5 and
alanine is catalyzed by the C-domain of LPSB in a condensation reaction. The
elongation to a tripeptide attaching phenylalanine and proline is then catalyzed by
the C1- and C2-domain of LPSA1. The C3-domain of LPSA1 releases the d-lysergyl
23 Alkaloids Derived from Tryptophan: A Focus on Ergot Alkaloids 703
tripeptide from the enzyme complex as lysergyl peptide lactam, after the cycliza-
tion between phenylalanine and proline. To obtain ergopeptine 4 as the end product
one further heterocyclization is needed, which is catalyzed by a putative cyto-
chrome P450 monooxygenase (Scheme 23.2).
6 Industrial Production of Ergot Alkaloids
6.1 Life Cycle of Claviceps purpurea
As aforementioned, C. purpurea is the most important fungus in the Claviceps
genus. Approximately 400 species of grasses serve as hosts for the infection by C.
purpurea [125, 126]. At the beginning of the life cycle, ascospores of C. purpurea
infect unfertilized rye ovaries. Under unfavorable conditions, a sclerotium is
formed as resting structure of the fungus. At springtime, fruiting bodies composing
of perithecia with haploid ascospores are developed from the sclerotium. After
releasing the ascospores from the tubular asci, they are transported by wind to
flourishing rye ears and initiate the primary infection of the host. The spores attach
to the stigmatic hairs of the ovary style and begin to germinate. Penetration of the
hyphae into the host is probably enforced by the release of cell wall-dissolving
enzymes [4]. The hyphae grow toward the ovary base and after reaching the base
a massive colonization of the entire ovary occurs by extensive branching of the
hyphae. Tissues below the base (rachilla) are not affected by fungal hyphae.
Constriction of the hyphae leads to the formation of conidiospores which serve
for vegetative propagation of the fungus before the sclerotium is formed again.
Approximately one week after infection, a syrupy fluid is discarded, which is
referred to as honeydew. The conidiospores are exuded into the honeydew. The
sugary honeydew attracts insects to spread the spores to other unfertilized ovaries in
a secondary infection [127–129]. After about 2 weeks, the production of honeydew
stops and leads to the maturation of the horny black sclerotium containing hardened
fungal mycelium [128, 130]. After 5 weeks, the maturation of sclerotium is
complete. The sclerotium ensures the survival of the fungus at low temperatures
in winter. Reaching of temperature to 20 C in springtime, germination can occur
beneath the soil surface [131].
6.2 Field Production of Ergot Alkaloids on Rye
Initially, EAs were produced on a large scale by field cultivation on infected rye or
triticale. C. purpurea, C. fusiformis, and Claviceps paspali are generally applied as
parasitic fungi to produce ergopeptines 4, clavine alkaloids, and single lysergic acid
derivatives as precursors for partial synthetic drugs, e.g., 22 [2, 77]. Chemical
synthesis is time-consuming and expensive. Inoculation of hosts with parasitic
cultures can be performed either with specific pricking machinery or by spraying
conidial suspension initiating the primary infection cycle. Improvement of field
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cultivation technology results in higher yield of generated EAs [132]. Several cell
lines of rye were interbred with each other to obtain a hybrid cell line with induced
male-sterility. Due to prevented self-pollination the florets stay open longer increas-
ing the probability of contact of the spore suspension with the stigmatic hairs of the
ovary style [133]. The EAs are synthesized during the sexual life cycle of the
parasitic fungi on their hosts. Mutants of Claviceps strains lead to increase of
generated sclerotia from 400 to 1,000 kg per hectare [134]. Field cultivation on
rye exhibits both advantages and disadvantages. The genetic variability of
Claviceps strains leads to the production of a wide range of EAs. In addition,
Claviceps strains used for cultivation on rye show genetic stability in comparison
to submerged cultures. Furthermore, hybrid ryes with prolonged flowering time
were used for field cultivation to ensure efficient infection by conidial suspension.
However, the disadvantages of parasitic EA production are the dependency on
environmental conditions such as weather, alternating quality of hybrid rye, and
expensive purification processes [77].
6.3 Production of Ergot Alkaloids in Submerged Cultures
The submerged cultivation is also used for the production of EAs, e.g., 3,4, and 5
[135]. The submerged cultivation requires a special media and is accomplished
independently of the host organisms. The prerequisite for successful cultivation are
suitable strains, which are capable to produce EAs in submerged cultures. To obtain
appropriate fungi cultures, various Claviceps strains were isolated from its sclerotia
modified by mutagenesis and selected according to desired properties. 5 serves as
a starting compound for the production of partially synthetic drugs such as 31 or 39.
Only low concentrations of pure 5 can be obtained in cultivation processes [77].
Therefore, isomerization of 42 or hydrolysis of 3 or 4 to 5 was performed [136]. To
assure a high quality of selected strains for EA production, storage in liquid
nitrogen or freeze drying in a preservative solution consisting of sucrose and
skimmed milk should be performed [137]. In nature, EA production is dependent
on the formation of sclerotium during the life cycle of Claviceps. Mycelium at
sphacelia stage is unable to synthesize EAs. The strains used in submerged cultures
show different cell morphology [138]. The sclerotia-like cells possess the ability to
produce EAs. Suitable medium for Claviceps cultivation in submerged culture
contains characteristic components [139, 140]. Sucrose is used in a concentration
of 300 g L 1 and glucose in concentration of 100 g L1 [48]. An osmotic pressure
of 10–20 bars is required to induce the formation of sclerotia-like cells, while the
conidiation is inhibited at these conditions [141]. Furthermore, a noninhibitory,
slowly metabolized carbon source such as mannitol, sorbitol, or sucrose is needed,
which acts as nutrient for the fungus [142, 143]. Organic acids are used as carbon
source for saturation of tricarboxylic acid cycle [48, 144] leading to increased
synthesis of acetyl-CoA at glycolysis and citric acid cycle [145, 146]. Acetyl-
CoA is the key substrate in the alkaloid and lipid synthesis [77]. Glyoxylate and
pentose phosphate pathway supply the reducing agent which is provided for the
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mevalonate pathway and lipid biosynthesis [147]. Limitation of phosphate
increases oxidative metabolism in cells of Claviceps strains and promotes the
production of secondary metabolites such as EAs [147, 148].
6.4 Semisynthetic Modifications of Natural Ergot Alkaloids Yield
Significant Pharmaceuticals
Dihydroergotamine 32 is produced by partial synthesis using the naturally occur-
ring ergotamine 22. Hydrogenation of the double bond at C-9 and C-10 of the 22 or
amidation of dihydrolysergic acid with synthesized tripeptide results in the forma-
tion of 32 [149]. Dihydroergotoxine is a mixture consisting of 33, 34, 35, and 36.
The peptidyl moieties of these compounds contain two identical amino acids, valine
and proline, whereas the third amino acid differs from each other. Dihydroer-
gotoxine is also obtained by hydrogenation of double bond between C-9 and C-10
of the natural EAs [76, 84]. Bromocryptine 37 is also an unnatural ergot alkaloid. It is
maintained by brominating the C-2 of the a-ergocryptine indole ring [149].
7 Conclusion
The relevance of EAs for modern medicine, pharmaceutical and food industry, as
well as for agriculture, leads to significant progresses in EA research. Identification of
EA gene clusters in different Ascomycota facilitated the molecular biological and
biochemical investigations of genes/enzymes in the EA biosynthesis. Based on the
obtained genetic information, new EA-producing strains could be reconstructed by
recombination of the biosynthetic genes and serve as sources for production of EAs
with new structural features. The total yield could be improved by genetic manipu-
lation. This field will be attractive for research on EAs in the near future.
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5. CONCLUSIONS AND FUTURE PROSPECTS 
This thesis demonstrates that tryptophan- and cyclic dipeptide PTs of the DMATS superfamily from 
different biosynthetic pathways can utilize the naturally occurring tripeptide derivative ardeemin FQ 
and its chemically synthesized stereoisomers for prenylation. These findings are of particular 
importance as ardeemin and derivatives have been proved to inhibit the MDR export pump and 
thus increase the retention time of cytotoxic drugs in cancer cells (Chou et al. 1998; Hayashi et al. 
2015; Hochlowski et al. 1993; Juliano and Ling 1976; Kartner et al. 1983; Karwowski et al. 1993; 
Zheng et al. 2014). In the course of this thesis, the biochemical experiments revealed that the two 
stereo centers of ardeemin FQ and its stereoisomers strongly influence the activity and 
regioselectivity of the investigated PTs. Almost all tryptophan- and cyclic dipeptide PTs converted 
ardeemin FQ with relatively high product yields. The tryptophan PTs show also a high activity with 
the enantiomer ent-ardeemin FQ whereas cyclic dipeptide PTs only poorly accepted this substrate. 
In the first study, the tryptophan PTs have been investigated by Peter Mai. In the second study, the 
experiments in terms of cyclic dipeptide PTs have been performed in cooperation with Lindsay 
Coby. The overproduction and purification of the His-tagged recombinant PTs has been performed 
by Peter Mai. The enzyme assays, analyses of product formation, NMR and mass analyses have 
been performed by Lindsay Coby and Peter Mai. Also the determination of the kinetic parameters 
has been performed by Lindsay Coby and Peter Mai. 
In total, 18 new prenylated tripeptide derivatives were produced by tryptophan PTs using ardeemin 
FQ and its three stereoisomers. 8 new tripeptide derivatives prenylated at the pyrrole ring could be 
generated by the investigated cyclic dipeptide PTs in the presence of ardeemin FQ and its 
enantiomer ent-ardeemin FQ. These studies show that PTs can be used as biocatalysts for the 
production of pharmacologically relevant substances by the combination of chemical and 
enzymatic synthesis. Furthermore, molecular modeling performed by Georg Zocher and site-
directed mutagenesis of FgaPT2 (performed by Peter Mai) indicated that the prenylation position 
can be guided, but further mutational experiments and crystal structures are necessary to achieve 
regioselective prenylations with sufficient product yields. 
In future studies, the biological activity including the potential to inhibit the MDR export pump needs 
to be evaluated for the obtained prenylated ardeemin FQ and its stereoisomers.  
Moreover, this thesis highlights the engineering of PTs based on their structural data in order to 
create mutants with new prenylation properties. 
In the course of this thesis, new biocatalysts have been generated by targeted protein manipulation 
using site-directed or site-saturation mutagenesis. 
• Firstly, the engineering of FgaPT2 (performed by Peter Mai and Liujuan Zheng) by the 
combination of two mutations resulted in the creation of four double mutants in total. These 
mutants possess the ability to catalyze a reverse C3-prenylation on various CDPs with 
DMAPP (performed by Liujuan Zheng). These findings highlight that FgaPT2, which 
catalyzes a strict regiospecific and regular transfer of the dimethylallyl moiety from DMAPP 
to the C-4 position of L-tryptophan, can be engineered to shift the prenylation position, to 
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extend the acceptance for other substrates and to attach the prenyl moiety in a reverse 
manner. 
• Secondly, on the basis of protein structure data, the amino acid residue M328 was identified 
to be crucial for the substrate specificity with regard to the prenyl donor in the DMAPP-
specific PT FgaPT2. The replacement of this residue to glycine produced a mutant with a 
high preference for GPP and at the same time a strong reduction of DMAPP-acceptance. 
The conversion of FPP could also be observed by this mutant. To study the steric and polar 
properties of the amino acids at the position 328 in terms of the prenyl donor specificity, the 
remaining 18 mutants were generated. Seven mutants with a smaller amino acid compared 
to the wildtype accept GPP as a prenyl donor, but due to their more polar properties a 
different activity towards DMAPP was observed. The generation of a double- and triple 
mutant further led to an increase of the FPP-acceptance. Out of these 21 generated 
mutants, seven can be used as geranyltransferases for chemoenzymatic syntheses. A 
natural or unnatural tryptophan geranyltransferase or farnesyltransferase has not been 
reported prior to this study. In order to achieve a high FPP-acceptance, other relevant 
amino acid residues need to be identified and thus additional structural data are required. 
The molecular modeling has been performed by Georg Zocher. The mutagenesis 
experiments, heterologous overexpression of the recombinant proteins, enzyme activity 
assays and structure elucidation via NMR and mass analysis as well as determination of 
kinetic parameters have been performed by Peter Mai. 
• Thirdly, protein sequence alignments, molecular modeling (performed by Georg Zocher), 
and subsequent mutation experiments (performed by Peter Mai) using the five other 
DMAPP-specific PTs FtmPT1, CdpC2PT, BrePT, CdpC3PT and CdpNPT also identified 
the amino acids responsible for the prenyl donor selectivity. The replacement with a smaller 
amino acid at the specific position provided a significant GPP-acceptance compared to the 
wildtype (performed by Peter Mai). 42 geranylated derivatives with 15 cyclic dipeptides and 
6 mutants could be obtained by Ge Liao and Peter Mai. One cyclic dipeptide could even be 
geranylated at all possible positions (performed by Ge Liao). 
This thesis highlights that a switch of the prenyl donor acceptance can be applied for enzymes 
which are practically limited to the use of DMAPP as a donor. Furthermore, these findings should 
encourage research groups to engineer additional ones of the approximately 45 DMATS-type PTs, 
which mainly use DMAPP as prenyl donor (Winkelblech et al. 2015). Several mutants show a high 
activity towards GPP and could already be used as geranyltransferases for chemoenzymatic 
synthesis and synthetic biology.
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